AMERICAN PSYCHIATRIC ASSOCIATION

2006 ANNUAL MEETING

FROM SCIENCE TO PUBLIC POLICY
ADVOCACY FOR PATIENTS & THE PROFESSION

AMERICAN PSYCHIATRIC ASSOCIATION
159TH ANNUAL MEETING
TORONTO, CANADA MAY 20-25, 2006

TORONTO, CANADA  •  MAY 20–25, 2006
KEY LOCATIONS
TORONTO METRO CONVENTION CENTRE

<table>
<thead>
<tr>
<th>Location</th>
<th>Address</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>American Journal of Psychiatry</td>
<td>APPI Bookstore</td>
<td>200</td>
</tr>
<tr>
<td>and Psychiatric Services</td>
<td>Halls D-G, South</td>
<td>800</td>
</tr>
<tr>
<td>Annual Meetings Office</td>
<td>Room 204</td>
<td>200</td>
</tr>
<tr>
<td>APA Communications Office</td>
<td>Room 101</td>
<td>100</td>
</tr>
<tr>
<td>APA Member Center</td>
<td>Halls D-G, South</td>
<td>800</td>
</tr>
<tr>
<td>A/V Preview Room</td>
<td>Room 203B</td>
<td>200</td>
</tr>
<tr>
<td>CME Course Enrollment</td>
<td>Hall C, North</td>
<td>305</td>
</tr>
<tr>
<td>Computerized Evaluation</td>
<td>South Building</td>
<td>600</td>
</tr>
<tr>
<td>Daily Bulletin</td>
<td>Room 103A, North</td>
<td>100</td>
</tr>
<tr>
<td>Exhibit Office</td>
<td>Halls D-G, South</td>
<td>800</td>
</tr>
<tr>
<td>Exhibits/Publishers' Bookfair</td>
<td>Halls D-G, South</td>
<td>800</td>
</tr>
<tr>
<td>Information Center</td>
<td>North Foyer, Level 200</td>
<td></td>
</tr>
<tr>
<td>Internet Village</td>
<td>South Building</td>
<td>600</td>
</tr>
<tr>
<td>Lost &amp; Found</td>
<td>Room 204</td>
<td>200</td>
</tr>
<tr>
<td>Message Center</td>
<td>North Foyer, Level 200</td>
<td></td>
</tr>
<tr>
<td>On-Site Job Bank and</td>
<td>APA Member Center, Halls D-G, Level 200</td>
<td></td>
</tr>
<tr>
<td>Placement Center</td>
<td>South, Level 800</td>
<td></td>
</tr>
<tr>
<td>Registration</td>
<td>Hall C, North</td>
<td>300</td>
</tr>
</tbody>
</table>

FIRST AID
There are two first aid offices in the Toronto Convention Centre. The North Building location is on Level 100, directly across from Room 106 and Constitution Hall. The South Building location is on Level 800, directly across from Hall D. Hours of operation: Tuesday, May 16, through Thursday, May 25, and opens one hour prior to show opening and closes one hour after the last event of the evening.

COURTESY SHUTTLE BUS SERVICE
Service will begin on Saturday, May 20, at approximately 7:00 a.m., and will operate daily throughout the meeting commensurate with the scientific program schedule and will conclude on Thursday, May 25, at 6:00 p.m. The Toronto Metro Convention Centre will serve as the “hub” for all shuttle bus routes. A detailed Shuttle Bus Schedule is included in your registration packet and will be posted in the lobbies of participating hotels. Refer to the city map on page XIII for the location of hotels in relation to the Convention Centre.

EXHIBITS
Commercial and educational exhibits will be located in Exhibit Halls D-G, South, Level 800, Toronto Metro Convention Centre, along with the Publishers’ Bookfair and the APA Member Center. For your convenience, the Publishers’ Bookfair and APA Member Center will be open Saturday, May 20, 10:00 a.m.-5:00 p.m. Educational and commercial exhibit hours are: Sunday, May 21, 10:00 a.m.-4:30 p.m.; Monday, May 22, 10:00 a.m.-5:30 p.m.; Tuesday, May 23, 10:00 a.m.-6:00 p.m.; and the final day, Wednesday, May 24, 10:00 a.m.-3:00 p.m.

INFORMATION CENTER
Located in the North Foyer, Level 200, Toronto Metro Convention Centre and staffed during registration hours (with the exception of Thursday, May 25, when the Center will be open until 5:00 p.m.). Up-to-date general information about the program, component meetings, the local area, and the locations of various activities and events can be obtained at the Information Center.

MESSAGE CENTER
Located in the North Foyer, Level 200, Toronto Metro Convention Centre and staffed during registration hours (with the exception of Thursday, May 25, when the Center will be open until 5:00 p.m.). Messages can be left and picked up at the Message Center. Ancillary message centers will also be located on Level 600 and Level 800 in the South Building in the Toronto Metro Convention Centre. Registrants whose names appear on these monitors should pick up their messages at the Message Center.

APA MEMBER CENTER
Located in Exhibit Halls D-G, South, Level 800, Toronto Metro Convention Centre. Hours of operation will be: Saturday, May 20, 10:00 a.m.-5:00 p.m.; Sunday, May 21, 10:00 a.m.-4:30 p.m.; Monday, May 22, 10:00 a.m.-5:30 p.m.; Tuesday, May 23, 10:00 a.m.-6:00 p.m.; and Wednesday, May 24, 10:00 a.m.-3:00 p.m. A few of the many APA activities exhibited include: membership, APAs internet-based programs, continuing medical education, quality improvement, psychiatric services, clinical resources, advocacy tools, career development, practice management, and APA periodicals.

APA JOB BANK
Visit the APA on-site Job Bank at APA 2006! The online APA Job Bank will power the popular on-site Job Bank providing improved tools for both employers and candidates at the APA’s Annual Meeting. Candidates and employers are encouraged to activate their resume and job postings in advance of the meeting for best results. For more information on the Job Bank, visit www.psych.org/jobbank.

APA COMMUNICATIONS OFFICE & PRESS ROOM
Located in Room 101, North, Level 100, Toronto Metro Convention Centre. Hours of operation: Saturday, May 20, 11:00 a.m.-5:00 p.m.; Sunday-Thursday, May 21-24, 8:00 a.m.-6:00 p.m.; and Thursday, May 25, 8:00 a.m.-12 noon. This room is for the use of registered press and credentialed public relations representatives only.

DAILY BULLETIN
The Daily Bulletin accepts written requests from APA members for publicity of component, committee, and allied group events as space allows. Four issues are published. The issue for Saturday/Sunday is printed in advance. Copy for the Monday, Tuesday, and Wednesday/Thursday issues can be dropped off in Room 103A, North Level 100, by 12 noon prior to the date of publication.

RESIDENTS’ RESOURCE CENTER
Located in the Niagara Room, Lower Level, Intercontinental Hotel. The Residents’ Resource Center will be open from 7:00 a.m. to 6:00 p.m., Sunday, May 21, through Wednesday, May 24. Daily activities are scheduled for residents (such as the orientation, Residents Only Discussion Groups, and Resident Summits) and medical students. Meet and network with your colleagues and leaders in psychiatry. Resources specifically for residents and medical students are available here.
BUSINESS CENTERS

Toronto Metro Convention Centre: North Building, Exhibitor Services Centre, Street Level (across from Room 206f). South Building, Business Services Centre, 800 Level (outside entrance to Hall D). Hours of operation: Monday-Friday (North Building: 8:00 a.m.-5:00 p.m.; South Building: 8:30 a.m.-4:30 p.m).

Royal York: East Lobby (outside of Epic Restaurant)

Sheraton Centre Toronto: Main Lobby

REGISTRATION

Admission to all sessions by registration badge

Located in Exhibit Hall C, North Level 300, Toronto Metro Convention Centre. Hours of operation: Saturday, 10:00 a.m.-5:00 p.m.; Sunday, 7:30 a.m.-5:00 p.m.; Monday, 7:30 a.m.-5:30 p.m.; Tuesday, 7:30 a.m.-6:00 p.m.; Wednesday, 7:30 a.m.-5:00 p.m.; and Thursday, 7:30 a.m.-2:00 p.m.

On-Site Registration Fee Schedule:

**APA MEMBERS**

<table>
<thead>
<tr>
<th>Registration Type</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full-Time Registration (North American Members)</td>
<td>$295</td>
</tr>
<tr>
<td>Full-Time Registration (International Members)</td>
<td>$295-$520</td>
</tr>
<tr>
<td>Members-in-Training (Member Class MT)</td>
<td>$85</td>
</tr>
<tr>
<td>Daily Registration (North American Members)</td>
<td>$150</td>
</tr>
<tr>
<td>Daily Registration (International Members)</td>
<td>$275</td>
</tr>
</tbody>
</table>

Medical Students: no charge

*Fee determined by country's gross national income according to the World Bank.

**NONMEMBERS**

<table>
<thead>
<tr>
<th>Registration Type</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full-Time Registration</td>
<td>$860</td>
</tr>
<tr>
<td>Nonmember Residents, Students, Advocacy</td>
<td></td>
</tr>
<tr>
<td>Group Members, or Mental Health Chaplains</td>
<td>$100</td>
</tr>
<tr>
<td>Daily Registration (all Nonmember categories)</td>
<td>$450</td>
</tr>
</tbody>
</table>

Medical Students: no charge

**GUEST REGISTRATION**

One only per full-time registrant: $100

Only one guest is allowed to register with each full-time meeting registrant. The guest must reside in the same household and be able to receive mail at the same address. APA members cannot register as a "guest"; they must register as an APA member. ID may be required.

One-Day Exhibit Hall Only Pass (18 and older): 10.00

(Only paid registrant can purchase an exhibit hall pass)

On-site fees can be paid by U.S. dollar cash, check, money order, American Express, VISA, or MasterCard. Registration fees are waived only for CME Course Faculty, APA Honorary Fellows (does not include APA Distinguished Fellows/Fellows/Life Fellows/Distinguished Life Fellows), medical students (with proper identification), District Board Executive Staff (who are not APA members), active members of the Association of Mental Health Clergy (with proper identification), and nonmember program participants (only for the day(s) they present, except for industry-supported symposium presenters who must pay the fee).

Nonmember psychiatric residents and other full-time students must present documentation to register in their respective category and qualify for the reduced fee. (Examples include: a valid full-time [12 + hours per semester] student ID; a letter from your instructor or director of training verifying your status as a psychiatric resident; or similar documentation.)

**Note: There are no exemptions or reduced fees available for CME courses.** The registration fee covers admission to all sessions (except courses), shuttle buses, and includes a badge and copy of the Program Book, APA Member Center Guide, and New Research Program and Abstracts Books, and for most categories, a copy of the Syllabus.

REGISTRATION BADGES

Badges are required for all sessions including the Opening Session and exhibit hall. Only an APA member badge will admit you to the Business Meeting.

**Badge Color Codes:** Blue-Members, Yellow-Nonmember, Silver-Press, Red-Exhibitors, Green-APA Staff, and Clear-Temporary Personnel.

Registered exhibitors will receive red badges, which allow access only to his or her exhibit booth in the exhibit hall and to ride the shuttle bus. If an exhibitor wants to attend sessions, he/she must register for the meeting and pay the appropriate fee.

CME COURSE ENROLLMENT

Ticket purchase required for CME Courses

Located in Exhibit Hall C, North, Level 300, Toronto Metro Convention Centre. Hours of operation are the same as registration. Tickets for Courses not sold by April 22 will be on sale beginning at 12 noon on Friday, May 19. You must be registered for the meeting before you can enroll in courses.

APA ART ASSOCIATION

Located in the South Building, Level 600, Toronto Metro Convention Centre and open during the commercial exhibit hours, the exhibit includes paintings, photography, ceramics, and crafts created by APA members and/or their significant others. Step by step for information on joining the APA Art Association.

APA ALLIANCE BOOTH

Located in the North Foyer, Level 200, Toronto Metro Convention Centre. Hours of operation: Saturday, May 20, through Wednesday, May 24, 9:00 a.m.-5:00 p.m. Stop by the booth to obtain information on the Alliance's program schedule and information on membership.

APA PERIODICALS

Editorial staff of The American Journal of Psychiatry, Psychiatric Services, Academic Psychiatry, Journal of Neurology and Clinical Neurosciences, Psychosomatics, and APA's CME journal, Focused will be on hand to demonstrate online access for subscribers, answer questions regarding submissions, and show the new state-of-the-art website, www.psychiatryonline.com. Visitors can also purchase or renew subscriptions to all APA/APPI journals at the booth. Complimentary copies of Psychiatric News will be available at stands located throughout the Convention Centre. Persons who wish to contact editors or reporters of Psychiatric News are asked to leave a message on the message board in the Annual Meetings Office. Written announcements, suggestions for articles, letters to the editor, or other material for the newspaper's consideration may be left with staff at the Periodicals Exhibit.
CONTINUING MEDICAL EDUCATION

Educational Objectives: At the conclusion of this meeting, participants will be able to:

- Better understand new research findings in the fields of psychiatry and neuroscience;
- Acquire new knowledge and skills in clinical psychiatry, which can be utilized to improve patient care;
- Identify and remove barriers to the transfer of new knowledge for their practice, including provision of culturally competent care for diverse populations;
- Assess a variety of treatment choices, including psychotherapeutic and pharmacological options; and
- Better understand mental health service delivery issues, including barriers to care.

The APA is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 66 category 1 credits toward the AMA Physician’s Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Please note: Most portions of the scientific program, as outlined below, have been approved for CME credit. The scientific sessions on the official Annual Meeting program, with some exceptions, meet the criteria for category 1 CME credit. Sessions in the following program formats are designated as category 1:

- Advances in... Series, Clinical Case and Continuous Clinical Case Conferences, CME Courses, Focus Live, Forums, Industry-Supported Symposia, Lectures, Medical Updates, New Research Young Investigators’ Oral/Slide Sessions, Presidential Symposia, Research Advances in Medicine, Review of Psychiatry, Roundtable Discussion, Scientific and Clinical Reports, Symposia, and Workshops. Other scientific sessions not listed may be reported as category 2 (Debates, Discussion Groups, Master Educator Clinical Consultations, New Research Poster Sessions, and Research Consultation). Scientific sessions are open to all Annual Meeting registrants, except for the Clinical Case and Continuous Clinical Case Conferences and the Master Educator Clinical Consultations, which are open to APA members only.

PLEASE NOTE: APA MEMBERS ARE REQUIRED TO MAINTAIN THEIR OWN RECORDS OF CME HOURS. REPORTING OF CME CREDIT IS ON AN HONOR BASIS.

To document CME credit earned at the Annual Meeting, participants should record the sessions they attended on the Certificate of Attendance log sheet found in the front of the 2006 Annual Meeting CME Sylabus & Proceeding Summary Book. Credit is earned on an hour-for-hour basis. A parchment Certificate of Attendance is also available.

The Certificate of Attendance (or copy) may be forwarded to other organizations requiring verification of participation in the APA Annual Meeting.

The APA requires members to participate in a total of 150 credits of CME activities within a three-year reporting period. At least 60 credits must be in category 1 activities.

CME report forms may be obtained from the Department of CME at the APA or online at www.psych.org. Staff will be available in the APA Member Center to answer any of your questions about CME.

ANNUAL MEETING EVALUATION

The Annual Meeting Scientific Program Committee needs your recommendations and evaluations to plan next year’s Annual Meeting. A participant evaluation form is enclosed with your registration packet and includes instructions for completing the form. Before you leave the meeting, please complete your form and drop it in one of the evaluation boxes located throughout the meeting sites or consider the options below.

You can receive a parchment Certificate of Attendance at the Annual Meeting by returning your completed form (to the Annual Meetings Office, Information Center, or APA Member Center, all located in Toronto Metro Convention Centre). A personalized Certificate of Attendance will be available by completing the computerized general evaluation in the South Building, Level 600, Toronto Metro Convention Centre. Attendees may also access the web-based evaluation from their own computer during or after the meeting, and the program automatically generates a CME certificate. Please complete the general evaluation one time only.

SESSION CAPACITY

So that all in attendance may benefit, we ask your assistance when overcrowding occurs:

- Please find seating as far forward as possible.
- Move to the center of the row and fill all seats so that chairs are available on aisles for additional attendees.
- Overflowing of meeting rooms may subject the session to shutdown by the Fire Marshal; therefore, we urge all attendees to locate seating rather than stand in aisles or against walls.
- If space does not permit you to attend a session, an audiotape of that session may be available. Please check the order form included in your registration packet.

AUDIO RECORDINGS OF SESSIONS

Audiotapes and CDs of most sessions are available shortly after each session concludes and may be purchased at the Mobilape Booth located in the North Foyer, Level 200, Toronto Metro Convention Centre.

SMOKING POLICY

There will be NO SMOKING in scientific sessions or in the exhibit hall. Smoking will only be permitted in designated areas.

TAPE RECORDING AND VISUAL REPRODUCTION POLICIES

Audiotape recording is only permitted for personal use. Registrants are welcome to use their own small, portable audiotape recorders to record any session except Master Educator Clinical Consultations, the Clinical Case Conferences, and the Continuous Clinical Case Conferences, or unless prohibited by the presenters. Larger, professional tape recorders are not permitted except for use by registered members of the working press in accordance with APA Press Policies. APA has authorized a professional taping firm to record and transcribe audio sessions. Badges of personnel representing this firm will clearly identify them. Registrants are not permitted to photograph (including with cell phone cameras) or videotape any session because the intrusive nature of the recording may disrupt the session.
**FUTURE APA MEETINGS**

**APA ANNUAL MEETINGS**
- 2007 May 19-24     San Diego, CA
- 2008 May 3-8       Washington, DC
- 2009 May 16-21     San Francisco, CA
- 2010 May 22-27     New Orleans, LA
- 2011 May 14-19     Honolulu, HI

**INSTITUTES ON PSYCHIATRIC SERVICES**
- 2006 October 6-10  New York, NY
- 2007 October 11-14 New Orleans, LA
- 2008 October 2-5   Chicago, IL

*Preliminary Programs* for the 2006 Institute on Psychiatric Services are available at the Information Center, located in the North Foyer, Level 200, Toronto Metro Convention Centre.

---

**GUIDE TO THE PROGRAM BOOK**

Below you will find the table of contents for ease in locating information about this meeting. A topic index is included to assist you with finding sessions of interest. The individual program for each day's sessions is listed by start time with the formats listed alphabetically under those times. **NOTE:** To make it easier for you to plan your day, we have prepared a separate "Days-at-a-Glance," which is included in your registration packet. You can also create your own personal schedule by using the online itinerary planner. Visit APA's homepage [www.psych.org](http://www.psych.org) and click on the 2006 Annual Meeting link. Then click on the link under the scientific session information heading and follow the instructions.

If you have any questions about this book or the scientific sessions, please feel free to stop by the Annual Meetings Office in Toronto Metro Convention Centre, and we will be glad to help you. Also, all APA staff will be wearing green badges. Please feel free to direct your questions to them.

---

**TABLE OF CONTENTS**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>VI-XII</td>
<td>Floor Plan for Toronto Metro Convention Centre; Intercontinental Toronto Centre; Royal York Sheraton Centre; Toronto</td>
<td></td>
</tr>
<tr>
<td>XIII</td>
<td>City Map</td>
<td></td>
</tr>
<tr>
<td>XIV</td>
<td>Local Information</td>
<td></td>
</tr>
<tr>
<td>XV-XVI</td>
<td>Special Acknowledgments</td>
<td></td>
</tr>
<tr>
<td>XVII-XIX</td>
<td>Format Descriptions</td>
<td></td>
</tr>
<tr>
<td>XX-XXXVII</td>
<td>Disclosure Information</td>
<td></td>
</tr>
<tr>
<td>XXXVIII</td>
<td>Benefits Concert</td>
<td></td>
</tr>
<tr>
<td>XXXIX</td>
<td>APA's Online Library of 2006 Annual Meeting Sessions</td>
<td></td>
</tr>
<tr>
<td>1-4</td>
<td>Saturday Sessions</td>
<td></td>
</tr>
<tr>
<td>5-15</td>
<td>Sunday Sessions</td>
<td></td>
</tr>
<tr>
<td>16-17</td>
<td>Audience and CD-Sales Information</td>
<td></td>
</tr>
<tr>
<td>17-12</td>
<td>Monday Sessions</td>
<td></td>
</tr>
<tr>
<td>13-54</td>
<td>Tuesday Sessions</td>
<td></td>
</tr>
<tr>
<td>54-90</td>
<td>Wednesday Sessions</td>
<td></td>
</tr>
<tr>
<td>91-102</td>
<td>Thursday Sessions</td>
<td></td>
</tr>
<tr>
<td>103-117</td>
<td>Topic Index</td>
<td></td>
</tr>
<tr>
<td>117-128</td>
<td>Join the APA Today</td>
<td></td>
</tr>
<tr>
<td>128-134</td>
<td>Participant Index</td>
<td></td>
</tr>
<tr>
<td>135-138</td>
<td>2006 Institute on Psychiatric Services</td>
<td></td>
</tr>
<tr>
<td>139-141</td>
<td>American Psychiatric Publishing, Inc.</td>
<td></td>
</tr>
<tr>
<td>142-143</td>
<td>American Psychiatric Foundation Special Events</td>
<td></td>
</tr>
<tr>
<td>144-145</td>
<td>Call for 2007 Annual Meeting Papers</td>
<td></td>
</tr>
<tr>
<td>146-147</td>
<td>Industry-Supported Symposans</td>
<td></td>
</tr>
<tr>
<td>148-149</td>
<td>APA Member Center</td>
<td></td>
</tr>
<tr>
<td>BACK COVER</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

News reports or summaries of APA presentations contained in these program materials may not be published or broadcast before the local time and date of the presentation.

Refer to the [APA Exhibit Guide](http://www.psych.org) for information on Exhibits, Publishers' Bookfair, and Dining Facilities at the Toronto Metro Convention Centre.

The information provided and views expressed by presenters on this program are not necessarily those of the American Psychiatric Association, nor does the American Psychiatric Association warrant the accuracy of any information reported.

© American Psychiatric Association
LOCAL INFORMATION

Situated 566 feet above sea level on the northern shore of Lake Ontario, Toronto is one of the southernmost cities in Canada. In fact, it has nearly the same latitude as northern California. Toronto is home to more than 100 cultures with a population of 4.7 million; it's the fifth-largest city in North America, after Mexico City, New York, Los Angeles, and Chicago. Toronto isn't just diverse — it's the most diverse city in the world — and that leads Torontonians to look at things a little differently, from the perspective of a hundred cultures. Two transit tokens can take you from one country to another, passing along the way through the quaint neighborhoods that make up their intimate metropolis. It's a place of energy exchange. It's Unlimited!

Airport
When entering Canada you will be asked to fill out a customs form to present to customs officials. When returning to the U.S., you will go through U.S. Customs & Immigration in Toronto, as well as a security check where you will possibly be asked to open your baggage for searching. Once outside the Canadian Terminal there is a small kiosk where you can purchase a round trip bus ticket for $27, which goes between downtown hotels and the airport.

Entering Canada
American visitors to Canada DO NOT need a passport to cross in either direction, however it is still highly recommended. Visitors who do not carry a passport will be asked to verify their citizenship and should therefore carry any one of the following documents: original birth certificate with raised seal, naturalization certificate, Green Card, or passport. Photo identification is also required so visitors should carry their driver's license or other photo ID. Individuals traveling from a country other than the U.S. may require a Visa. Please check with your Consulate or Embassy.

Languages Spoken
There are two official languages in Canada – English and French. In addition to these official languages, the top five languages spoken in Toronto are Chinese, Italian, Tamil, Portuguese, and Spanish.

Weather
Springtime in Toronto is a sight to behold as the bulbs and buds begin to bloom. This seems to energize the population – the first time the temperature rises into warm spring temperatures. What to pack: A light jacket and umbrella for those cool, rainy days.

Transit Safety -- Public Transit
Explore Toronto on one of North America's finest transportation systems -- the TTC. When using the TTC (public transit), a single fare will take you anywhere in the city on a one-way trip. You can freely transfer between subway, streetcar, and bus, but make sure you obtain a transfer (a slip of paper) when and where you pay your fare. On buses and streetcars, exact change is required. TTC day passes are also available. Buses offer a "request-stop" program between 9:00 p.m. and 5:00 a.m. which allows a female to exit the bus between regular TTC stops.

Driving Around Town
Toronto's streets follow a basic grid pattern and are fairly easy to navigate, although some of the one-way streets can be confusing. The city's rush hour is more than an hour long -- count on heavy traffic from 7:00 a.m.-9:00 a.m. and again from 4:00 p.m.-6:00 p.m.

Parking
Parking on most downtown streets is limited to specific times of day and often requires you to purchase and display a ticket from one of the parking machines located along the street.

The Underground City
PATH is downtown Toronto's underground walkway linking 27 km (16 miles) of subterranean shopping, services, and entertainment. Follow the brightly colored PATH signs and you'll reach your downtown destination easily in weather-proof comfort.

Currency
Here's what you need to know to spend money in Toronto: Toronto's currency is the Canadian Dollar. For denominations under five dollars, coins, including the "Loonie" (one dollar coin) and "Twonie" (two dollar coin) are used. U.S. dollars are accepted in most Toronto establishments; although change from your transactions will be given in Canadian currency and exchange rates will differ with each merchant.

Taxes
The Goods and Services Tax (GST) is a 7% tax that is charged on all goods and services sold or provided in Canada. Toronto is part of the Province of Ontario, so purchases made in Toronto are also subject to the 8% Provincial Sales Tax (PST). Tax Rebates: The good news is, foreign visitors to Canada can apply for a rebate on the GST that is paid on accommodations (up to 30 nights per visit), and on goods purchased in Canada and exported within 60 days of the purchase. Be sure to keep your receipts -- you'll need to have them validated by Canada Customs at the airport or border crossing when you leave. For more information about the visitors' tax refund and to obtain an application, visit www.cra.gc.ca/visitors or call 1-800-668-4748 (within Canada) or 1-902-432-5608 (from outside Canada).

Emergencies
Toronto's universal emergency number is 911. Use it for police, fire, and medical emergencies. Each hotel has its own procedures for handling medical emergencies. If you experience a medical emergency, call the front desk at your hotel and they will assist in getting an ambulance or necessary medical help. Toronto Police Services has over 5,000 uniformed officers on patrol in the city and can be reached at 416-868-2222.

What to See
Tours? Visitor Information
Attendees are encouraged to use their hotel's concierge services to assist them with local information and dinner reservations. Please refer to pages 21-23 in this booklet for tours offered during the Annual Meeting. For local information, you may refer to www.mytorontomeeting.com.

Harbourfront Centre
Toronto's one-of-a-kind waterfront setting offers the arts, culture, and recreation. The outdoor patio bar, Splash, and indoor cafe, Lakeside EATS, offer a great place to meet friends and enjoy great snacks, meals, and drinks. Annual events include concerts, dance, theatre, and musical performances; art exhibitions; literary readings; craft activities; children's activities; outdoor ice-skating; and much more. Activities and events are either free or reasonably priced.
SPECIAL ACKNOWLEDGMENTS

The American Psychiatric Association expresses its deep appreciation for the following:

Abbott Laboratories: partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.; and support of the Industry-Supported Symposium, “Multiple and Complex Presentations of Bipolar Disorder,” Tuesday, May 23, 7:00 p.m.; and the Internet Village.

Alkermes: co-support of the Industry-Supported Symposium, “Diagnosing and Treating Alcohol Dependence in the Office,” Wednesday, May 24, 7:00 p.m.

American Academy of Psychiatry and the Law: co-support of the Manfred S. Guttmacher Award Lecture, Sunday, May 21, 2:30 p.m.

American Association of Chairs of Departments of Psychiatry: support of the APA/AACDP Research Mentorship Award.

American Psychiatric Association / Hurricane Disaster Relief Fund: support of the Disaster Psychiatry Fellowship.

American Psychiatric Foundation: support of the APIRE Practice Research Network.

Association of Women Psychiatrists: support of the joint AWP/APA Women’s Caucus reception and meeting, Monday, May 22, 7:00 p.m.; and co-support of the Alexandra Symonds Award Lecture, Tuesday, May 23 2:00 p.m.

AstraZeneca Pharmaceuticals: support of the Industry-Supported Symposia, “Pharmacotherapy of Psychotic and Mood Disorders With Co-Existing Medical Illness,” Monday, May 22, 7:00 p.m.; and “Treating the Early Stages of Schizophrenia,” Tuesday, May 23 7:00 p.m.; the Industry-Supported Breakfast Symposium, “Emerging Evidence in the Treatment of Bipolar Depression,” Wednesday and Thursday, May 24-25, 7:00 a.m.; partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.; support of the APA/AstraZeneca Minority Fellowship, minority fellows poster session and reception, Tuesday, May 23, 7:00 p.m.; the American Psychiatric Foundation “Conversations” event, Tuesday, May 23, 5:30 p.m.; the George Tarjan Award Lecture, Wednesday, May 24, 9:00 a.m.; and the APA/AstraZeneca Young Minds in Psychiatry Award.


Bristol-Myers Squibb Company: co-support of the Industry-Supported Symposia, “Strategies for Maintaining Wellness in Patients With Bipolar Disorder: Moving Beyond Efficacy to Effectiveness,” Saturday, May 20, 12:30 p.m.; “Verging on Reality: Emergent Therapeutic Approaches for Schizophrenia,” Saturday, May 20, 6:00 p.m.; “Atypical Depression: Merging Evidence and Public Policy,” Sunday, May 21, 7:00 p.m.; “Helping Depressed Patients Achieve Remission: Advocacy for Improvement,” Monday, May 22, 7:00 p.m.; and the Industry-Supported Breakfast Symposia, “Clinical Implications of Choices of Atypical Antipsychotics: Realities and Myths,” Monday and Tuesday, May 22-23, 7:00 a.m.; and “Bipolar Illness: The Road to Remission,” Wednesday and Thursday, May 24-25, 7:00 a.m.; support of the President’s Dessert and Reception; and the Solomon Carter Fuller Award Lecture, Tuesday, May 23, 11:00 a.m., the Solomon Carter Fuller Award Reception; and partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.

Bristol-Myers Squibb Sweden: support of Global Psychiatry: A Session for U.S. and International Residents, Sunday, May 21, 2:00 p.m.

Center for Mental Health Services: support of the APIRE Practice Research Network (PRN); and the APA’s HIV-related education programs and materials.

Center for Substance Abuse Treatment: support of the APIRE Practice Research Network (PRN); and an audience response system for the course, “Office-Based Buprenorphine Treatment of Opioid-Dependent Patients.”

Cephalon, Inc.: support of the Industry-Supported Symposia, “The Impact of Anxiety Disorders: A Case-Based Approach to Improving Outcomes and Removing Stigma,” Sunday, May 21, 8:00 a.m.; “Advances in the Neurobiology and Therapeutics of ADHD,” Sunday, May 21, 7:00 p.m.; “The Cognition, Neurocircuitry, and Disability Interface: Bringing Evidence to Practice,” Monday, May 22, 7:00 p.m.; and “Advocating for Change Through Evidence-Based Medicine: A Focus on ADHD,” Tuesday, May 23, 7:00 p.m.; the Industry-Supported Breakfast Symposium, “Evidence, Outcomes, and Advocacy: Shaping the Management of GAD,” Monday and Tuesday, May 22-23, 7:00 a.m.; and co-support of the Industry-Supported Symposium, “Diagnosing and Treating Alcohol Dependence in the Office,” Wednesday, May 24, 7:00 p.m.

Cyberonics, Inc.: support of the Industry-Supported Symposia, “Treatment-Resistant Depression: New Data, New Approaches,” Saturday, May 20, 6:00 p.m.; and partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.

Eisai, Inc.: co-support of the Industry-Supported Symposia, “Advances in the Understanding of the Dementia Spectrum,” Sunday, May 21, 1:30 p.m.

Eli Lilly and Company: support of the Industry-Supported Symposia, “Fibromyalgia: Scientific Advances to Reduce the Burden of Illness,” Sunday, May 21, 8:00 a.m.; and “Effectiveness of Antipsychotic Drugs in Chronic Schizophrenia: Complete Results of the CATIE Trial,” Sunday, May 21, 7:00 p.m.; partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.; and the Simon Bolivar Award Lecture, Monday, May 22, 11:00 a.m.; support of the APIRE/Lilly Psychiatric Research Fellowship; the symposium entitled, “Strengthening of Mental Health Systems in Low and Middle Income Countries,” Monday, May 22, 2006,
SPECIAL ACKNOWLEDGMENTS

7:00 p.m.; and the APA/Lilly Resident Research Awards.

Estate of Agnes Purcell McGavin: support of the Agnes Purcell McGavin Awards for Distinguished Career Achievement in Child and Adolescent psychiatry, and for Prevention.

Estate of Dorothy C. Kempf: support of APIRE/Kempf Fund Award for Research Development in Psychobiological Psychiatry Awards.

Estate of Kun-Po Soo, M.D., Ph.D.: support of the Kun-Po Soo Award Lecture, Monday, May 22, 9:00 a.m.

Psychiatric Foundation's Fund for Research in Psychiatry: co-support of the Research in Psychiatry Award Lecture, Monday, May 22, 9:00 a.m.

Forest Laboratories, Inc.: support of the Industry-Supported Symposia, “Navigating the Maze: Understanding Methods, Results, and Risks in Psychiatric Research,” Saturday, May 20, 12:30 p.m.; “Interrupting the Cycle of Vascular Disease and Depression,” Sunday, May 21, 1:30 p.m.; and “Alzheimer’s Disease: Challenging the Practice Paradigm,” Sunday, May 21, 7:00 p.m.; partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.; and support of the registration portfolios.

GlaxoSmithKline: support of the Industry-Supported Symposia, “New Augmentation Strategies in Depression for Better Outcomes,” Saturday, May 20, 12:30 p.m.; “Misdiagnosis of Bipolar II: Methods for Screening Patients at Risk for Bipolar Disorder,” Sunday, May 21, 1:30 p.m.; and “The Maze of Mood and Anxiety in the Elderly: Patient: A Case Series,” Tuesday, May 23, 7:00 p.m.; the Industry-Sponsored Breakfast Symposium, “What the Psychiatrist Needs to Know About Sleep-Related Movement Disorders,” Wednesday and Thursday, May 24-25, 7:00 a.m.; partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.; support of the APA/GlaxoSmithKline Fellowship Program and reception; and the APIRE/GlaxoSmithKline Young Faculty Award for Research Development in Biological Psychiatry.

Ittleson Foundation: support of the Blanche F. Ittleson Award for Research in Child Psychiatry.

Janssen Pharmaceutica and Research Foundation: partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.; the support of the Committee of Asian-American Psychiatrists recruitment reception; and the American Psychiatric Institute for Research and Education/Janssen Resident Psychiatric Research Scholars.

Merck & Co., Inc.: support of the APA/Merck & Co., Inc. Early Academic Career Research Award.

National Institute of Mental Health: co-support of the Research Colloquium for Junior Investigators; support of the American Psychiatric Institute for Research in Education (APIRE) Annual Meeting activities for research trainees; the Program for Minority Research Training in Psychiatry (PMRTP).

National Institute on Alcohol Abuse and Alcoholism (NIAAA): support of annual meeting research track, “Rethinking Alcohol Use Disorders: Science, Diagnosis, Treatment, and Policy.”

National Institute on Drug Abuse: support of annual meeting activities of trainees of the APIRE Drug Abuse Research Scholars Program.

Neurocine Biosciences, Inc.: co-support of the Industry-Supported Symposium, “Insomnia From the Inside Out: From Neuroscience to Clinical Experience to Public Policy,” Sunday, May 21, 7:00 p.m.

Organon USA, Inc.: co-support of the Industry-Supported Symposium, “Taking Control of Negative Symptoms: The Next Step for Improved Patient Outcomes in Schizophrenia,” Monday, May 22, 7:00 p.m.

Otsuka America Pharmaceutical, Inc.: co-support of the Industry-Supported Symposium, “Strategies for Maintaining Wellness in Patients With Bipolar Disorder: Moving Beyond Efficacy to Effectiveness,” Saturday, May 20, 12:30 p.m.; “Verging on Reality: Emergent Therapeutic Approaches for Schizophrenia,” Saturday, May 20, 6:00 p.m.; and the Industry-Supported Breakfast Symposium, “Clinical Implications of Choices of Atypical Antipsychotics: Realities and Myths,” Monday and Tuesday, May 22-23, 7:00 a.m.; and “Bipolar Illness: The Road to Remission,” Wednesday and Thursday, May 24-25, 7:00 a.m.; partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.; and support of the APF Awards for Advancing Minority Mental Health.

Pfizer, Inc.: support of the Industry-Supported Symposium, “Differentiating Atypical Antipsychotics in the Treatment of Schizophrenia: From Theory to Practice,” Sunday, May 21, 8:00 a.m.; and “New Vistas in Treatment-Resistant Depression,” Sunday, May 21, 8:00 a.m.; and “Remission and Recovery in Schizophrenia: Advocating for Our Patients,” Wednesday, May 24, 7:00 p.m.; and co-support of the Industry-Supported Symposium, “Advances in the Understanding of the Dementia Spectrum,” Sunday, May 21, 1:30 p.m.; “Insomnia From the Inside Out: From Neuroscience to Clinical Experience to Public Policy,” Sunday, May 21, 7:00 p.m.; and “Taking Control of Negative Symptoms: The Next Step for Improved Patient Outcomes in Schizophrenia,” Monday, May 22, 7:00 p.m.; support of the Psychiatric Services Achievement Awards; the “Abstracts-On-Disk” Program; and the APA/Pfizer Minority Psychiatric Research Fellowship Award; and partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.; and the Simon Bolivar Award Lecture, Monday, May 22, 11:00 a.m.

Professional Risk Management Services, Inc.: co-support of the Manfred S. Guttmacher Award Lecture, Sunday, May 21, 2:30 p.m.; and partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.

Sepracor, Inc.: support of the Industry-Supported Symposium, “Vital Signs in Psychiatry: A Perspective on Sleep Across the Life Cycle,” Sunday, May 21, 1:30 p.m.
SPECIAL ACKNOWLEDGMENTS

Shire US, Inc.: support of the Industry-Supported Symposia, “Mania in Special Populations,” Saturday, May 20, 6:00 p.m.; “Expanding the Neurobiological and Neuropsychological Foundation of ADHD: Impact to Clinical Practice,” Sunday, May 21, 8:00 a.m.; and “Understanding and Managing the Transition of ADHD From Adolescence to Young Adulthood: The Maturation of the Disorder,” Monday, May 22, 7:00 p.m.; the Residents’ Session, “Meet the Experts: Sunny-Side Up,” Monday, May 22, 7:00 a.m.; the APA/Shire Child and Adolescent Psychiatry Fellowships; and partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.


Substance Abuse and Mental Health Services Administration (CMHS, CSAP, CSA): sponsorship of the APA/SAMHSA Minority Fellowship Program.


University of Nebraska: support of the Frank J. Menolascino Award for Psychiatric Services for persons with Mental Retardation/Developmental Disabilities.

Wyeth Pharmaceuticals: support of the Industry-Supported Symposia, “The Long-Term Clinical Course and Treatment of Recurrent Major Depression in 2006: New Data and Future Directions,” Sunday, May 21, 1:30 p.m.; and “What Is the Role of Somatic and Physical Symptoms in Depression?,” Wednesday, May 24, 7:00 p.m.; the Industry-Supported Breakfast Symposium, “Attaining and Sustaining Remission in Treatment of Depression With Comorbid or Residual Anxiety,” Monday and Tuesday, May 22-23, 7:00 a.m.; co-support of the Industry-Supported Symposia, “Bipolar Disorder: Creating a Consensus From Science to Public Policy,” Saturday, May 20, 6:00 p.m.; “New Developments in Schizophrenia: From Neurobiology to Public Health,” Sunday, May 21, 1:30 p.m.; “Management of Psychosis in the Elderly: The Science and the Art,” Tuesday, May 23, 7:00 p.m.; and “Managing Unmet Needs in Psychiatric Illnesses: A Critical Look at Disorders and Public Policy,” Wednesday, May 24, 7:00 p.m.; the Industry-Supported Breakfast Symposium, “New Frontiers in Depression: Providing Solutions to Unmet Needs,” Wednesday and Thursday, May 24-25, 7:00 a.m.; support of the APIRE/Wyeth Laboratories M.D., Ph.D., Psychiatric Research Fellowship; the Jeanne Spurlock, M.D. Congressional Fellowship; and the daily in-house TV program, APA TV, New Programs, partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.; and co-support of the Alexandra Symonds Award Lecture, Tuesday, May 23, 2:00 p.m.
ADVANCES IN....SERIES
These three-hour and thirty-minute sessions are intended to highlight important new advances occurring in the field of psychiatry involving selected disorders or treatments. The sessions are chaired by editors of recent textbooks published by the American Psychiatric Publishing, Inc (APPI) and feature selected chapter authors from these texts. The books discussed at these sessions may be purchased at the APPI bookstore or online at www.appi.org.

CLINICAL CASE CONFERENCES
During these 90-minute sessions, clinical material is presented by videotape or the treating therapist. One or more experts then discuss the case. THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

CONTINUOUS CLINICAL CASE CONFERENCES
The presenters will review the progress of psychotherapy in two successive three-hour sessions on consecutive days (Monday–Tuesday and Wednesday–Thursday, beginning at 9:00 a.m.). Audience participation is encouraged throughout. Participants are requested to attend both sessions in their entirety. THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

COURSES
Courses are designed to emphasize learning experiences that actively involve participants and include the opportunity for informal exchange with the faculty. Offered in four-hour (full-day), six-hour (full-day), and eight-hour (full-day) sessions, courses either review basic concepts in a special subject area or present advanced material on a circumscripted topic. Participants must purchase tickets to attend.

DEBATE
Experts in the field, including psychiatrists and nonpsychiatrists, will debate a controversial topic in psychiatry. The debate format allows for members to hear both pro and con views about important, interesting and timely concerns for our members. Someone who has expertise in the topic area moderates the debate. A portion of the time is allocated for questions from the audience to the presenters with active participation by participants.

DISCUSSION GROUPS
This 90-minute format allows small groups to meet informally with selected experts in psychiatry to discuss topics chosen by the expert. Some of these are reserved for residents only. These sessions are limited to 25 participants on a first-come, first-served basis.

FOCUS LIVE
These 90-minute sessions allow participants to test their knowledge using an interactive Audience Response System (ARS), offering a new and entertaining way to learn. ARS sessions can make a group of 300 feel like they are having a small group consultation with an expert clinician. Experts, who served as guest editors of FOCUS, will lead lively multiple-choice question-based discussions, and the audience will enter their answers with hand-held devices. Results are instantly tallied and projected on the screen.

FORUMS
These are flexible presentations that afford an opportunity to highlight and select topics that are of timely interest to psychiatrists. Speakers and panel members are chosen for their expertise and leadership in the field.

LECTURES
Lectures feature a small number of distinguished speakers discussing scientific and cultural topics, many of which will extend our understanding beyond the usual limits of clinical psychiatry. The Scientific Program Committee invites the lecturers.

MASTER EDUCATOR CLINICAL CONSULTATIONS
These 90-minute, clinically-based seminars are presented by outstanding educators. Formats and subject matter will vary, but all will utilize clinical material offered by participants. These sessions are limited to 25 participants on a first-come, first-served basis. THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDICAL UPDATES
These 90-minute sessions are designed to provide psychiatrists with the latest clinical developments in other areas of medicine. Topics may range from subspecialty areas of adult or pediatric medicine (infectious disease, cardiology, gastroenterology, etc.) to new techniques or procedures in surgery or radiology. The interface between psychiatry and these areas is not necessarily emphasized. The intent is to give participants an update from a physician in a particular specialty.

NEW RESEARCH
This format allows for presentation of the very recent findings. The three types of presentations include: Posters, which are visual, self-explanatory presentations; Young Investigators’ Posters, with presentations from young investigators, residents, medical students, and research or clinical fellows; and Young Investigators’ Oral/Slide which are fifteen-minute presentations with three minutes for discussion.

RESEARCH ADVANCES IN MEDICINE
This two-hour format presents an overview of cutting-edge research in various aspects of medicine. In contrast to the Medical Update series, which is more clinically focused, this session will help participants keep pace with the rapidly expanding knowledge base and technology in various branches of medicine. Several speakers, authorities in their fields, will present on their topics.

RESEARCH CONSULTATIONS WITH
This 90-minute format provides an opportunity, in a small group setting, for participants to obtain consultations around problems in research from outstanding senior researchers. Participants should come prepared to present a specific problem in research, whether it’s one of research design, methodology, subject selection or data analysis, etc., which could be presented briefly to the consultant. These sessions are limited to 25 participants on a first-come, first-served basis.
FORMAT DESCRIPTIONS

SCIENTIFIC AND CLINICAL REPORT SESSIONS
Scientific and Clinical Reports are oral presentations of papers prepared for submission before publication. In this 90-minute format, reports are grouped by topic, with floor discussion from the audience following the presentation of each paper. There is no formal discussant.

SYMPOSIA
Symposia are three-hour sessions consisting of four to six presentations that are thematically linked and focus on a specific topic relevant to clinical psychiatry. They are designed to provide comprehensive treatment of a topic or discussion of the topic from several points of view by the participants and stimulate discussion with the audience. Some symposia are supported by industry and are designated as "Industry-Supported Symposia" in this Program Book.

WORKSHOPS
Workshops are 90-minute sessions (either Issue or Component), which typically involve brief presentations from individual panel members, followed by the opportunity for lively and informative discussion. This format provides for substantial audience participation and should be highly interactive.

Media Workshops are three-hour sessions held Monday-Thursday, in which a feature-length film is shown and discussed.
The American Psychiatric Association requires disclosure, by presenters at CME activities, of any significant financial or other affiliation with commercial organization(s) regulated by the Food and Drug Administration, which may have a direct or indirect interest in the subject matter of the scientific program. A "financial interest" may include, but is not limited to, being a shareholder in the organization; being on retainer with the organization; or having research or honoraria paid by the organization. An "affiliation" may include holding a position on an advisory committee or some other role or benefit to a supporting organization.

Under the ACCME Standards for Commercial Support that were in effect when the 2006 Annual Meeting was planned, the existence of such relationships does not necessarily constitute a conflict of interest; but the prospective audience must be informed of the presenter's affiliation with every commercial supporter by an acknowledgement in the printed program and verbal or visual disclosure to participants at the session (disclosure by slide or overhead is required if audiovisual equipment is used for the presentation). This policy is intended to openly identify any potential conflict(s) so that members of the audience in an educational activity are able to form their own judgments about the presentation. The APA also requires verbal disclosure of discussion of unlabeled uses of a commercial product or investigational use of a product not yet approved for this purpose.

The list of presenters below have indicated that either they or an immediate family member has a significant interest or other affiliation with a commercial supporter of this meeting and/or with the manufacturer(s) of a commercial product(s) and/or provider of commercial services(s). The presenter's name and the company's name are listed, along with the page number the presenter appears on in this Program Book. The nature of the presenter's relationship with the disclosed company is indicated by the following code: consultant or advisory board¹, full-time employment², research/grant support³, speakers' bureau⁴, stock or other financial options⁵, other financial or business relationships⁶. If a number has not been assigned, the presenter has not disclosed the relationship to the company.

The second list of presenters, beginning on page XXXVI, have indicated neither they nor an immediate family member has any significant relationship to disclose. Voting member of the Board of Trustees, Assembly officers, and member of the Scientific Program Committee cannot receive honoraria or travel reimbursement for participating in Industry-Supported Symposia.

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gene G. Abel, M.D.</td>
<td>Abel Screening, Inc.⁶</td>
</tr>
<tr>
<td>Anissa Abi-Dargham, M.D.</td>
<td>Bristol-Myers Squibb Company⁴⁶; Eli Lilly and Company⁴⁶; Lieber Center for Schizophrenia⁴⁶; National Institute of Alcohol Abuse and Alcoholism⁴⁶; National Institute of Mental Health⁴⁶; Otsuka America Pharmaceutical, Inc.⁴⁶; Sanofi-Aventis⁴⁶</td>
</tr>
<tr>
<td>Jean Addington, Ph.D.</td>
<td>Eli Lilly and Company⁴⁶; Janssen Pharmaceutica Products, LP³; Pfizer Inc.¹; PharmaStar, LLC¹</td>
</tr>
<tr>
<td>Lawrence W. Adler, M.D.</td>
<td>GlaxoSmithKline¹³</td>
</tr>
<tr>
<td>David E. Adson, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP³⁴; Bristol-Myers Squibb Company³⁴⁴; Cyberonics, Inc.¹⁴; Eli Lilly and Company³⁴⁴; Forest Laboratories, Inc.²⁴; GlaxoSmithKline¹⁴⁴; Pfizer Inc.³⁴⁴</td>
</tr>
<tr>
<td>Hagop S. Akiskal, M.D.</td>
<td>Abbott Laboratories, Inc.⁴; AstraZeneca Pharmaceuticals LP³⁴; Bristol-Myers Squibb Company³⁴⁴; Eli Lilly and Company³⁴⁴; GlaxoSmithKline¹³⁴; Sanofi-Aventis³⁴⁴</td>
</tr>
<tr>
<td>Jonathan E. Alpert, M.D.</td>
<td>Aspect Medical Systems¹; Eli Lilly and Company³; Forest Laboratories, Inc.²; Organon Pharmaceuticals Inc.³⁴; Pfizer Inc.³; Pharmavite LLC³⁴</td>
</tr>
<tr>
<td>Sonia Ancoli-Israel</td>
<td>Acadia Pharmaceuticals Inc.; Cephalon Inc.¹⁴; King Pharmaceuticals, Inc.¹⁴; Merck &amp; Co., Inc.; Neurocrine Biosciences Inc.¹³⁴; Neurogen¹; Pfizer Inc.¹⁴; Sanofi-Aventis¹³⁰; Sepharco, Inc.¹³; Somaxon Pharmaceuticals¹³; Takeda Pharmaceuticals North America, Inc.¹³⁴</td>
</tr>
<tr>
<td>Allan A. Anderson, M.D.</td>
<td>Forest Laboratories, Inc.⁴; Pfizer Inc.⁵⁵</td>
</tr>
<tr>
<td>Nancy C. Andreassen, M.D.</td>
<td>Janssen Pharmaceutica Products, LP⁴; Pfizer Inc.¹</td>
</tr>
<tr>
<td>Terrance H. Andree, Ph.D.</td>
<td>Wyeth Pharmaceuticals²</td>
</tr>
<tr>
<td>David B. Arciniegas, M.D.</td>
<td>Avanir Pharmaceuticals¹; Eisai Inc.²; Forest Laboratories, Inc.³</td>
</tr>
<tr>
<td>Lesley M. Arnold, M.D.</td>
<td>Boehringer-Ingelheim Pharmaceuticals GmbH; Cypress Bioscience Inc.¹¹; Eli Lilly and Company⁴³⁴; Forest Laboratories, Inc.; Pfizer Inc.¹³⁴; Sanofi-Synthelabo¹³; Sepracor, Inc.¹³; Wyeth Pharmaceuticals¹³⁴</td>
</tr>
<tr>
<td>Amy Arnsten, Ph.D.</td>
<td>Shire Pharmaceuticals Group plc.³⁶</td>
</tr>
<tr>
<td>George Awad</td>
<td>AstraZeneca Pharmaceuticals LP³⁴; Eli Lilly and Company³⁴⁴; Janssen Pharmaceutica Products, LP³⁴; Johnson and Johnson Pharmaceutical Research and Development¹; Pfizer Inc.¹</td>
</tr>
<tr>
<td>Jerold Bain, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP³⁴; Eli Lilly and Company³⁴⁴; Organon Pharmaceuticals Inc.³⁴; Pfizer Inc.⁴; Solvay Pharmaceuticals¹³⁴</td>
</tr>
<tr>
<td>F. M. Baker, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP³⁴; Pfizer Inc.³</td>
</tr>
<tr>
<td>Claudia F. Baldassano, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP³⁴; Elan Pharmaceuticals, Inc.; GlaxoSmithKline; Pfizer Inc.³⁴</td>
</tr>
<tr>
<td>Ross J. Baldessarini, M.D.</td>
<td>Eli Lilly and Company⁴; Janssen Pharmaceutica Products, LP¹³</td>
</tr>
<tr>
<td>Nigel Bark, M.D.</td>
<td>Bristol-Myers Squibb Company; Pfizer Inc.³⁴⁴</td>
</tr>
<tr>
<td>David Baron, D.O.</td>
<td>Bristol-Myers Squibb Company³⁴; Eli Lilly and Company³⁴⁴; Janssen Pharmaceutica Products, LP³⁴; Shire Pharmaceuticals Group plc.¹³⁴</td>
</tr>
<tr>
<td>Steven L. Batki, M.D.</td>
<td>GlaxoSmithKline; National Institute of Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; Novartis Pharmaceuticals Corporation; Ortho-McNeil Pharmaceutical, Inc.¹; Pfizer Inc.³⁴</td>
</tr>
<tr>
<td>XX</td>
<td></td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Elizabeth A. Baxter, M.D.</td>
<td>Pfizer Inc.4</td>
</tr>
<tr>
<td>Philip M. Becker, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Boehringer-Ingelheim Pharmaceuticals GmbH; Cephalon Inc; GlaxoSmithKline; Orphan Medical; Sanofi-Aventis; Takeda Pharmaceuticals North America, Inc.; Xenoprot, Inc.3</td>
</tr>
<tr>
<td>Julian Beezhold, M.B.</td>
<td>AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; Janssen-Flag; Lundbeck Pharmaceuticals; Pfizer Inc.6</td>
</tr>
<tr>
<td>Bernard D. Beitzman, M.D.</td>
<td>Bristol-Myers Squibb Company4</td>
</tr>
<tr>
<td>Gregory Beldenky, M.D.</td>
<td>Boeing Corporation1</td>
</tr>
<tr>
<td>John L. Beyer, M.D.</td>
<td>Avaris Pharmaceuticals; Boehringer-Ingelheim Pharmaceuticals GmbH; Bristol-Myers Squibb Company; Eisai Inc; Eli Lilly and Company4; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; Myriad Genetics, Inc; National Alliance for Research in Schizophrenia and Depression; National Institute of Mental Health; Ono Pharmaceuticals, Inc; Sanofi-Aventis; Sanofi-Synthelabo3</td>
</tr>
<tr>
<td>Joseph Biederman, M.D.</td>
<td>Abbott Laboratories, Inc; Bristol-Myers Squibb Company; Cephalon Inc; Eli Lilly and Company; Janssen Pharmaceutica Products, LP; McNeil Consumer Healthcare; McNeil Pharmaceuticals; National Institute of Child Health and Human Development; National Institute of Mental Health; National Institute on Drug Abuse; New River Pharmaceuticals; NIH Institute; NIMH; Novartis Pharmaceuticals Corporation; NRP; Pfizer Inc; Shire Laboratories Inc; Shire Laboratories; Shire Pharmaceuticals Group plc; Stanley Foundation; Stanley-Medical Research Institute; UCB Pharmaceuticals4</td>
</tr>
<tr>
<td>Robert M. Bikker, Ph.D.</td>
<td>Acadia Pharmaceuticals Inc; AstraZeneca Pharmaceuticals LP; Janssen Pharmaceutica Products, LP; Pfizer Inc.1</td>
</tr>
<tr>
<td>Adam M. Bisaga</td>
<td>Forest Laboratories, Inc4</td>
</tr>
<tr>
<td>Donald W. Black, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Forest Laboratories, Inc; GlaxoSmithKline; Shire Pharmaceuticals Group plc14</td>
</tr>
<tr>
<td>Carlos Blanco-Jerez M.D.</td>
<td>Pfizer Inc; Somaxon Pharmaceuticals3</td>
</tr>
<tr>
<td>Dan G. Blazer II, M.D.</td>
<td>National Institute of Mental Health3</td>
</tr>
<tr>
<td>Michael Blumenfield, M.D.</td>
<td>Forest Laboratories, Inc; Gerson Lehrman Group; GlaxoSmithKline; Pfizer Inc3</td>
</tr>
<tr>
<td>Samuel W. Boeliner, M.D.</td>
<td>Cephalon Inc1; Wyeth Pharmaceuticals1</td>
</tr>
<tr>
<td>John J. Boronow, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Janssen Pharmaceutica Products, LP; Pfizer Inc2; Stanley-Medical Research Institute3</td>
</tr>
<tr>
<td>Jeff Q. Bostic, M.D.</td>
<td>Abbott Laboratories, Inc; Eli Lilly and Company; Forest Laboratories, Inc; GlaxoSmithKline; Pfizer Inc3</td>
</tr>
<tr>
<td>Guylain Bouchard, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; GlaxoSmithKline; Organon Pharmaceuticals Inc; Wyeth Pharmaceuticals1</td>
</tr>
<tr>
<td>Charles L. Bowden, M.D.</td>
<td>Abbott Laboratories, Inc; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Elan Pharmaceuticals, Inc; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; National Institute of Mental Health; Pfizer Inc; Robert Wood Johnson Foundation; Sanofi-Synthelabo; Stanley-Medical Research Institute; UCB Pharmaceuticals</td>
</tr>
<tr>
<td>Richard Bowskill</td>
<td>AstraZeneca Pharmaceuticals LP; Eli Lilly and Company4</td>
</tr>
<tr>
<td>Dianne Bradford, M.D.</td>
<td>GlaxoSmithKline1</td>
</tr>
<tr>
<td>John M. Bradford, M.D.</td>
<td>Canadian Institutes of Health Research; Eli Lilly and Company4</td>
</tr>
<tr>
<td>Kathleen T. Brady, M.D.</td>
<td>Abbott Laboratories, Inc; Bristol-Myers Squibb Company; Cephalon Inc; Eli Lilly and Company; GlaxoSmithKline; Ovation Pharmaceuticals, Inc14; Pfizer Inc; Wyeth Pharmaceuticals3</td>
</tr>
<tr>
<td>E. Sherwood Brown, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Forest Laboratories, Inc; GlaxoSmithKline; Pfizer Inc; UCB Pharmaceuticals3</td>
</tr>
<tr>
<td>Thomas E. Brown, Ph.D.</td>
<td>American Psychiatric Publishing, Inc4; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; McNeil Consumer Healthcare; Novartis Pharmaceuticals Corporation; Shire Pharmaceuticals Group plc1</td>
</tr>
<tr>
<td>Peter F. Buckley, M.D.</td>
<td>Abbott Laboratories, Inc; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Janssen Pharmaceutica Products, LP; Pfizer Inc; Pharmaceutical Product Development, Inc3</td>
</tr>
<tr>
<td>Ronald M. Burd, M.D.</td>
<td>Blue Cross Blue Shield Association1</td>
</tr>
<tr>
<td>George Bush, M.D.</td>
<td>Janssen Pharmaceutica Products, LP; Johnson and Johnson Pharmaceutical Research and Development; McNeil Consumer Healthcare; Pfizer Inc; Shire Pharmaceuticals Group plc1</td>
</tr>
<tr>
<td>Marian L. Butterfield, M.D.</td>
<td>Bristol-Myers Squibb Company3</td>
</tr>
<tr>
<td>Daniel J. Buyse, M.D.</td>
<td>Eli Lilly and Company; GlaxoSmithKline; Merck &amp; Co., Inc; Pfizer Inc; Sanofi-Aventis; Sepracor, Inc; Takeda Pharmaceuticals North America, Inc13</td>
</tr>
<tr>
<td>Joseph R. Callabrese, M.D.</td>
<td>Abbott Laboratories, Inc; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; Merck &amp; Co., Inc; National Alliance for Research in Schizophrenia and Depression; National Institute of Mental Health; Novartis Pharmaceuticals Corporation; Parke-Davis; Pfizer Inc; Robert Wood Johnson Foundation; Shire Pharmaceuticals Group plc; Stanley Foundation; TAP Pharmaceuticals Product, Inc; Teva Pharmaceutical Industries Ltd; UCB Pharmaceuticals; Wyeth Pharmaceuticals3</td>
</tr>
<tr>
<td>William E. Callahan, Jr., M.D.</td>
<td>Bristol-Myers Squibb Company4; Otsuka America Pharmaceutical, Inc14</td>
</tr>
<tr>
<td>William H. Campbell, M.D.</td>
<td>Pfizer Inc4</td>
</tr>
</tbody>
</table>

XXI
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pedro L. Delgado, M.D.</td>
<td>Boehringer-Ingelheim Pharmaceuticals GmbH; Bristol-Myers Squibb Company; Corcept Therapeutics; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; National Institute of Health; National Institute of Mental Health; Pfizer Inc.; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Nicholas Dematinis, M.D.</td>
<td>Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Mark Demitrack, M.D.</td>
<td>Eli Lilly and Company; NeuroNect Inc.; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Mantosh J. Dewan, M.D.</td>
<td>Eli Lilly and Company</td>
</tr>
<tr>
<td>Nakshet A. Dewan, M.D.</td>
<td>Collaborate on Projects with Gold Standard</td>
</tr>
<tr>
<td>P. Murali Doraiswamy, M.D.</td>
<td>Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen Pharmaceutical Products, LP; Myriad Genetics, Inc.; National Institute of Mental Health; Pfizer Inc.; Saegis</td>
</tr>
<tr>
<td>Martin Dossenbach</td>
<td>Eli Lilly and Company</td>
</tr>
<tr>
<td>Robert Drake, Ph.D.</td>
<td>Janssen Pharmaceutical Products, LP; Johnson and Johnson Pharmaceutical Research and Development</td>
</tr>
<tr>
<td>Roxanne Dryden-Edwards, M.D.</td>
<td>Eli Lilly and Company</td>
</tr>
<tr>
<td>Sanjay Dube, M.D.</td>
<td>Eli Lilly and Company</td>
</tr>
<tr>
<td>Hector J. Duenas, M.D.</td>
<td>Eli Lilly and Company</td>
</tr>
<tr>
<td>Boadie W. Dunlop, M.D.</td>
<td>Cephalon; Forest Laboratories, Inc.; Janssen Pharmaceutical Products, LP; Novartis Pharmaceuticals Corporation; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>David L. Dunner, M.D.</td>
<td>Bristol-Myers Squibb Company; Corcept Therapeutics; Cyberonics, Inc.; Cypress Bioscience Inc.; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen Pharmaceutical Products, LP; Novartis Pharmaceuticals Corporation; Organon Pharmaceutical Inc.; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.; Sanofi-Aventis; Shire Pharmaceuticals Group plc.; SomerSET Pharmaceuticals Inc.; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Esther Eisenberg, M.D.</td>
<td>Merck &amp; Co., Inc.</td>
</tr>
<tr>
<td>James M. Ellison, M.D.</td>
<td>Bristol-Myers Squibb Company; Forest Laboratories, Inc.; GlaxoSmithKline; Pfizer Inc.; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Larry Ereshefsky, Pharm.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Celgene Corporation; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen Pharmaceutical Products, LP; Johnson and Johnson Pharmaceutical Research and Development; Merck &amp; Co., Inc.; Ono Pharmaceuticals, Inc.; Organon Pharmaceuticals Inc.; Pfizer Inc.; Quintiles Transnational Corp.; Sanofi-Aventis; Sepracor, Inc.; Solvay Pharmaceuticals, Inc.; Somaxon Pharmaceuticals; Sumitomo Pharmaceuticals Co., Ltd.; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Milton Ernan, M.D.</td>
<td>Cephalon Inc.</td>
</tr>
<tr>
<td>Javier I. Escobar, M.D.</td>
<td>American Association of Geriatric Psychiatry; Bristol-Myers Squibb Company; Eli Lilly and Company; Johnson and Johnson Pharmaceutical Research and Development; National Institute of Mental Health; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Randall T. Espinoza, M.D.</td>
<td>Janssen Medical Affairs, LLC</td>
</tr>
<tr>
<td>Raymond A. Faber, M.D.</td>
<td>Bristol-Myers Squibb Company; Forest Laboratories, Inc.; Pfizer Inc.</td>
</tr>
<tr>
<td>Waranchal E. Faison, M.D.</td>
<td>Bristol-Myers Squibb Company; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen Pharmaceutical Products; LP; National Institute on Aging; Organon Pharmaceuticals Inc.; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.</td>
</tr>
<tr>
<td>Alexander H. Fan, M.D.</td>
<td>Bristol-Myers Squibb Company; Pfizer Inc.; Shire Pharmaceuticals Group plc.; Stanley Medical Research Institute</td>
</tr>
<tr>
<td>Stephen V. Farame, Ph.D.</td>
<td>Eli Lilly and Company; McNeil Consumer Healthcare; Novartis Pharmaceuticals Corporation; Shire Pharmaceuticals Group plc.</td>
</tr>
<tr>
<td>Maurizio Fava, M.D.</td>
<td>Abbott Laboratories, Inc.; Aspect Medical Systems; AstraZeneca Pharmaceuticals LP; Bayer Corporation, Pharmaceutical Division; Biovail Corporation; Brain Cells; Bristol-Myers Squibb Company; Cephalon Inc.; Compellis; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; H. Lundbeck A/S; Janssen Pharmaceutical Products; LP; Johnson and Johnson Pharmaceutical Research and Development; Lichtwer Pharma GmbH; Loxir; Novartis Pharmaceuticals Corporation; Organon Pharmaceuticals Inc.; Parke-Davis; Pfizer Inc.; Pharmacia &amp; Upjohn; Pharmavite LLC; Roche; Sanofi-Synthelabo; Sepracor, Inc.; Solvay Pharmaceuticals, Inc.; SomerSET Pharmaceuticals Inc.; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Howard Feldman, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Eisai Inc.; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen Pharmaceutical Products; Lundbeck Pharmaceuticals; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Sanofi-Synthelabo; Servier; Targacept, Inc.</td>
</tr>
<tr>
<td>Stephen J. Ferrando, M.D.</td>
<td>Bristol-Myers Squibb Company; Cephalon Inc.; Forest Laboratories, Inc.; National Institute of Health; Pfizer Inc.</td>
</tr>
<tr>
<td>Marie Josee Filteau, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Biovail Corporation; Eli Lilly and Company; GlaxoSmithKline; H. Lundbeck A/S; Janssen Pharmaceutical Products, LP; Merck &amp; Co., Inc.; Shire Pharmaceuticals Group plc.; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Robert L. Findling, M.D.</td>
<td>Abbott Laboratories, Inc.; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Johnson and Johnson Pharmaceutical Research and Development; Novartis Pharmaceuticals Corporation; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.; Sanofi-Synthelabo; Shire Pharmaceuticals Group plc.; Solvay Pharmaceuticals, Inc.; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Naomi A. Fineberg, M.A.</td>
<td>AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Cephalon Inc.; H. Lundbeck A/S; Janssen Pharmaceutical Products, LP</td>
</tr>
<tr>
<td>Mary Jo Fitz-Gerald, M.D.</td>
<td>Cephalon Inc.</td>
</tr>
</tbody>
</table>
DISCLOSURE INDEX

**Presenter** | **Manufacturer(s)**
--- | ---
Edna B. Foa, Ph.D. | American Psychiatric Association; Bristol-Myers Squibb Company; Cephalon Inc.; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; National Institute of Alcohol Abuse and Alcoholism; National Institute of Mental Health; Pfizer Inc.; Solvay Pharmaceuticals, Inc.

Peter Fonagy, M.D. | Borderline Personality Disorder Research Foundation; Community Fund; Diana, Princess of Wales Memorial Fund; FHLM Foundation; National Institute for Clinical Excellence

Brent P. Forester, M.D. | Abbott Laboratories, Inc.; AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; Janssen Pharmaceuticals Products, LP; National Alliance for Research in Schizophrenia and Depression; Novartis Pharmaceuticals Corporation; Pfizer Inc.

Richard J. Frances, M.D. | Amgen, Inc.; Forest Laboratories, Inc.

Ellen Frank, Ph.D. | Eli Lilly and Company; Forest Laboratories, Inc.; National Institute of Mental Health; Pfizer Inc.; Pittsburgh Foundation; Servier

W. Gordon Franklin, M.D. | Bristol-Myers Squibb Company; Ono Pharmaceuticals, Inc.; Pfizer Inc.

Marlene P. Freeman, M.D. | AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; Forest Laboratories, Inc.; National Institute of Mental Health; Pfizer Inc.; Pronova Biocare; U.S. Food and Drug Administration

Frederick J. Fresc, Ph.D. | AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Janssen Pharmaceuticals Products, LP; National Institute of Mental Health; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Stanley Medical Research Institute

Joseph Friedman, M.D. | Eli Lilly and Company

Wolfgang Gaebel, Prof. Dr. | Janssen Pharmaceuticals Products, LP; Wyeth Pharmaceuticals

Joseph M. Garbely, D.O. | AstraZeneca Pharmaceuticals LP; Janssen Pharmaceuticals Products, LP; Pfizer Inc.

Susan Shur-Feng Gau, M.D. | Eli Lilly and Company; Janssen Pharmaceuticals Products, LP

Alan J. Gelenberg, M.D. | AstraZeneca Pharmaceuticals LP; Best Practice; Cyberonics, Inc.; Eli Lilly and Company; Pfizer Inc.; Roche; Vela Pharmaceuticals, Inc.; Wyeth Pharmaceuticals

Barbara Geller, M.D. | Abbott Laboratories, Inc.

Mark S. George, M.D. | Advanced Neuromodulation Systems, Inc.; Aventis Pharmaceuticals, Inc.; Cephas Corporation; Cortec Pharmaceuticals, Inc.; Cyberonics, Inc.; Dana Foundation; GlaxoSmithKline; Jazz Pharmaceuticals, Inc.; Medtronic, Inc.; National Alliance for Research in Schizophrenia and Depression; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke; Neuretics, Inc.; NeuroPace, Inc.; Stanley Foundation; Stanley Medical Research Institute; U.S. Department of Defense

Tony P. George, M.D. | National Alliance for Research in Schizophrenia and Depression; National Institute on Drug Abuse; Tarceva, Inc.

S. Nassir Ghaemi, M.D. | Abbott Laboratories, Inc.; Bristol-Myers Squibb Company; Eisai Inc.; GlaxoSmithKline; Janssen Pharmaceuticals Products, LP; Novartis Pharmaceuticals Corporation; Pfizer Inc.

Martin Gignac, M.D. | Eli Lilly and Company; Janssen Pharmaceuticals Products, LP; Shire Pharmaceuticals Group plc

Rachel L. Glick, M.D. | Eli Lilly and Company; Janssen Pharmaceuticals Products, LP; Pfizer Inc.

Donald C. Goff, M.D. | Bristol-Myers Squibb Company; Cephalon Inc.; Cortex Pharmaceuticals, Inc.; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceuticals Products, LP; Pfizer Inc.

Stephen M. Goldfinger, M.D. | AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; GlaxoSmithKline; Ivax Corporation; Janssen Pharmaceuticals Products, LP; National Foundation for Mental Health; Oska America Pharmaceutical, Inc.; Pfizer Inc.; Teva Pharmaceutical Industries Ltd.; Vanda Pharmaceuticals Inc.

Morris B. Goldman, M.D. | Bristol-Myers Squibb Company; Eli Lilly and Company; National Alliance for Research in Schizophrenia and Depression; National Institute of Health; Novartis Pharmaceuticals Corporation; Oska America Pharmaceutical, Inc.; Pfizer Inc.

Marion Zucker Goldstein, M.D. | GlaxoSmithKline

Wayne K. Goodman, M.D. | Bristol-Myers Squibb Company; Cyberonics, Inc.; Forest Laboratories, Inc.; Janssen Pharmaceuticals Products, LP

Frederick K. Goodwin, M.D. | Abbott Laboratories, Inc.; Bristol-Myers Squibb Company; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals Products, LP; Novartis Pharmaceuticals Corporation; Pfizer Inc.

Ken Graup, M.Ed. | Virtually Better

Tana A. Grady-Welisky, M.D. | Bristol-Myers Squibb Company; Eli Lilly and Company; GlaxoSmithKline; Pfizer Inc.

Jon E. Grant, M.D. | Somaxon Pharmaceuticals

Michael C. Graves, M.D. | Amgen, Inc.; Genentech; Guillain-Barre Support Group International; National Institute of Health; Sanofi-Aventis

Kevin F. Gray, M.D. | Eli Lilly and Company; Forest Laboratories, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.

Michael Green, M.D. | Abbott Laboratories, Inc.; AstraZeneca Pharmaceuticals LP; Pfizer Inc.; Wyeth Pharmaceuticals

Benjamin D. Greenberg, M.D. | Dana Foundation; Forest Laboratories, Inc.; Medtronic, Inc.; National Alliance for Research in Schizophrenia and Depression; National Institute of Mental Health; Pfizer Inc.

Lawrence S. Gross, M.D. | Aspect Medical Systems; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Janssen Pharmaceuticals Products, LP; National Institute of Mental Health; Organon Pharmaceuticals Inc.; Solvay Pharmaceuticals, Inc.

George T. Grossberg, M.D. | Abbott Laboratories, Inc.; Alzheimer Association; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals Products, LP; Novartis Pharmaceuticals Corporation

Ellen Haller, M.D. | Forest Laboratories, Inc.; GlaxoSmithKline; Pfizer Inc.; Wyeth Pharmaceuticals
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basil D. Halliday, M.S.C.</td>
<td>GlaxoSmithKline; Otsuka America Pharmaceutical, Inc.</td>
</tr>
<tr>
<td>Thomas E. Hansen, M.D.</td>
<td>Bristol-Myers Squibb Company; Eli Lilly and Company; Janssen Pharmaceutica Products, LP; Pfizer Inc.</td>
</tr>
<tr>
<td>Philip D. Harvey, Ph.D.</td>
<td>Abbott Laboratories, Inc.; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Janssen Pharmaceutica Products, LP; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Sanofi-Aventis; Solvay Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>Peter Hauser, M.D.</td>
<td>Abbott Laboratories, Inc.; AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; Roche.</td>
</tr>
<tr>
<td>David C. Henderson, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Janssen Pharmaceutica Products, LP; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.</td>
</tr>
<tr>
<td>Alan R. Hirsch, M.D.</td>
<td>Abbott Laboratories, Inc.; Eli Lilly and Company; GlaxoSmithKline; Johnson and Johnson Pharmaceutical Research and Development; Parke-Davis; Pharma &amp; Upjohn; Proctor &amp; Gamble Company</td>
</tr>
<tr>
<td>Robert A. Hirschfeld, M.D.</td>
<td>Abbott Laboratories, Inc.; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; Novartis Pharmaceuticals Corporation; Organon Pharmaceuticals Inc; Pfizer Inc.; Shire Pharmaceuticals Group plc; UCB Pharmaceuticals; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Steven K. Hoge, M.D.</td>
<td>Life-Pool, LLC</td>
</tr>
<tr>
<td>Eric Hollander, M.D.</td>
<td>Abbott Laboratories, Inc.; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke; Ortho-McNeil Pharmaceutical, Inc.; Pfizer Inc.; Somaxon Pharmaceuticals; UCB Pharmaceuticals; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Rob Horne</td>
<td>AstraZeneca Pharmaceuticals LP; Eli Lilly and Company</td>
</tr>
<tr>
<td>Robert H. Howland, M.D.</td>
<td>Cyberonics, Inc.</td>
</tr>
<tr>
<td>William Huang, M.D.</td>
<td>Bristol-Myers Squibb Company</td>
</tr>
<tr>
<td>James J. Hudziak, M.D.</td>
<td>GlaxoSmithKline; Pfizer Inc.</td>
</tr>
<tr>
<td>Steven Hull, M.D.</td>
<td>Cephalon Inc.</td>
</tr>
<tr>
<td>Mustafa Hussain</td>
<td>AstraZeneca Pharmaceuticals LP; Cyberonics, Inc.; Forest Laboratories, Inc.; Janssen Pharmaceutica Products, LP; National Institute of Mental Health; Neurotis, Inc.; Novartis Pharmaceuticals Corporation</td>
</tr>
<tr>
<td>Michael Y. Hwang, M.D.</td>
<td>Janssen Pharmaceutica Products, LP; Pfizer Inc.</td>
</tr>
<tr>
<td>Steven E. Hyman</td>
<td>Merck &amp; Co., Inc.; National Institute of Mental Health; Novartis Pharmaceuticals Corporation</td>
</tr>
<tr>
<td>Dan V. Iosifescu, M.D.</td>
<td>Aspect Medical Systems; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; National Alliance for Research in Schizophrenia and Depression; National Institute of Mental Health; Pfizer Inc.</td>
</tr>
<tr>
<td>Wagshl W. Ishak, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Janssen Pharmaceutica Products, LP</td>
</tr>
<tr>
<td>M. Saleem Ismail, M.D.</td>
<td>Eisai Inc.; Forest Laboratories, Inc.; Janssen Pharmaceutica Products, LP; National Institute of Mental Health; NIA; Pfizer Inc.</td>
</tr>
<tr>
<td>Shalay Jain, M.D.</td>
<td>UT Southwestern Medical Center at Dallas</td>
</tr>
<tr>
<td>Philip G. Janick, M.D.</td>
<td>Abbott Laboratories, Inc.; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Janssen Pharmaceutica Products, LP; Neurontis, Inc.; Pfizer Inc.; Sanofi-Synthelabo; Shire Pharmaceuticals Group plc.</td>
</tr>
<tr>
<td>Daniel C. Javitt, M.D.</td>
<td>Janssen Pharmaceutica Products, LP; Medicaments, LLC; National Institute of Mental Health; National Institute on Drug Abuse; NPS Pharmaceuticals; Organon Pharmaceuticals Inc; Prestwick Pharmaceuticals, Inc; Stanley Medical Research Institute</td>
</tr>
<tr>
<td>Geetha Jayaram, M.D.</td>
<td>Cephalon Inc.; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Dilip V. Jeste, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Janssen Medical Affairs, LLC; Janssen Pharmaceutica Products, LP; Solvay Pharmaceuticals, Inc; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Peter B. Jones, M.D.</td>
<td>Bristol-Myers Squibb Company; Eli Lilly and Company; Janssen Pharmaceutica Products, LP</td>
</tr>
<tr>
<td>Rimma F. Kaddurab-Dauk, Ph.D.</td>
<td>Metabolon Inc.</td>
</tr>
<tr>
<td>Rémi S. Kahn, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; Pfizer Inc.</td>
</tr>
<tr>
<td>Ned H. Kalin, M.D.</td>
<td>Angen, Inc.; Bristol-Myers Squibb Company; Concept Therapeutics; Cypress Biosciences Inc.; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; National Institute of Mental Health; Neurocrine Biosciences; Neurontis, Inc.; Pfizer Inc.; Promoter Neurosciences, LLC; Sanley Foundation; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>John M. Kane, M.D.</td>
<td>Bristol-Myers Squibb Company; Eli Lilly and Company; Johnson and Johnson Pharmaceutical Research and Development; MDS Pharma; Pfizer Inc.; Solvay Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>Shatij Kapur, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; EMD Biosciences, Inc.; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; Neuroromolecular Inc.; Pfizer Inc.; Solvay Pharmaceuticals, Inc; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Wayne J. Katon, M.D.</td>
<td>Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Pfizer Inc.; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Cornelius Katanza, M.D.</td>
<td>Eli Lilly and Company; H. Lundbeck A/S; Shire Pharmaceuticals Group plc</td>
</tr>
<tr>
<td>Nathaniel P. Katz, M.D.</td>
<td>Abbott Laboratories, Inc.; Allergan Inc.; Biocorporation; Cephalon Inc.; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; Ligand Pharmaceuticals; Pfizer Inc.; Purdue Pharma LP; Wyeth Pharmaceuticals</td>
</tr>
</tbody>
</table>

XXV
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Helen Lavretsky, M.D.</td>
<td>Eisai Inc., 4; Forest Laboratories, Inc., 3, 4; JanssenPharmaceutica Products, LP; National Institute of Mental Health; Pfizer Inc., 4</td>
</tr>
<tr>
<td>William B. Lawson, M.D.</td>
<td>Abbott Laboratories, Inc., 3, 4; Bristol-Myers Squibb Company, 4; Pfizer Inc., 3, 4; Shire Pharmaceuticals Group plc, 3, 4</td>
</tr>
<tr>
<td>Arthur L. Lazarus, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP5, 35</td>
</tr>
<tr>
<td>Gerard A. Leblanc, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP1; Biovail Corporation; Canadian Network for Mood and Anxiety Treatments; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; Prestwick Pharmaceuticals, Inc.; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>James F. Leckman</td>
<td>National Institute of Mental Health</td>
</tr>
<tr>
<td>Matthias K. Lee, M.D.</td>
<td>Pfizer Inc., 3; Sanofi-Aventis, 4</td>
</tr>
<tr>
<td>Eric J. Lenze, M.D.</td>
<td>Forest Laboratories, Inc., 3; Johnson and Johnson Pharmaceutical Research and Development; Pfizer Inc., 3</td>
</tr>
<tr>
<td>Alan I. Levinson, M.D.</td>
<td>Addex Pharmaceuticals, 6</td>
</tr>
<tr>
<td>Frances R. Levin, M.D.</td>
<td>Eli Lilly and Company; Ortho-McNeil Pharmaceutical, Inc., 3; UCB Pharmaceuticals, 1, 3</td>
</tr>
<tr>
<td>Petros Levounis, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP4; Forest Laboratories, Inc., 3; Reckitt Benckiser plc, 1, 4</td>
</tr>
<tr>
<td>Roberto Lewis-Fernandez, M.D.</td>
<td>GlaxoSmithKline, 1; Pfizer Inc., 3</td>
</tr>
<tr>
<td>Jeffrey A. Lieberman, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP, 1, 3; Bristol-Myers Squibb Company, 1, 3; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; Johnson and Johnson Pharmaceutical Research and Development; Novartis Pharmaceuticals Corporation; Organon Pharmaceuticals Inc.; Pfizer Inc., 1, 3; Repligen Corporation; Sanofi-Synthelabo; Solvay Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>Susan J. Lieff, M.D.</td>
<td>Eli Lilly and Company, 6</td>
</tr>
<tr>
<td>Russell F. Lim, M.D.</td>
<td>Abbott Laboratories, Inc., 3; Cephalon Inc., 1</td>
</tr>
<tr>
<td>Jean-Pierre Lindemann, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Eli Lilly and Company, 9</td>
</tr>
<tr>
<td>Sarah H.H. Lisanby, M.D.</td>
<td>American Federation for Aging Research; Cyberonics, Inc., 3, 4; National Alliance for Research in Schizophrenia and Depression; National Institute of Mental Health; Neurontics, Inc., 3; Stanley Medical Research Institute, 3</td>
</tr>
<tr>
<td>Shari Lustkin, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP1; GlaxoSmithKline; Wyeth Pharmaceuticals, 4</td>
</tr>
<tr>
<td>Constantine Lyketsos, M.D.</td>
<td>Eisai Inc., 1, 2; Eli Lilly and Company; Forest Laboratories, Inc., 1, 2; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer Inc., 3</td>
</tr>
<tr>
<td>Avram H. Mack, M.D.</td>
<td>Forest Laboratories, Inc., 1, 4</td>
</tr>
<tr>
<td>Glenda M. MacQueen</td>
<td>AstraZeneca Pharmaceuticals LP5; Biovail Corporation; Canadian Institutes of Health Research; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; National Institute of Mental Health; Novartis Pharmaceuticals Corporation; Oryx Pharmaceuticals, Inc.; Stanley Medical Research Institute; Wyeth Pharmaceuticals, 4</td>
</tr>
<tr>
<td>Bertha K. Madras, Ph.D.</td>
<td>Boston Life Sciences, Inc., 5</td>
</tr>
<tr>
<td>Anil K. Malhotra, M.D.</td>
<td>Eli Lilly and Company; Pfizer Inc., 3, 4</td>
</tr>
<tr>
<td>Donald A. Malone, Jr., M.D.</td>
<td>Bristol-Myers Squibb Company, 4; Eli Lilly and Company, 4; Forest Laboratories, Inc., 4; GlaxoSmithKline; Medtronic, Inc., 1; 3; Pfizer Inc., 4</td>
</tr>
<tr>
<td>Catherine Mancini, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Cephalon Inc.; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; Novartis Pharmaceuticals Corporation; Pfizer Inc., 3</td>
</tr>
<tr>
<td>G. Kent Mangelson, B.S.</td>
<td>National Medical Foundation, 4</td>
</tr>
<tr>
<td>Karl F. Mann, M.D.</td>
<td>Sanofi-Synthelabo, 1</td>
</tr>
<tr>
<td>Theo C. Manschreck, M.D.</td>
<td>Pfizer Inc., 4</td>
</tr>
<tr>
<td>Lauren B. Maraungell, M.D.</td>
<td>Bristol-Myers Squibb Company; Cyberonics, Inc., 1, 3; Eli Lilly and Company; Forest Laboratories, Inc., 4; GlaxoSmithKline; Medtronic, Inc., 1; 3; Neurontics, Inc., 3; Pfizer Inc., 3; Stanley Foundation, 3</td>
</tr>
<tr>
<td>Stephen R. Marder, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP1; Bristol-Myers Squibb Company; H. Lundbeck A/S; Merck &amp; Co., Inc.; National Institute of Mental Health; Organon Pharmaceuticals Inc.; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.; Solvay Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>Humberto Marin, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP1; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; National Institute of Neurological Disorders and Stroke; Pfizer Inc.; Sanofi-Aventis; Seprocin, Inc.; Takeda Pharmaceuticals North America, Inc.</td>
</tr>
<tr>
<td>James M. Martinez, M.D.</td>
<td>Abbott Laboratories, Inc.; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Cyberonics, Inc., 1, 3; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; National Institute of Health; Neurontics, Inc.; Organon Pharmaceuticals Inc.; Pfizer Inc.; Sanofi-Aventis; Stanley Foundation; UCB Pharmaceuticals, Inc; Wyeth Pharmaceuticals, 4</td>
</tr>
<tr>
<td>Christine E. Marx, M.D.</td>
<td>Eli Lilly and Company, 6</td>
</tr>
<tr>
<td>Prakash S. Masand, M.D.</td>
<td>Abbott Laboratories, Inc.; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Cyberonics, Inc., 3, 4; Eli Lilly and Company; Forest Laboratories, Inc., 3, 4; GlaxoSmithKline; Healthcare Technology Systems, Inc.; Janssen Pharmaceutica Products, LP; M-Science; Novartis Pharmaceuticals Corporation; Organon Pharmaceuticals Inc.; Ortho-McNeil Pharmaceutical, Inc.; Pfizer Inc.; Psychene; Wyeth Pharmaceuticals, 3, 4</td>
</tr>
<tr>
<td>Barbara J. Mason, Ph.D.</td>
<td>Addex Pharmaceuticals; Allermes, Inc.; Forest Laboratories, Inc., 1; Somaxon Pharmaceuticals</td>
</tr>
<tr>
<td>Sanjay Mathew, M.D.</td>
<td>Cephalon Inc.; Pfizer Inc.</td>
</tr>
<tr>
<td>Annette M. Matthews, M.D.</td>
<td>Bristol-Myers Squibb Company, 6</td>
</tr>
</tbody>
</table>

XXVII
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paulo E. Mattos, M.D.</td>
<td>Eli Lilly and Company, Janssen Pharmaceutica Products, LP, National Institute of Mental Health, Novartis Pharmaceuticals Corporation, Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Elinore F. McCance-Katz, M.D.</td>
<td>Reckitt Benckiser plc</td>
</tr>
<tr>
<td>Gregory McCarthy</td>
<td>GlaxoSmithKline, Janssen Pharmaceutica Products, LP</td>
</tr>
<tr>
<td>Stephen P. McDermott, M.D.</td>
<td>Shire Pharmaceuticals Group plc</td>
</tr>
<tr>
<td>David M. McDowell, M.D.</td>
<td>Bristol-Myers Squibb Company, Mallinckrodt Inc., Reckitt Benckiser plc, Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Jacqueline M. Melonas, J.D.</td>
<td>Professional Risk Management Services, Inc</td>
</tr>
<tr>
<td>Herbert Y. Melzer, M.D.</td>
<td>Acadia Pharmaceuticals Inc, Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Samanta E. Melzer-Brody, M.D.</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td>David Michelson, M.D.</td>
<td>Eli Lilly and Company</td>
</tr>
<tr>
<td>Jodi A. Mindell, Ph.D.</td>
<td>Johnson and Johnsson Pharmaceutical Research and Development, King Pharmaceuticals, Inc., Sepracor, Inc.</td>
</tr>
<tr>
<td>Elena Moro, M.D.</td>
<td>Medtronic, Inc.</td>
</tr>
<tr>
<td>Eric D. Morse, M.D.</td>
<td>Forest Laboratories, Inc., Pfizer Inc., Reckitt Benckiser plc</td>
</tr>
<tr>
<td>Quinton E. Moss, M.D.</td>
<td>Pfizer Pharmaceuticals, Janssen Pharmaceuticals, Eli Lilly and Company</td>
</tr>
<tr>
<td>Rodrigo A. Munoz, M.D.</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td>Dominique L. Musselman, M.D.</td>
<td>Dana Foundation, Forest Laboratories, Inc., GlaxoSmithKline, Janssen Pharmaceutica Products, LP, NIH Institute, Organon Pharmaceuticals Inc, Pfizer Inc., Pharmacl &amp; Upjohn, Schering-Plough Corporation</td>
</tr>
<tr>
<td>David K. Nace, M.D.</td>
<td>McKesson Corporation, United Health Group</td>
</tr>
<tr>
<td>Joseph C. Napoli, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP, Forest Laboratories, Inc., GlaxoSmithKline, Pfizer Inc.</td>
</tr>
</tbody>
</table>

**XXVIII**
Disclosures for the following contributors:

Presenter: Meera Narasimhan, M.D.
Manufacturer(s): Abbott Laboratories, Inc.; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Janssen Medical Affairs, LLC; Janssen Pharmaceuticals Products, LP; Pfizer Inc.

Presenter: Henry A. Natallah, M.D.
Manufacturer(s): Abbott Laboratories, Inc.; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Forest Laboratories, Inc.; Janssen Pharmaceuticals Products, LP; Pfizer Inc.; Shire Pharmaceuticals Group plc.

Presenter: J. Craig Nelson, M.D.
Manufacturer(s): Abbott Laboratories, Inc.; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Corcept Therapeutics; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals Products, LP; Orexigen Therapeutics, Inc.; Organon Pharmaceuticals Inc.; Pfizer Inc.; Sepracor, Inc.; Wyeth Pharmaceuticals

Presenter: Charles B. Nemeroff, M.D.
Manufacturer(s): Abbott Laboratories, Inc.; Acadia Pharmaceuticals Inc.; American Foundation for Suicide Prevention; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; CeNeRo; Corcept Therapeutics; Cyberonics, Inc.; Cypress Bioscience Inc.; Eli Lilly and Company; Forest Laboratories, Inc.; George West Health Foundation; GlaxoSmithKline; Janssen Pharmaceuticals Products, LP; National Alliance for Research in Schizophrenia and Depression; National Institute of Mental Health; NovaDel Pharma Inc.; Osuka America Pharmaceutical, Inc.; Pfizer Inc.; Quintiles Transnational Corp.; Reexx; Stanley Foundation; UCB Pharmaceuticals; Wyeth Pharmaceuticals

Presenter: David N. Neubauer, M.D.
Manufacturer(s): Neurocrine Biosciences Inc.; Orphan Medical; Pfizer Inc.; Sanofi-Aventis; Takeda Pharmaceuticals North America, Inc.

Presenter: John W. Newcomer, M.D.
Manufacturer(s): AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; GlaxoSmithKline; Janssen Pharmaceuticals Products, LP; National Alliance for Research in Schizophrenia and Depression; National Institute of Mental Health; Pfizer Inc.; Sidney Baer Foundation

Presenter: Anthony T. Ng, M.D.
Manufacturer(s): Pfizer Inc.

Presenter: Andrew A. Nierenberg, M.D.
Manufacturer(s): Bristol-Myers Squibb Company; Cederroth International; Cyberonics, Inc.; Eli Lilly and Company; Forest Laboratories, Inc.; Genaissance Pharmaceuticals; GlaxoSmithKline; Inapharma, Inc.; Janssen Pharmaceuticals Products, LP; Lichtwer Pharma GmbH; National Alliance for Research in Schizophrenia and Depression; National Institute of Mental Health; Pfizer Inc.; Somerest Pharmaceuticals Inc.; Wyeth Pharmaceuticals

Presenter: Frank G. Njenga, M.D.
Manufacturer(s): Eli Lilly and Company; GlaxoSmithKline; UCB Pharmaceuticals

Presenter: Eric A. Nozanger, M.D.
Manufacturer(s): Pfizer Inc.; Respironics, Inc.; Sanofi-Aventis; Sepracor, Inc.; Takeda Pharmaceuticals North America, Inc.

Presenter: Douglas Noordsy, M.D.
Manufacturer(s): AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Forest Laboratories, Inc.; Janssen Pharmaceuticals Products, LP

Presenter: Carol S. North, M.D.
Manufacturer(s): GlaxoSmithKline; National Institute of Alcohol Abuse and Alcoholism; National Institute of Mental Health; National Institute on Drug Abuse

Presenter: H. George Nurnberg, M.D.
Manufacturer(s): Pfizer Inc.

Presenter: David J. Nuss, M.D.
Manufacturer(s): Bristol-Myers Squibb Company; GlaxoSmithKline; Organon Pharmaceuticals Inc.; Pfizer Inc.; Wyeth Pharmaceuticals

Presenter: Charles P. O'Brien, M.D.
Manufacturer(s): Consultant for Cephalon Inc.; Forest Laboratories, Inc.; McNeil Consumer Healthcare

Presenter: Christopher M. O'Connor, M.D.
Manufacturer(s): Amgen, Inc.; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Medtronic, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.

Presenter: Claire M. O'Donovan, M.B.
Manufacturer(s): Multi-Health Systems, Inc.

Presenter: Lewis A. Opler, M.D.
Manufacturer(s): Cyberonics, Inc.; Eli Lilly and Company; Magstim Company Ltd; Neurotech, Inc.; Sanofi-Aventis

Presenter: John P. O'Reardon, M.D.
Manufacturer(s): Cephalon Inc.; Eli Lilly and Company; Johnson and Johnson Pharmaceutical Research and Development; Sepracor, Inc.; Shire Pharmaceuticals Group plc.

Presenter: Anand Pandya, M.D.
Manufacturer(s): Janssen Pharmaceuticals Products, LP

Presenter: George I. Papakostas, M.D.
Manufacturer(s): Bristol-Myers Squibb Company; GlaxoSmithKline; Pfizer Inc.

Presenter: Jose V. Pardo, M.D.
Manufacturer(s): Cyberonics, Inc.

Presenter: Sagar V. Parikh, M.D.
Manufacturer(s): AstraZeneca Pharmaceuticals LP; Bioworld Corporation; Canadian Institutes of Health Research; Canadian Network for Mood and Anxiety Treatments; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceuticals Products, LP; Stanley Foundation; Wyeth Pharmaceuticals

Presenter: Joseph J. Parks III, M.D.
Manufacturer(s): Abbott Laboratories, Inc.; AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; Janssen Pharmaceuticals Products, LP

Presenter: Ashwin A. Patkar, M.D.
Manufacturer(s): AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Forest Laboratories, Inc.; GlaxoSmithKline; Jazz Pharmaceuticals, Inc.; National Institute on Drug Abuse; Organon Pharmaceuticals Inc.; Ortho-McNeil Pharmaceutical, Inc.; Pfizer Inc.

Presenter: Simon Patry, M.D.
Manufacturer(s): AstraZeneca Pharmaceuticals LP; Bioworld Corporation; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceuticals Products, LP; Organon Pharmaceuticals Inc.; Pfizer Inc.; Wyeth Pharmaceuticals

Presenter: Diana O. Perkins, M.D.
Manufacturer(s): AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Organon Pharmaceuticals Inc.; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.; Shire Pharmaceuticals Group plc.

Presenter: Eric D. Peselow, M.D.
Manufacturer(s): Forest Laboratories, Inc.; GlaxoSmithKline; Pfizer Inc.

Presenter: Francois C.F. Petitjean, Psy.D.
Manufacturer(s): Bristol-Myers Squibb Company; Janssen Pharmaceuticals Products, LP; Sanofi-Aventis

Presenter: Joseph M. Pierre, M.D.
Manufacturer(s): Bristol-Myers Squibb Company; Janssen Pharmaceuticals Products, LP; Pfizer Inc.
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Teresa A. Pigott, M.D.</td>
<td>Eli Lilly and Company&lt;sup&gt;6&lt;/sup&gt;; Janssen Pharmaceuticals Products&lt;sup&gt;1,4&lt;/sup&gt;; National Institute of Mental Health&lt;sup&gt;2&lt;/sup&gt;; Sepracor, Inc.&lt;sup&gt;4&lt;/sup&gt;</td>
</tr>
<tr>
<td>Bruce G. Pollock</td>
<td>Forest Laboratories, Inc.&lt;sup&gt;1,4&lt;/sup&gt;; Janssen Pharmaceuticals Products, LP&lt;sup&gt;1,2&lt;/sup&gt;; National Institute of Mental Health&lt;sup&gt;2&lt;/sup&gt;; Sepracor, Inc.&lt;sup&gt;4&lt;/sup&gt;</td>
</tr>
<tr>
<td>Steven G. Potkin, M.D.</td>
<td>Academic Pharmaceuticals Inc&lt;sup&gt;1&lt;/sup&gt;; AstraZeneca Pharmaceuticals LP&lt;sup&gt;1,3&lt;/sup&gt;; Bristol-Myers Squibb Company&lt;sup&gt;3,4&lt;/sup&gt;; Forest Laboratories, Inc.&lt;sup&gt;1,3&lt;/sup&gt;; Fujisawa Pharmaceutical Co.&lt;sup&gt;13&lt;/sup&gt;; Janssen Pharmaceuticals Products, LP&lt;sup&gt;1,2&lt;/sup&gt;; Mitsubishi Pharma Corporation&lt;sup&gt;1,2&lt;/sup&gt;; Novartis Pharmaceuticals Corporation&lt;sup&gt;1,3&lt;/sup&gt;; Ono Pharmaceuticals, Inc.&lt;sup&gt;3&lt;/sup&gt;; Organon Pharmaceuticals Inc&lt;sup&gt;1,2&lt;/sup&gt;; Otsuka America Pharmaceutical, Inc.&lt;sup&gt;1,3&lt;/sup&gt;; Pfizer Inc.&lt;sup&gt;1,3&lt;/sup&gt;; Praxis Pharmaceuticals Incorporated&lt;sup&gt;1&lt;/sup&gt;; Roche&lt;sup&gt;1&lt;/sup&gt;; Sano-I Synthelabo&lt;sup&gt;1&lt;/sup&gt;; Solvay Pharmaceuticals, Inc.&lt;sup&gt;3,13&lt;/sup&gt;; Wyeth Pharmaceuticals&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td>Annelie B. Primm, M.D.</td>
<td>Eli Lilly and Company&lt;sup&gt;6&lt;/sup&gt;; Pfizer Inc.&lt;sup&gt;1,3,6&lt;/sup&gt;</td>
</tr>
<tr>
<td>Jefferson B. Prince, M.D.</td>
<td>Eli Lilly and Company&lt;sup&gt;1,3,6&lt;/sup&gt;; Forest Laboratories, Inc.&lt;sup&gt;1,3&lt;/sup&gt;; GlaxoSmithKline&lt;sup&gt;1,3&lt;/sup&gt;; McNeil Consumer Healthcare&lt;sup&gt;1,3,4&lt;/sup&gt;; Pfizer Inc.&lt;sup&gt;1,3&lt;/sup&gt;; Shire Pharmaceuticals Group plc&lt;sup&gt;1,3&lt;/sup&gt;</td>
</tr>
<tr>
<td>Andres J. Pumariega, M.D.</td>
<td>Eli Lilly and Company&lt;sup&gt;6&lt;/sup&gt;; Forest Laboratories, Inc.&lt;sup&gt;4&lt;/sup&gt;</td>
</tr>
<tr>
<td>Paul M. Ramirez, Ph.D.</td>
<td>Multi-Health Systems, Inc.&lt;sup&gt;6&lt;/sup&gt;</td>
</tr>
<tr>
<td>Carrie L. Randall, Ph.D.</td>
<td>Eli Lilly and Company&lt;sup&gt;6&lt;/sup&gt;; Pfizer Inc.&lt;sup&gt;5&lt;/sup&gt;</td>
</tr>
<tr>
<td>Mark H. Rapaport, M.D.</td>
<td>Abbott Laboratories, Inc.&lt;sup&gt;3&lt;/sup&gt;; AstraZeneca Pharmaceuticals LP&lt;sup&gt;3&lt;/sup&gt;; Concept Therapeutics&lt;sup&gt;3&lt;/sup&gt;; Cyberonics, Inc.&lt;sup&gt;1,3,4&lt;/sup&gt;; Eli Lilly and Company&lt;sup&gt;1,3&lt;/sup&gt;; Forest Laboratories, Inc.&lt;sup&gt;1,3,4,5&lt;/sup&gt;; GlaxoSmithKline&lt;sup&gt;1,3&lt;/sup&gt;; Janssen Pharmaceuticals Products, LP&lt;sup&gt;1,3,4&lt;/sup&gt;; National Cancer Institute Advisory Board&lt;sup&gt;1&lt;/sup&gt;; National Institute of Mental Health&lt;sup&gt;1&lt;/sup&gt;; National Institute on Drug Abuse&lt;sup&gt;1&lt;/sup&gt;; Neurocrine Biosciences Inc.&lt;sup&gt;1&lt;/sup&gt;; Novartis Pharmaceuticals Corporation&lt;sup&gt;1,3&lt;/sup&gt;; Pfizer Inc.&lt;sup&gt;1,3&lt;/sup&gt;; Pharmacia &amp; Upjohn&lt;sup&gt;1&lt;/sup&gt;; Roche&lt;sup&gt;1&lt;/sup&gt;; Sanofi-Synthelabo&lt;sup&gt;1&lt;/sup&gt;; Solvay Pharmaceuticals, Inc.&lt;sup&gt;1,3&lt;/sup&gt;; Stanley Medical Research Institute&lt;sup&gt;1&lt;/sup&gt;; Sumitomo Pharmaceuticals Co., Ltd&lt;sup&gt;1&lt;/sup&gt;; Wyeth Pharmaceuticals&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>Natalie L. Rasgon, M.D.</td>
<td>Abbott Laboratories, Inc.&lt;sup&gt;1,3,4,6&lt;/sup&gt;; Bristol-Myers Squibb Company&lt;sup&gt;4&lt;/sup&gt;; Eli Lilly and Company&lt;sup&gt;4,6&lt;/sup&gt;; Forest Laboratories, Inc.&lt;sup&gt;3,4&lt;/sup&gt;; GlaxoSmithKline&lt;sup&gt;3,4&lt;/sup&gt;; National Institute of Mental Health&lt;sup&gt;1&lt;/sup&gt;; Novartis Pharmaceuticals Corporation&lt;sup&gt;1,3&lt;/sup&gt;; Pfizer Inc.&lt;sup&gt;4,6&lt;/sup&gt;; Wyeth Pharmaceuticals&lt;sup&gt;3,4,6&lt;/sup&gt;</td>
</tr>
<tr>
<td>Joel Raskin, M.D.</td>
<td>Eli Lilly and Company&lt;sup&gt;6,5&lt;/sup&gt;</td>
</tr>
<tr>
<td>Artur V. Ravindran, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP&lt;sup&gt;1,3&lt;/sup&gt;; GlaxoSmithKline&lt;sup&gt;1,3&lt;/sup&gt;; Pfizer Inc.&lt;sup&gt;1,3&lt;/sup&gt;; Roche&lt;sup&gt;1&lt;/sup&gt;; Servier&lt;sup&gt;1,3&lt;/sup&gt;; Wyeth Pharmaceuticals&lt;sup&gt;1,3&lt;/sup&gt;</td>
</tr>
<tr>
<td>Burton V. Reifler, M.D.</td>
<td>Johnson and Johnson Pharmaceutical Research and Development&lt;sup&gt;5&lt;/sup&gt;</td>
</tr>
<tr>
<td>John A. Renner, Jr., M.D.</td>
<td>Eli Lilly and Company&lt;sup&gt;6&lt;/sup&gt;; Shire Pharmaceuticals Group plc&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>Roy O. Resnikoff, M.D.</td>
<td>Wyeth Pharmaceuticals&lt;sup&gt;6&lt;/sup&gt;</td>
</tr>
<tr>
<td>Victor I. Reus, M.D.</td>
<td>Concept Therapeutics&lt;sup&gt;3&lt;/sup&gt;; Gerson Lehrman Group&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>Charles F. Reynolds III, M.D.</td>
<td>Eli Lilly and Company&lt;sup&gt;4&lt;/sup&gt;; Forest Laboratories, Inc.&lt;sup&gt;1&lt;/sup&gt;; GlaxoSmithKline&lt;sup&gt;3&lt;/sup&gt;; Pfizer Inc.&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td>Ali R. Rezaei, M.D.</td>
<td>Medtronics, Inc.&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td>Michelle B. Riba, M.D.</td>
<td>Eli Lilly and Company&lt;sup&gt;3&lt;/sup&gt;; GlaxoSmithKline&lt;sup&gt;1&lt;/sup&gt;; Pfizer Inc.&lt;sup&gt;3&lt;/sup&gt;; Shire Pharmaceuticals Group plc&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>Steven H. Richeimer, M.D.</td>
<td>Janssen Pharmaceutical Products, LP&lt;sup&gt;3&lt;/sup&gt;; Merck &amp; Co., Inc.&lt;sup&gt;4&lt;/sup&gt;; Pfizer Inc.&lt;sup&gt;4&lt;/sup&gt;; Purdue Pharma L.P&lt;sup&gt;4&lt;/sup&gt;; mentyonetics, Inc.&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>Elliott Richelson, M.D.</td>
<td>Cyberonics, Inc.&lt;sup&gt;1&lt;/sup&gt;; Neurontics, Inc.&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td>Judith A. Richman, Ph.D.</td>
<td>National Institute of Alcohol Abuse and Alcoholism&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td>Muhammad A. Rifai, M.D.</td>
<td>American Psychiatric Association&lt;sup&gt;1&lt;/sup&gt;; National Institute of Mental Health&lt;sup&gt;6&lt;/sup&gt;</td>
</tr>
<tr>
<td>Thomas Rinne, Ph.D.</td>
<td>Solvay Pharmaceuticals, Inc.&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td>Trevor Robbins, Ph.D.</td>
<td>Cambridge Cognition&lt;sup&gt;1&lt;/sup&gt;; CeNeS Pharmaceuticals pic&lt;sup&gt;1&lt;/sup&gt;; Cephalon Inc.&lt;sup&gt;1&lt;/sup&gt;; Eli Lilly and Company&lt;sup&gt;1&lt;/sup&gt;; GlaxoSmithKline&lt;sup&gt;1&lt;/sup&gt;; Lundbeck Pharmaceuticals&lt;sup&gt;1&lt;/sup&gt;; Merck &amp; Co., Inc.&lt;sup&gt;1&lt;/sup&gt;; Organon Pharmaceuticals Inc.&lt;sup&gt;1&lt;/sup&gt;; Pfizer Inc.&lt;sup&gt;1&lt;/sup&gt;; Roche&lt;sup&gt;1&lt;/sup&gt;; Bristol-Myers Squibb Company&lt;sup&gt;1&lt;/sup&gt;; Eli Lily and Company&lt;sup&gt;1&lt;/sup&gt;; Forest Laboratories, Inc.&lt;sup&gt;1&lt;/sup&gt;; Wyeth Pharmaceuticals&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>Laura Roberts, M.D.</td>
<td>National Alliance for Research in Schizophrenia and Depression&lt;sup&gt;1&lt;/sup&gt;; National Institute of Mental Health&lt;sup&gt;3&lt;/sup&gt;; National Institute on Drug Abuse&lt;sup&gt;1&lt;/sup&gt;; NIH Institute&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td>Delbert G. Robinson, M.D.</td>
<td>Bristol-Myers Squibb Company&lt;sup&gt;3&lt;/sup&gt;; Janssen Pharmaceutical Products, LP&lt;sup&gt;1,3&lt;/sup&gt;; National Institute of Mental Health&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td>Robert G. Robinson, M.D.</td>
<td>Forest Laboratories, Inc.&lt;sup&gt;4&lt;/sup&gt;; Pfizer Inc.&lt;sup&gt;4&lt;/sup&gt;; PharmaStar, LLC&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>Timothy A. Roders</td>
<td>Sanofi-Aventis&lt;sup&gt;1,3&lt;/sup&gt;; Sepracor, Inc.&lt;sup&gt;1,3,4&lt;/sup&gt;</td>
</tr>
<tr>
<td>Steven P. Roose, M.D.</td>
<td>Bristol-Myers Squibb Company&lt;sup&gt;3&lt;/sup&gt;; Eli Lilly and Company&lt;sup&gt;3&lt;/sup&gt;; Forest Laboratories, Inc.&lt;sup&gt;1&lt;/sup&gt;; Wyeth Pharmaceuticals&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>Russell Rosenberg, Ph.D.</td>
<td>Cephalon, Inc.&lt;sup&gt;1,3&lt;/sup&gt;; AstraZeneca Pharmaceuticals LP&lt;sup&gt;1&lt;/sup&gt;; Aventis Pharmaceuticals, Inc.&lt;sup&gt;1,3&lt;/sup&gt;; Eli Lilly and Company&lt;sup&gt;1,3&lt;/sup&gt;; GlaxoSmithKline&lt;sup&gt;1,3&lt;/sup&gt;; King Pharmaceuticals, Inc.&lt;sup&gt;1&lt;/sup&gt;; Merck &amp; Co., Inc.&lt;sup&gt;3,4&lt;/sup&gt;; Neurocrine Biosciences Inc.&lt;sup&gt;1,3&lt;/sup&gt;; Organon Pharmaceuticals Inc.&lt;sup&gt;1,3&lt;/sup&gt;; Pfizer Inc.&lt;sup&gt;1,3&lt;/sup&gt;; Roche&lt;sup&gt;1&lt;/sup&gt;; Sanofi-Synthelabo&lt;sup&gt;1&lt;/sup&gt;; Sepracor, Inc.&lt;sup&gt;1,3,4&lt;/sup&gt;; Somaxen Pharmaceuticals&lt;sup&gt;1,3&lt;/sup&gt;</td>
</tr>
<tr>
<td>Paul J. Rosenfield, M.D.</td>
<td>Takeda Pharmaceuticals North America, Inc.&lt;sup&gt;1,3&lt;/sup&gt;; Wyeth Pharmaceuticals&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>Robert A. Rosenheck</td>
<td>Eli Lilly and Company&lt;sup&gt;3&lt;/sup&gt;; McNeil Consumer Healthcare&lt;sup&gt;3&lt;/sup&gt;; Shire Pharmaceuticals Group plc&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>Richard N. Rosenthal MD, M.D.</td>
<td>Acadia Pharmaceuticals Inc&lt;sup&gt;1&lt;/sup&gt;; AstraZeneca Pharmaceuticals LP&lt;sup&gt;1&lt;/sup&gt;; Aventis Pharmaceuticals, Inc.&lt;sup&gt;1,3&lt;/sup&gt;; Cephalon Inc.&lt;sup&gt;1,3&lt;/sup&gt;; Eli Lilly and Company&lt;sup&gt;1,3&lt;/sup&gt;; GlaxoSmithKline&lt;sup&gt;1,3&lt;/sup&gt;; King Pharmaceuticals, Inc.&lt;sup&gt;1&lt;/sup&gt;; Merck &amp; Co., Inc.&lt;sup&gt;3,4&lt;/sup&gt;; Neurocrine Biosciences Inc.&lt;sup&gt;1,3&lt;/sup&gt;; Organon Pharmaceuticals Inc.&lt;sup&gt;1,3&lt;/sup&gt;; Pfizer Inc.&lt;sup&gt;1,3&lt;/sup&gt;; Roche&lt;sup&gt;1&lt;/sup&gt;; Sanofi-Synthelabo&lt;sup&gt;1&lt;/sup&gt;; Sepracor, Inc.&lt;sup&gt;1,3,4&lt;/sup&gt;; Somaxen Pharmaceuticals&lt;sup&gt;1,3&lt;/sup&gt;</td>
</tr>
<tr>
<td>Heather Ross, M.D.</td>
<td>McNeil Consumer Healthcare&lt;sup&gt;14&lt;/sup&gt;</td>
</tr>
<tr>
<td>Stephen Ross</td>
<td>MST Services, Inc.&lt;sup&gt;5&lt;/sup&gt;</td>
</tr>
<tr>
<td>Anthony L. Rostain, M.D.</td>
<td>Eli Lilly and Company&lt;sup&gt;4&lt;/sup&gt;; GlaxoSmithKline&lt;sup&gt;1&lt;/sup&gt;; Wyeth Pharmaceuticals&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>Thomas Roth</td>
<td>Forest Laboratories, Inc.&lt;sup&gt;1,2&lt;/sup&gt;; GlaxoSmithKline&lt;sup&gt;1&lt;/sup&gt;; Wyeth Pharmaceuticals&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>Eugenio M. Rothe, M.D.</td>
<td>Forest Laboratories, Inc.&lt;sup&gt;1,2&lt;/sup&gt;; GlaxoSmithKline&lt;sup&gt;1&lt;/sup&gt;; Wyeth Pharmaceuticals&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>Melissa D. Rowland, M.D.</td>
<td>Forest Laboratories, Inc.&lt;sup&gt;1,2&lt;/sup&gt;; GlaxoSmithKline&lt;sup&gt;1&lt;/sup&gt;; Wyeth Pharmaceuticals&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>Peter P. Roy-Byrne, M.D.</td>
<td>Forest Laboratories, Inc.&lt;sup&gt;1,2&lt;/sup&gt;; GlaxoSmithKline&lt;sup&gt;1&lt;/sup&gt;; Wyeth Pharmaceuticals&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>XXX</td>
<td>Forest Laboratories, Inc.&lt;sup&gt;1,2&lt;/sup&gt;; GlaxoSmithKline&lt;sup&gt;1&lt;/sup&gt;; Wyeth Pharmaceuticals&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Pedro Ruiz, M.D.</td>
<td>Eli Lilly and Company¹, Bristol-Myers Squibb Company¹, Cyberonics, Inc.¹, Eli Lilly and Company²,³, Forest Laboratories, Inc.¹,³, GlaxoSmithKline⁴,⁵, Merck &amp; Co., Inc.⁴, National Institute of Mental Health¹, Organon Pharmaceuticals Inc., Stanley Foundation¹, Stanley Medical Research Institute¹, Urban Institute¹</td>
</tr>
<tr>
<td>A. John Rush, M.D.</td>
<td>NIH Institute²</td>
</tr>
<tr>
<td>Joni L. Rutter, Ph.D.</td>
<td>H. Lundbeck A/S², Wyeth Pharmaceuticals³</td>
</tr>
<tr>
<td>Deirdre M. Ryan, M.D.</td>
<td>Abbott Laboratories, Inc.¹,², AstraZeneca Pharmaceuticals LP¹,², Bristol-Myers Squibb Company¹,²,³, GlaxoSmithKline⁴,⁵, Pfizer Inc.⁴</td>
</tr>
<tr>
<td>Gary S. Sachs, M.D.</td>
<td>Abbott Laboratories, Inc.¹,², AstraZeneca Pharmaceuticals LP¹,², Bristol-Myers Squibb Company¹,²,³, GlaxoSmithKline⁴,⁵, Pfizer Inc.⁴</td>
</tr>
<tr>
<td>Martha Sajatovic, M.D.</td>
<td>Abbott Laboratories, Inc.¹,², AstraZeneca Pharmaceuticals LP¹,², Bristol-Myers Squibb Company¹,²,³, GlaxoSmithKline⁴,⁵, Pfizer Inc.⁴</td>
</tr>
<tr>
<td>Carl Salzman, M.D.</td>
<td>Bristol-Myers Squibb Company¹, Pfizer Inc.¹, Takeda Pharmaceuticals North America, Inc.¹</td>
</tr>
<tr>
<td>Shirlene M. Sampson, M.D.</td>
<td>Neurontics, Inc.³</td>
</tr>
<tr>
<td>David Satcher, M.D.</td>
<td>American Program Bureau¹, Johnson and Johnson Pharmaceutical Research and Development¹, Wyeth Pharmaceuticals³</td>
</tr>
<tr>
<td>Sanjaya Saxena, M.D.</td>
<td>Ortho-McNeil Pharmaceutical, Inc.³</td>
</tr>
<tr>
<td>Alan F. Scharzberg, M.D.</td>
<td>Abbott Laboratories, Inc.¹,², Bristol-Myers Squibb Company¹,², Concept Therapeutics¹,², Eli Lilly and Company²,³, Forest Laboratories, Inc.¹,², GlaxoSmithKline¹,², Janssen Pharmaceutica Products, LP¹,², Merck &amp; Co., Inc.¹,², Neurontics, Inc.¹,², Organon Pharmaceuticals Inc., Pathway Diagnostics¹,², Pfizer Inc.¹,², Sanofi-Aventis¹, Somaxon Pharmaceuticals¹,², Somerset Pharmaceuticals Inc.¹,², Wyeth Pharmaceuticals¹,²,³</td>
</tr>
<tr>
<td>Randolph B. Schiffer, M.D.</td>
<td>Avanir Corp¹,²,³, AstraZeneca Pharmaceuticals LP¹,², Forest Laboratories, Inc.¹,², Johnson and Johnson Pharmaceutical Research and Development¹, Novartis Pharmaceuticals Corporation¹, Pfizer Inc.¹</td>
</tr>
<tr>
<td>Lon S. Schneider, M.D.</td>
<td>Forest Laboratories, Inc.¹,², Ortho-McNeil Pharmaceutical, Inc.¹,², Ortho-McNeil Pharmaceutical, Inc.¹,²</td>
</tr>
<tr>
<td>Marc A. Schuckit, M.D.</td>
<td>Abbott Laboratories, Inc.¹,², AstraZeneca Pharmaceuticals LP¹,², Eli Lilly and Company¹,²,³, Janssen Pharmaceutica Products, LP¹,²</td>
</tr>
<tr>
<td>S. Charles Schulz, M.D.</td>
<td>Larry J. Seidman, Ph.D.</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
</tr>
<tr>
<td>------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Murray B. Stein, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Avera Pharmaceuticals, Inc; Cephalon Inc; Eli Lilly and Company; Forest Laboratories, Inc; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; Jazz Pharmaceuticals, Inc; Johnson and Johnson Pharmaceutical Research and Development; Pfizer Inc; UCB Pharmaceuticals; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Ham Steiner, M.D.</td>
<td>Abbott Laboratories, Inc; Eli Lilly and Company; Forest Laboratories, Inc; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; McNeil Consumer Healthcare; Novartis Pharmaceuticals Corporation; Ocho-McNeil Pharmaceutical Products, Inc; Otsuka America Pharmaceutical, Inc; Pfizer Inc; Solvay Pharmaceuticals, Inc; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Altha J. Stewart, M.D.</td>
<td>Pfizer Inc; Eli Lilly and Company; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Donna E. Stewart, M.D.</td>
<td>Eli Lilly and Company; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Jonathan T. Stewart, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; Forest Laboratories, Inc; Pfizer Inc</td>
</tr>
<tr>
<td>Frederick Stoddard</td>
<td>Pfizer Inc</td>
</tr>
<tr>
<td>Frederick J. Stoddard, Jr., M.D.</td>
<td>Pfizer Inc</td>
</tr>
<tr>
<td>Eric C. Strain, M.D.</td>
<td>GlaxoSmithKline; National Institute on Drug Abuse; Reckitt Benckiser plc; The Oak Group; Titan Pharmaceutical, Inc</td>
</tr>
<tr>
<td>T. Scott Stroup, M.D.</td>
<td>Eli Lilly and Company; GlaxoSmithKline; Pfizer Inc</td>
</tr>
<tr>
<td>Thomas S. Stroup, M.D.</td>
<td>Eli Lilly and Company; GlaxoSmithKline</td>
</tr>
<tr>
<td>Rima Styra, M.D.</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td>Steve Sugden, M.D.</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td>Calvin R. Sumner, M.D.</td>
<td>Eli Lilly and Company</td>
</tr>
<tr>
<td>Craig B.J. Surman, M.D.</td>
<td>McNeil Consumer Healthcare; National Institute of Health</td>
</tr>
<tr>
<td>Conrad M. Swartz, M.D.</td>
<td>Somatics, LLC</td>
</tr>
<tr>
<td>Holly A. Swartz, M.D.</td>
<td>Eli Lilly and Company; Pfizer Inc</td>
</tr>
<tr>
<td>Marvin S. Swartz, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Pfizer Inc</td>
</tr>
<tr>
<td>Robert M. Swift, M.D.</td>
<td>Alkermes, Inc; Bristol-Myers Squibb Company; Drug Abuse Sciences, Inc; Forest Laboratories, Inc; National Institute of Alcohol Abuse and Alcoholism; Ortho-McNeil Pharmaceutical, Inc; Pfizer Inc</td>
</tr>
<tr>
<td>Robyn Sysko, M.S.</td>
<td>Pfizer Inc</td>
</tr>
<tr>
<td>Carol A. Tammenga, M.D.</td>
<td>Abbott Laboratories, Inc; Acadia Pharmaceuticals Inc; Avera Pharmaceuticals, Inc; Intercellular Therapies; Janssen Pharmaceutical Products, LP; National Institute of Mental Health; Neurogen; Stanley Medical Research Institute; Sumitomo Pharmaceuticals Co., Ltd; UT Southwestern Medical Center at Dallas</td>
</tr>
<tr>
<td>Pierre N. Tariot, M.D.</td>
<td>Abbott Laboratories, Inc; Amgen, Inc; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eisai Inc; Elan Pharmaceuticals, Inc; Eli Lilly and Company; Forest Laboratories, Inc; Janssen Pharmaceutical Products, LP; Merck &amp; Co, Inc; Mitsubishi Pharma Corporation; Myriad Genetics, Inc; Neurochem, Inc; Novartis Pharmaceuticals Corporation; Ono Pharmaceuticals, Inc; Pfizer Inc; Sanofi-Aventis; Sanofi-Synthelabo; Schwabe; Takeda Pharmaceuticals North America, Inc</td>
</tr>
<tr>
<td>Warren D. Taylor, M.D.</td>
<td>GlaxoSmithKline; Janssen Pharmaceutica Products, LP; Pfizer Inc; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>George E. Tesar, M.D.</td>
<td>Medtronics, Inc</td>
</tr>
<tr>
<td>Michael E. Thase, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Cephalon Inc; Cyberonics, Inc; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; Novartis Pharmaceuticals Corporation; Organon Pharmaceuticals Inc; Pfizer Inc; Sepracor, Inc; Shire Pharmaceuticals Group plc; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Nicole Thibodeau, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; Organon Pharmaceuticals Inc; Pfizer Inc; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Martin G. Tracy, J.D.</td>
<td>Professional Risk Management Services, Inc</td>
</tr>
<tr>
<td>Patrick T. Triplet, M.D.</td>
<td>Forest Laboratories, Inc</td>
</tr>
<tr>
<td>Madhular H. Trivedi, M.D.</td>
<td>Abbott Laboratories, Inc; Bayer Corporation, Pharmaceutical Division; Bristol-Myers Squibb Company; Cyberonics, Inc; Eli Lilly and Company; Forest Laboratories, Inc; GlaxoSmithKline; Janssen Pharmaceutical Products, LP; Johnson and Johnson Pharmaceutical Research and Development; National Alliance for Research in Schizophrenia and Depression; National Institute of Mental Health; Organon Pharmaceuticals Inc; Parke-Davis; Pfizer Inc; Pharmacia &amp; Upjohn; Solvay Pharmaceuticals, Inc; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Douglas Turkington, M.D.</td>
<td>Pfizer Inc</td>
</tr>
<tr>
<td>Audrey R. Tyrya, M.D.</td>
<td>Cephalon; Concept Therapeutics; Cyberonics, Inc; Janssen Pharmaceutica Products, LP; Medtronics, Inc; Pfizer Inc; UCB Pharmaceuticals</td>
</tr>
<tr>
<td>Donna Vanderpool, J.D.</td>
<td>Professional Risk Management Services, Inc</td>
</tr>
<tr>
<td>Dawn I. Velligan, Ph.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; InforMedia; Janssen Pharmaceutical Products, LP; Organon Pharmaceuticals Inc; Pfizer Inc</td>
</tr>
<tr>
<td>Jeff Victoroff, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; Novartis Pharmaceuticals Corporation; Organon Pharmaceuticals Inc; Pfizer Inc; Sanofi-Aventis; Servier; Stanley Medical Research Institute; UCB Pharmaceuticals</td>
</tr>
<tr>
<td>Eduard Vieta, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; Novartis Pharmaceuticals Corporation; Organon Pharmaceuticals Inc; Pfizer Inc; Sanofi-Aventis; Stanley Foundation; UCB Pharmaceuticals</td>
</tr>
<tr>
<td>XXXII</td>
<td></td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
</tr>
<tr>
<td>---------------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Frank Voci, Ph.D.</td>
<td>Amgen, Inc; Dupont E I De Nemours &amp; Co; Proctor &amp; Gamble Company</td>
</tr>
<tr>
<td>Suzanne E. Vogel-Scibilia, M.D.</td>
<td>GlaxoSmithKline; National Institute of Mental Health; Pfizer Inc.</td>
</tr>
<tr>
<td>Karen D. Wagner, M.D.</td>
<td>Abbott Laboratories, Inc; Bristol-Myers Squibb Company; Eli Lilly and Company; Forest Laboratories, Inc; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; Jazz Pharmaceuticals, Inc; Johnson and Johnson Pharmaceutical Research and Development; National Institute of Mental Health; Novartis Pharmaceuticals Corporation; Organon Pharmaceuticals Inc; Ortho-McNeil Pharmaceutical, Inc; Pfizer Inc; UCB Pharmaceuticals; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>B. Timothy Walsh, M.D.</td>
<td>Eli Lilly and Company; Ortho-McNeil Pharmaceutical, Inc</td>
</tr>
<tr>
<td>Roger T. Webb, M.S.C.</td>
<td>Wellcome Trust</td>
</tr>
<tr>
<td>Peter J. Weiden, M.D.</td>
<td>Alkermes, Inc; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Janssen Medical Affairs, LLC; Janssen Pharmaceutica Products, LP; Johnson and Johnson Pharmaceutical Research and Development; Osaka America Pharmaceutical, Inc; Pfizer Inc; Virtually Better</td>
</tr>
<tr>
<td>Elyse D. Weiner, M.D.</td>
<td>Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Lisa B. Weisberg, Ph.D.</td>
<td>Eli Lilly and Company; National Institute of Mental Health; Pfizer Inc.</td>
</tr>
<tr>
<td>Roger D. Weiss, M.D.</td>
<td>Abbott Laboratories, Inc; Alkermes, Inc; National Institute of Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; Ortho-McNeil Pharmaceutical, Inc</td>
</tr>
<tr>
<td>Keith Wesnes, Ph.D.</td>
<td>Cephalon Inc; CellTech; NRPI</td>
</tr>
<tr>
<td>Sharon B. Wigal, Ph.D.</td>
<td>Abbott Laboratories, Inc; Alza Corporation; Celltech; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; National Institute of Mental Health; National Institute on Drug Abuse; NeuroSearch; Pharmacia &amp; Upjohn; Sanofi-Synthelabo; Schering-Plough Corporation; Schwarz Pharmaceuticals; Seprocin, Inc; Takeda Pharmaceuticals North America, Inc; UCB Pharmaceuticals; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Timothy E. Wilens, M.D.</td>
<td>Alkermes, Inc; AstraZeneca Pharmaceuticals LP; Forest Laboratories, Inc; Hythium</td>
</tr>
<tr>
<td>Jeffery N. Wilkins, M.D.</td>
<td>Eisai Inc; GlaxoSmithKline; H. Lundbeck A/S; Janssen Pharmaceutica Products, LP; Novartis Pharmaceuticals Corporation; Pfizer Inc</td>
</tr>
<tr>
<td>David Wilkinson, M.B.</td>
<td>Abbott Laboratories, Inc; Johnson and Johnson Pharmaceutical Research and Development</td>
</tr>
<tr>
<td>Adela Cubi Williams, M.D.</td>
<td>Boehringer-Ingelheim Pharmaceuticals GmbH; Cephalon Inc; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; Janssen Pharmaceuticals Corporation; Pfizer Inc; Pharmacia &amp; Upjohn; Sanofi-Aventis; Schering-Plough Corporation; Schwarz Pharmaceuticals; Takeda Pharmaceuticals North America, Inc; UCB Pharmaceuticals; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Jill Williams, M.D.</td>
<td>National Institute on Drug Abuse</td>
</tr>
<tr>
<td>John W. Winkelman, M.D.</td>
<td>Boehringer-Ingelheim Pharmaceuticals GmbH; Cephalon Inc; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; NovaDel Pharma Inc; Novartis Pharmaceuticals Corporation; Pfizer Inc; Pharmacia &amp; Upjohn; Sanofi-Synthelabo; Schering-Plough Corporation; Schwarz Pharmaceuticals; Takeda Pharmaceuticals North America, Inc; UCB Pharmaceuticals; Wyeth Pharmaceuticals</td>
</tr>
<tr>
<td>Daniel K. Winstead, M.D.</td>
<td>Forest Laboratories, Inc</td>
</tr>
<tr>
<td>Madeleine M. Wohlfleisch, M.D.</td>
<td>Eli Lilly and Company; National Alliance for Research in Schizophrenia and Depression; National Institute of Mental Health; Stanley Medical Research Institute</td>
</tr>
<tr>
<td>Scott W. Woods, M.D.</td>
<td>Bristol-Myers Squibb Company; Eli Lilly and Company; National Alliance for Research in Schizophrenia and Depression; National Institute of Mental Health; Stanley Medical Research Institute</td>
</tr>
<tr>
<td>Jesse H. Wright III, M.D.</td>
<td>AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; Novartis Pharmaceuticals Corporation</td>
</tr>
<tr>
<td>Lakshmi N. Yatham, M.D.</td>
<td>Robert C. Young, M.D.</td>
</tr>
<tr>
<td>Stuart C. Youngsky, M.D.</td>
<td>Bristol-Myers Squibb Company</td>
</tr>
<tr>
<td>Sun Young, Yum, M.D.</td>
<td>American Medical Association Foundation</td>
</tr>
<tr>
<td>Mary C. Zanari, M.D.</td>
<td>Eli Lilly and Company; Boehringer-Ingelheim Pharmaceuticals GmbH; Neurocrine Biosciences Inc; Pfizer Inc; Sanofi-Synthelabo; Seprocin, Inc; Takeda Pharmaceuticals North America, Inc</td>
</tr>
<tr>
<td>Phyllis C. Zee, M.D.</td>
<td>Bristol-Myers Squibb Company; Eli Lilly and Company; Forest Laboratories, Inc; Janssen Pharmaceutica Products, LP; National Institute of Mental Health; National Institute on Drug Abuse; Pfizer Inc</td>
</tr>
<tr>
<td>Douglas M. Ziedonis, M.D.</td>
<td>Symyx Biosciences, Inc; Forest Laboratories, Inc; GlaxoSmithKline; National Institute of Mental Health; Pfizer Inc</td>
</tr>
<tr>
<td>Sidney Zisook, M.D.</td>
<td>Pfizer Inc</td>
</tr>
<tr>
<td>Joseph Zohar, M.D.</td>
<td>Alkermes, Inc; National Institute of Alcohol Abuse and Alcoholism; National Institute on Drug Abuse</td>
</tr>
</tbody>
</table>

The following presenters did not provide us with their disclosure information.

Joseph Califano, M.D.  
Angela M. Cheung, M.D.  
Ponjola Coney  
Diana Dell, M.D.  

Jeffrey L. Geller, M.D.  
Adrian Grounds  
Alyson R. Kuroski-Mazzei, D.O.  
David A. Lewis  

Christian D. Perring, Ph.D.  
Norman Sartorius, M.D.  
Jacob Widroff, M.D.  
Theresa A. Yuschok, M.D.  

XXXIII
The following presenters indicated neither they nor an immediate family member has any significant relationship to disclose.

Susan Abbey, M.D.
Karen M. Abrams, M.D.
Ronald D. Abrahamson
Margot S. Adams
Babatunde A. Adetunji
Iqbal Ahmed, M.D.
Dov Aizenberg, M.D.
Jeffrey Akala, M.D.
Evastio O. Akerele, M.D.
Amit S. Alarikisen, M.D.
Renato D. Alarcon, M.D.
David B. Albert, Ph.D.
Margarita Alegría, Ph.D.
George S. Alexopoulos, M.D.
Ian E. Alger, M.D.
Jon G. Allen, Ph.D.
Sadiq H. Al-Samarrai, M.D.
Steven I. Altschuler, M.D.
Margaret Alterman, M.D.
Carol L. Alter, M.D.
Jean-Marie E. Alves-Bradford, M.D.
Chris Ambidge
Shahd R. Amiri, M.D.
Lisa F. Andermann, M.D.
Tanya R. Anderson, M.D.
Nabeen N. Andrade, M.D.
Diana Antia, M.D.
Joan M. Anza, M.D.
Paul S. Appelbaum, M.D.
Gisle Apter-Danon, M.D.
Julio Arboleda-Florez, M.D.
Britton A. Arey, M.D.
Kimberly A. Arlinghaus, M.D.
William Arroyo, M.D.
Sayed Mohammad Assadi, M.D.
Robert Atkins, M.D.
Nutan Atre-Vaidya, M.D.
Evelyn Attia, M.D.
R. Robert Auger, M.D.
Alex Aviv, M.D.
R. Michael Bagby, Ph.D.
Bruce C. Balkin, M.D.
Aziza O. Bankole, M.D.
Elisabeth Banon
Yoram Bank, M.D.
Mary E. Barber, M.D.
David A. Baron, D.O.
Paul J. Barreira, M.D.
Monica A. Basco, M.D.
Anne S. Basset, M.D.
Dorothy Bates
G. William Bates, M.D.
Antonia L. Baum, M.D.
Aaron T. Beck, M.D.
Judith S. Beck, Ph.D.
Daniel F. Becker, M.D.
Judith V. Becker, Ph.D.
Alan R. Beeber, M.D.
Edgard Belfort M.D.
Carl C. Bell, M.D.
Alan S. Bellack, Ph.D.
Selim Benbadis, M.D.
Donna S. Bender, Ph.D.
David Benecke, M.D.
Elisa P. Benedek, M.D.
Lara M. Benedek, M.D.
David A. Benzer, M.D.
Jon S. Berlin, M.D.
Carol A. Bernstein, M.D.
David P. Bernstein, Ph.D.
Vladimir Berthaud
Nadeem H. Bhanji, M.D.
Shyam Bhak, M.D.
Laura J. Bienet, M.D.
Rene L. Binder, M.D.
Sarah Bingham, M.D.
Catherine A. Birndorf, M.D.
Nancy M. Bivens, M.D.
Edward Bixler, M.D.
Anelia Bizarkierz, M.D.
Thorstur Bjorgvinsson, Ph.D.
John L. Black, M.D.
Vincent J. Blanch, M.D.
Roger Bland, M.D.
Karen Blank, M.D.
Mel Blaustein, M.D.
Efraim Bleiberg, M.D.
Barton J. Blinder, M.D.
Floyd E. Bloom, M.D.
Nancee Blum, M.S.W.
Sheila B. Blume, M.D.
Martin Bobus, M.D.
Vladimir Bolarious, M.D.
Robert J. Boland, M.D.
Angelo S. Boka, Ph.D.
Michael P. Bond, M.D.
Richard Bonnie, J.D.
Howard E. Book, M.D.
Soo Borson, M.D.
Jonathan F. Borus, M.D.
Pierre Boulanger, M.D.
Stephanie J. Brister, M.D.
Thomas M. Brod, M.D.
Edward S. Brodlin, M.D.
David W. Brooks, M.D.
Bet Ann Brooks, M.D.
Glenn A. Brotman, M.D.
Richard P. Brown, M.D.
Kumaraswamy Budur, M.D.
Viet Q. Bu, M.D.
Stephen E. Bue, M.D.
Page Burkholder, M.D.
Harold J. Buvrzajz, M.D.
Vivien K. Burt, M.D.
Kenneth G. Bush, M.D.
Jeremy R. Butler, M.D.
Victor J. Buwakda, M.D.
Robert P. Cabaj, M.D.
Consuelo C. Caigade, M.D.
Norana I. Caviño, M.D.
Jose M. Caldas de Almeida, Ph.D.
Eve Caligero, M.D.
Nicola N. Campbell, M.D.
Ana F. Camo, M.D.
Adalberto Campo-Arias, M.D.
Francesca Cannato Antognini, Ph.D.
Angel A. Carbollo, M.D.
Alex A. Cardoni, M.S.
Daniel J. Carlas, M.D.
Rosalind D. Cartwright, Ph.D.
Brady G. Case, M.D.
Delane E. Casiano, M.D.
Daniel Castellanos, M.D.
Lisa A. Carapano, M.D.
Josephine M. Caubel, M.D.
Andrea Celentano, Ph.D.
Leon-Patrice Celestin, M.D.
Smodar Celestin-Westreich, Ph.D.
Kenneth M. Certa, M.D.
Carlyle H. Chan, M.D.
Prabha S. Chandra, M.D.
Grace Chang, M.D.
Laura M. Chapman, M.D.
Irene Chatooor, M.D.
Haroon R. Chaudhry, M.D.
Joseph A. Cheong, M.D.
Anna R. Childress, M.D.
Lois W. Choi-Kain, M.D.
Steve Choong Kim Chong, M.D.
Frank H. Chon, M.D.
Eva W.C. Chow, M.D.
George Christodoulou, M.D.
Henry T. Chuang, M.D.
Roberto Cecchiocito, Ph.D.
J. Richard Ciccone
Domenic Ciraulo, M.D.
Connie L. Clark, M.D.
David Clarke
Norma V. Clarke, M.D.
John F. Clarkin, Ph.D.
Norman A. Clemens, M.D.
Marylene Cloitre, Ph.D.
C. Robert Clowing, M.D.
Susan D. Cochran, Ph.D.
G. Edward Coffey, Ph.D.
Carl I. Cohen, M.D.
Judith Cohen, M.D.
Yolonda R. Coleman, M.D.
Pierre Collant, Ph.D.
Gary R. Collins, M.D.
Pamela Y. Collins
Joan M. Collison, M.D.
James D. Collinver, Ph.D.
Lilliam Conos-Diaz, Ph.D.
Lee Cramb-Neumann-Graham, M.D.
James P. Comer, M.D.
Wilco M. Connop, M.D.
Kevin Conway Ph.D.
Gabriella Corona-Locatelli, M.D.
Cheryl Corcoran, M.D.
Maurice Corosoc, Ph.D.
Jack R. Cornelius, M.D.
Benedette M. Cortese, M.D.
William H. Corry, M.D.
Linda B. Cottier, Ph.D.
Francine Couroz, M.D.
Jennifer Covino, M.P.A.
John L. Cox, M.D.
Stephen J. Cozza, M.D.
Marlyn Craven, M.D.
Margaret Geal, LL.B.
Brian Crowley, M.D.
Anne Marie Crustoio, B.S.N.
Mario Cruz, M.D.
Pin Cuiipers, M.D.
Cristina Cusin, M.D.
Ronald E. Dalh, M.D.
Richard E. D’Alli, M.D.
Arthur Dalton Ph.D.
Patricia A. Daly, M.D.
Kieran T. Dang, M.D.
Pinhas N. Dannon, M.D.
Deborah Danoff, M.D.
Donald A. Davidoff, Ph.D.
Larry Davidsno, Ph.D.
Leah Davidso, M.D.
Max Day, M.D.
John M. De Figueiredo, M.D.
Roger J. Debevoise, Ph.D.
Prashant Debiprasad, B.A.
Jack J. Dekker, Ph.D.
Salvador R. Del Rosario, Jr., M.D.
Mark H. Dell, M.D.
Mark A. Demidovich, M.D.
Wayne H. Denton, M.D., Ph.D.
Yves Depauw, M.D.
Ablasha K. Dese, M.D.
Parameshwarra P. Deva, M.D.
Michael J. Devlin, M.D.
Vasant P. Dhople, M.D.
Danielle M. Dick, Ph.D.
Daniel P. Dickstein, M.D.
Leah Dickstein, M.D.
Steven G. Dickstein, M.D.
Lawrence H. Diller M.D.
Rosalinda Dierienozo, M.D.
Brent Divetry
Shilpa P. Diwan, M.D.
Nisha Dogra, M.D.
Antoine B. Douaisiy, M.D.
Jennifer F. Downey, M.D.
Jennifer F. Dray, M.D.
Jack Drescher, M.D.
Nehama Dresner, M.D.
Laura Drury, M.S.W.
Stacy S. Drury, M.D.
Benjamin G. Druss, M.D.
Russell F. D’Souza, M.D.
Dralle Duan, M.D.
Kenneth Duckworth, M.D.
Scott Dudgen, M.B.A.
Furfriends F. Dufly, Ph.D.
Laura B. Dunn, M.D.
Joanne Dunnigan, M.S.W.
Stephanie S. Duvathy, M.D.
Loretta E. Duvall
Gregg Dwyer, M.D.
Howard J. Ebergey, Ph.D.
Christopher Edwards, Ph.D.
Anke A. ELHadj, Ph.D.
Jane L. Eisen, M.D.
Leon Eisenberg, M.D.
Harold I. Eis, M.D.
Juliana I. Ekon, M.D.
Zeinab S. Eljab, Ph.D.
Todd Elwyn, M.D.
Mary Jane England, M.D.
Spencer Erb, M.D.
Amir Erkin, M.D.
Amy Farabaugh, Ph.D.
Tiffany R. Farchione, M.D.
Larry R. Faulkner, M.D.
Paul Farley
Fawzy I. Fawzy, M.D.
Paul Pearson
Paul Feasley
Rudolf A. Feinjen, M.D.
Theodore B. Feldman, M.D.
Leah A. Fennell, M.D.
Francisco Fernandez, M.D.
Donald C. Fidler, M.D.
Sanford I. Finkel, M.D.
Michael B. First, M.D.
Ellen R. Fischbein, M.D.
Bernard A. Fischer IV, M.D.
Alison Fleming, Ph.D.
Candace M. Fleming, Ph.D.
Juliane Flynn, M.D.
Laura J. Fochtman, M.D.
Timothy W. Fong, M.D.
Julian Ford
Benefit Concert

Toronto Welsh Male Voice Choir
Lenard Whiting conducting
Kathryn Tremills accompanist

Giles Tomkins soloist

May 22, 2006 at 7:00 PM
Metro Toronto Convention Centre

Proceeds to the Disaster relief Fund
AMERICAN
PSYCHIATRIC
ASSOCIATION™
159TH ANNUAL MEETING, TORONTO, CANADA MAY 20-25, 2006

Slides and Audio of the Top Annual Meeting Sessions Captured On-Line

2006 Annual Meeting Online
Your One-Stop Educational Resource Library

“APA Annual Meeting Online” is an e-resource for psychiatrists to learn and earn CME credits through the 2006 Annual Meeting Online library - providing state-of-the-art audio-visual programs that offer a dynamic learning experience 24/7.

• FREE access for those attending APA 2006
• 100+ hours of content to review from the 2006 and 2005 Annual Meetings
• Vast online, searchable database
• Review presentations from world renowned faculty
• Participate online and earn CME credit
• Free admission to everyone for Industry-supported Symposia
• Select sessions also available on DVD-ROMs

More information will be available post-meeting. Look for more details to follow. Save your meeting badge for your access number to the site.

Visit the APA Annual Meeting Online
www.psych.org/amlibrary
SATURDAY, MAY 20, 2006

199TH ANNUAL MEETING

8:00 a.m. Sessions

COURSES 1-3

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

Course 1 8:00 a.m.-12 noon
Room 703, Level 700, Toronto Convention Centre South

DYNAMIC PSYCHOTHERAPY FOR CANCER PATIENTS AND THEIR SPOUSES

Director: Norman Straker, M.D.

Course 2 8:00 a.m.-12 noon
Room 705, Level 700, Toronto Convention Centre South

RESEARCH ON A SHOESTRING BUDGET

Director: Mantosh J. Dewan, M.D.
Faculty: Michele T. Pato, M.D., Stephen V. Faraone, Ph.D.

Course 3 8:00 a.m.-12 noon
Room 715 A, Level 700, Toronto Convention Centre South

COGNITIVE THERAPY FOR SCHIZOPHRENIA

Director: Jesse H. Wright III, M.D.
Faculty: David G. Kingdon, M.D., Douglas Turkington, M.D.

9:00 a.m. Sessions

COURSES 4-9

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

Course 4 9:00 a.m.-4:00 p.m.
Room 709, Level 700, Toronto Convention Centre South

INTERPERSONAL PSYCHOTHERAPY

Co-Directors: Scott P. Stuart, M.D., Paula Ravitz, M.D.

Course 5 9:00 a.m.-4:00 p.m.
Room 714 B, Level 700, Toronto Convention Centre South

A PRACTICAL APPROACH TO RISK ASSESSMENT

Director: William H. Campbell, M.D.

Course 6 9:00 a.m.-4:00 p.m.
Room 716 A, Level 700, Toronto Convention Centre South

BASIC CONCEPTS IN ADMINISTRATIVE PSYCHIATRY I: THEORY, HUMAN RESOURCES, AND FISCAL MANAGEMENT

Director: Shivkumar S. Hatti, M.D.
Faculty: Stuart B. Silver, M.D., Arthur L. Lazarus, M.D., Mark Russakoff, M.D., Sy A. Saeed, M.D.

Course 7 9:00 a.m.-4:00 p.m.
Room 716 B, Level 700, Toronto Convention Centre South

TEACHING ADDICTION MEDICINE USING FILMS

Director: Petros Levounis, M.D.
Faculty: Christopher J. Welsh, M.D., Tony Juneja, M.D., Glenn A. Brottmann, M.D.

Course 8 9:00 a.m.-4:00 p.m.
Room 717 A, Level 700, Toronto Convention Centre South

THERAPEUTIC INTERVENTIONS IN EATING DISORDERS: BASIC PRINCIPLES

Director: David C. Jimerson, M.D.
Faculty: Joel Yager, M.D., Michael J. Devlin, M.D., James E. Mitchell, M.D., Katherine A. Halmi, M.D.

Course 9 9:00 a.m.-4:00 p.m.
Room 809, Level 800, Toronto Convention Centre South

A COMPREHENSIVE REVIEW OF HYPNOSIS USE IN CLINICAL PSYCHIATRY

Director: Jose R. Maldonado, M.D.
Faculty: David Spiegel, M.D., Matthew May, M.D.

12:30 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 1-4

INDUSTRY-SUPPORTED SYMPOSIUM 1
12:30 p.m.-3:30 p.m.
John Basset Theatre, Level 100, Convention Centre North

NEW AUGMENTATION STRATEGIES IN DEPRESSION FOR BETTER OUTCOMES
Supported by GlaxoSmithKline

Chp.: Jonathan E. Alpert, M.D.

A Polypharmacy for Depression: How Often Is It Used and Why?
Joshua A. Israel, M.D.

(Continued on next page)
B  “How To”: Augmentation Strategies in Resistant Depression  
   Charles DeBattista, M.D.

C  When Does Polypharmacy Lead to Higher Remission Rates?  
   Jonathan E. Alpert, M.D.

D  Adding Psychotherapy: Pearls for Improved Outcomes  
   Amy Farabaugh, Ph.D.

E  Pharmacological Antidotes for Antidepressant-Induced Side Effects  
   Anita H. Clayton, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 2  
12:30 p.m.-3:30 p.m.  
Canadian Room, Convention Floor, Royal York

STRATEGIES FOR MAINTAINING WELLNESS IN PATIENTS WITH BIPOLAR DISORDER: MOVING BEYOND EFFICACY TO EFFECTIVENESS  
Supported by Bristol-Myers Squibb Company and Otsuka America Pharmaceuticals, Inc.

Chp.: Gary S. Sachs, M.D.

A  Brains and Genes: Implications for the Treatment of Bipolar Disorder  
   Kiki D. Chang, M.D.

B  Impact of Patient Satisfaction With Treatment on Treatment Options  
   Holly A. Swartz, M.D.

C  Evaluation of Bipolar Trials  
   Gary S. Sachs, M.D.

D  Impact of Misdiagnosis of Bipolar Disorder  
   Claudia F. Baldassano, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 3  
12:30 p.m.-3:30 p.m.  
Concert Hall, Convention Floor, Royal York

NAVIGATING THE MAZE: UNDERSTANDING METHODS, RESULTS, AND RISKS IN PSYCHIATRIC RESEARCH  
Supported by Forest Pharmaceuticals, Inc.

Chp.: David J. Kupfer, M.D.

A  Assessing Statistical and Clinical Significance in Medical Research  
   David J. Kupfer, M.D.

B  All Risk Factors Are Not Created Equal: The Importance of Defining and Interpreting Risk on Medical Decision Making and Patient Care  
   Helena C. Kraemer, Ph.D.

C  Determining Efficacy: Sound Clinical Trial Design and Interpretation  
   Cornelius Katona, M.D.

D  Treating Depression in Children and Adolescents: What’s a Clinician To Do?  
   Jeff Q. Bostic, M.D.

E  How to Treat in the Absence of Scientific Evidence: A Focus on Anxiety Disorders in the Elderly  
   Eric J. Lenze, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 4  
12:30 p.m.-3:30 p.m.  
Grand Ballroom, Lower Concourse, Sheraton Centre

BRIDGING SLEEP, SCIENCE, AND PUBLIC POLICY  
Supported by Takeda Pharmaceuticals North America, Inc.

Chp.: David N. Neubauer, M.D.

A  The Science of Sleep  
   David N. Neubauer, M.D.

B  Adolescents and School Start Times: The Intersection of Research and Public Policy  
   R. Robert Auger, M.D.

C  Shiftwork, Sleep, and Performance  
   Gregory Belenky, M.D.

D  Medical Education and Resident Duty Hours  
   Phyllis C. Zee, M.D.

E  Insomnia and Public Policy  
   Daniel J. Buysse, M.D.

1:00 p.m. Sessions

COURSES 10-14  
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

Course 10  
1:00 p.m.-5:00 p.m.  
Room 703, Level 700, Toronto Convention Centre South

DREAM TRANSLATION: ONE EMPIRICALLY-BASED APPROACH

Director: Milton Kramer, M.D.

Course 11  
1:00 p.m.-5:00 p.m.  
Room 705, Level 700, Toronto Convention Centre South

CLINICIAN ADMINISTERED RATING SCALES FOR MOOD AND ANXIETY DISORDERS

Co-Directors: Sagar V. Parikh, M.D., Vytas P. Velyvis, M.A.
Course 12  1:00 p.m.-5:00 p.m.
Room 713 A, Level 700, Toronto Convention Centre South

INTRODUCTION TO TRANSCRANIAL MAGNETIC STIMULATION

Director: Ziad H. Nahas, M.D.
Faculty: Mark Demitrack, M.D., Frank A. Koziel, M.D., John P. O'Reardon, M.D., Shirlene M. Sampson, M.D.

Course 13  1:00 p.m.-5:00 p.m.
Room 714 A, Level 700, Toronto Convention Centre South

THE EVALUATION AND IDENTIFICATION OF THE MAJOR DEMENTIAS

Director: Raymond A. Faber, M.D.
Faculty: Kevin F. Gray, M.D., Randolph B. Schiffer, M.D.

Course 14  1:00 p.m.-5:00 p.m.
Room 717 B, Level 700, Toronto Convention Centre South

COLLABORATION BETWEEN MENTAL HEALTH AND PRIMARY CARE PROVIDERS: WHAT WORKS AND HOW TO DO IT

Director: Nick Kates, M.B.
Faculty: Marilyn Craven, M.D., Lindsey George, M.D., Jonathan S. Davine, M.D., Michele Mach, M.S.W., Anne Marie Crustolo, B.S.N., Roger Bland, M.B.

6:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 5-8

INDUSTRY-SUPPORTED SYMPOSIUM 5
6:00 p.m.-9:00 p.m.
John Basset Theatre, Level 100, Convention Centre North

MANIA IN SPECIAL POPULATIONS
Supported by Shire US, Inc.

Chp.: Robert M.A. Hirschfeld, M.D.

A  Recent Developments in the Treatment of Mania
Robert M.A. Hirschfeld, M.D.

B  Recognition and Management of Child and Adolescent Bipolar Disorder
Karen D. Wagner, M.D.

C  Bipolar Disorders in Women: Clinical and Metabolic Correlates
Natalie L. Rasgon, M.D.

D  Bipolar Disorders in the Older Patient
Brent P. Forester, M.D.

E  Recognizing Bipolar Disorder in African Americans
William B. Lawson, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 6
6:00 p.m.-9:00 p.m.
Canadian Room, Convention Floor, Royal York

VERGING ON REALITY: EMERGENT THERAPEUTIC ADVANCES IN SCHIZOPHRENIA
Supported by Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

Chp.: Peter F. Buckley, M.D.

A  Functional Genomics and the Therapeutic Effects of Antipsychotics
Anil K. Malhotra, M.D.

B  Brain Imaging Techniques as Clinical Tools
Carol A. Tamminga, M.D.

C  In Search of Wellness: Subjective Tolerability of Second Generation Antipsychotics
Meera Narasimhan, M.D.

D  Recovery and Remission: Definitions, Dilemmas, and the Emergent Role of Peer Support Specialists
Peter F. Buckley, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 7
6:00 p.m.-9:00 p.m.
Concert Hall, Convention Floor, Royal York

BIPOLAR DISORDER: CREATING A CONSENSUS FROM SCIENCE TO PUBLIC POLICY
Supported by Solvay Pharmaceuticals and Wyeth Pharmaceuticals

Chp.: Mark H. Rapaport, M.D.

A  The Impact of Psychosocial Treatment on the Course and Prognosis of Bipolar Disorder
Ellen Frank, Ph.D.

B  A Rational Approach for the Longitudinal Pharmacologic Management of Patients With Bipolar Disorder: An Argument for Changing Public Policy
Mark H. Rapaport, M.D.

C  Alternative Pharmacologic Approaches to the Care of Bipolar Patients
Alexander H. Fan, M.D.

D  Treatment Considerations for Mania in Young Children
Barbara Geller, M.D.

E  Treatment of Bipolar Disorder in U.S. Jails and Prisons
Joseph R. Calabrese, M.D.

3
SATURDAY

INDUSTRY-SUPPORTED SYMPOSIUM 8
6:00 p.m.-9:00 p.m.
Grand Ballroom, Lower Concourse, Sheraton Centre

TREATMENT-RESISTANT DEPRESSION: NEW DATA, NEW APPROACHES
Supported by Cyberonics, Inc.

Chp.: David L. Dunner, M.D.

A Definitions and Clinical Characteristics of Treatment-Resistant Depression
David L. Dunner, M.D.

B Treatment Resistance and Genes: The Biology Versus Pharmacology Enigma
Francisco A. Moreno, M.D.

C PET of Chronic Vagal Nerve Stimulation for Severe, Treatment-Resistant Depression
Jose V. Pardo, M.D.

D Augmentation Strategies for Patients With Difficult-to-Treat MDD
Alicia R. Ruelaz, M.D.

E Brain Stimulation Therapies for Treatment-Resistant Depression
Linda L. Carpenter, M.D.
SUNDAY, MAY 21, 2006

159TH ANNUAL MEETING

8:00 a.m. Sessions

COURSES 15-22

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

Course 15 8:00 a.m.-12 noon
Room 701 A, Level 700, Toronto Convention Centre South

ADD IN CHILDREN AND ADOLESCENTS

Director: Thomas E. Brown, Ph.D.
Faculty: Jefferson B. Prince, M.D.

Course 16 8:00 a.m.-12 noon
Room 703, Level 700, Toronto Convention Centre South

IMPROVING YOUR PRESENTATION SKILLS: A COACHING APPROACH

Director: Luis F. Ramirez, M.D.

Course 17 8:00 a.m.-12 noon
Room 709, Level 700, Toronto Convention Centre South

HOME TREATMENT FOR ACUTE MENTAL DISORDERS: AN ALTERNATIVE TO HOSPITALIZATION

Director: David S. Heath, M.B.

Course 18 8:00 a.m.-12 noon
Room 711, Level 700, Toronto Convention Centre South

RECOVERY AND SUPPORTED EMPLOYMENT: EVIDENCE-BASED INTEGRATION FOR PSYCHIATRY

Co-Directors: Eugene A. Oulvey, Ph.D., Karen L. Lee, M.A.
Faculty: Connie L. Clark, M.Ed., Michael J. Martin, M.D.

Course 19 8:00 a.m.-12 noon
Room 713 B, Level 700, Toronto Convention Centre South

MANAGEMENT OF PSYCHIATRIC DISORDERS IN PREGNANT AND POSTPARTUM MOTHERS

Co-Directors: Shara Misri, M.D., Diana Carter, M.D.
Faculty: Maria R. Corral, M.D., Shari Lusskin, M.D., Deirdre M. Ryan, M.D.

Course 20 8:00 a.m.-12 noon
Room 714 B, Level 700, Toronto Convention Centre South

INTERPERSONAL PSYCHOTHERAPY

Director: John C. Markowitz, M.D.

Course 21 8:00 a.m.-12 noon
Room 715 A, Level 700, Toronto Convention Centre South

RISK ASSESSMENT FOR VIOLENCE

Director: Phillip J. Resnick, M.D.

Course 22 8:00 a.m.-12 noon
Room 717 A, Level 700, Toronto Convention Centre South

USING BOUNDARY CROSSINGS AS CREATIVE THERAPY INSTEAD OF SLIPPERY SLOPES

Director: Gail E. Robinson, M.D.
Faculty: Gary R. Schoener, Psy.D., Howard E. Book, M.D., Linda M. Jorgenson, J.D.

INDUSTRY-SUPPORTED SYMPOSIA 9-13

INDUSTRY-SUPPORTED SYMPOSIUM 9
8:00 a.m.-11:00 a.m.
John Basset Theatre, Level 100, Convention Centre North

DIFFERENTIATING ATYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA: FROM THEORY TO PRACTICE
Supported by Pfizer, Inc.

Chp.: Anissa Abi-Dargham, M.D.

A Pharmacodynamic Differences Among Antipsychotic Treatments
Anissa Abi-Dargham, M.D.

B The Antipsychotic Effect: Lessons From Occupancy Studies
W. Gordon Frankle, M.D.

C Evaluation of Metabolic Outcome During Antipsychotic Treatment: Lessons From CATIE and Other Recent Studies
John W. Newcomer, M.D.

D Cognitive Responses to Atypical Antipsychotic Medications: Factors Affecting the Potential to Differentiate Treatments
Philip D. Harvey, Ph.D.

E Clinical Integration in the Care for Patients With Schizophrenia: What Are the Current Best Practices?
Robert A. Rosenheck, M.D.
INDUSTRY-SUPPORTED SYMPOSIUM 10
8:00 a.m.-11:00 a.m.
Canadian Room, Convention Floor, Royal York

FIBROMYALGIA: SCIENTIFIC ADVANCES TO REDUCE THE BURDEN OF ILLNESS
Supported by Eli Lilly and Company

Chp.: Lesley M. Arnold, M.D.

A The Socioeconomic Burden of Fibromyalgia
   Sharon B. Stanford, M.D.

B New Evidence for the Pathophysiological Basis of Fibromyalgia
   Lesley M. Arnold, M.D.

C Current and Emerging Strategies for the Pharmacologic Management of Fibromyalgia
   Leslie J. Crofford, M.D.

D Living With Fibromyalgia: A Patient's Perspective
   Lesley M. Arnold, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 11
8:00 a.m.-11:00 a.m.
Concert Hall, Convention Floor, Royal York

EXPANDING THE NEUROBIOLOGICAL AND NEUROPSYCHOLOGICAL FOUNDATION OF ADHD: IMPACT TO CLINICAL PRACTICE
Supported by Shire US, Inc.

Chp.: Thomas J. Spencer, M.D.

A ADHD Neuropsychology and Executive Function Deficits
   Larry J. Seidman, Ph.D.

B Stimulants: Therapeutic and Reinforcing Effects
   Nora D. Volkow, M.D.

C The Relevance of the Trace Amine Phenylethylamine (PEA) to ADHD
   Bertha K. Madras, Ph.D.

D New Insights Into the Noradrenergic System in ADHD
   Amy F. Arnsen, Ph.D.

E Advances in the Therapeutics of ADHD
   Paul G. Hammerness, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 12
8:00 a.m.-11:00 a.m.
Grand Ballroom, Lower Concourse, Sheraton Centre

THE IMPACT OF ANXIETY DISORDERS: A CASE-BASED APPROACH TO IMPROVING OUTCOMES AND REMOVING STIGMA
Supported by Cephalon, Inc.

Chp.: Ned H. Kalin, M.D.

A Public Health Consequences of Anxiety: A Surgeon General's Perspective
   David Satcher, M.D.

B Individual Consequences of Anxiety
   Risa B. Weisberg, Ph.D.

C Anxiety Disorders: A Glimpse Inside the Brain
   Ned H. Kalin, M.D.

D Linking Symptoms to Treatment Selection in Anxiety Disorders
   Murray B. Stein, M.D.

E Nonpharmacologic Approach to the Treatment of Anxiety Disorders
   Edna B. Foa, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 13
8:00 a.m.-11:00 a.m.
Metro Grand Ballroom, Second Level, Westin Harbour Castle

NEW VISTAS IN TREATMENT-RESISTANT DEPRESSION
Supported by Pfizer, Inc.

Chp.: Charles B. Nemeroff, M.D.

A Evolving Concepts in Treatment-Resistant Depression
   Charles B. Nemeroff, M.D.

B Neuropharmacological Basis for Treatment Strategies in the Management of Refractory Depression
   Stephen M. Stahl, M.D.

C New Strategies for Treatment-Resistant Depression
   Linda L. Carpenter, M.D.

D Re-Evaluating Concepts of Depression: Bipolar Spectrum
   S. Nassir Ghaemi, M.D.

9:00 a.m. Sessions

COURSES 23-30

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

Course 23 9:00 a.m.-4:00 p.m.
Room 705, Level 700, Toronto Convention Centre South

DAVANLOO'S INTENSIVE SHORT-TERM DYNAMIC PSYCHOTHERAPY IN CLINICAL PRACTICE

Director: James Q. Schubmehl, M.D.
Faculty: Alan R. Beeber, M.D.
Course 24 9:00 a.m.-4:00 p.m.  
Room 707, Level 700, Toronto Convention Centre South  
KUNDALINI YOGA MEDITATION TECHNIQUES FOR MENTAL HEALTH  
Director: David Shannahoff-Khalsa, B.A.

Course 25 9:00 a.m.-4:00 p.m.  
Room 713 A, Level 700, Toronto Convention Centre South  
INTRODUCTION TO COGNITIVE-BEHAVIORAL THERAPY  
Co-Directors: Robert M. Goisman, M.D., Philip G. Levendusky, Ph.D.

Course 26 9:00 a.m.-4:00 p.m.  
Room 714 A, Level 700, Toronto Convention Centre South  
THE MANAGEMENT OF THE SEXUAL ABUSE PHENOMENON: A GLOBAL PERSPECTIVE: A BELGIAN APPROACH  
Director: Yves Depauw, M.D.  
Faculty: Pierre Collart, Ph.D.

Course 27 9:00 a.m.-4:00 p.m.  
Room 715 B, Level 700, Toronto Convention Centre South  
PSYCHOTHERAPY FOR BORDERLINE PERSONALITY  
Co-Directors: Otto F. Kernberg, M.D., Frank E. Yeomans, M.D.  
Faculty: John F. Clarkin, Ph.D., Eve Caligor, M.D.

Course 28 9:00 a.m.-4:00 p.m.  
Room 716 A, Level 700, Toronto Convention Centre South  
BASIC CONCEPTS IN ADMINISTRATIVE PSYCHIATRY II: CARE MANAGEMENT, LAW, AND ETHICS  
Director: Shivlukumar S. Hatti, M.D.  
Faculty: Arthur L. Lazarus, M.D., Robert Atkins, M.D., William H. Reid, M.D.

Course 29 9:00 a.m.-4:00 p.m.  
Room 716 B, Level 700, Toronto Convention Centre South  
TREATING BPD WITH THE SYSTEMS TRAINING FOR EMOTIONAL PREDICTABILITY AND PROBLEM SOLVING (STEPSS) MODEL  
Director: Donald W. Black, M.D.  
Faculty: Bruce M. Pfohl, M.D., Nancee Blum, M.S.W.

12:30 p.m. Session

BUSINESS MEETING  
(Voting Members Only)  
12:30 p.m.-1:30 p.m.  
Room 106, Level 100, Toronto Convention Centre North  
CALL TO ORDER  
Steven S. Shapiro, M.D., President

MEMORIAL TO DECEASED MEMBERS  
ANNOUNCEMENT OF ELECTION RESULTS  
Lisa H. Gold, M.D., President, Committee of Fellows

REPORTS TO THE MEMBERSHIP  
Secretary-Treasurer: Carolyn B. Robinson, M.D.  
Speaker, Assembly: Joseph E. Van Ryn, M.D.  
Speaker, East Assembly: Michael Black, M.D.  
Chairperson, Committee on Ethics: William C. Wood, M.D.  
Chairperson, Election Committee: David S. Wohl, M.D.  
Chairperson, Membership Committee: Mary K. Marron, M.D.  
Medical Director and CEO: James H. Scully, Jr., M.D.  
Chairperson of Council (Written Reports Only)

ANNUAL FORUM

ADJOURNMENT  
*Members-in-Training, General Members, Distinguished Fellows, Fellows, Life Fellows, Distinguished Life Fellows, and Life Members: Badge or APA membership card necessary for admission. No cameras or tape recorders will be permitted.

1:00 p.m. Sessions

COURSES 31-37  
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

Course 31 1:00 p.m.-5:00 p.m.  
Room 701 A, Level 700, Toronto Convention Centre South  
DRUG TREATMENT OF SCHIZOPHRENIA  
Co-Directors: Philip C. Janicak, M.D., Morris B. Goldman, M.D.  
Faculty: Stephen R. Marder, M.D., Rajiv Tandon, M.D.
1:30 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 14-19

INDUSTRY-SUPPORTED SYMPOSIUM 14
1:30 p.m.-4:30 p.m.
John Basset Theatre, Level 100, Convention Centre North

NEW DEVELOPMENTS IN SCHIZOPHRENIA:
FROM NEUROBIOLOGY TO PUBLIC HEALTH
Supported by Solvay Pharmaceuticals and Wyeth Pharmaceuticals

Chp.: John M. Kane, M.D.

A Pharmacologic Treatment of Schizophrenia: The State-of-the-Art
John M. Kane, M.D.

B From Dopamine to Delusions: Understanding Psychosis From the Bench to the Bedside
Shitij Kapur, M.D.

C Cognitive Functioning in Schizophrenia: Cognitive Impairments as Clues for Treatment Development
Robert M. Bilder, Ph.D.

D Metabolic Risks of Second-Generation Antipsychotic Medications
Christoph U. Correll, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 15
1:30 p.m.-4:30 p.m.
Canadian Room, Convention Floor, Royal York

VITAL SIGNS IN PSYCHIATRY: A PERSPECTIVE ON SLEEP ACROSS THE LIFE CYCLE
Supported by Sepracor, Inc.

Chp.: Eric A. Nofzinger, M.D.

A Sleep in Infancy, Childhood, and Adolescence: Normal Sleep Patterns, Developmental Issues, and Sleep Problems
Jodi Mindell, M.D.

B Insomnia in Adulthood: Causes, Consequences, and Treatment
Ned H. Kalin, M.D.

C Insomnia Secondary to Medical or Psychiatric Comorbidity: Implications for Evaluation and Management
Matthias K. Lee, M.D.

D Sleep in Women Across the Life Cycle: How the Reproductive Cycle Impacts Sleep
Meir Kryger, M.D.

E Sleep in the Elderly: Is Poor Sleep a Normal Concomitant of Advancing Age?
Sanford Finkel, M.D.
INDUSTRY-SUPPORTED SYMPOSIUM 16
1:30 p.m.-4:30 p.m.
Concert Hall, Convention Floor, Royal York

INTERRUPTING THE CYCLE OF VASCULAR DISEASE AND DEPRESSION
Supported by Forest Pharmaceuticals, Inc.

Chp.: Steven P. Roose, M.D.

A Vascular Disease: Mechanisms Underlying the Relationship
Dominique L. Musselman, M.D.

B The Bidirectional Relationship Between Diabetes and Depression
Sanjay T. Mathew, M.D.

C Post-Stroke Depression and the Vascular Depression Hypothesis
David C. Steffens, M.D.

D Vascular Disease and Depression: Challenges in Management and Treatment
Christopher M. O'Connor, M.D.

E Clinical Treatment Perspectives: A Focus on Diagnosis and Safety
J. Craig Nelson, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 18
1:30 p.m.-4:30 p.m.
Frontenac Room, Street Level, Westin Harbour Castle

MISDIAGNOSIS OF BIPOLAR II: METHODS FOR SCREENING PATIENTS AT RISK FOR BIPOLAR DISORDER
Supported by GlaxoSmithKline

Chp.: Frederick K. Goodwin, M.D.

A Diagnosing Bipolar Disorder and the Role of Screening Instruments
Terence A. Ketter, M.D.

B Major Depression: Clues to Bipolarity
Hagop S. Akiskal, M.D.

C Bipolar Depression: Implications for Morbidity, Mortality, and Therapeutics
Ross J. Baldessarini, M.D.

D Antidepressants and the Bipolar Spectrum
S. Nassir Ghaemi, M.D.

E Depression and the Affective Spectrum: The Role of Mood Stabilizers
Frederick K. Goodwin, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 17
1:30 p.m.-4:30 p.m.
Grand Ballroom, Lower Concourse, Sheraton Centre

THE LONG-TERM CLINICAL COURSE AND TREATMENT OF RECURRENT MAJOR DEPRESSION IN 2006: NEW DATA AND FUTURE DIRECTIONS
Supported by Wyeth Pharmaceuticals

Chp.: Martin B. Keller, M.D.

A The Pernicious Course of Major Depression: New Findings From a 20-Year Prospective Follow-Up Study
Martin B. Keller, M.D.

B Risk for Major Depression: Genes, Stress, and the HPA Axis
Audrey R. Tyrka, M.D.

C Biological and Imaging Changes in Depression
K. Ranga R. Krishnan, M.B.

D Using Pharmacogenetics in Practice
Alan F. Schatzberg, M.D.

E Current State of Evidence-Based Treatment of Depression
Madhukar H. Trivedi, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 19
1:30 p.m.-4:30 p.m.
Metro Grand Ballroom, Second Level, Westin Harbour Castle

ADVANCES IN THE UNDERSTANDING OF THE DEMENTIA SPECTRUM
Supported by Eisai, Inc. and Pfizer, Inc.

Chp.: Jeffrey L. Cummings, M.D.

A The Neurobiology of Alzheimer's Disease
David A. Bennett, M.D.

B Therapeutic Options in the Management of Vascular Dementia
David Wilkinson, M.B.

C Evolution in the Understanding and Treatment of Mild Cognitive Impairment
Gregory A. Jicha, M.D.

D Improving Outcomes for Patients With Advanced Dementia
Howard Feldman, M.D.

E Optimizing Behavioral Outcomes Across the Dementia Spectrum
Jeffrey L. Cummings, M.D.
2:30 p.m. Session

LECTURE 1
2:30 p.m.-4:00 p.m.
Room 127, Level 100
Forum Convention Centre North

AAPI / APA'S MANFRED S. GUTTMACHER
AWARD LECTURE

Liza H. Gold, M.D.

The Challenge of Employment-Related
Psychiatric Evaluations

Chp.: Michael A. Norko, M.D.

Liza H. Gold, M.D., a Clinical Associate Professor of
Psychiatry at Georgetown University School of
Medicine in Washington, D.C. She is Associate
Director of the Georgetown Psychiatry Residency
Program in Psychiatry and Law. She received her B.A.,
magna cum laude, from Harvard/Radcliffe College; a
Master of Philosophy Degree in the History of
Medicine from Cambridge University; and her M.D.
from the New York University School of Medicine.
She completed her psychiatric residency training at
Boston University. She has a private clinical and
forensic practice in Arlington, VA. Dr. Gold is the
author of Social Housing: Psychiatric Assessment in
Employment Litigation (2004). She is the coeditor of The
She has contributed chapters on the history of
forensic psychiatry and on employment litigation. She
has authored multiple articles and chapters for other
books relating to employment litigation and other
subjects in forensic psychiatry.
THIS SESSION WILL BE AUDIOTAPED.

5:00 p.m. Session

OFFICIAL OPENING SESSION
5:00 p.m.-6:30 p.m.
Exhibit Hall A, Level 100, Toronto Convention
Centre North

CALL TO ORDER
Steven S. Sharitstein, M.D., President

INTRODUCTION OF STAGE GUESTS
INTRODUCTION OF CHAIRPERSON OF
THE SCIENTIFIC PROGRAM COMMITTEE
Marion I. Butterfield, M.D.
Chapman, Annual Meeting Scientific Program Committee

INTRODUCTION OF DIGNITARIES (Please refer to page 17-18 for a listing of
the presidents of allied organizations.)

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 20-25
INDUSTRY-SUPPORTED SYMPOSIUM 20
7:00 p.m.-10:00 p.m.
John Bassett Theatre, Level 100, Convention Centre North

ALZHEIMER'S DISEASE: CHALLENGING THE
PRACTICE PARADIGM
Supported by Forest Pharmaceuticals, Inc.

Chp.: Pierre N. Tariot, M.D.

A Variability in the Clinical Presentation of Alzheimer's
Disease
M. Saleem Ismail, M.D.

B Treatment Initiation in Alzheimer's Disease
Pierre N. Tariot, M.D.

C Individualizing Alzheimer's Disease Therapy Over the
Disease Course
Constantine Lyketsos, M.D.

D Neuropsychiatric Symptoms in Alzheimer's Disease:
Preventing Emergence and Decreasing Severity
Jeffrey L. Cummings, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 21
7:00 p.m.-10:00 p.m.
Canadian Room, Convention Floor, Royal York

EFFECTIVENESS OF ANTIPSYCHOTIC DRUGS IN
CHRONIC SCHIZOPHRENIA: COMPLETE RESULTS
OF THE CATIE TRIAL
Supported by Eli Lilly and Company

Chp.: Jeffrey A. Lieberman, M.D.

A Comparison of the Primary Outcome Measures of
Efficacy and Safety
Jeffrey A. Lieberman, M.D.

B Comparison of Clozapine Versus Other Atypical Drugs
in Prospectively Defined, Unresponsive Patients
Joseph P. McEvoy, M.D.

C Comparison of Ziprasidone Versus Other Atypical
Drugs in Prospectively Defined, Unresponsive Patients
Thomas S. Stroup, M.D.

D Comparison of Treatment Effects on Cognition
Richard S.E. Keefe, Ph.D.
E  Comparison of Treatments on Health Service Utilization and Cost Effectiveness Measures
   Robert A. Rosenheck, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 22
7:00 p.m.- 10:00 p.m.
Concert Hall, Convention Floor, Royal York

PSEUDOBULBAR AFFECT: A COMMON SYNDROME THAT IS UNDERRECOGNIZED, MISDIAGNOSED, AND UNDERTREATED
Supported by Aventis Pharmaceuticals

Chp.: Randolph B. Schiffer, M.D.

A  The Differential Diagnosis of Pseudobulbar Affect
   David B. Arciniegas, M.D.

B  The Pathophysiology of Pseudobulbar Affect
   Edward C. Lauterbach, M.D.

C  Treatment Options for Pseudobulbar Affect
   Michael C. Graves, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 23
7:00 p.m.- 10:00 p.m.
Grand Ballroom, Lower Concourse, Sheraton Centre

ADVANCES IN THE NEUROBIOLOGY AND THERAPEUTICS OF ADHD
Supported by Cephalon, Inc.

Chp.: Joseph Biederman, M.D.

A  Sleep and ADHD
   Eric Mick, Sc.D.

B  New Therapeutic Developments in ADHD
   Joseph Biederman, M.D.

C  Defining Executive Function Deficits in ADHD
   Ronna Fried, Ed.D.

D  Advances in f-MRI Research in ADHD
   George Bush, M.D.

E  New Targets for Pharmacogenetic Research in ADHD
   Stephen V. Faraone, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 24
7:00 p.m.- 10:00 p.m.
Frontenac Room, Street Level, Westin Harbour Castle

ATYPICAL DEPRESSION: MERGING EVIDENCE AND PUBLIC POLICY
Supported by Bristol-Myers Squibb Company

Chp.: Michael E. Thase, M.D.

A  The Neurobiology of Depression: Bringing the Latest in Science to Clinicians
   Charles B. Nemeroff, M.D.

B  Phenomenology of Atypical Depression
   Hans-Juergen Moeller, M.D.

C  An Evidence-Based Approach to Managing the Disabilities of Atypical Depression
   Justine M. Kent, M.D.

D  Future Directions in the Treatment of Atypical Depression
   Michael E. Thase, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 25
7:00 p.m.- 10:00 p.m.
Metro Grand Ballroom, Second Level, Westin Harbour Castle

INSOMNIA FROM THE INSIDE OUT: FROM NEUROSCIENCE TO CLINICAL EXPERIENCE TO PUBLIC POLICY
Supported by Pfizer, Inc. and Neurocrine Biosciences, Inc.

Chp.: Ellen Frank, Ph.D.
   Co-Chp.: David J. Kupfer, M.D.

A  Insomnia: Symptom, Syndrome, or Disorder?
   Martin B. Keller, M.D.

B  The Science of Insomnia
   Phyllis C. Zee, M.D.

C  Putting the Science to Work
   Daniel J. Buysse, M.D.

D  Insomnia: Cost of Illness, Public Policy, and Medicolegal Issues
   Alan W. Newman, M.D.
2006 Presidents of Allied Organizations

Academy of Organizational and Occupational Psychiatry
Sandra Cohen, M.D.

Academy of Psychosomatic Medicine
Stephen M. Samuels, M.D.

Albanian Psychiatric Society
Professor Austras Suli

American Academy of Addiction Psychiatry
Kathleen Brady, Ph.D.

American Academy of Child and Adolescent Psychiatry
Richard Sarles, M.D.

American Academy of Family Physicians
Mary E. Frank, M.D.

American Academy of Neurology
Thomas R. Stuif, M.D.

American Academy of Psychiatry and the Law
Robert I. Simon, M.D.

American Academy of Psychoanalysis and Dynamic Psychiatry
Joseph P. Merino, M.D.

American Association for Emergency Psychiatry
Jon S. Berlin, M.D.

American Association for Geriatric Psychiatry
Christopher Colenda, M.D.

American Association for Social Psychiatry
Zebulon C. Taintor, M.D.

American Association for the Advancement of Science
John Holden, Ph.D.

American Association of Practicing Psychiatrists
James G. Chester, M.D.

American Association of Chairs of Departments of Psychiatry
John G. Greden, M.D.

American Association of Community Psychiatrists
Wesley Sowers, M.D.

American Association of Directors of Psychiatric Residency Training
Ronald Krusner, M.D.

American Association on Mental Retardation
Valerie J. Bradley

American Board of Psychiatry and Neurology, Inc.
Alan K. Perry, M.D.

American College of Emergency Physicians
Frederick C. Blum, M.D.

American College of Mental Health Administration
Sandra L. Forquer, Ph.D.

American College of Obstetricians and Gynecologists
Douglas W. Laake, M.D.

American College of Physicians-American Society of Internal Medicine
Lyne M. Kirk, M.D.

American College of Psychiatrists
Glen O. Galbraith, M.D.

American College of Psychoanalysis
David E. Ulstein, M.D.

American College of Surgeons
Kathryn D. Anderson, M.D.

American Group Psychotherapy Association
Elizabeth Knight, M.S.W.

American Medical Association
J. Edward Hill, M.D.

American Medical Women's Association
Susan L. Jey, M.D.

American Neurological Association
John Griffin, M.D.

American Neuropsychiatric Association
Richard Restak, M.D.

American Nurses Association
Barbara Blakerney, M.S.

American Orthopsychiatric Association
Diane Willis, M.D.

American Psychiatric Association Alliance
Mary Thurwell

American Psychoanalytic Association
Jon Meyer, M.D.

American Psychological Association
Gerald P. Koocher, Ph.D.

American Psychosomatic Society
Peter Shapiro, M.D.

American Society for Adolescent Psychiatry
Dominic Varo, M.D.

American Society of Addiction Medicine
Elizabeth F. Howell, M.D.

American Society of Clinical Psychopharmacology, Inc.
John M. Kane, M.D.

American Society of Hispanic Psychiatry
Marcel Trujillo, M.D.

American Society of Law, Medicine, and Ethics
Philip Reilly, M.D.

American Society of Psychoanalytic Physicians
Ernest Galis, M.D.

Arab American Psychiatric Association
Donald Hily, M.D.

Arab Federation of Psychiatrists
Dr. Ali Matar

Arab Gulf Psychiatric Association
Dr. M.K. Al Haddad

Argentinean Association of Psychiatrists
Dr. Nestor Marchant
2006 Presidents of Allied Organizations

Amenian Psychiatric Association
Dr. Marietta Melik-Pashkenyan

Association of Argentinean Psychiatrists
Dr. Garcia L. Medastelli

Association of Reformers in Psychiatry/Former USSR and Eastern/Central Europe
Professor Tomu Tomov

Association for Academic Psychiatry
Linda Worley, M.D.

Association for Behavioral and Cognitive Therapies
Martin M. Antony, Ph.D.

Association of American Medical Colleges
Darrell G. Kirch, M.D.

Association of Chinese American Psychiatrists
Edward Pi, M.D.

Association of Directors of Medical Student Education in Psychiatry
Myrl Mandl, M.D.

Association of Free Psychiatrists in Romania
Dr. Aurel Romila

Association of Gay and Lesbian Psychiatrists
Dan Kanisto, M.D.

Association of Psychiatrists in Nigeria
Professor Taiwo Adamson

Association of Psychiatrists of Tajikistan
Dr. Abdurakhid Bokoboev

Association of Women Psychiatrists
Mary Kay Smith, M.D.

Azerbaijan Psychiatric Association
Professor Nadiy Ismaylov

Bangladesh Association of Psychiatrists
Dr. Abul Sobhan

Barbados Association of Psychiatrists
Dr. George Mathy

Black Psychiatrists of America
Patrice A. Harris, M.D.

Bolivian Society of Psychiatry
Dr. Nils Noya-Tapia

Brazilian Association of Psychiatry
Dr. Josimar M.F. Frana

Bulgarian Psychiatric Association
Professor Eugene Georgiev

Byelorussian Psychiatric Association
Dr. Roman A. Evtugnev

Canadian Psychiatric Association
A. Donald Milliken, M.D.

Caribbean Psychiatric Association
Dr. Jacqueline Sherpe

Chinese Society of Psychiatry
Professor Ming Yuan Chang

Colombian Society of Psychiatry
Dr. Pedro Gomez Merced

Costa Rican Psychiatric Association
Dr. Rosa M. Villalobos Rodriguez

Council of Medical Specialty Societies
Gerald B. Holdman, M.D.

Croatian Psychiatric Association
Professor Ljubomir Hotjac

Cuban Society of Psychiatrists
Dr. Ricardo Gonzalez Merced

Cyprus Society of Psychiatry
Dr. Argyris Angriotou

Czech Psychiatric Association
Dr. Jiri Raboch

Danish Psychiatric Society
Dr. Merete Nordenstadi

Danubian Psychiatric Association
Dr. Werner Schony

Depression and Bipolar Support Alliance
Lydia Lewis

Ecuadorian Psychiatric Association
Dr. Fabrizio V. Dolyaga Campero

Estonian Psychiatric Association
Dr. Valdur Janev

Finnish Psychiatric Association
Professor Raimo Salokangas

Flemish Neurologists and Psychiatrists
Dr. J. Paekens

Francophone International Federation of Psychiatry
Dr. Francois Caroli

French Association of Psychiatrists in Private Practice
Dr. Antoine Besse

French Association of Psychiatry
Dr. Christian C. Vasseur

French Scientific Association of Psychiatrists In Public Service
Professor J.C. Pascal

Georgian Psychiatric Association
Professor George Naneishvili

German Society for Psychiatry and Neurology
Dr. J. Vogt

Ghana Psychiatric Association
Dr. Sammy Hene

Global Alliance of Mental Illness
Dr. Paolo Lucio Moselli

Group for the Advancement of Psychiatry
Paul J. Fish, M.D.

Haitian Society of Psychiatry
Dr. Max Desvissers

Hellenic Psychiatric Association
Professor George N. Christodoulou

Hellenic Society of Neurology and Psychiatry
Professor Costas Stefanis

Honduran Psychiatric Association
Dr. Octavio R. Sanchez Miledre

Hong Kong College of Psychiatrist
Professor C.N. Chen

Hungarian Psychiatric Association
Dr. Attila Nemeth

Icelandic Psychiatric Association
Professor Sigur率达到 Pall Palson
2006 Presidents of Allied Organizations

Independent Psychiatric Association
Dr. Yuri Sergeich Savenko

Indian Association for Social Psychiatry
Professor Ranbir Bhatti

Indian Psychiatric Society
Dr. Siva Naruki

Indo-American Psychiatric Association
Sanjay Duke, M.D.

Indonesian Psychiatric Association
Dr. Sasanto Wirawan

International Association of Ethno-Psychologists 7
Dr. Valentin Ya. Senke

International Society of Psychopathology of Expression
Dr. Guy Roux

Iranian Psychiatric Association
Dr. Hamid Duradian

Iraqi Society of Psychiatrists
Professor Mudhaffar Zubaidi Al-Qassim

Irish College of Psychiatrists
Dr. Kathleen Garner

Israeli Psychiatric Association
Dr. Michael Schneidman

Italian Association for Research in Schizophrenia
Professor Carlo L. Cazzullo

Italian Psychiatric Association
Professor E. Agresta Agenzia

Italian Psychiatric Society
Professor Mario Maj

Ivory Coast Association of Psychiatry
Professor Joseph Delafesse

Jamaican Psychiatric Association
Dr. G. Leveridge

Japanese Society of Psychiatry & Neurology
Professor Toshio Yamuchi

Jordan Association of Psychiatrists
Professor Wael Shomali

Kazakh Association of Psychiatrists and Narcoologists
Professor Jafizbek Alimbekov

Korean Neuropsychiatric Association
Dr. Sung Kil Min

Kuwait Psychiatric Association
Professor Essam A. Al-Ansari

Kyrgyz Science and Practical Community of Psychiatrists 1
Professor Valery Saljenkin

Latin American Psychiatric Association
Dr. Rafael Nuñez

Latvian Psychiatric Association
Dr. Elmar Ramans

Lebanese Psychiatric Association
Dr. Dona Hashem

Lithuanian Psychiatric Association
Dr. Professor habil Algintas Dembinskas

Luxembourg Society of Neurology and Psychiatry
Dr. Christian Fauky

Malaysian Psychiatric Association
Professor Cheok Ngen

Mauritius Psychiatric Association
Dr. Parmanan Jaganath

Mental Health Association of Tanzania
Dr. Gau P. Kiloro

Mexican Psychiatric Association
Professor Enrique Camarena Robles

Mexican Society of Neurology and Psychiatry
Dr. Sergio Sanchez-Pintado

Moroccan Society of Psychiatry
Professor Mohammed Foua Benzenkou

National Alliance for Research on Schizophrenia and Depression
Constance E. Lieber

National Alliance on Mental Illness (NAMI)
Suzanne Vogel-Scibilia, M.D.

National Association of Psychiatric Health Systems
Patricia R. Rechero, J.D., M.D.

National Association of Social Workers, Inc.
Evelina De Silva, D.S.W.

National Council for Community Behavioral Healthcare
Linda Rosenberg, M.S.W.

National Institute of Mental Health
Thomas Insel, M.D.

National Institute on Alcohol Abuse and Alcoholism
Tung Kai Li, M.D.

National Institute on Drug Abuse, NIH
Nora D. Volkow, M.D.

National Mental Health Association
Michael Fuerza, M.S.S.W.

Netherlands Psychiatric Association
Dr. Willem van Tilburg

Nicaraguan Psychiatric Association
Dr. Roberto Aguilar Briano

Norwegian Psychiatric Association
Dr. Bjarte Stokke

Pakistan Psychiatric Association of North America
Zahid Irani, M.D.

Pakistan Psychiatric Society
Professor Khalid A. Mufli

Panamanian Psychiatric Society
Dr. Manel Pennic

Papua New Guinea Psychiatric Association
Dr. Michael Mai

Paraguayan Society of Psychiatry
Dr. Jose Vera Gomez

Peruvian Psychiatric Association
Dr. Dante Warhurn Gnajeda

Psychiatric Association of Ecuador
Dr. Gonzalo Matezrae

Polish Psychiatric Association
Professor Janusz Rychkowski

Portuguese Association of Psychiatry
Dr. Jose Dias Cordeiro
2006 Presidents of Allied Organizations

Portuguese Society of Psychiatry and Mental Health
Professor Antonio Fernandes da Fonseca

Russian Society of Psychiatrists
Professor Valery Krasnov

Swedish Psychiatric Association
Dr. Anna-Maria of Sandeberg

Psychiatric Association of Austria
Dr. H.G. Zapotoszky

SA Society of Psychiatrists
Dr. Eugene Allers

Swiss Society of Psychiatry & Psychotherapy
Dr. Taby Hubenmil

Psychiatric Association of Bosnia-Herzegovina
Professor Ismet Ceranic

Salvadoran Psychiatric Association
Dr. Miguel Portin Magana

Syrian Arab Association of Psychiatrists
Professor Mahmoud Abdul Al

Psychiatric Association of Guatemala
Dr. Ismael Salazar

Singapore Psychiatric Association
Professor Thieu Chai Ong

Taiwanese Society of Psychiatry
Professor Ru-Bard Lu

Psychiatric Association of Macedonia
Professor Predrag Kiroski

Taiwanese Society of Psychiatry 7
Professor Ming-Been Lee

Psychiatric Association of Rio de Janeiro State
Dr. Maria Fatima Vasconcelos

The Psychiatric Evolution
Professor Jean Garnache

Psychiatric Association of Slovenia
Professor Andrej Mrzljak

Tunisian Psychiatric Society
Professor Saïda Douki

Psychiatric Association of Thailand
Dr. Piboon Udomrat

Turkish Neuropsychiatric Society
Professor Rasit Tükel

Psychiatric Association of Turkey
Dr. Halik Özbek

Turkmen Scientific Society of Psychiatrists
Dr. Nima Kerimi

Psychiatric Association of Zimbabwe
Dr. S.M. Nthiwatira

Ukraine Scientific Society of Neurologists, Psychiatrists & Narcologists
Professor Petar Velchyn

Psychiatrists Association of Nepal
Dr. Desh Raj Bahadur Koirav

Ukrainian Psychiatric Association
Professor Victor Shumyansky

Romanian League for Mental Health
Professor Bogdara Tudorache

Uzbek Association of Psychiatrists
Dr. Shakh Zade Mentallov

Romanian Psychiatric Association
Professor Vasile Chirita

Venezuelan Society of Psychiatry
Dr. Robert Lepśnie Zulayag

Royal Australian and New Zealand College of Psychiatrists
Dr. Julian Freidin

World Association for Dynamic Psychiatry
Dr. Maria Ammon

Royal College of Psychiatrists
Professor Sheila Hollins

World Psychiatric Association
Juan E. Mezzich, M.D.

Royal College of Psychiatrists of Thailand
Lt. Gen. Arnon Showanasi

Yemen Psychiatrists and Neurologists Association
Dr. Abdalmajid Al-Khulaifi

Royal Society of Mental Medicine of Belgium
Professor A. Seguers

Yugoslav Association of Psychiatric Institutions
Professor Ljubica Kusocić

Royal Society of Mental Medicine of Belgium
Professor A. Seguers

Yugoslav Psychiatric Association
Professor Miro Pejovic

Royal Society of Mental Medicine of Belgium
Professor A. Seguers

Zambian Neuropsychiatric Association
Professor A. Hatworth
American Psychiatric Association

CDs and Audiotapes
Recorded Live!

High Quality Continues for the 2006 Annual Meeting ...

Live recordings will be available for most of the following:

- Lectures • Advances in... Series
- Presidential Symposia • Medical Updates
- Scientific and Clinical Reports • Symposia
- Debate • Roundtable Discussion
  Advances in Research
- Research Advances in Medicine

CDs and tapes may be purchased/ordered on site at Mobiltape's booth at the Toronto Metro Convention Centre.

Mobiltape Company, Incorporated
24730 Avenue Tibbitts, Suite 170
Valencia, CA 91355
Phone: (661) 295-0504 • (800) 369-5718
Fax: (661) 295-8474
Website: www.mobiltape.com
7:00 a.m. Sessions

PART 1 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 26-28

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 26, PART 1
7:00 a.m.-8:30 a.m.
Canadian Room, Convention Floor, Royal York

CLINICAL IMPLICATIONS OF CHOICES OF ATYPICAL ANTI-PYSCHOTICS: REALITIES AND MYTHS
Supported by Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

Chp.: Robert E. Hales, M.D.
Co-Chp.: Stuart C. Yudofsky, M.D.

A Impact of Short-Term Decision on Long-Term Outcomes
Stephen R. Marder, M.D.

B Neurocognition, Functional Outcomes, and Psychopharmacology
Michael Green, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 27, PART 1
7:00 a.m.-8:30 a.m.
Grand Ballroom, Lower Concourse, Sheraton Centre

EVIDENCE, OUTCOMES, AND ADVOCACY: SHAPING THE MANAGEMENT OF GAD
Supported by Cephalon, Inc.

Chp.: David V. Sheehan, M.D.

A Evidence-Based Advocacy: A Data-Driven Look at the Somatic Expression of GAD
Philip R. Muskin, M.D.

B Comorbidity in GAD: A Public Health Challenge
John L. Beyer, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 28, PART 1
7:00 a.m.-8:30 a.m.
Metro Grand Ballroom, Second Level, Westin Harbour Castle

ATTAINING AND SUSTAINING REMISSION IN TREATMENT OF DEPRESSION WITH COMORBID OR RESIDUAL ANXIETY
Supported by Wyeth Pharmaceuticals

Chp.: Madhukar H. Trivedi, M.D.

A Impact of Associated Anxiety Symptoms on Depression
Peter P. Roy-Byrne, M.D.

B Collaborative Management Strategies for Patients With Comorbid Anxiety With Depression
Wayne J. Katon, M.D.

C Strategies to Achieve and Sustain Remission in Patients
Shailly Jain, M.D.

RESIDENTS' SESSION
7:00 a.m.-8:30 a.m.
Ballroom B, Lower Level, Intercontinental Hotel

MEET THE EXPERTS: SUNNY-SIDE UP
Chp.: Steven S. Sharfstein, M.D.
Co-Chp.: Pedro Ruiz, M.D.

At this breakfast, nationally recognized "experts" will sit at tables with small groups of residents and discuss a variety of career issues and opportunities in psychiatry. Topic areas include: Addiction/Substance Abuse, AIDS/HIV, Child and Adolescent Psychiatry, Consultation-Liaison, Cultural Competence; Forensic, Law and Ethics in Psychiatry, Geriatrics, Medical Student Issues, Public and Community Mental Health, Professional and Leadership Development, Psychodynamic Psychotherapy, and Research in Psychiatry.

8:00 a.m. Sessions

COURSES 38-44
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 38 8:00 a.m.-12 noon
Conference Room D/E, Mezzanine, Sheraton Centre

FAMILY SKILLS FOR A GENERAL PSYCHIATRIST
Director: Alison M. Heru, M.D.
Faculty: Laura Drury, M.S.W.

COURSE 39 8:00 a.m.-12 noon
Conference Room F, Mezzanine, Sheraton Centre

STREET DRUGS AND MENTAL DISORDERS: OVERVIEW AND TREATMENT
Director: John W. Tsuang, M.D.
Faculty: Karen Miotto, M.D., Timothy W. Fong, M.D.
MONDAY

COURSE 40 8:00 a.m.-12 noon
Conference Room G, Mezzanine, Sheraton Centre

TEACHING PSYCHIATRY? LET HOLLYWOOD HELP!

Director: Steven E. Hylar, M.D.
Faculty: Carol A. Bernstein, M.D., Michael B. First, M.D.,
Jeremy R. Butler, M.D.

COURSE 41 8:00 a.m.-12 noon
Windsor Room East, Mezzanine, Sheraton Centre

PSYCHIATRIC CONSULTATION IN LONG-TERM CARE: BASIC COURSE

Director: George T. Grossberg, M.D.
Faculty: Abhilash K. Desai, M.D.

COURSE 42 8:00 a.m.-12 noon
City Hall, Second Floor, Sheraton Centre

THE PSYCHIATRIST AS EXPERT WITNESS

Director: Phillip J. Resnick, M.D.

COURSE 43 8:00 a.m.-12 noon
Kent Room, Second Floor, Sheraton Centre

ENGAGING RESISTANT AND DIFFICULT-TO-
TREAT PATIENTS INTO COLLABORATIVE TREATMENT

Director: David Mee-Lee, M.D.

COURSE 44 8:00 a.m.-5:00 p.m.
Essex Room, Mezzanine, Sheraton Centre

OFFICE-BASED BUPRENORPHINE TREATMENT OF OPIOID-DEPENDENT PATIENTS

Co-Directors: Gerardo Gonzalez, M.D., Laura F.
McNicholas, M.D.
Faculty: Eric C. Strain, M.D., Thomas R. Kosten, M.D.

9:00 a.m. Sessions

CLINICAL CASE CONFERENCES 1-2

CLINICAL CASE CONFERENCE 1
9:00 a.m.-10:30 a.m.
Room 104 B, Level 100, Toronto Convention Centre North

HONORABLE DISCHARGE: SEVERE BRAIN INJURY AND PSYCHOLOGICAL SYMPTOMS IN A FEMALE VETERAN

Moderator: Susan Stabinsky, M.D.
Presenters: Stephen Ferrando, M.D., Frances Stewart, M.D.,
Maria L.A. Tiamson-Kassab, M.D.

CLINICAL CASE CONFERENCE 2
9:00 a.m.-10:30 a.m.
Room 104 C, Level 100, Toronto Convention Centre North

SEALED WITH A KISS: USING THE SEXUAL HISTORY IN PSYCHODYNAMIC PSYCHOTHERAPY

Moderator: Jennifer I. Downey, M.D.
Presenters: Richard C. Friedman, M.D., Diane E. McLean, M.D.

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

COURSES 45-50
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 45 9:00 a.m.-4:00 p.m.
Conference Rooms B/C, Mezzanine, Sheraton Centre

TREATING THE SELF AND INTERPERSONAL PROBLEMS OF PERSONALITY DISORDER

Director: John Livesley, M.D.

COURSE 46 9:00 a.m.-4:00 p.m.
Windsor Room West, Mezzanine, Sheraton Centre

TRAUMATIC BRAIN INJURY: NEUROPSYCHIATRIC ASSESSMENT

Director: Robert P. Granacher, Jr., M.D.

COURSE 47 9:00 a.m.-4:00 p.m.
Dominion Ballroom North, Second Floor, Sheraton Centre

ADVANCES IN NEUROPSYCHIATRY

Director: C. Edward Coffey, M.D.
Faculty: Jeffrey L. Cummings, M.D., Mark S. George, M.D.,
Matthew A. Menza, M.D.

COURSE 48 9:00 a.m.-4:00 p.m.
Kenora Room, Second Floor, Sheraton Centre

COGNITIVE THERAPY ON THE FLY

Director: Ari E. Zaritsky, M.D.
Faculty: Phillip Maerov, M.D., Patricia Rockman, M.D.

COURSE 49 9:00 a.m.-4:00 p.m.
Simcoe/Dufferin Room, Second Floor, Sheraton Centre

ADVANCED INTERVIEWING TECHNIQUES

Director: Shawn Shea, M.D.
COURSE 50 9:00 a.m.-4:00 p.m.
Wentworth Room, Second Floor, Sheraton Centre

MANAGED CARE CONTRACTING FOR PSYCHIATRISTS

Director: William H. Campbell, M.D.

DEBATE 1
9:00 a.m.-10:30 a.m.
Room 716 A, Level 700, Toronto Convention Centre South

DOES CATIE REALLY INFORM THE PRACTICE OF PSYCHIATRY?

Moderator: Richard E. D'Alli, M.D.
Affirmative: Joseph P. McEvoy, M.D., William T. Carpenter, Jr., M.D.
Negative: Robert R. Conley, M.D., Herbert Y. Melzer, M.D.
THIS SESSION WILL BE AUDIOTAPED.

DISCUSSION GROUPS 1-4
9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

1 Laura Roberts, M.D., on the New Handbook on Professional Development for Academic Psychiatrists (Meet the Authors)
Grenadier Room, Main Level, Intercontinental Hotel

2 Donna E. Stewart, M.D., on Why Women's Mental Health? (Meet the Authors)
Halton Room, Main Level, Intercontinental Hotel

3 Jesse H. Wright III, M.D., on Learning From Cognitive-Behavior Therapy: What Are the Most Powerful Methods for Everyday Clinical Use? (Meet the Authors)
Humber Room, Main Level, Intercontinental Hotel

4 Michelle B. Riba, M.D., on Leadership Opportunities: Where and How to Look (Meet the Authors)
Kingsway Room, Main Level, Intercontinental Hotel

FOCUS LIVE SESSION 1
9:00 a.m.-10:30 a.m.
Room 714 A, Level 700, Toronto Convention Centre South

PERSONALITY DISORDERS

Moderators: Deborah J. Hales, M.D., Mark H. Rapaport, M.D.
Presenter: Glen O. Gabbard, M.D.

Expert clinicians, who served as the guest editors of the first two issues of *Focus*, will lead lively multiple-choice, question-based discussions. This session covers Personality Disorders, the second session at 11:00 a.m. covers Eating Disorders and Sexual Disorders, and the third session at 2:00 p.m. covers Psychotherapy. Presented with multiple-choice questions, participants will test their knowledge with an interactive audience response system, which instantly presents the audience responses as a histogram on the screen. Each participant is able to take a self-assessment exam with answers and discussion led by the expert faculty.

LECTURES 2-4

LECTURE 2
9:00 a.m.-10:30 a.m.
Room 105, Level 100
Toronto Convention Centre North

Krishnamachari Srinivasan, M.D.

Heart Rate Variability and Psychiatry: Beyond Heart-Mind Link

Chap. Ciretha Jayarani, M.D.
Co-Chap. Roman Snihurovy, M.D.

Krishnamachari Srinivasan, M.D., is professor and chairman of the Department of Psychiatry at St. John's Medical College and Vice-Dean at the St. John's Research Institute, Bangalore, India. He completed his training in psychiatry at the National Institute of Mental Health and Neurosciences, and has completed a two-year research fellowship at Lafayette Clinic, Wayne State University, Detroit, Michigan. He runs an outpatient and inpatient service and is involved in training of medical undergraduates, nursing students and psychiatry residents. He has several funded research projects to his credit. He has published approximately 60 publications in various national and international peer-reviewed journals. He has a special interest in Biological Psychology, Autonomic Neuroscience, Psychopharmacology and Psychiatry Research. His main research interests include the study of autonomic regulation in anxiety and panic disorders in both children and adults, psychological and physiological underpinning of anxiety vulnerability, and community-based outcome studies of anxiety and depression.

International Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPED.
LECTURE 3
9:00 a.m.-10:30 a.m.
Exhibit Hall A, Level 300
Toronto Convention Centre North

David T. Suzuki, Ph.D.

Rediscovering Our Place in the World

Chp.: Claudia S. Miller, M.D.
Co-Chp.: Sherri M. Simpson, M.D.

David T. Suzuki, Ph.D., Chair of the David Suzuki Foundation, is an award-winning scientist, environmentalist, and broadcaster. He is renowned for his radio and television programs that explain the complexities of the natural sciences in a compelling, easily understood way. Dr. Suzuki is a geneticist. He graduated from Amherst College in 1958 with an Honors B.A. in Biology, followed by a Ph.D. in Zoology from the University of Chicago. He became a faculty member of the University of British Columbia in 1963, and is now Professor Emeritus of CBC Sustainable Development Research Institute. Dr. Suzuki has written 42 books; and his 1976 textbook An Introduction to Genetic Analysis with A.J.F. Griffiths, remains the most widely used genetics textbook in the U.S. and has been translated into Italian, Spanish, Greek, Indonesian, Arabic, French, and German. Dr. Suzuki has received high acclaim for his 30 years of award-winning work in broadcasting. In 1974 he developed and hosted the CBC radio program Quarks and Quarks. In 1979 he became the host for the award-winning science show, The Nature of Things With David Suzuki on CBC television. Dr. Suzuki is also recognized as a world leader in sustainable ecology. For more information: www.davidsuzuki.org,
Frontiers of Science Lecture Series

LECTURE 4
9:00 a.m.-10:30 a.m.
Room 718 A/B, Level 700
Toronto Convention Centre South

APA'S RESEARCH IN PSYCHIATRY AWARD LECTURE

Kenneth B. Wells, M.D.

The Search for Quality and Equity in Care for Psychiatric Disorders:
A Story of Opportunity, Evidence, and Partners

Chp.: Alan P. Schatzberg, M.D.

Kenneth B. Wells, M.D., received his medical degree from UCSP and his M.P.H. from UCLA. He is a psychiatrist, a Senior Scientist at RAND, Professor of Psychiatry and Biobehavioral Sciences at the Geffen School of Medicine, and Professor of Health Services at the UCLA School of Public Health. He directs the Health Services Research Center of the Samuel Institute for Neuroscience and Human Behavior at UCLA, which focuses on improving quality of care for psychiatric and neurological disorders across the lifespan. He is Principal Investigator of the NIMH UCLA/RAND Center for Research on Quality in Managed Care and the Robert Wood Johnson Foundation Community Partnership Initiative. He is Co-Director of the RWJF UCLA Clinical Scholars Program and Chair of the Community Health Improvement Collaborative. Dr. Wells is an elected member of the Institute of Medicine (IOM), and for four years chaired its Board on Neuroscience and Behavioral Health. He was the first recipient of the Young Investigator Award and received the Distinguished Investigator Award of Academy Health and the Senior Health Services Research Award from the American Psychiatric Association. His current research interests focus on improving quality of care and reducing mental health disparities through partnered, participatory research strategies with healthcare and community organizations.

MASTER EDUCATOR CLINICAL CONSULTATIONS 1-3
9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

1. Renato D. Alarcon, M.D., on Clinical Dimensions of Cultural Psychiatry
   Room 201 A, Level 200, Toronto Convention Centre North

2. Laura J. Miller, M.D., on Psychiatric Disorders Across the Female Reproductive Cycle
   Room 201 B, Level 200, Toronto Convention Centre North

3. Meera Narasimhan, M.D., on Refractory Depression: Diagnostic and Treatment Implications
   Room 201 C, Level 200, Toronto Convention Centre North

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.
NEW RESEARCH YOUNG INVESTIGATORS' POSTER SESSION 1
9:00 a.m.-10:30 a.m.
Exhibit Hall B, Level 300, Toronto Convention Centre North

For further information on New Research submissions, please refer to the New Research Program Book included in your registration packet.

WORKSHOPS

COMPONENTS 1-9

COMPONENT WORKSHOP 1  9:00 a.m.-10:30 a.m.
Room 104 A, Level 100, Toronto Convention Centre North

DISASTER PSYCHIATRY: PRACTICAL SKILLS TO HELP DISTRICT BRANCHES DEVELOP DISASTER PLANS FOR THEIR COMMUNITIES
APA Committee on Psychiatric Dimensions of Disasters

Co-Chairs: Christina V. Mangurian, M.D., Lisa A. Catapano, M.D.
Participants: Anthony T. Ng, M.D., Edward M. Kantor, M.D., Mary Jo Fitz-Gerald, M.D., Joseph C. Napoli, M.D., Jon S. Berlin, M.D.

COMPONENT WORKSHOP 2  9:00 a.m.-10:30 a.m.
Room 104 D, Level 100, Toronto Convention Centre North

PAY FOR PERFORMANCE: LINKING INCENTIVES TO PROVIDER PERFORMANCE ON QUALITY MEASURES
APA Council on Quality Care and APA Council on Healthcare Systems and Financing

Co-Chairs: Richard C. Hermann, M.D., Bruce J. Schwartz, M.D.
Participants: John M. Oldham, M.D., Nicholas Meyers

COMPONENT WORKSHOP 3  9:00 a.m.-10:30 a.m.
Room 205 A, Level 200, Toronto Convention Centre North

CAREER CHOICES IN PSYCHIATRY: EXPLORING FELLOWSHIP TRAINING
APA Assembly Committee of Ama Members in Training Representatives

Chairs: Vincent J. Blanch, M.D.
Participants: Chad Y. Koyanagi, M.D., Martin Gignac, M.D., William F. Haning, III, M.D., Brian A. Greenlee, M.D.

COMPONENT WORKSHOP 4  9:00 a.m.-10:30 a.m.
Room 205 B, Level 200, Toronto Convention Centre North

SEVERELY MENTALLY ILL PERSONS IN JAILS AND PRISONS: WHO SHOULD STAY?
APA Corresponding Committee on Jails and Prisons

Chairs: Henry C. Weinstein, M.D.
Participants: H. Richard Lamb, Cassandra F. Newkirk, M.D., Tom Hamilton, Erik J. Roskes, M.D.

COMPONENT WORKSHOP 5  9:00 a.m.-10:30 a.m.
Room 205 C, Level 200, Toronto Convention Centre North

CRIME AND CRUEL NOT UNUSUAL PUNISHMENT: THE NEED FOR JUVENILE JUSTICE MENTAL HEALTH CARE REFORM
APA Alliance

Chairs: Louis J. Kraus, M.D.
Participants: William Arroyo, M.D., Niranjan Karnik, M.D.

COMPONENT WORKSHOP 6  9:00 a.m.-10:30 a.m.
Room 205 D, Level 200, Toronto Convention Centre North

CLOSING A PRACTICE: WHAT EVERY PSYCHIATRIST'S OFFICE AND THEIR FAMILY SHOULD KNOW
APA Corresponding Committee on Physician Health, Illness, and Impairment

Chairs: John A. Fromson, M.D.
Participants: Michael F. Myers, M.D., Margo S. Adams

COMPONENT WORKSHOP 7  9:00 a.m.-10:30 a.m.
Room 206 A/B, Level 200, Toronto Convention Centre North

CONQUERING THE SHAME, SECRECY, AND STIGMA OF SUICIDE IN YOUNG ASIAN-AMERICAN ADULTS
APA Committee of Asian American Psychiatrists

Chairs: Surinder S. Nand, M.D.
Participants: Eric C. Li, M.D., Lois W. Choi-Kain, M.D., Aruna Jha, Ph.D.

COMPONENT WORKSHOP 8  9:00 a.m.-10:30 a.m.
Room 701 A, Level 700, Toronto Convention Centre South

CPT CODING AND DOCUMENTATION UPDATE
APA Committee on RBRVS, Codes, and Reimbursements

Chairs: Chester W. Schmidt, Jr., M.D.
Participants: Tracy R. Gordy, M.D., Edward Gordon, M.D., Napoleon B. Higgins, Jr., M.D., Ronald M. Burd, M.D., Allan A. Anderson, M.D., David K. Nace, M.D.

COMPONENT WORKSHOP 9  9:00 a.m.-10:30 a.m.
Room 711 A/B, Level 700, Toronto Convention Centre South

NEW DEVELOPMENTS IN APA PRACTICE GUIDELINES ON BIPOLAR DISORDER, MDD, AND PANIC DISORDER
APA Steering Committee on Practice Guidelines

Chairs: Jack S. McIntyre, M.D.
Participants: Laura J. Fochtmann, M.D., Robert M.A. Hirschfeld, M.D., Alan J. Gelenberg, M.D., Murray B. Stein, M.D.
MONDAY

ISSUES 1-15

ISSUE WORKSHOP 1 9:00 a.m.-10:30 a.m.
Room 201 D, Level 200, Toronto Convention Centre North

A DIMENSION OF MIND: SIMULATIONS/EMULATIONS OF PSYCHIATRIC SYMPTOMS USING THE PERFORMING ART OF MAGIC

Chp.: Bruce C. Ballon, M.D.
Participant: Ivan Silver, M.D.

ISSUE WORKSHOP 2 9:00 a.m.-10:30 a.m.
Room 206 C/D, Level 200, Toronto Convention Centre North

WHAT DO YOU DO WITH A PATIENT WHO HAS ACCESS TO A GUN?

Chp.: Donna M. Norris, M.D.
Participants: Marilyn Price, M.D., Thomas G. Gutheil, M.D., William H. Reid, M.D.

ISSUE WORKSHOP 3 9:00 a.m.-10:30 a.m.
Room 206 E/F, Level 200, Toronto Convention Centre North

MANAGING COMPLEX COMORBID PSYCHIATRIC AND ALCOHOL USE DISORDERS IN PSYCHIATRIC PRACTICE
Collaborative Session With the National Institute on Alcohol Abuse and Alcoholism

Chp.: Mark L. Willenbring, M.D.
Participant: Robert Drake, Ph.D.

ISSUE WORKSHOP 4 9:00 a.m.-10:30 a.m.
Room 701 B, Level 700, Toronto Convention Centre South

EXTRAPYRAMIDAL SIDE EFFECTS AND TARDIVE DYSKINESIA IN THE ATYPICAL ANTIPSYCHOTIC ERA

Chp.: Thomas E. Hansen, M.D.
Participants: Daniel E. Casey, M.D., Joseph P. McEvoy, M.D.

ISSUE WORKSHOP 5 9:00 a.m.-10:30 a.m.
Room 703, Level 700, Toronto Convention Centre South

NEUROCYBERNETICS: NOVEL APPROACH IN THE TREATMENT OF PSYCHIATRIC DISORDERS

Chp.: Alan L. Summers, M.D.

ISSUE WORKSHOP 6 9:00 a.m.-10:30 a.m.
Room 705, Level 700, Toronto Convention Centre South

TREATMENT OF PREGNANCY-RELATED MOOD DISORDERS: FROM PSYCHIATRY TO PEDIATRICS

Co-Chps.: Janet A. Martin, M.D., Syed S.A. Naqvi, M.D.
Participants: Shari Lusskin, M.D., Vivien K. Burt, M.D., Stephanie M. Stewart, M.D.

ISSUE WORKSHOP 7 9:00 a.m.-10:30 a.m.
Room 707, Level 700, Toronto Convention Centre South

RISK MANAGEMENT ISSUES IN PSYCHIATRIC PRACTICE

Chp.: Alan I. Levenson, M.D.
Participants: Ellen R. Fischbein, M.D., Martin G. Tracy, J.D., Jacqueline M. Melonas, J.D.

ISSUE WORKSHOP 8 9:00 a.m.-10:30 a.m.
Room 709, Level 700, Toronto Convention Centre South

BUT CAN WE DO IT HERE? CHALLENGES OF IMPLEMENTING COGNITIVE-BEHAVIOR THERAPY FOR SCHIZOPHRENIA PROGRAMS IN THE U.S.

Co-Chps.: Page Burkholder, M.D., Peter J. Weiden, M.D.
Participants: David G. Kingdon, M.D., Yulia Landa, Ph.D., Scott Temple, Ph.D., Narisumma R. Pinninated, M.D.

ISSUE WORKSHOP 9 9:00 a.m.-10:30 a.m.
Room 714 B, Level 700, Toronto Convention Centre South

RELIGIOUS AND SPIRITUAL ASSESSMENT IN CLINICAL PRACTICE

Co-Chps.: Francis G. Lu, M.D., Christina M. Puchalski, M.D.
Participant: James L. Griffith, M.D.

ISSUE WORKSHOP 10 9:00 a.m.-10:30 a.m.
Room 716 B, Level 700, Toronto Convention Centre South

EARLY DETECTION AND TREATMENT OF BIPOLAR ILLNESS

Chp.: Eric R. Marcus, M.D.
Participants: Clarice E. Kestenbaum, M.D., Lewis A. Opler, M.D., Ian E. Alger, M.D.

ISSUE WORKSHOP 11 9:00 a.m.-10:30 a.m.
Room 717 A, Level 700, Toronto Convention Centre South

WHAT IS A MOOD STABILIZER?

Chp.: Eduard Vieta, M.D.
Participants: S. Nassiri Ghaemi, M.D., Frederick K. Goodwin, M.D.

ISSUE WORKSHOP 12 9:00 a.m.-10:30 a.m.
Room 717 B, Level 700, Toronto Convention Centre South

REINVENTING CAREERS: TRANSITIONS AND LATER-LIFE STRATEGIES FOR PSYCHIATRISTS

Co-Chps.: Carolyn B. Robinowicz, M.D., Abram M. Hostetter, M.D.
Participants: Carol C. Nadelson, M.D., Edward Hanin, M.D., Zebulon C. Taintor, M.D., Joel Yager, M.D.
Monday

**Issue Workshop 13**
9:00 a.m.-10:30 a.m.
Room 801 A, Level 800, Toronto Convention Centre South

American Board of Psychiatry and Neurology Update: Certification and Maintenance of Certification in Psychiatry and Its Subspecialties

Chp.: Stephen C. Scheiber, M.D.
Participants: Naleen N. Andrade, M.D., Beth Ann Brooks, M.D., Larry R. Faulkner, M.D., Burton V. Reifler, M.D., James H. Scully, Jr., M.D., Daniel K. Winstead, M.D.

**Issue Workshop 14**
9:00 a.m.-10:30 a.m.
Room 801 B, Level 800, Toronto Convention Centre South

New Research Advances in Ethnopsychopharmacology

Chp.: Pedro Ruiz, M.D., William B. Lawson, M.D.
Participants: Edmond H. Pi, M.D., Tarek A. Okasha, M.D.

**Issue Workshop 15**
9:00 a.m.-10:30 a.m.
Room 803 A/B, Level 800, Toronto Convention Centre South

Online Peer Support Groups and Support Group Members

Chp.: Robert C. Hsiung, M.D.
Participant: Kali Munro, M.Ed.

**Media 1-2**

**Media Workshop 1**
9:00 a.m.-12 noon
Alberta Room, Mezzanine Floor, Royal York

**Gof a Triple-Take in the World of Drugs**

Chp.: Petros Levounis, M.D., Jose P. Vito, M.D.

**Media Workshop 2**
9:00 a.m.-12 noon
Quebec Room, Mezzanine Floor, Royal York

**Do I Look Fat? Eating Disorder Pathology in Gay Men**

Chp.: Daniel Garza, M.D.
Participant: Travis D. Mathews, M.A.

**10:30 a.m. Session**

Advances in Research
10:30 a.m.-12:30 p.m.
Room 107, Level 100, Toronto Convention Centre North

An Update for the Clinician

*APA Scientific Program Committee and APA Council on Research*

Chp.: Herbert Pardes, M.D.
Co-Chps.: Marian I. Butterfield, M.D., David J. Kupfer, M.D., Leah J. Dickstein, M.D.

Participants: Floyd E. Bloom, M.D., Katherine L. Wisner, M.D., Jeffrey A. Lieberman, M.D., Martha L. Bruce, Ph.D.

This session will be audiotaaped.

**11:00 a.m. Sessions**

**Discussion Groups 5-9**

11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

5 Jack Drescher, M.D., on the Psychology of the Closet
   Grenadier Room, Main Level, Intercontinental Hotel

6 Russell F. Lim, M.D., on Culturally Appropriate
   Diagnosis and Treatment (Meet the Authors)
   Halton Room, Main Level, Intercontinental Hotel

7 Mary Jane Massie, M.D., on Psychotherapy With Women
   With Breast Cancer
   Humber Room, Main Level, Intercontinental Hotel

8 Ashwin Patkar, M.D., on Alcohol Dependence: What
   Clinicians Need to Know
   Kingsway Room, Main Level, Intercontinental Hotel

9 Christine F. Marx, M.D. and Kathryn M. Connor, M.D.,
   on Your Research Career: Getting Started, Getting Funded
   (For Residents Only)
   Niagara Room, Lower Level, Intercontinental Hotel

**Focus Live Session 2**

11:00 a.m.-12:30 p.m.
Room 714 A, Level 700, Toronto Convention Centre South

Eating Disorders and Sexual Disorders

Moderators: Deborah J. Hales, M.D., Mark H. Rapaport, M.D.
Presenters: Stephen B. Levine, M.D., Joel Yager, M.D.

Expert clinicians, who served as the guest editors of the first two issues of *Fosse*, will lead lively multiple-choice, question-based discussions. The 9:30 a.m. session covered Personality Disorders, this session will cover Eating Disorders and Sexual Disorders, and the third session at 2:00 p.m. covers Psychotherapy. Presented with multiple-choice questions, participants will test their knowledge with an interactive audience response system, which instantly presents the audience responses as a histogram on the screen. Each participant is able to take a self-assessment exam with answers and discussion led by the expert faculty.
LECTURE 5
11:00 a.m. - 12:30 p.m.
Room 103, Level 102
Toronto Convention Centre North
APA SIMON BOLIVAR AWARD LECTURE
Pedro L. Delgado, M.D.
Gene-Environment Interactions and Risk of Major Depression: Implications for Community-Based Prevention Strategies
Chp.: Ana E. Carmona, M.D.

Pedro L. Delgado, M.D., is Diehlmann Professor and Chairman of the Department of Psychiatry and Associate Dean for Faculty Development and Professionalism at the School of Medicine, The University of Texas Health Sciences Center at San Antonio. He earned his medical degree with electives into AGA and a research in pharmacology from the University of Texas in Galveston. His internship and residency in psychiatry were completed at Yale University after which he served for several years on the Yale faculty. Between 1992 and 2000, he served as the University of Arizona where he was Professor, Associate Department Head, and Director of Research in the Department of Psychiatry. From 2000-2005, he served as the Douglas Bond Professor and Chairman of the Department of Psychiatry at Case Western Reserve University. Dr. Delgado is an internationally renowned researcher and frequent lecturer on the neurobiology of major depression and the biological mechanisms underlying antidepressant action. He has had continuous federal funding for over 14 years for his research on the biology and treatment of depression. He is past President of the American Society of Hispanic Psychiatrist and takes an active role in mentoring young physician scientists.

THIS SESSION WILL BE AUDIOTAPEED.

LECTURE 6
11:00 a.m. - 12:30 p.m.
Exhibit Hall A, Level 300
Toronto Convention Centre North
Raquel E. Gur, M.D.
Emotion Processing and Schizophrenia: Neuropsychiatric Perspectives
Chp.: Susan G. Kornstein, M.D.
Co-Chp.: Amy M. Ursano, M.D.

Raquel E. Gur, M.D., is a Kean and Linda Rickels Professor of Psychiatry, with appointments in neurology and radiology at the University of Pennsylvania. Her academic career has been devoted to the study of brain function in schizophrenia. After completing her Ph.D. at Michigan State University in 1974, she joined the University of Pennsylvania, first as a Fellow, then as a medical student, a resident in neurology and psychiatry, and a faculty member. Dr. Gur has directed the Neuropsychiatry Section and the Schizophrenia Research Center and has established an interdisciplinary program dedicated to advancing the understanding of the pathophysiology of this complex disorder through the application of diverse strategies, from neurobehavioral to molecular. The research has been supported by the NIMH, where she is currently serving on Council. She has over 300 refereed publications, and her accomplishment has been acknowledged by awards and membership in the Institute of Medicine. She is President-Elect of the Society of Biological Psychiatry.

This session will be audiotaaped.

LECTURE 7
11:00 a.m. - 12:30 p.m.
Room 708 A/B, Level 700
Toronto Convention Centre South
Anke A. Ehnhardt, Ph.D.
The Discourse on Human Sexuality In the Time of AIDS
Chp.: Robert M. Kintzes, M.D.
Co-Chp.: Priscine Coutou, M.D.

Anke A. Ehnhardt, Ph.D., is a Professor of Medical Psychology in the Department of Psychiatry at Columbia University and is Director of the HIV Center for Clinical and Behavioral Studies at the NY State Psychiatric Institute. She is an internationally known researcher in the field of sexual and gender development of children, adolescents, and adults. Her bibliography currently includes more than 200 scientific publications. Dr. Ehnhardt has been the Director of the HIV Center for Clinical and Behavioral Studies at the New York State Psychiatric Institute and Columbia University since 1987. The HIV Center's purpose is to study all aspects of HIV/AIDS, with a special focus on sex and gender as it applies to women, children and adolescents, the chronically mentally ill, and the gay population. The Center is dedicated to interdisciplinary investigations with teams of scientists, clinicians, and health educators collaborating on research on HIV/AIDS in the U.S. and around the world. In 1991, Dr. Ehnhardt served as President of the International Academy of Sex Research and she is currently a trustee on the Board of Directors of the Ford Foundation.

Frontiers of Science Lecture Series
This session will be audiotaaped.
MASTER EDUCATOR CLINICAL CONSULTATIONS 4-6

11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

4 Shaila Misri, M.D., on Perinatal Psychiatric Disorders
   Room 201 A, Level 200, Toronto Convention Centre North

5 Marion Zucker Goldstein, M.D., on Late-Life Aging Processes and Mental Illness
   Room 201 B, Level 200, Toronto Convention Centre North

6 David Baron, D.O., and Geetha Jayaram, M.D., on Clinical Research Across Geographic Borders: Challenges and Opportunities
   Room 201 C, Level 200, Toronto Convention Centre North

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDICAL UPDATE 1
11:00 a.m.-12:30 p.m.
Room 716 A, Level 700, Toronto Convention Centre South

CONGESTIVE HEART FAILURE

Presenter: Heather Ross, M.D.
Chp.: Donna E. Stewart, M.D.

THIS SESSION WILL BE AUDIOTAPE.

RESEARCH CONSULTATION WITH

11:00 a.m.-12:30 p.m.

This session is limited to 25 participants on a first-come, first-served basis.

1 Mark L. Willenbring, M.D., on Clinical Research on Alcohol Use Disorders
   Collaborative Session With the National Institute on Alcohol Abuse and Alcoholism
   Oakville Room, Main Level, Intercontinental Hotel

PRESIDENTIAL THEME: FROM SCIENCE TO PUBLIC POLICY: ADVOCACY FOR PATIENTS AND THE PROFESSION

Chp.: Jeffrey Janofsky, M.D.
Co-Chp.: Joshua Roffman, M.D.

11:00 a.m.
1 The Impact of an Integrated Community Arts Studio on Stigmatizing Beliefs and Experiences
   Thomas C. Zelnik, M.D., Valerie L. Howells, Ph.D.

11:30 a.m.
2 Health Policies and the Diagnostic and Statistical Manual
   Roger Peele, M.D., Mozdeh Roozegar, M.D., Maryam Razavi, M.D.

12 noon
3 The System for Classification of Inpatient Psychiatry: A New Case-Mix Methodology for Mental Health
   John P. Hirdes, Ph.D., Brant Fries, Ph.D., Edgardo L. Perez, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SCIENTIFIC AND CLINICAL REPORT SESSION 2
11:00 a.m.-12:30 p.m.
Room 104 D, Level 100, Toronto Convention Centre North

ETHICS AND HUMAN RIGHTS

Chp.: William Cardasis, M.D.
Co-Chp.: Zubin Bhagwager, M.D.

11:00 a.m.
4 Ethics and Psychobiological Research
   Cherise Rosen, Ph.D., Linda S. Grossman, Ph.D., Henry W. Dove, M.D.

11:30 a.m.
5 Terrorism and Medical Ethics: Conflicting Loyalties for American Psychiatrists
   David A. Rothstein, M.D.

12 noon
6 A New Mental Health Act: An Australian Experience
   Darryl P. Watson, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SCIENTIFIC AND CLINICAL REPORT SESSION 3
11:00 a.m.-12:30 p.m.
Room 201 D, Level 200, Toronto Convention Centre North

ATTENTION SPECTRUM DISORDERS

Chp.: Michael Demas, M.D.
Co-Chp.: Kareem Ghalib, M.D.

(Continued next page)
11:00 a.m.
7 Transdermal Methylphenidate Versus Placebo in Pediatric ADHD
   Robert L. Findling, M.D., Frank A. Lopez, M.D.

11:30 a.m.
8 Effects of Transdermal Methylphenidate in a Laboratory Classroom Study
   James J. McGough, M.D., Sharon B. Wigal, Ph.D., Howard Abikoff, Ph.D., John M. Turnbow, M.D., Kelly Posner, Ph.D., Eliot Moon, M.D.

12 noon
9 Modafinil-ADHD: Long-Term Efficacy and Safety in Children and Adolescents With ADHD
   Samuel W. Boellner, M.D., James A. Knutson, M.D., John G. Jiang, Ph.D., Ronghua Yang, Ph.D., Craig Q. Earl, Ph.D.
   THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 4
11:00 a.m.-12:30 p.m.
Room 205 A, Level 200, Toronto Convention Centre North
CURRENT TRENDS IN SCHIZOPHRENIA

Chp.: Rajiv Tandon, M.D.
Co-Chp.: Peter F. Buckley, M.D.

11:00 a.m.
10 Recurring Psychosis in Schizophrenia: A 20-Year Multi, Follow-Up Study
   Martin Harrow, Ph.D., Thomas H. Jobe, M.D., Linda S. Grossman, Ph.D., Joseph F. Goldberg, M.D., Kalman J. Kaplan, Ph.D., Robert Faull, B.S.

11:30 a.m.
11 Identifying the Neurobiological Basis for Schizophrenia
   Zeinab S. Elbaz, M.D.

12 noon
12 Key Findings From the Intercontinental Schizophrenia Outpatients Health Outcomes Study (IC-SOHO); Disease Burden and Clinical Outcomes Associated With Antipsychotic Treatment for Schizophrenia
   Martin Dossenbach, Jan Pecenak, Urban Groleger, Agata Szule, Yulia Dyachkova, Amanda J. Lowry
   THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 5
11:00 a.m.-12:30 p.m.
Room 206 A/B, Level 200, Toronto Convention Centre North
MEDICATION RESPONSE IN MDD

Chp.: Edward Kingstone, M.D.
Co-Chp.: Adel A. Gabriel, M.D.

11:00 a.m.
13 Duloxetine Versus Escitalopram and Placebo in the Long-Term Treatment of Patients With MDD
   Teresa A. Pigott, M.D., Lesley M. Arnold, M.D., Scott T. Aaronson, M.D., Apurva Prakash, Craig H. Mallinckrodt, Michael J. Robinson, Madelaine M. Wohlreich, M.D.

11:30 a.m.
14 Conditional Probability of Response to Placebo in MDD
   Jennifer Covino M.P.A., David Mischoulon, M.D., Jonathan E. Alpert, M.D., Andrew A. Nierenberg, M.D., John M. Zajecka, M.D., Harald Murck, M.D., Jerrcll F. Rosenbaum, M.D.

12 noon
15 Addition of Atomoxetine for Depression Incompletely Responsive to Sertraline: A Randomized, Double-Blind, Placebo-Controlled Study
   David Michelson, M.D., Lenard A. Adler, M.D., Jay D. Amsterdam, M.D., David L. Dunner, M.D., Andrew A. Nierenberg, M.D., Frederick W. Reimherr, M.D., Alan F. Schatzberg, M.D.
   THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 6
11:00 a.m.-12:30 p.m.
Room 206 E/F, Level 200, Toronto Convention Centre North
TREATMENT MANAGEMENT AND OUTCOMES IN MOOD DISORDERS

Chp.: John F. Greden, M.D.
Co-Chp.: Robert B. Shulman, M.D.

11:00 a.m.
16 Management of Side Effects Associated With New Treatments for Bipolar Depression
   Joseph R. Calabrese, M.D., Robert M.A. Hirschfeld, M.D.

11:30 a.m.
17 Treatment-Resistant Depression: Changes in Symptoms and Functioning in a Clinical Sample
   Alex A. Cardoni, M.S., Stephen B. Woolley, M.P.H., Deborah Piez, M.S., John W. Goethe, M.D.

12 noon
18 Specificity of Effect of Quetiapine in Bipolar Depression
   Robert M.A. Hirschfeld, M.D., Joseph R. Calabrese, M.D.
   THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 7
11:00 a.m.-12:30 p.m.
British Columbia Room, Mezzanine Floor, Royal York
DIAGNOSTIC ISSUES

Chp.: Suzanne Renaud, M.D.
Co-Chp.: Paul Fedoroff, M.D.
11:00 a.m.  
19 Screening for History of Physical, Emotional, and Sexual Abuse: How Do We Ask About Abuse?  
Brett D. Thombs, Ph.D., Roy C. Ziegelstein, M.D., David P. Bernstein, Ph.D., Christine D. Scher, Ph.D., David R. Forde, Ph.D., Edward A. Walker, M.D., Murray B. Stein, M.D.

11:30 a.m.  
20 Kennedy Axis V: The Next Step for Axis V?  
James A. Kennedy, M.D.

12 noon  
21 Dimensional Approaches to DSM and the Impact on Diagnostic Instruments  
Mariza Rubio-Stipec, Sc.D.

THIS SESSION WILL BE AUDIOTAPEd.

SCIENTIFIC AND CLINICAL REPORT SESSION 8  
11:00 a.m.-12:30 p.m.  
Confederation 3 Room, Mezzanine Floor, Royal York

CONSULTATION-LIAISON PSYCHIATRY  
Chp.: Asher Aledjem, M.D.  
Co-Chp.: Daniel Chapman, M.D.

11:00 a.m.  
22 Teaching of Psychiatry in Primary Care Residencies: Do Training Directors of Primary Care and Psychiatry See Eye to Eye?  
Hoyle Leigh, M.D., Ronna Mallios, M.P.H., Deborah C. Stewart, M.D.

11:30 a.m.  
23 Unrecognized Post-Traumatic Symptoms Triggered by Routine Hospital Care in Patients With Previous Trauma Histories  
Sarah Birmingham, M.D., Lynne M. Gaby, M.D., James I. Griffith, M.D.

12 noon  
24 Is Asthma Severity Related to Current Major Depressive Episode and Generalized Anxiety Disorder? A Case-Control Study  
Claudia Meneses, M.D., Diana M.C. Padra, M.D., Adriana M. Martínez, M.D., Claudia Manchego, M.D., Carlos A. Machado-Romero, M.D., Luis A. Díaz-Martínez M.S., Adalberto Campo-Arias, M.D.

SCIENTIFIC AND CLINICAL REPORT SESSION 9  
11:00 a.m.-12:30 p.m.  
Confederation 5 Room, Mezzanine Floor, Royal York

PSYCHIATRIC EDUCATION  
Chp.: Laura W. Roberts, M.D.  
Co-Chp.: Ronald F. Krasner, M.D.

11:00 a.m.  
25 Psychiatric CMEs and Commercial Bias: Are New ACCME Standards Effective?  
Daniel J. Carlat, M.D.

11:30 a.m.  
26 Relationships Between Self-Assessment Skills, Test Performance, and Other Variables in Psychiatry Residents  
David J. Lynn, M.D., Patrick T. O'Neil, M.D.

12 noon  
27 Coaching Communication Using Standardized Patient Encounters: An Educational Research Study  
Paula Ravitz, M.D., William Lancee, Ph.D., Robert Maunder, M.D., Milyn Leshcz, M.D., Jiahui Wong, M.D., Nancy L. McNaughton, M.D., Allan D. Peterkin, M.D.

THIS SESSION WILL BE AUDIOTAPEd.

SCIENTIFIC AND CLINICAL REPORT SESSION 10  
11:00 a.m.-12:30 p.m.  
Library, Mezzanine Floor, Royal York

BIOLOGICAL PSYCHIATRY AND NEUROSCIENCE  
Chp.: Anton C. Trinidad, M.D.  
Co-Chp.: Hamada Hamid, D.O.

11:00 a.m.  
28 From Synapse to Psychotherapy: The Fascinating Evolution of Neuroscience  
Bernadette Grosjean, M.D.

11:30 a.m.  
29 Can Neurological Soft Signs Discriminate Between Four Axis-I Diagnostic Categories in the Prison Population?  
Seyed Mohammad Assadi, M.D., Mohammad Reza Nakhai, M.D.

12 noon  
30 An Association Study of a Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Zotepine Response of Inpatients With Acute Schizophrenia  
Ching-Hua Lin, M.D., Li-Shiu Chou, M.D., Chich-Hsin Lin, M.D., Ming-Chao Chen, M.D., Gwo-Jen Wei

SCIENTIFIC AND CLINICAL REPORT SESSION 11  
11:00 a.m.-12:30 p.m.  
Toronto Room, Convention Floor, Royal York

GERIATRIC PSYCHIATRY  
Chp.: Kathy Kim, M.D.  
Co-Chp.: Raquel Lugo, M.D.

(Continued next page)
11:50 a.m.
31 The Influence of Dementia on the Treatment of Depression in Geriatric Inpatients
Karen Blank, M.D., Bonnie L. Szarek R.N., John W. Goethe, M.D.

11:30 a.m.
32 Overall Efficacy and Time to Response for Duloxetine 60mg Once Daily Versus Placebo in Elderly Patients With MDD
Ira R. Katz, M.D., Joel Raskin, M.D., Jimmy Y. Xu, Ph.D., Daniel K. Kajdasz, Ph.D.

12 noon
33 Safety and Efficacy of Intra-Muscular Ziprasidone Treatment of Acute Psychotic Agitation in Elderly Patients With Schizophrenia
Alex Aviv, M.D., Yoram Barak, M.D., Yehuda Baruch, M.D.

THIS SESSION WILL BE AUDIOTAPE.

WORKSHOPS

COMPONENTS 10-19

COMPONENT WORKSHOP 10 11:00 a.m.-12:30 p.m.
Room 104 A, Level 100, Toronto Convention Centre North
THE GIFT OF LIFE: A PSYCHIATRIC PERSPECTIVE ON LIVING HEPATIC ORGAN DONATION
APA Council on Psychosomatic Medicine
Co-Chps.: Philip R. Muskin, M.D., Silvia Hafliger, M.D.
Participants: Beth A. Grube, Ph.D., Matthew Muskin

COMPONENT WORKSHOP 11 11:00 a.m.-12:30 p.m.
Room 205 B, Level 200, Toronto Convention Centre North
TOWARDS A BETTER UNDERSTANDING OF CULTURAL ISSUES IN CLINICAL PRACTICE: RESIDENT'S PERSPECTIVE OF A MODEL CURRICULUM FOR RESIDENCY TRAINING PROGRAMS
APA/AstraZeneca Minority Fellows
Chp.: Angel A. Caraballo, M.D.
Participants: Lois W. Choi-Kain, M.D., Alphonso Nichols III, M.D., Jennifer D. Pender, M.D., Yanni C. Rho, M.D., Francis G. Lu, M.D.

COMPONENT WORKSHOP 12 11:00 a.m.-12:30 p.m.
Room 205 C, Level 200, Toronto Convention Centre North
ETHNICITY AND CAREGIVING ACROSS THE PSYCHIATRIC SPECTRUM
APA Committee on Ethnic Minority Elderly
Co-Chps.: Iqbal Ahmed, M.D., Warachal E. Faison, M.D.
Participants: Carl I. Cohen, M.D., Alveth J. Young, M.D., Yolonda R. Coleman, M.D., Cynthia I. Resendez, M.D., Nhi-Ha T. Trinh, M.D.

COMPONENT WORKSHOP 13 11:00 a.m.-12:30 p.m.
Room 205 D, Level 200, Toronto Convention Centre North
SEXUALITY AND ITS IMPACT ON THE HIV PANDEMIC
APA Committee on HIV/AIDS
Chp.: Marshall Forstein, M.D.
Participants: Milton L. Wainberg, M.D., Khakasa H. Wapenj, M.D.

COMPONENT WORKSHOP 14 11:00 a.m.-12:30 p.m.
Room 206 C/D, Level 200, Toronto Convention Centre North
PSYCHIATRIC ETHICS IN THE UNITED STATES AND THROUGHOUT THE WORLD
APA Ethics Committee
Co-Chps.: Spencer Eth, M.D., George Christodoulou, M.D.
Participants: Wade C. Myers, M.D., Julio Arboleda-Flores, M.D., Philip T. Merideth, M.D.

COMPONENT WORKSHOP 15 11:00 a.m.-12:30 p.m.
Room 701 B, Level 700, Toronto Convention Centre South
TEACHING THE WORKING ALLIANCE AS A CORE PROCESS ACROSS THE PSYCHOTHERAPIES
APA Committee on Psychotherapy by Psychiatrists
Chp.: Eric M. Plakun, M.D.
Participants: Bernard D. Beinman, M.D., Donna M. Sudak, M.D., Norman A. Clemens, M.D.

COMPONENT WORKSHOP 16 11:00 a.m.-12:30 p.m.
Room 703, Level 700, Toronto Convention Centre South
SCALES IN THE CLINICAL PRACTICE OF GERIATRIC PSYCHIATRY
APA Committee on Access and Effectiveness of Psychiatric Services for the Elderly
Chp.: Allan A. Anderson, M.D.
Participants: Lina S. Shihabuddin, M.D., Colleen J. Northcott, M.D.

COMPONENT WORKSHOP 17 11:00 a.m.-12:30 p.m.
Room 705, Level 700, Toronto Convention Centre South
WINNING THE FIGHT FOR MENTAL HEALTH BENEFITS: PARTNERING WITH EMPLOYERS
APA Committee on APA/Business Relationships
Chp.: Dauda A. Griffin, M.D.
Participants: Avram H. Mack, M.D., Alan Langlieb, M.D.

COMPONENT WORKSHOP 18 11:00 a.m.-12:30 p.m.
Room 707, Level 700, Toronto Convention Centre South
CULTURE AS A RATIONALIZATION FOR VIOLENCE AGAINST WOMEN
APA Committee on Family Violence and Abuse
Chp.: Gail E. Robinson, M.D.
<table>
<thead>
<tr>
<th>COMPONENT WORKSHOP 19</th>
<th>11:00 a.m.-12:30 p.m.</th>
<th>Room 801 A, Level 800, Toronto Convention Centre South</th>
</tr>
</thead>
</table>

**FACILITATING MINORITY TO EXCEL IN ACADEMIC PSYCHIATRY**

*APA Assembly Committee of Representatives of Minority/Underrepresented Groups*

Chp.: Jagannathan Srinivasaraghavan, M.D.

Participants: Pedro Ruiz, M.D., Nutan Atre-Vaidya, M.D., Stephen M. Goldfinger, M.D., Carl C. Bell, M.D.

---

<table>
<thead>
<tr>
<th>ISSUES 16-28</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>ISSUE WORKSHOP 16</th>
<th>11:00 a.m.-12:30 p.m.</th>
<th>Room 709, Level 700, Toronto Convention Centre South</th>
</tr>
</thead>
</table>

**ASSESSMENT OF CAPACITY: DEVELOPMENTS, DVDS, AND DEFENSE ORGANIZATIONS**

Chp.: M.E. Jan Wisc, M.D.

Participant: Julian Beezhold, M.B.

---

<table>
<thead>
<tr>
<th>ISSUE WORKSHOP 17</th>
<th>11:00 a.m.-12:30 p.m.</th>
<th>Room 711, Level 700, Toronto Convention Centre South</th>
</tr>
</thead>
</table>

**BIOPSYCHOSOCIAL AND SPIRITUAL ASPECTS OF TREATING OUR PHYSICIAN COLLEAGUES**

Co-Chps.: Monisha R. Vasa, M.D., Syed S.A. Naqvi, M.D.

Participants: Michael F. Myers, M.D., Leo L. Gallofin, M.D.

---

<table>
<thead>
<tr>
<th>ISSUE WORKSHOP 18</th>
<th>11:00 a.m.-12:30 p.m.</th>
<th>Room 713 A/B, Level 700, Toronto Convention Centre South</th>
</tr>
</thead>
</table>

**ORAL BOARDS BOOT CAMP: 2006**

Chp.: Elyse D. Weiner, M.D.

Participant: Eric D. Peselow, M.D.

---

<table>
<thead>
<tr>
<th>ISSUE WORKSHOP 19</th>
<th>11:00 a.m.-12:30 p.m.</th>
<th>Room 716 B, Level 700, Toronto Convention Centre South</th>
</tr>
</thead>
</table>

**THE OTHER DESPERATE HOUSE WIVES: HIDDEN VIOLENCE IN THE HOME**

Chp.: Susan J. Hatters-Friedman, M.D.

Participants: Renee M. Sorrentino, M.D., Joy E. Stankowski, M.D.

---

<table>
<thead>
<tr>
<th>ISSUE WORKSHOP 20</th>
<th>11:00 a.m.-12:30 p.m.</th>
<th>Room 717 A, Level 700, Toronto Convention Centre South</th>
</tr>
</thead>
</table>

**TREATING FIRST AND SECOND GENERATION IMMIGRANTS WITH PSYCHOTHERAPY DURING RESIDENCY TRAINING**

Chp.: Anu A. Matorin, M.D.

Participants: Andres J. Pumariega, M.D., Aradhana B. Sood, M.D., Lina M. Lopez, M.D., Ayesha I. Mian, M.D.

---

<table>
<thead>
<tr>
<th>ISSUE WORKSHOP 21</th>
<th>11:00 a.m.-12:30 p.m.</th>
<th>Room 717 B, Level 700, Toronto Convention Centre South</th>
</tr>
</thead>
</table>

**PHYSICIAN HEAL THYSELF: WORKPLACE BURNOUT AMONG PSYCHIATRISTS**

Co-Chps.: John Sharkey, M.D., Steve Choong Kam Chong, M.D.

---

<table>
<thead>
<tr>
<th>ISSUE WORKSHOP 22</th>
<th>11:00 a.m.-12:30 p.m.</th>
<th>Room 803 A/B, Level 800, Toronto Convention Centre South</th>
</tr>
</thead>
</table>

**PSYCHOTHERAPY TRAINING AND INTERNATIONAL MEDICAL GRADUATES: THE INFLUENCE OF CULTURAL FACTORS**

Chp.: Nyapati R. Rao, M.D.

Participants: Jerald Kay, M.D., Stephen M. Goldfinger, M.D., Michael D. Garrett, M.D., Damir Huremovic, M.D.

---

<table>
<thead>
<tr>
<th>ISSUE WORKSHOP 23</th>
<th>11:00 a.m.-12:30 p.m.</th>
<th>Room 816, Level 800, Toronto Convention Centre South</th>
</tr>
</thead>
</table>

**COGNITIVE-BEHAVIOR THERAPY FOR PSYCHOSIS: BASIC TECHNIQUES FOR PSYCHIATRISTS**

Chp.: Shanaya Rathod, M.D.

Participants: David G. Kingdon, M.D., Douglas Turkelingor, M.D.

---

<table>
<thead>
<tr>
<th>ISSUE WORKSHOP 24</th>
<th>11:00 a.m.-12:30 p.m.</th>
<th>Manitoba Room, Mezzanine Floor, Royal York</th>
</tr>
</thead>
</table>

**DOES BEAUTY EQUAL HAPPINESS?**

Co-Chps.: Stephanie M. Stewart, M.D., Alicia R. Ruelaz, M.D.

Participants: Novana I. Caivano, M.D., Tara Klein, M.D., Suzanne Hollingshead, B.A.

---

<table>
<thead>
<tr>
<th>ISSUE WORKSHOP 25</th>
<th>11:00 a.m.-12:30 p.m.</th>
<th>Tudor 7 Room, Mezzanine Floor, Royal York</th>
</tr>
</thead>
</table>

**ESTABLISHING A WOMEN'S MENTAL HEALTH PROGRAM IN AN ACADEMIC OR PRIVATE SETTING**

Co-Chps.: Catherine A. Birnordf, M.D., Nehama Dresner, M.D.

Participants: Margaret Altemus, M.D., Nicole Regent, M.D., Rachel Goldstein, M.D.

---

<table>
<thead>
<tr>
<th>ISSUE WORKSHOP 26</th>
<th>11:00 a.m.-12:30 p.m.</th>
<th>Tudor 8 Room, Mezzanine Floor, Royal York</th>
</tr>
</thead>
</table>

**SECRETS IN FAMILY THERAPY: TO TELL OR NOT TO TELL**

Co-Chps.: Eva C. Ritvo, M.D., Michael Hughes, M.D.

Participant: Jon A. Shaw, M.D.
ISSUE WORKSHOP 27 11:00 a.m.-12:30 p.m.
Salon A, Convention Floor, Royal York

VIRTUAL REALITY AND VIDEO GAMES IN THE TREATMENT OF MENTAL HEALTH DISORDERS AND ADDICTIONS: AN EVIDENCE-BASED ANALYSIS

Co-Chps.: William Huang, M.D., Jeffery N. Wilkins, M.D.
Participants: Jack Kuo, M.D.

ISSUE WORKSHOP 28 11:00 a.m.-12:30 p.m.
Salon B, Convention Floor, Royal York

MULTIDISCIPLINARY TREATMENT OF ADULTS WITH ASPERGER’S SYNDROME AND RELATED DISORDERS: LESSONS FROM THE UNIVERSITY OF PENNSYLVANIA SOCIAL LEARNING DISORDERS PROGRAM

Co-Chps.: Anthony L. Rostain, M.D., Edward S. Brodkin, M.D.
Participant: J. Russell Ramsay, Ph.D.

12 noon Sessions

FORUMS 1-6

FORUM 1 12 noon-1:30 p.m.
Room 701 A, Level 700, Toronto Convention Centre South

HARRY POTTER AND THE HALF-BLOOD PRINCE: HARRY GROWS UP

Chp.: JoAnne Isbey
Participants: Daniel P. Dickstein, M.D., Cheryl C. Munday, Ph.D.,
Steven G. Dickstein, M.D., Theresa A. Yuschock, Eva M.
Szigethy, M.D., Leah J. Dickstein, M.D., Dorothy Bates

FORUM 2 12 noon-1:30 p.m.
Room 714 B, Level 700, Toronto Convention Centre South

RESEARCH PLANNING FOR DSM-V

Chp.: Darrel A. Regier, M.D.
Participants: Wilson M. Compton, M.D., Carol A.
Tamura, M.D., Trey Sunderland, Dennis S. Charney, Norman
Satorius, M.D.

FORUM 3 12 noon-1:30 p.m.
Room 715 A/B, Level 700, Toronto Convention Centre South

MOZART AT 250: THE MIND AND MUSIC OF A GENIUS

Chp.: Richard Kogan, M.D.

FORUM 4 12 noon-1:30 p.m.
Room 801 B, Level 800, Toronto Convention Centre South

WOMEN AND ALCOHOL USE DISORDERS
Collaborative Session With the National Institute on Alcohol Abuse and Alcoholism

Chp.: Shelly F. Greenfield, M.D.
Participants: Grace Chang, M.D., Susan M. Gordon, Ph.D., Carrie L.
Randall, Ph.D.

FORUM 5 12 noon-1:30 p.m.
Ballroom, Lower Level, Intercontinental Hotel

ANTIPSYCHOTIC DRUGS EFFECTIVENESS:
RESULTS OF THE NIMH CATIE TRIAL

Chp.: Jeffrey A. Lieberman, M.D.
Participants: Joseph P. McEvoy, M.D., Richard S.E.
Keefe, Ph.D., Robert A. Rosenheck, M.D.

FORUM 6 12 noon-1:30 p.m.
 Territories Room, Mezzanine Floor, Royal York

THE THEORY AND PRACTICE OF APOLOGY

Chp.: Aaron Lazare, M.D.
Participants: David Spiegel, M.D., Jeffrey L. Geller, M.D.

1:00 p.m. Sessions

COURSES 51-57

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 51 1:00 p.m.-5:00 p.m.
Conference Room D/E, Mezzanine, Sheraton Centre

CONTEMPORARY MALPRACTICE LIABILITY 2006: A PRACTICAL GUIDE

Co-Directors: Eugene M. Lowenkopf, M.D., Abe M. Rychik, J.D.
Faculty: Jacqueline M. Melonas, J.D.

COURSE 52 1:00 p.m.-5:00 p.m.
Conference Room F, Mezzanine, Sheraton Centre

FAMILIES COPING WITH MEDICAL ILLNESS: A TREATMENT APPROACH FOR PSYCHIATRY

Director: John S. Rolland, M.D.
2:00 p.m. Sessions

ADVANCES IN PSYCHOPHARMACOLOGY
2:00 p.m.-5:30 p.m.
Room 107, Level 100, Toronto Convention Centre North
Chp.: Alan F. Schatzberg, M.D.

A Pharmacological Treatment of Bipolar Disorder
Paul E. Keck, Jr.

B Brain Stimulation Techniques in Psychiatry
William M. McDonald, M.D.

C Advances in the Pharmacotherapy of GAD
David V. Sheehan, M.D.

FOCUS LIVE SESSION 3
2:00 p.m.-3:30 p.m.
Room 714 A, Level 700, Toronto Convention Centre South

PSYCHOTHERAPY

Moderators: Deborah J. Hales, M.D., Mark H. Rapaport, M.D.
Presenter: Jerald Kay, M.D.

Expert clinicians, who served as the guest editors of the first two issues of FOCUS, will lead lively multiple-choice, question-based discussions. The 9:00 a.m. session covered Personality Disorders, the 11:00 a.m. session covered Eating Disorders and Sexual Disorders, and this session will cover Psychotherapy. Presented with multiple-choice questions, participants will test their knowledge with an interactive audience response system, which instantly presents the audience responses as a histogram on the screen. Each participant is able to take a self-assessment exam with answers and discussion led by the expert faculty.

LECTURES 8-9

LECTURE 8
2:00 p.m.-3:30 p.m.
Room 103, Level 100
Toronto Convention Centre North

APA'S KUN-PYO SOO AWARD LECTURE
Albert C. Caw, M.D.

Culture, Spirituality, and Psychiatry: A Psycho-Historical Study of King Saul

Chp.: Simiroid S. Nand, M.D.

Albert C. Caw, M.D., was born in the Philippines of Chinese parentage. Dr. Caw obtained his medical degree from the University of the East Medical Center in the Philippines, interned at Rochester General Hospital...
PRESIDENTIAL SYMPOSIUM 1
2:00 p.m.-5:00 p.m.
Room 701 A, Level 700, Toronto Convention Centre South

THE PUBLIC MENTAL HEALTH SYSTEM: CRITICAL ISSUES
APA Committee on Family Violence and Abuse and Council on Social Issues and Public Psychiatry
Chp.: Yvonne B. Ferguson, M.D.

A Domestic Violence, Lifetime Trauma, and Public Mental Health: Critical Issues for Policy, Prevention, and Service Delivery
Carole Warshaw, M.D.

B Ballot Initiative Creates New Services for Children and Youth
William Arroyo, M.D.

Discussant: Steven S. Sharfstein, M.D.
THIS SESSION WILL BE AUDIOTAPE D.

SYMPOSIA 1-33

SYMPOSIUM 1
2:00 p.m.-5:00 p.m.
Room 104 A, Level 100, Toronto Convention Centre North

HIV PREVENTION INTERVENTIONS WITH PSYCHIATRIC PATIENTS FROM AROUND THE WORLD: TURNING RESEARCH INTO PRACTICE
Chp.: Milton L. Wainberg, M.D.
Co-Chp.: Francine Cournos, M.D.

A Severe Mental Illness: HIV Research Trajectory and Needs
Karen McKinnon, M.A.

B Ethnography of HIV Risk in Two Psychiatric Settings
Paulo E. Mattos

C Severe Mental Illness and HIV Risk in India With an Emphasis on the Special Threats to Women
Prabha S. Chandra, M.D., Michael P. Carey, Ph.D.

D HIV Prevention and People With Mental Illness in South Africa: Prevalence, Policies, and Practice
Pamela Y. Collins, Keziah Mistry L.L.B., Alan Berkman, M.D., David Hoos, M.D.

E HIV Risk and Risk-Reduction Efforts Among Persons Having Serious Mental Illness and Substance Use Issues in the U.S.
Laura Otto-Salaj, Ph.D.
THIS SESSION WILL BE AUDIOTAPE D.
SYMPOSIUM 2  2:00 p.m.-5:00 p.m.
Room 104 B, Level 100, Toronto Convention Centre North

THERAPEUTIC MISCONCEPTION IN CLINICAL RESEARCH

Chp.: Paul S. Appelbaum, M.D.
Co-Chp.: Charles Lidz, Ph.D.

A  Therapeutic Misconception: An Overview of the Phenomenon
   Paul S. Appelbaum, M.D.

B  How Prevalent Is Therapeutic Misconception?
   Charles W. Lidz, Ph.D.

C  Assessment of Therapeutic Misconception in Older Patients With Schizophrenia
   Laura B. Dunn, M.D., Barton W. Palmer, Ph.D., Monique Keehan, B.S., Dilip V.Jeste, M.D., Paul S. Appelbaum, M.D.

D  Reaching Consensus on the Conceptual Definition of Therapeutic Misconception
   Gail Henderson

E  The Ethical Significance of the Therapeutic Misconception
   Franklin G. Miller, Ph.D.

THIS SESSION WILL BE AUDIOTAPEd.

SYMPOSIUM 4  2:00 p.m.-5:00 p.m.
Room 104 D, Level 100, Toronto Convention Centre North

PSYCHOSOCIAL INTERVENTION AND CANCER SURVIVAL

Chp.: David Spiegel, M.D.
Co-Chp.: Fawzy Fawzy, M.D.

A  Supportive-Expressive Group Therapy and Survival in Patients With Metastatic Breast Cancer: A Randomized Clinical Intervention Trial
   David Spiegel, M.D., Lisa D. Butler, Ph.D., Janine Giese-Davis, Ph.D., Cheryl Koopman, Ph.D., Sue DiMiceli B.A., Catherine Classen, Ph.D., Pat Fobair M.P.H., Robert W. Carlson, M.D., Helena C Kraemer, Ph.D.

B  RCT of Supportive-Expressive Group Therapy in Advanced Breast Cancer: Survival, Psychosocial, and Anti-Cancer Treatment Adherence Outcomes
   David W. Kissane, M.D., Brenda Grabsch M.S.W., David M. Clarke, Ph.D., Graeme C. Smith, M.D., Anthony Love, Ph.D., Sidney Bloch, M.D.

C  Treatment Outcomes of Group Supportive-Expressive Therapy for Women With Metastatic Breast Cancer
   Molyn Leszcz, M.D.

D  Impact of Psychotherapeutic Support on Gastrointestinal Cancer Patients Undergoing Surgery: Ten-Year Follow-Up Survival Results of a Randomized Trial
   Thomas Kuechler, Ph.D.

E  Malignant Melanoma: Effects of a Brief, Structured Psychiatric Intervention on Survival and Recurrence at Ten-Year Follow-Up
   Fawzy I. Fawzy, M.D.

Discussant: Michael Stefanek, Ph.D.
THIS SESSION WILL BE AUDIOTAPEd.

SYMPOSIUM 3  2:00 p.m.-5:00 p.m.
Room 104 C, Level 100, Toronto Convention Centre North

MIGRATION AND MENTAL ILLNESS AROUND THE WORLD
Royal College of Psychiatrists

Chp.: Nigel Bark, M.D.
Co-Chp.: Hamid Ghodse, M.D.

A  Refugee Mental Health Challenges in Africa
   Frank G. Njenga, M.D.

B  Mental Health of Sudanese Refugees: An Egyptian Perspective
   Nasser F. Loza, M.D., Nael Hassan, M.D.

C  PTSD Among a Group of Afghan Refugees Attending a Psychiatric Service in Peshawar, Pakistan
   Khalid A. Mutfi, M.D., Haroon R. Chaudhry, M.D.

D  Immigration-Repatriation and Mental Health: The Case of Greece
   George G. Christodoulou, M.D., Michael G. Madianos, M.D.

E  Raised Incidence of Psychosis in Ethnic Minority Groups in the UK: The AESOP Study
   Paul Fearon

F  Migration and Mental Health in Canada: Can Provincial Policy Help?
   Stephen R. Kisely, M.D.

Discussant: Ezra S. Susser, M.D.
THIS SESSION WILL BE AUDIOTAPEd.

SYMPOSIUM 5  2:00 p.m.-5:00 p.m.
Room 206 A/B, Level 200, Toronto Convention Centre North

SEXUAL ORIENTATION AND SPORTS
International Society for Sport Psychiatry

Chp.: Eric D Morse, M.D.

A  Being Gay in Sports
   Eric D. Morse, M.D.

B  Gender Role Conflict in Female Athletes
   Altha J. Stewart, M.D.

C  Suicide and the Homosexual Athlete
   Antonia L. Baum, M.D.

THIS SESSION WILL BE AUDIOTAPEd.
MONDAY

SYMPOSIUM 6  2:00 p.m.-5:00 p.m.
Room 206 C/D, Level 200, Toronto Convention Centre North

INSOMNIA: WHAT IS IT?
Chp.: Thomas W. Uhde, M.D.

A Insomnia: Diagnosis and Treatment Challenges
   Thomas W. Uhde, M.D.

B Epidemiology of Chronic Insomnia
   Edward Bixler, Ph.D.

C Chronic Insomnia: Cause-Effect Relationship to
   Depression and Anxiety Disorders
   Ravi K. Singhareddy, M.D.

D Biological Models of Chronic Insomnia: Clinical
   Implications
   Alexandros Vgontzas, M.D.

E Health Correlates of Insomnia in Young Adults
   Antonio Vela-Bueno, M.D., Sara Olavarrieta-Bernardino, Psy.D.,
   Julio Fernandez-Mendoza, Psy.D.,
   Alfredo Rodriguez-Muñoz, Psy.D.

Discussant: Thomas Roth
THIS SESSION WILL BE AUDIOTAPEd.

SYMPOSIUM 7  2:00 p.m.-5:00 p.m.
Room 206 E/F, Level 200, Toronto Convention Centre North

THE AFRICAN DIASPORA: IDENTIFYING AND
ELIMINATING BARRIERS TO MENTAL HEALTH

Chp.: Annelle B. Primm, M.D.
Co-Chp.: G. Chiadi U. Onyike, M.D.

A African Belief Systems and Corresponding Healing
   Practices
   Samuel O. Olpakau, M.D.

B Why Is Stigma so Rife in Nigeria?
   Oye Gureje

C The Haitian Diaspora: Barriers to Accessing Mental
   Health Services
   Mary Titus-Villedrouin

D Barriers to Mental Health Service Delivery to
   Ethiopian Immigrants and Refugees in the U.S.: How
   Should We Tackle This Problem?
   Yeshashwork Kibour

E The Postcolonial Challenge to the Stigma of Mental
   Illness in Jamaica
   Frederick W. Hickling

F Stigma and Mental Health: A South African Perspective
   Solomon Rataeme

G Recruitment of Minorities into Clinical Trials in
   Neuropsychiatry: The ADAPT Experience
   G. Chiadi U. Onyike, M.D.

Discussant: Ikwunda Wonodi, M.D.
THIS SESSION WILL BE AUDIOTAPEd.

SYMPOSIUM 8  2:00 p.m.-5:00 p.m.
Room 701 B, Level 700, Toronto Convention Centre South

TREATMENT ISSUES IN SCHIZOPHRENIA WITH
COMORBID DISORDERS
American Association of Practicing Psychiatrists

Chp.: Michael Y. Hwang, M.D.
Co-Chp.: Leslie Citrome, M.D.

A Depressive Symptoms in People With Schizophrenia
   Robert R. Conley

B Treatment of Schizophrenia With OCD
   Michael Y. Hwang, M.D.

C Substance Abuse Among Patients With Schizophrenia
   Spectrum Disorders
   Douglas Noordsy, M.D.

D Cognitive Functioning and Outcome in Schizophrenia
   Philip D. Harvey, Ph.D.

E Schizophrenia and Comorbid Aggressive Behavior:
   Update 2006
   Leslie L. Citrome, M.D.

F Eating Disorders in Schizophrenia
   Sun Young Yum, M.D., David P. Law, M.D., Sandra
   Denis, M.D., Sun Young Yum, M.D., Marcia Klein, Ph.D.,
   Michael Y. Hwang, M.D.

Discussant: Lewis A. Opfer, M.D.
THIS SESSION WILL BE AUDIOTAPEd.

SYMPOSIUM 9  2:00 p.m.-5:00 p.m.
Room 705, Level 700, Toronto Convention Centre South

REHABILITATION IN FRANCE, CANADA, AND THE
U.S.: FROM SCIENCE TO RECOVERY: VIVE LA
DIFFERENCE
French Psychiatric Association

Chp.: John A. Talbott, M.D.
Co-Chp.: Francois Petitjean, Psy.D.

A Neuropsychological Therapy Protocol on Young
   Schizophrenic Patients in Day Hospitals
   Christine Germain

B Implementing Innovative Rehabilitation Modules: The
   Case of IPT in Canadian Province Sites
   Alain D. Lesage, M.D.

C Recovery From Schizophrenia: Current Research
   Robert P. Liberman, M.D.

D Evidence-Based Practices and Recovery in
   Schizophrenia
   Alan S. Bellack, Ph.D.

E A New Rehabilitation Program for Patients With
   Schizophrenia: Development and Preliminary Results
   Christophe Lancon, Christophe Boulanger, M.D.

Discussant: Ann Thompson, M.S.W.
THIS SESSION WILL BE AUDIOTAPEd.
MONDAY

SYMPOSIUM 10  2:00 p.m.-5:00 p.m.
Room 707, Level 700, Toronto Convention Centre South

MODEL CURRICULA ON RELIGION AND
SPIRITUALITY FOR PSYCHIATRY RESIDENCY
TRAINING PROGRAMS

Chp.: Francis G. Lu, M.D.
Co-Chp.: Christina M. Puchalski, M.D.

A  Development of a Departmental-Based Curriculum of
Spirituality in Healthcare for Psychiatry Residents,
Other Healthcare Professionals, and Clergypastoral
Care Professionals
Joan M. Collison, M.D.

B  Incorporating a Spiritual Worldview Within Psychiatry
in the Bible Belt: University of South Carolina/
Palmetto Health Curriculum on Spirituality
Niaoka N. Campbell, M.D., Craig A. Stuck, M.D.

C  Bridging the Gap: Science and Spirituality
Patricia E. Murphy, Ph.D.

D  The Interface Between Spirituality, Religion, and
Psychiatry: A Course for Psychiatry Residents at the
University of British Columbia
Andrea D. Grabovac, M.D.

E  Spirituality and Psychiatry: The Harvard Longwood
Psychiatry Residency Course: Eight Years Later
John R. Pettee, M.D.

Discussant: Allan M. Josephson, M.D.
THIS SESSION WILL BE AUDIOTAPEd.

SYMPOSIUM 12  2:00 p.m.-5:00 p.m.
Room 711, Level 700, Toronto Convention Centre South

WHEN USUAL TREATMENTS FAIL:
AUGMENTATION STRATEGIES FOR REFRACTORY
SCHIZOPHRENIA

Chp.: Jean-Pierre Lindenmayer, M.D.
Co-Chp.: Joseph Friedman, M.D.

A  Herbal Medicinal Strategies in Refractory
Schizophrenia
Richard P. Brown, M.D.

B  NMDA Intervention Strategies in Refractory
Schizophrenia
Guoqiuai E. Tsai, M.D.

C  Augmentation Strategies for the Patient With
Treatment Refractory Schizophrenia
Peter F. Buckley, M.D.

D  High Dose Antipsychotic Strategies
Jean-Pierre Lindenmayer, M.D.

THIS SESSION WILL BE AUDIOTAPEd.

SYMPOSIUM 13  2:00 p.m.-5:00 p.m.
Room 713 A/B, Level 700, Toronto Convention Centre South

SUBSTANCE USE DISORDERS IN THE U.S.
Collaborative Session With the National Institute on Alcohol Abuse and
Alcoholism

Chp.: Deborah S. Hasin, Ph.D.
Co-Chp.: Bridget F. Grant, Ph.D.

A  Prevalence and Correlates of Prescription Drugs
Carlos Blanco-Jerez, M.D.

B  Alcohol and Drug Dependence and the Specificity of
Family History
Deborah S. Hasin, Ph.D.

C  Prevalence, Correlates, and Comorbidity of DSM-IV
Drug Use Disorders
Bridget F. Grant, Ph.D.

D  Lifetime Comorbidity of DSM-IV Mood and Anxiety
Disorders and Specific Drug Use Disorders: Results
From the National Epidemiologic Survey on Alcohol
and Related Conditions
Kevin Conway, Ph.D., Wilson M. Compton III, M.D.,
Frederick S. Stinson, Ph.D., Bridget F. Grant, Ph.D.

E  The Relationship of Family History to Cocaine and
Cannabis First Use and Dependence
Gary Heiman, Ph.D.

Discussant: Wilson M. Compton, M.D.
THIS SESSION WILL BE AUDIOTAPEd.

35
MONDAY

SYMPOSIUM 14 2:00 p.m.-5:00 p.m.
Room 714 B, Level 700, Toronto Convention Centre South

THE MID-LIFE CRISIS AS INTERPRETED IN FILM AND TELEVISION

Chp.: Anton C. Trinidad, M.D.
Co-Chp.: Robert Boland, M.D.

A Depression and Other Psychopathology at Mid Life
Anton C. Trinidad, M.D.

B The Mind of the Mid-Life TV Addict
Robert J. Boland, M.D.

C TBD
Josepha A. Cheong, M.D.

Discusant: Peter D. Kramer
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 15 2:00 p.m.-5:00 p.m.
Room 716 A, Level 700, Toronto Convention Centre South

FIRST-Episode Schizophrenia: How Can We Improve Treatment Outcome?

Chp.: Wolfgang Gaebel, M.D.
Co-Chp.: George Awad

A Measures to Prevent Relapse in Long-Term Treatment: Results From the German Research Network on Schizophrenia
Wolfgang Gaebel, M.D., Hans-Jurgen Moeller, M.D.

B The European First-Episode Schizophrenia Trial
René S Kuhn, M.D., Wolfgang W. Fleischhacker, M.D.

C Management of Impaired Cognition
Stephen R. Marder, M.D.

D Social Cognition in Schizophrenia: Impairments and Psychological Treatment
Wolfgang Woelwer, Ph.D., Nicole Frommann, Ph.D.,
Wolfgang Gaebel, M.D.

E Effects of Pharmacological Treatment on the Quality of Life
George Awad
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 16 2:00 p.m.-5:00 p.m.
Room 716 B, Level 700, Toronto Convention Centre South

Adolescent Brain Development: Implications for Psychiatric Treatment
National Institute on Drug Abuse

Chp.: Minda R. Lynch, Ph.D.
Co-Chp.: David Shurtleff

A Adolescent Brain Development: A Period of Vulnerabilities and Opportunities
Ronald E. Dahl, M.D.

B Interacting Effects of Cannabis and Tobacco Use on Brain Function in Adolescents.
Leslie K. Jacobsen, Kenneth R. Pugh, Ph.D., Robert T.
Constable, Ph.D., Michael Westerveld, Ph.D., W. Einar
Mencel, Ph.D.

C Prefrontal-Limbic Brain Maturation and Risk for Psychopathology in Adolescence
Isabelle M. Rosso, Ph.D., Marisa M. Silveri, Ph.D., Staci A.
Gruber, Ph.D., Deborah A. Yurgelun-Todd, Ph.D.

D The Immature Adolescent Brain and Cognitive Control
Beatriz Luna
Discussant: Laurence R. Stanford, Ph.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 17 2:00 p.m.-5:00 p.m.
Room 717 A, Level 700, Toronto Convention Centre South

Ethnicity, Age, and Gender as Factors in the Management of Anxiety and Depression

Chp.: S. Charles Schulz, M.D.

A A Clinical Update on Response Rates in Psychiatric Disorders and Ethnicity
DiAnne Bradford, M.D.

B Identifying and Treating Depressive and Anxiety Disorders in Children and Adolescents
Melissa P. DelBello, M.D.

C Treatment Considerations in Special Populations: Sex Differences
Diana O. Perkins, M.D.

D New Pharmacologic Approaches in Treating Depression and Anxiety
David E. Adson, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 18 2:00 p.m.-5:00 p.m.
Room 717 B, Level 700, Toronto Convention Centre South

Personality Disorders and Comorbidity: Predictive Factors and Clinical Implications

Chp.: Simone Kool, Ph.D.
Co-Chp.: S. Charles Schulz, M.D.

A Personality Disorders and Affective Disorders: Plowing the Sands or Fertile Soil? Predictors and Clinical Implications
Simone Kool, Ph.D., Jack Dekker, Ph.D.
B Efficacy of Depression Treatment in Patients With or Without Comorbid Personality Disorders: Does Clinical Lore Reflect the Findings From the Literature? 
Robert A. Schoevers, Ph.D., Simone Kool, Ph.D., Henricus L. Van, M.D., Prof. Dr. Jack J. Delkär, Mariëlle Hendriksen M.SC.

C The Relation Between Personality, Pathology, and Pathological Gambling 
R. Michael Bagby, Ph.D., Peter Farvolden, Ph.D., Tony Toneatto, Ph.D., Eric Bulmash, B.A.

D Gender Differences in Personality Disorders Among Depressed Outpatients as Compared to the General Population 
Cecilia M.T. Gijsbers Van Wijk, Ph.D.

E Drug Treatment of Personality Disorder: A Critical Review 
Theo Ingenhoven, M.D., Thomas Rinne, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 19
2:00 p.m.-5:00 p.m.
Room 801 A, Level 800, Toronto Convention Centre South

TOWARDS A DEVELOPMENTAL TRAUMA DISORDER

Chp.: Bessel A. Van Der Kolk, M.D.
Co-Chp.: Robert S. Pynoos, M.D.

A Childhood Abuse, Regional Brain Development, and Psychiatric Vulnerabilities: Evidence for Sensitive Periods 
Martin H. Teicher, M.D., Susan L. Andersen, Ph.D., Akemi Tomoda, M.D., Elizabeth Valente M.A., Ann M. Polcari, Ph.D.

B Developmental Trauma Disorder: Evidence From the Adolescent Years 
Marylene Cloitre, Ph.D.

C Empirical Foundations for a Developmental Trauma Disorder 
Bessel A. Van Der Kolk, M.D.

D Developmental Trauma Disorder: A Missing Link in Child Psychiatric Nosology and Treatment Planning 
Julian Ford

E Child Trauma History Profile, Interference With Developmental Competencies, and Influence on Other Major Psychiatric Disorders in Children and Adolescents 
Robert S. Pynoos, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 20
2:00 p.m.-5:00 p.m.
Room 801 B, Level 800, Toronto Convention Centre South

BORDERLINE MOTHERS AND INFANT INTERACTIONS: CHAOTIC CONTINGENCY

Chp.: Gisèle Apter-Danon, M.D.

A Neurobiological Insights Into the Consequences of Early Nurturing Experience 
Cort A. Pedersen, M.D.

B Distortion of Borderline Mothers and Infant Interaction and Emotional Regulation at Three Months 
Gisèle Apter-Danon, M.D., Marina Gianoli-Valente M.A., Rozenn Graignic-Philippe, Ph.D., Emmanuel Devouche, Ph.D., Maya Gratier, Ph.D., Annick Le Nestour, M.D.

C Practical Applications of Treating Women in the Postpartum Period 
Samantha E. Meltzer-Brody

D Interventions for New Mothers With PTSD and EPD 
Marian I. Butterfield, M.D., Jennifer L. Strauss, Ph.D.

Discussant: Carol C. Nadelson, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 21
2:00 p.m.-5:00 p.m.
Room 803 A/B, Level 800, Toronto Convention Centre South

CRIMINALIZATION OF MENTAL ILLNESS: GETTING IN AND OUT IN NEW YORK
American Association for Social Psychiatry

Chp.: Zebulon C. Taintor, M.D.
Co-Chp.: Henry C. Weinstein, M.D.

A Only Some People With Mental Illness Are Criminalized 
Zebulon C. Taintor, M.D.

B Substance Abuse, Spirituality, and Deviant Behavior 
Richard J. Frances, M.D.

C Mental Health Treatment in New York State Prisons and Outcome 
Abraham L. Halpern, M.D.

D Alternatives to Incarceration: Assisted Outpatient Treatment and Drug Courts 
Gary R. Collins, M.D.

THIS SESSION WILL BE AUDIOTAPED.
MONDAY

SYMPOSIUM 22 2:00 p.m.-5:00 p.m.
Imperial Room, Main Floor, Royal York

PSYCHOCULTURAL FOUNDATIONS OF POLITICAL TERRORISM
APA Council on Global Psychiatry and International Society of Political Psychology

Chp.: Jerrold M. Post, M.D.
Co-Chp.: Stevan M. Weine, M.D.

A Combating the Virus of Islamist Militancy: A Public Health Perspective
Jerrold M. Post, M.D.

B Toward a Scientific Revolution in the Application of Behavioral Sciences to the Study of the Deep Roots of Terrorism
Jeff Victoroff, M.D.

C The Appeal of Radical Islam for Young British Muslims
Amy Waldman

D Terrorism and Diasporas
Stevan M. Weine, M.D.

E Religion and Terrorism in U.S. Prisons: Crucible for Commitment or Contagion?
Gregory B. Saithoff

F Moral Agents, Immoral Violence: Mechanisms of Moral Disengagement in Islamic Suicide Missions
Mohammad Hafez

Discussant: David A. Rothstein, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 23 2:00 p.m.-5:00 p.m.
Alberta Room, Mezzanine Floor, Royal York

SCIENCE, DIAGNOSES, AND THE CLINICIAN
World Psychiatric Association

Chp.: Rodrigo A. Munoz, M.D.
Co-Chp.: G. Scott Waterman, M.D.

A A Proposal to Include a Dimensional Component in DSM-IV
John E. Helzer

B Dualism and the DSM: Emerging From the Shadow of the 17th Century
G. Scott Waterman, M.D.

C DSM in the 21st Century and Beyond: The Interface of Genomics and Neuroscience With Our Diagnostic System
James J. Hudziak, M.D.

D Improving the Validity of DSM Categories
Lee N. Robins, D.Phil.

Discussant: Darrel A. Regier, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 24 2:00 p.m.-5:00 p.m.
British Columbia Room, Mezzanine Floor, Royal York

THE EFFECTIVE PSYCHOTHERAPIST: THE ROLE OF COMMON AND SPECIFIC FACTORS

Chp.: Mantosh J. Dewan, M.D.

A Factors Common to All Evidence-Based Psychotherapies
John Manning, Priyanthi Weerasekera, M.D.

B Cognitive-Behavioral Therapy for Anxiety Disorders: Common and Specific Aspects
Edna B. Foa, Ph.D.

C Integrating Common and Specific Factors in Psychotherapy Training: McMaster and Syracuse Models
Priyanthi Weerasekera, M.D., John Manning, M.D.

D Interpersonal Therapy: Common and Specific Factors
Scott P. Stuart, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 25 2:00 p.m.-5:00 p.m.
Confederation 5 Room, Mezzanine Floor, Royal York

DEVELOPING STRATEGIES IN PSYCHOTHERAPY RESEARCH

Chp.: Andrew J. Gerber, M.D.
Co-Chp.: James H. Kocsis, M.D.

A Assessing The Quality of Randomized Controlled Trials of Psychotherapy
Andrew J. Gerber, M.D., James H. Kocsis, M.D., Jacques Barber, Ph.D., Steven D. Hollon, Ph.D., Barbara L. Milrod, M.D., Steven P. Roose, M.D., Michael E. Thase, M.D.

B Long-Term Outcome in Psychotherapy Research
James H. Kocsis, M.D.

C An Outcome Study for Psychoanalysis
Steven P. Roose, M.D., Andrew J. Gerber, M.D., Bret R. Rutherford, M.D.

D Comparison and Combination of Psychotherapy and Medication in Outcome Trials
Michael E. Thase, M.D.

Discussant: M. Katherine Shear, M.D.
THIS SESSION WILL BE AUDIOTAPED.
MONDAY

SYMPOSIUM 26 2:00 p.m.-5:00 p.m.
Manitoba Room, Mezzanine Floor, Royal York

TAKING SCIENCE TO POLICY: EFFORTS TO REDUCE HARMs RELATED TO ALCOHOL MISUSE
Collaborative Session With the National Institute on Alcohol Abuse and Alcoholism

Chp.: Mark L. Willenbring, M.D.
Co-Chp.: Ralph Hingson

A The Magnitude and Prevention of Underage Drinking Problems
Ralph Hingson

B Pragmatic Science: The New NIAAA Clinicians Guide
Mark L. Willenbring, M.D.

C Alcohol Interventions in Trauma Centers Reduce Reinjury Rates: State Laws and Insurance Regulations Prevent Their Implementation
Larry Gentilello

D Implementing Alcohol Treatment for People With Co-Occurring Disorders in Psychiatric Treatment Settings
Robert Drake, Mary F. Brunette, M.D., Kim T. Mueser, Ph.D., Gregory J. McHugo, Ph.D.

E What Kind of Treatment System Is Necessary to Implement Evidence-Based Practices?
A. Thomas McLellan, Ph.D.
THIS SESSION WILL BE AUDIOTAPEd.

SYMPOSIUM 28 2:00 p.m.-5:00 p.m.
Territories Room, Mezzanine Floor, Royal York

CANMAT GUIDELINES FOR THE MANAGEMENT OF BIPOLAR DISORDER: AN EFFORT TOWARDS INTERNATIONAL CONSENSUS

Chp.: Sidney H. Kennedy, M.D.

A Foundations of Management-Applying Chronic Disease Models and Psychosocial Interventions to Bipolar Disorder
Sagar V. Parikh, M.D.

B CANMAT Guidelines for Acute and Continuation Treatment of Mania
Lakshmi N. Yatham, M.D.

C Acute Management of Bipolar Depression
Sidney H. Kennedy, M.D.

D Bipolar II Disorder: Emerging Guidelines for Treatment
Claire M. O’Donovan, M.B.

E A U.S. and International Perspective on CANMAT Guidelines for Bipolar Disorder
Joseph R. Calabrese, M.D.
THIS SESSION WILL BE AUDIOTAPEd.

SYMPOSIUM 27 2:00 p.m.-5:00 p.m.
Quebec Room, Mezzanine Floor, Royal York

NOT JUST DOPAMINE ANY MORE: EMERGING GLUTAMATERGIC THERAPIES FOR SCHIZOPHRENIA

Chp.: Daniel C. Javitt, M.D.

A Endogenous Modulators of Glutamatergic Neurotransmission and the Pathophysiology of Schizophrenia
Joseph T. Coyle, Jr.

B AMPA Agonists (Ampakines) in Schizophrenia
Donald C. Goff

C The PCP Model of Schizophrenia: 45 Years and Counting
Daniel Javitt, M.D.

D NMDA Glycine Site Agonists in the Treatment of the Schizophrenia Prodome
Scott W. Woods, M.D.
THIS SESSION WILL BE AUDIOTAPEd.

SYMPOSIUM 29 2:00 p.m.-5:00 p.m.
Tudor 7 Room, Mezzanine Floor, Royal York

DEMENTIA IN PATIENTS WITH DOWN SYNDROME: RISK FACTORS, BIOMARKERS, DIAGNOSIS, AND TREATMENT

Chp.: John M. de Figueiredo, M.D.

A Risk Factors and Biomarkers for Dementia in Adults With Down Syndrome
Nicole Schupf, Deborah Pang, M.P.H., Bindu N. Patel, M.P.H., Warren B. Zigman, Ph.D., Wayne Silverman, Ph.D.

B Cognitive Assessment of Aging Persons With Down Syndrome
Arthur Dalton, Ph.D.

C Trials to Assess Treatment Strategies for Dementia in Down Syndrome
Mary Sano, Ph.D., Paul Aisen, M.D., Arthur Dalton, Ph.D.
THIS SESSION WILL BE AUDIOTAPEd.
MONDAY

SYMPOSIUM 30  2:00 p.m.-5:00 p.m.
Tudor 8 Room, Mezzanine Floor, Royal York

GERIATRIC PSYCHIATRY: NEW IDEAS AND NEW PRACTICES FOR THE 21ST CENTURY

Chp.: Sandra A. Jacobson
Co-Chp.: Larry Ereshefsky, Pharm.D.

A Pharmacogenomics in Clinical Practice and Research
Larry Ereshefsky, Pharm.D., Stanford Jhee, Pharm.D.

B The Future of Magnetic and Electrical Stimulation Therapies in Geriatrics
Sarah H. Lisanby, M.D.

C New Pharmaceuticals
Sandra A. Jacobson, M.D.

D Best New Technologies For Improved Patient Care
Myron L. Pulier, M.D.

Discussant: Trey Sunderland, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 31  2:00 p.m.-5:00 p.m.
Ballroom, Convention Floor, Royal York

NANCY C. ANDREASEN, M.D.: FESTSCHRIFT FOR HER 13 YEARS AS JOURNAL EDITOR

Chp.: Robert Freedman, M.D.

A Scientific Journals and the Transmission of Knowledge to Clinicians
Floyd E. Bloom

B Interaction Between Gene Expression and Social Behavior
Leon Eisenberg, M.D.

C Brain Imaging and the Human Brain at Work
Marcus Raichle, M.D.

D The History of Episodic Memory
Endel Tulving, Ph.D.

Discussant: Nancy C. Andreassen M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 32  2:00 p.m.-5:00 p.m.
Salon A, Convention Floor, Royal York

A SPANISH LANGUAGE UPDATE ON THE ASSESSMENT AND MANAGEMENT OF DEPRESSION
American Society of Hispanic Psychiatry

Chp.: Gabriel Kaplan, M.D.
Co-Chp.: Javier I. Escobar, M.D.

A Update on the Neurobiology of Depression
Pedro L. Delgado, M.D.

B Suicide
Maria A. Oquendo, M.D.

C Treatment of Depression in Parkinson's Disease
Humberto Marin, M.D.

D Depression in Cognitive Intact and Cognitive Impaired Elderly Persons
Jacobo E. Mintzer, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 33  2:00 p.m.-5:00 p.m.
Salon B, Convention Floor, Royal York

RECENT ADVANCES IN CLINICAL CARE AND CLINICAL RESEARCH IN BPD

Chp.: Mary C. Zanarini, M.D.
Co-Chp.: John G. Gunderson, M.D.

A Course of Acute and Temperamental Symptoms of BPD Over Ten Years of Prospective Follow-Up
Mary C. Zanarini, Ed.D., Frances R. Frankenburg, M.D., D. Bradford Reich, M.D., Kenneth R. Silk, M.D.

B Randomized Controlled Trial Comparing DBT to APA Practice Guidelines for BPD: Clinician Adherence
Paul S. Links, M.D., Shelley McMain, Ph.D., Michele Cook R.N., Andrea Januszewski, B.S.C., Nathan J. Kolla, M.D.

C Effectiveness of Inpatient DBT for BPD: A Controlled Trial and Follow-Up Data
Martin Bohus, M.D.

D Empirical Observations on the Relationship Between BPD and Bipolar Disorders
John G. Gunderson, M.D.

E Randomized Controlled Trial of Psychodynamic Treatments Compared to DBT for BPD
John F. Clarkin, Ph.D., Kenneth N. Levy, Ph.D., Mark F. Lenzenweger, Ph.D.

Discussant: Kenneth R. Silk, M.D.
THIS SESSION WILL BE AUDIOTAPE.

3:00 p.m. Session

NEW RESEARCH POSTER SESSION 5
3:00 p.m.-5:00 p.m.
Exhibit Hall B, Level 300, Toronto Convention Centre North

MOOD DISORDERS

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.
5:30 p.m. Session

CONVOCATION OF DISTINGUISHED FELLOWS

5:30 p.m. 6:15 p.m.
Exhibit Hall A, Level 350
Toronto Convention Centre North

All Distinguished Life Fellows, Distinguished Fellows, Life Fellows, International Fellows, members, and registered guests are invited.

Presiding: Steven S. Sharstein, M.D., President

Grand Marshal: Jack S. Brandes, M.D., Gerald Schoedeckman, M.D.

Marshal: Howard E. Book, M.D., Donna E. Stewart, M.D.

INTRODUCTION OF DISTINGUISHED LIFE FELLOWS
Pedro Ruiz, M.D., President-Elect

INDUCTION OF DISTINGUISHED FELLOWS
Pedro Ruiz, M.D.

INTRODUCTION OF FIFTY-YEAR DISTINGUISHED LIFE FELLOWS, FIFTY-YEAR LIFE MEMBERS, AND INTERNATIONAL FELLOWS
Steven S. Sharstein, M.D.

INTRODUCTION OF FELLOWS
Steven S. Sharstein, M.D.

PRESENTATION OF SPECIAL PRESIDENTIAL COMMENDATIONS
Steven S. Sharstein, M.D.

PRESENTATION OF DISTINGUISHED SERVICE AWARDS
Steven S. Sharstein, M.D.

INTRODUCTION OF THE MEMBERSHIP COMMITTEE CHAIRPERSON AND AWARDS BOARD CHAIRPERSONS
Steven S. Sharstein, M.D.

PRESENTATION OF AWARDS
Steven S. Sharstein, M.D.

APA/Lilly Resident Research Awards
Human Rights Awards
Bianco H. Lippincott Award for Research in Child Psychiatry
APIE/Avenir Fund Award for Research Development in Psychological Psychiatry
Agnes Purcell McGavin Awards
Isaac Kat Award
Jack Weinberg Memorial Award for Geriatric Psychiatry

WILLIAM C. MENNINGER MEMORIAL CONVOCATION LECTURE
David K. Shipler

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 29-33

INDUSTRY-SUPPORTED SYMPOSIUM 29
7:00 p.m.-10:00 p.m.
Room 106, Level 105, Toronto Convention Centre North

PHARMACOTHERAPY OF PSYCHOTIC AND MOOD DISORDERS WITH EXISTING MEDICAL ILLNESS
Supported by AstraZeneca Pharmaceuticals

Chp.: Michelle B. Riba, M.D.
Co-Chp.: Henry A. Nasrallah, M.D.

A Optimal Selection of Pharmacotherapy in Psychotic and Mood Disorders With Coexisting Metabolic Disorders
Henry A. Nasrallah, M.D.
MONDAY

B Management Approaches to Schizophrenia With Co-Occurring Cancer
Diana O. Perkins, M.D.

C Pharmacotherapy of Psychotic and Mood Disorders in the Context of Thromboembolic Disease
Quinton E. Moss, M.D.

D When Mental Illness Is Complicated By Respiratory Symptoms: Management Implications
Peter J. Weiden, M.D.

E When HIV Complicates Serious Psychiatric Disorders
Glenn J. Treisman, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 30
7:00 p.m.-10:00 p.m.
Canadian Room, Convention Floor, Royal York

HELPING DEPRESSED PATIENTS ACHIEVE REMISSION: ADVOCACY FOR IMPROVEMENT
Supported by Bristol-Myers Squibb Company
Chp.: A. John Rush, M.D.

A Heterogeneity in Response and Remission: Implications for Optimizing Treatment
A. John Rush, M.D.

B Switching Treatments: For Whom and to What Effect?
Maurizio Fava, M.D.

C Optimizing Antidepressant Treatments: Use of Augmentations and Combinations to Achieve Remission
Andrew A. Nierenberg, M.D.

D Psychotherapy: For Whom and to What Effect?
Michael E. Thase, M.D.

E Pharmacogenetics: Can We Customize the Treatments of Depression?
Roy H. Perlis, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 31
7:00 p.m.-10:00 p.m.
Concert Hall, Convention Floor, Royal York

UNDERSTANDING AND MANAGING THE TRANSITION OF ADHD FROM ADOLESCENCE TO YOUNG ADULTHOOD: THE MATURATION OF THE DISORDER
Supported by Shire US, Inc.
Chp.: Timothy E. Wilens, M.D.

A Imaging the Brains of ADHD Adults: New Findings
George Bush, M.D.

B ADHD 'Not Otherwise Specified': Conceptual Issues
Stephen V. Faraone, Ph.D.

C ADHD Behind the Wheel: Driving With ADHD
Craig B. Surman, M.D.

D ADHD Goes to College: Planning, Protecting, and Prospering
Sharon B. Wigal, Ph.D.

E Emerging Therapies in the Treatment of ADHD
Timothy E. Wilens, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 32
7:00 p.m.-10:00 p.m.
Grand Ballroom, Lower Concourse, Sheraton Centre

THE COGNITION, NEUROCIRCUITRY, AND DISABILITY INTERFACE: BRINGING EVIDENCE TO PRACTICE
Supported by Cephalon, Inc.
Chp.: John H. Krystal, M.D.

A The Neurocircuitry of Cognition
John H. Krystal, M.D.

B Cognition: What Is the Role of Genetics?
Daniel R. Weinberger, M.D.

C Cognition, Attention, and Executive Function: How Do They Translate in Our Patients?
Philip D. Harvey, Ph.D.

D From Brain to Bedside: Understanding the Clinical Interface of Cognition and Neurocircuitry of Depression
Boadie W. Dunlop, M.D.

E Novel Treatments for Cognitive Enhancement: Can Drugs Make People Smarter?
Trevor Robbins, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 33
7:00 p.m.-10:00 p.m.
Metro Grand Ballroom, Second Level, Westin Harbour Castle

TAKING CONTROL OF NEGATIVE SYMPTOMS: THE NEXT STEP FOR IMPROVED PATIENT OUTCOMES IN SCHIZOPHRENIA
Supported by Organon USA Inc. and Pfizer Inc.
Chp.: Steven G. Potkin, M.D.

A Recognizing Negative Symptoms and Their Importance
Joseph M. Pierre, M.D.

B Psychosis Circuits, Negative Symptoms, and Brain Imaging
Steven G. Potkin, M.D.

C Positive Outcomes With Negative Symptoms: Measuring and Monitoring Your Patients
Dawn I. Velligan, Ph.D.

D Treatment of Negative Symptoms
Hans-Juergen Moeller, M.D.
Whatever your specialty, whatever your background, there’s something for you at the 160th Annual Meeting of the American Psychiatric Association in one of the world’s most beautiful cities.

Learn from the experts...
Earn up to 66 hours of Category 1 CME credits...
Meet colleagues from around the world...
Visit hundreds of commercial and educational exhibits...
Experience San Diego’s beautiful beaches, gentle climate, and world renowned San Diego Zoo.

FOR MEMBERS ONLY
Small clinically-based seminars led by outstanding educators...
Save up to $515 on registration fees compared to nonmember rates...
Enjoy discounts at APPI Bookstore...
Early member-only housing and registration
December 1-31, 2006

The advance registration packet and housing information will be available online January 2, 2007 at www.psych.org.
American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington • VA 22209-3901
American Psychiatric Association

2007 Annual Meeting
May 19–24, 2007 • San Diego, CA

More than 1,000 sessions...

- Advances in Research
- Symposia
- Scientific and Clinical Reports
- Medical Updates
- Forms
- Workshops
- New Research Posters & Oral/Slide Sessions
- Research Advances in Medicine
- CME Courses
- Debates
- Distinguished Lecturers

Continuing Medical Education Credit

The American Psychiatric Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 66 hours in Category 1 credits toward the AMA Physician’s Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Contact Information
http://www.psych.org
E-mail: apa@psych.org

or call the APA toll free at: 1.888.357.7924
TUESDAY, MAY 23, 2006

159TH ANNUAL MEETING

7:00 a.m. Sessions

PART 2 OF INDUSTRY-SUPPORTED BREAKFAST
SYMPOSIA 26-28

INDUSTRY-SUPPORTED BREAKFAST
SYMPOSIUM 26, PART 2
7:00 a.m.-8:30 a.m.
Canadian Room, Convention Floor, Royal York

CLINICAL IMPLICATIONS OF CHOICES OF
ATYPICAL ANTIPSYCHOTICS: REALITIES AND
MYTHS
Supported by Bristol-Myers Squibb Company and Otsuka America
Pharmaceutical, Inc.

Chp.: Robert E. Hales, M.D.
Co-Chp.: Stuart C. Yudofsky, M.D.

A Bridging Pharmacology and Clinical Effectiveness in
Schizophrenia
Anissa Abi-Dargham, M.D.

B Advances in Pharmacotherapy for Maintenance
Treatment in Bipolar Disorder
Terence A. Ketter, M.D.

INDUSTRY-SUPPORTED BREAKFAST
SYMPOSIUM 27, PART 2
7:00 a.m.-8:30 a.m.
Grand Ballroom, Lower Concourse, Sheraton Centre

EVIDENCE, OUTCOMES, AND ADVOCACY: SHAPING
THE MANAGEMENT OF GAD
Supported by Cephalon, Inc.

Chp.: David V. Sheehan, M.D.

A The Cognitive Expression of GAD
David J. Nutt, M.D.

B Gender Differences in GAD From Menarche to
Menopause
Marlene P. Freeman, M.D.

C The Evidence Supporting Targeted Pharmacotherapy in
GAD
David V. Sheehan, M.D.

INDUSTRY-SUPPORTED BREAKFAST
SYMPOSIUM 28, PART 2
7:00 a.m.-8:30 a.m.
Metro Grand Ballroom, Second Level, Westin Harbour Castle

ATTAINING AND SUSTAINING REMISSION IN
TREATMENT OF DEPRESSION WITH COMORBID OR RESIDUAL ANXIETY
Supported by Wyeth Pharmaceuticals

Chp.: Madhukar H. Trivedi, M.D.

A New Strategies to Address Anxiety and Resistant
Somatic Symptoms
Mark H. Rapaport, M.D.

B How to Monitor Progress of Treatment of Depression
With Anxiety
Madhukar H. Trivedi, M.D.

8:00 a.m. Sessions

COURSES 58-64
Course descriptions are available in the CME
Course Brochure included in your registration
packet. Admission by ticket only.

COURSE 58 8:00 a.m.-12 noon
Conference Room F, Mezzanine, Sheraton Centre

HOW TO USE YOUR PALM OS PERSONAL DIGITAL
ASSISTANT IN PSYCHIATRIC PRACTICE:
INTRODUCTORY COURSE

Co-Directors: John Luo, M.D., Richard A. Montgomery, M.D.
Faculty: Robert C. Hsuung, M.D., Carlyle H. Chan, M.D., Jeffrey
Spector, M.D.

COURSE 59 8:00 a.m.-12 noon
Essex Room, Mezzanine, Sheraton Centre

PSYCHIATRIC GENOMICS: APPLICATIONS FOR
CLINICAL PRACTICE

Director: David A. Mrazek, M.D.
Faculty: John L. Black, M.D., Brett A. Koplin, M.D.

COURSE 60 8:00 a.m.-12 noon
Windsor Room East, Mezzanine, Sheraton Centre

PSYCHIATRIC CONSULTATION IN LONG-TERM
CARE: ADVANCED COURSE

Director: George T. Grossberg, M.D.
Faculty: Abhijit K. Desai, M.D.

COURSE 61 8:00 a.m.-12 noon
Windsor Room West, Mezzanine, Sheraton Centre

DISASTER PSYCHIATRY: TERRORISM, TRAUMA,
AND THINGS TO DO

Director: Joseph C. Napoli, M.D.
Faculty: Michael Blumenfield, M.D., V. Alex Kehayan, Ed.D.
TUESDAY

COURSE 62  8:00 a.m.-12 noon
City Hall, Second Floor, Sheraton Centre

THE DETECTION OF MALINGERED MENTAL ILLNESS

Director: Phillip J. Resnick, M.D.

COURSE 63  8:00 a.m.-12 noon
Dominion Ballroom North, Second Floor, Sheraton Centre

ADD IN ADULTS

Director: Thomas E. Brown, Ph.D.
Faculty: Jefferson B. Prince, M.D.

COURSE 64  8:00 a.m.-12 noon
Kent Room, Second Floor, Sheraton Centre

COGNITIVE BEHAVIORAL THERAPY BOOT CAMP FOR PSYCHIATRISTS: EMPHASIZING THE PRACTICAL

Director: Anton C. Trinidad, M.D.
Faculty: Stephen P. McDermott, M.D., Robert Leahy, Ph.D.

9:00 a.m. Sessions

ADVANCES IN PERSONALITY DISORDERS  
9:00 a.m.-12:30 p.m.
Room 107, Level 100, Toronto Convention Centre North

Chp.: John M. Oldham, M.D.

A  Theories of Personality and Personality Disorders  
Drew Westen, Ph.D.

B  Manifestations and Clinical Diagnosis: Recent Findings From the Collaborative Longitudinal Personality Disorders Study  
Andrew E. Skodol II, M.D.

C  Boundary Issues and Personality Disorders  
Thomas G. Guthell, M.D.

D  Gender and Personality Disorder  
Leslie C. Morey, Ph.D.

E  Update on Neurobiology and Neuroimaging In BPD and Related Personality Disorders  
Martin Bohus, M.D.

Discussant: Glen O. Gabbard, M.D.

CLINICAL CASE CONFERENCE 3  
9:00 a.m.-10:30 a.m.
Room 104 B, Level 100, Toronto Convention Centre North

ROCKING THE CRADLE: A CASE OF POSTPARTUM INFANTICIDE

Moderator: Nicole F. Wolfe, M.D.
Presenters: Alyson R. Kuroski-Mazzei, D.O., Donna M. Norris, M.D., Diana Dell, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

CONTINUOUS CLINICAL CASE CONFERENCE 1: PART 1  
9:00 a.m.-12:30 p.m.
Room 104 C, Level 100, Toronto Convention Centre North

TWENTY THERAPIES LATER: ADDRESSING TRANSFERENCE RESISTANCE

Moderator: R. Rao Gogineni, M.D.
Presenters: Robert Michels, M.D., Richard P. Kluft, M.D., Sheila Judge, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

COURSES 65-70

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 65  9:00 a.m.-4:00 p.m.
Conference Rooms B/C, Mezzanine, Sheraton Centre

PERSONALITY AND POLITICAL BEHAVIOR

Director: Jerrold M. Post, M.D.

COURSE 66  9:00 a.m.-4:00 p.m.
Conference Room D/E, Mezzanine, Sheraton Centre

A PSYCHODYNAMIC APPROACH TO TREATMENT REFRACTORY MOOD DISORDERS

Director: Eric M. Plakun, M.D.
Faculty: Edward R. Shapiro, M.D., David L. Mintz, M.D.
COURSE 67 9:00 a.m.-4:00 p.m.
Conference Room G, Mezzanine, Sheraton Centre

MONEY MATTERS: USING THEORY IN CLINICAL PRACTICE

Director: Cecilia M. Mikalac, M.D.

COURSE 68 9:00 a.m.-4:00 p.m.
Dominion Ballroom South, Second Floor, Sheraton Centre

ACHEIVING AND SUSTAINING PSYCHOTHERAPY EFFECTIVENESS

Director: Paula Ravitz, M.D.
Faculty: Molyn Leszcz, M.D., Nancy L. McNaughton, M.Ed., Allan D. Peterkin, M.D., Clare M. Pain, M.D., Robert Maunder, M.D., Jonathan J. Hunter, M.D., Rex Kay, M.D.

COURSE 69 9:00 a.m.-4:00 p.m.
Kensota Room, Second Floor, Sheraton Centre

PERSONNEL MANAGEMENT FOR CLINICIAN-ADMINISTRATORS

Director: Stephen M. Solzys, M.D.
Faculty: Kay Titchenal, SPHR, Joseph J. Parks III, M.D.

COURSE 70 9:00 a.m.-4:00 p.m.
Simco/Dufferin Room, Second Floor, Sheraton Centre

UNDERSTANDING THE PERSON BEHIND THE ILLNESS: AN APPROACH TO PSYCHODYNAMIC FORMULATION

Director: William H. Campbell, M.D.

DEBATE 2
9:00 a.m.-10:30 a.m.
Room 716 A, Level 700, Toronto Convention Centre South

MEDICATIONS IN PREGNANCY AND LACTATION: WHAT HAVE WE LEARNED?

Moderator: Linda L.M. Worley, M.D.
Presenters: Zachary N. Stowe, M.D., Donna E. Stewart, M.D., Jay A. Gingrich, M.D.

THIS SESSION WILL BE AUDIOTAPE DC.

DISCUSSION GROUPS 10-13
9:00 a.m.-10:30 a.m.
These sessions are limited to 25 participants on a first-come, first-served basis.

11 John F. Clarkin, Ph.D., on the Therapists' Experience With Borderline Patients (Meet the Author)
Halton Room, Main Level, Intercontinental Hotel

12 Robert P. Cabaj, M.D., on Gay Men and Crystal Meth Abuse
Humber Room, Main Level, Intercontinental Hotel

13 Carol A. Bernstein, M.D., on Directing a Residency Program: All You Ever Wanted to Know But Were Afraid to Ask
Kingsway Room, Main Level, Intercontinental Hotel

LECTURES 11-13
MASTER EDUCATOR CLINICAL CONSULTATIONS 7-9
9:00 a.m.-10:30 a.m.
These sessions are limited to 25 participants on a first-come, first-served basis.

7 Ronald O. Rieder, M.D., on Building a Research Career in Psychiatry
Room 201 A, Level 200, Toronto Convention Centre North

8 Michael Myers, M.D., on Treating Physicians and Their Families: Clinical Dilemmas
Room 201 B, Level 200, Toronto Convention Centre North

9 Zebulon Taintor, on Internet Addiction
Room 201 C, Level 200, Toronto Convention Centre North

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

RESEARCH ADVANCES IN MEDICINE
9:00 a.m.-11:00 a.m.
Room 716 B, Level 700, Toronto Convention Centre South

AGING, LONGEVITY, AND NEUROLOGICAL DISORDERS
Chp.: Anand Pandya, M.D.

Participants: Donald Redelmeier, M.D., on Death Rates and Success
Janis Miyasaki, M.D., on Just Do It Again and Again and Again: The Dopamine Dysregulation Syndrome in Parkinson's Disease
Angela M. Cheung, M.D., on Research Advances in Osteoporosis
Stephanie J. Brister, M.D., on Neurobehavioral Outcomes Following Cardiac Surgery: How Can They Be Improved?

WORKSHOPS

COMPONENTS 20-28

COMPONENT WORKSHOP 20 9:00 a.m.-10:30 a.m.
Room 104 A, Level 100, Toronto Convention Centre North

THE END OF HOSPITALIZATION? TRENDS IN INTENSIVE MENTAL HEALTH SERVICES FOR CHILDREN AND ADOLESCENTS
APA Council on Children, Adolescents, and Their Families

Co-Chps.: Harold Alan Pincus, M.D., Brady G. Case, M.D.
Participants: Bradley D. Stein, M.D., Melisa D. Rowland, M.D., Mark A. Demidovich, M.D.
COMPONENT WORKSHOP 21  9:00 a.m.-10:30 a.m.
Room 104 D, Level 100, Toronto Convention Centre North

BRIDGE SUICIDE: THE PRINCE EDWARD VIADUCT IN TORONTO AND THE GOLDEN GATE BRIDGE IN SAN FRANCISCO
APA Northern California Psychiatric Society

Chp.: Mel Blaustein, M.D.
Participant: John K. Hines

COMPONENT WORKSHOP 22  9:00 a.m.-10:30 a.m.
Room 201 D, Level 200, Toronto Convention Centre North

YOU CAN BE LEADERS TOO: A WORKSHOP FOR IMGs AND MINORITIES
APA Committee on International Medical Graduates

Chp.: Josie L. Olympia, M.D.
Participants: Sanjay Dubey, M.D., Albert C. Gau, M.D., Rodrigo A. Munoz, M.D., Amelle B. Prinpin, M.D., Francis M. Sanchez, M.D.

COMPONENT WORKSHOP 23  9:00 a.m.-10:30 a.m.
Room 205 A, Level 200, Toronto Convention Centre North

MANAGED PHARMACY AND PAY FOR PERFORMANCE: THE NEW MANAGED CARE
APA Committee on Managed Care

Chp.: Paul H. Wick, M.D.
Participants: Carol L. Alter, M.D., Gregory G. Harris, M.D., David K. Nace, M.D.

COMPONENT WORKSHOP 24  9:00 a.m.-10:30 a.m.
Room 205 B, Level 200, Toronto Convention Centre North

DOING IT IN PUBLIC: OPPORTUNITIES IN PUBLIC SECTOR PSYCHIATRY
APA Council on Social Issues and Public Psychiatry

Co-Chps.: Cassandra F. Newkirk, M.D., Matthew O. Hurford, M.D.
Participants: Delane E. Casiano, M.D., Jagannathan Srinivasaraghavan, M.D., Debra F. Kirsch, M.D.

COMPONENT WORKSHOP 25  9:00 a.m.-10:30 a.m.
Room 205 C, Level 200, Toronto Convention Centre North

IT TAKES A VILLAGE: ASSESSING BEHAVIORAL AND PSYCHIATRIC DISORDERS IN MENTALLY RETARDED INDIVIDUALS
APA Committee on Developmental Disabilities

Chp.: Roxanne Dryden-Edwards, M.D.
Participants: Steve Sugden, M.D., Stephanie Hamarman, M.D., Karen G. Gennaro, M.D., Lee Combrinck-Graham, M.D.

COMPONENT WORKSHOP 26  9:00 a.m.-10:30 a.m.
Room 205 D, Level 200, Toronto Convention Centre North

MEDIA OUTREACH TO LATINOS: ENHANCING ACCESS AND REDUCING STIGMA
APA Committee of Hispanic Psychiatrists

Co-Chps.: Andris J. Pumariega, M.D., Ana E. Campo, M.D.
Participants: Gabriella Cora-Locatelli, M.D., Gamaliel Ramos, Lydia Serumans-Ward

COMPONENT WORKSHOP 27  9:00 a.m.-10:30 a.m.
Room 206 A/B, Level 200, Toronto Convention Centre North

BUPRENORPHINE: CLINICAL ISSUES AND MANAGING MORE COMPLICATED PATIENTS
APA Corresponding Committee on Training and Education in Addiction Psychiatry

Chp.: John A. Renner, Jr, M.D.
Participants: Herbert D. Kleber, M.D., Eric C. Strain, M.D., George Kolodner, M.D.

COMPONENT WORKSHOP 28  9:00 a.m.-10:30 a.m.
Room 206 C/D, Level 200, Toronto Convention Centre North

TEN WAYS TO STAY OUT OF TROUBLE: ETHICS AND ETIQUETTE
APA Ethics Committee and APA Ethics Appeal Board

Chp.: Spencer Eth, M.D.
Participants: Wade C. Myers, M.D., William Arroyo, M.D., Laura W. Roberts, M.D., Harriet C. Stern, M.D., Scott Y. Kim, M.D., Richard D. Milone, M.D.

ISSUES 29-41

ISSUE WORKSHOP 29  9:00 a.m.-10:30 a.m.
Room 701 A, Level 700, Toronto Convention Centre South

PHARMACEUTICAL BIASES IN PRESENTATIONS: DO'S AND DON'TS FOR EDUCATORS
Association for Academic Psychiatry

Co-Chps.: Donald M. Hilty, M.D., Kelli J.R. Harding, M.D.
Participant: Philip R. Muskin, M.D.

ISSUE WORKSHOP 30  9:00 a.m.-10:30 a.m.
Room 701 B, Level 700, Toronto Convention Centre South

WHEN PSYCHIATRISTS GET CANCER

Co-Chps.: Michelle B. Riba, M.D., Leah J. Dickstein, M.D.
Participants: Marion Zucker Goldstein, M.D., Lawrence Hartmann, M.D., Abigail B. Schlesinger, M.D., Madelaine M. Wohlreich, M.D.
<table>
<thead>
<tr>
<th>Issue Workshop</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>31</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Room 703, Level 700, Toronto Convention Centre South</td>
</tr>
<tr>
<td>32</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Room 705, Level 700, Toronto Convention Centre South</td>
</tr>
<tr>
<td>33</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Room 707, Level 700, Toronto Convention Centre South</td>
</tr>
<tr>
<td>34</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Room 709, Level 700, Toronto Convention Centre South</td>
</tr>
<tr>
<td>35</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Room 711, Level 700, Toronto Convention Centre South</td>
</tr>
<tr>
<td>36</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Room 713 A/B, Level 700, Toronto Convention Centre South</td>
</tr>
<tr>
<td>37</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Room 714 A, Level 700, Toronto Convention Centre South</td>
</tr>
<tr>
<td>38</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Room 714 B, Level 700, Toronto Convention Centre South</td>
</tr>
<tr>
<td>39</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Room 717 A, Level 700, Toronto Convention Centre South</td>
</tr>
<tr>
<td>40</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Room 801 A, Level 800, Toronto Convention Centre South</td>
</tr>
<tr>
<td>41</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Room 801 A, Level 800, Toronto Convention Centre South</td>
</tr>
</tbody>
</table>

**Tuesday**

**ISSUE WORKSHOP 31**

**THE CREATION AND FUNCTION OF A MENTAL HEALTH COURT**

Co-Chps.: Lawrence K. Richards, M.D., Roger Peele, M.D.
Participants: Edward F. Ornston, Richard D. Schneider, Margaret Creal L.L.B., Derek Pallandi, M.D., Sander G. Gensler, M.D.

**ISSUE WORKSHOP 32**

**METABOLIC SCREENING OF PATIENTS ON ANTIPSYCHOTIC MEDICATIONS: DEVELOPMENT OF A QUALITY IMPROVEMENT PROGRAM IN AN URBAN TRAINING CLINIC**

Co-Chps.: Diane B. Gottlieb, M.D., Karen L. Melendez, M.D.
Participants: Aurelia Bizaner, M.D., Mallika Patri, M.D., Harviniia Gahunia, M.D., Diana Antia, M.D.

**ISSUE WORKSHOP 33**

**THE DIFFICULT-TO-TREAT BULIMIA NERVOSA**

Chp.: Jennifer L. McLain, M.D.
Participant: Waguhi W. Ishak, M.D.

**ISSUE WORKSHOP 34**

**INITIATING COUPLES THERAPY TODAY**

Chp.: Ian E. Alger, M.D.
Participant: Anita Menfi, R.N.

**ISSUE WORKSHOP 35**

**LEGAL ISSUES IN CONSULTATION-LIAISON PSYCHIATRY**

Chp.: Renee M. Sorrentino, M.D.

**ISSUE WORKSHOP 36**

**COMPULSIVE HOARDING: CONCEPTUALIZATION AND TREATMENT**

Chp.: Jose A. Yaryura-Tobias, M.D.
Participant: Fugen Neziroglu, Ph.D.

**ISSUE WORKSHOP 37**

**COGNITIVE THERAPY FOR PERSONALITY DISORDERS**

Chp.: Judith S. Beck, Ph.D.

**ISSUE WORKSHOP 38**

**EVIDENCE-SUPPORTED, RISK-MINIMIZING, AND COST-CONSCIOUS APPROACHES IN PSYCHOPHARMACOLOGY**

Chp.: David N. Osse, M.D.
Participants: Andrew A. Nierenberg, M.D., Theo C. Manschreck, M.D., Dan V. Iosifescu, M.D.

**ISSUE WORKSHOP 39**

**MURDER MYSTERIES, GAMES, AND PSYCHIATRIC EDUCATION: HOW AND WHY TO DO A "WHO DONE IT?"**

Chp.: Andrea Waddell, M.D.
Participants: Susan Abbey, M.D., Lana M. Benedek, M.D., Bruce C. Ballon, M.D.

**ISSUE WORKSHOP 40**

**PRACTICAL PHARMACOTHERAPY FOR THE TREATMENT OF ALCOHOL DEPENDENCE Collaborative Session With the National Institute on Alcohol Abuse and Alcoholism**

Chp.: Robert M. Swift, M.D.
Participants: Roger D. Weiss, M.D., Allen Zweben, D.S.W.

**ISSUE WORKSHOP 41**

**HOW TO LAUNCH A SUCCESSFUL PRIVATE PRACTICE: PART 1**

Co-Chps.: William E. Callahan, Jr., M.D., Keith W. Young, M.D.
Participants: Donna Vanderpool, J.D., Jacqueline M. Melonas, J.D., Martin G. Tracy, J.D.

**MEDIA WORKSHOP 3**

**CRASH: A PORTRAIT OF MULTICULTURAL AMERICA AT THE FLASHPOINT APA Council on Minority Mental Health and Health Disparities**

Co-Chps.: Francis G. Lu, M.D., Heather M. Hall, M.D.
Participants: Lilliam Comas-Diaz, Ph.D., Frederick M. Jacobsen, M.D.
11:00 a.m. Sessions

DISCUSSION GROUPS 14-17

11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

14 David M. McDowell, M.D., on the Clinical Use of Buprenorphine
Grenadier Room, Main Level, Intercontinental Hotel

15 Nada L. Stotland, M.D., on Getting the Psychiatric Message to the Public: You Can Do It
Halton Room, Main Level, Intercontinental Hotel

16 Avram H. Mack, M.D., on Killer Adolescents: Drugs, School, and the Courts
Humber Room, Main Level, Intercontinental Hotel

17 Randall D. Marshall, on Trauma in the Modern World: The Role of the Psychiatrist (Residents Only)
Niagara Room, Lower Level, Intercontinental Hotel

LECTURES 14-16

LECTURE 14
11:00 a.m.-12:30 p.m.
Room 106, Level 106
Toronto Convention Centre North

APA'S SOLOMON CARTER FULLER AWARD LECTURE

Milton C. Hollar, M.D.

History of and Corrective Proposals for Disparities in Mental Health Care

Chp.: Sondra C. Walker, M.D.

Dr. Hollar was raised in Newark, N.J., spending summers in Durham, N.C., with his aunts, uncles, and cousins. At graduation, Dr. Hollar received the Class of 1948 award for outstanding excellence and a scholarship to Syracuse University. In January 1951, Dr. Hollar started a military stint with the U.S. Army that lasted through the Korean Conflict ending September 1953, with enrollment at the University College of New York University. Currently, Dr. Hollar is a retired, Major, U.S. Army Medical Corps. Service time included training as a pilot at San Marcos Texas Air Force Base and positions as Executive and Commanding Officer of the Ordinance Corps training school for noncommissioned officers. Following a bachelor's degree in 1955, Dr. Hollar earned a master's degree at NYU and completed a psychology internship at the State Island Mental Health Center. During the following four years at Howard University College of Medicine, Dr. Hollar worked as a psychologist at the Department of Psychiatry, served as summer intern at Walter Reed Army Hospital and was the E.Y. Williams Award Recipient. Since 1975, Dr. Hollar has worked at the Bronx Psychiatric Center, a public mental health facility, as a supervisor in training and monitoring psychiatry residents.

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 15
11:00 a.m.-12:30 p.m.
Exhibit Hall A, Level 300
Toronto Convention Centre North

Vivian W. Pinn, M.D.

Priorities, Initiatives, and Women's Health Research

Chp.: Leah J. Dickstein, M.D.
Co-Chp.: David Benaceraf, M.D.

Vivian W. Pinn, M.D., has been the Director of NIH's Office of Research on Women's Health since 1991, when it was established, and in 1994, was also named Associate Director for Research on Women's Health, NIH. Graduating from Wellesley College, then the University of Virginia School of Medicine, she completed pathology postgraduate training at Harvard's Massachusetts General Hospital, was Assistant Dean for Students Affairs at Tufts University School of Medicine, and then Professor and Pathology Department Chair at Howard University, Washington, D.C. Her career goals focused primarily on health and career opportunities for women and minorities, and more recently include educating the scientific community about the importance of sex and gender factors in basic science, clinical research, and health care.

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 16
11:00 a.m.-12:30 p.m.
Room 718 A/B, Level 700
Toronto Convention Centre South

Mindy Thompson-Pullilove, M.D.

Psychiatric Implications of Displacement: The Emotional Costs of Losing Human Habitat

Chp.: Mary Kay Smith, M.D.
Co-Chp.: Siobhan W. Clarke, M.D.

Mindy Thompson-Pullilove, M.D., is a research psychiatrist at New York State Psychiatric Institute and a professor of clinical psychiatry and public health at Columbia University. She was educated at Yale M.D.
RESEARCH CONSULTATION WITH
11:00 a.m.-12:30 p.m.
These sessions are limited to 25 participants on a first-come, first-served basis.

2 Paul S. Links, M.D., on Clinical Research Into Suicide
Oakville Room, Main Level, Intercontinental Hotel

SCIENTIFIC AND CLINICAL REPORT
SESSIONS 12-22

SCIENTIFIC AND CLINICAL REPORT SESSION 12
11:00 a.m.-12:30 p.m.
Room 104 B, Level 100, Toronto Convention Centre North

GENDER DIFFERENCES IN CHILD AND
ADOLESCENT BEHAVIORS

Chp.: Kimberly A. Yonkers, M.D.
Co-Chp.: Daniel Chapman, M.D.
11:00 a.m.
34 Prediction of Suicidality and Violence in Hospitalized
Adolescents: Comparisons by Gender
Daniel F. Becker, M.D., Carlos M. Grilo, Ph.D.
11:30 a.m.
35 Daily Cigarette Smoking Among Colombian High
School Students: Gender Related Factors
Jorge A. Martínez-Mantilla, Walter Amaya-Naranjo, Horacio
Campillo, Luis A. Díaz-Martínez M.S., Adalberto Campo-
Arias, M.D.
12 noon
36 Subtypes of Aggression: Incidence and Gender
Differences in Adolescents
Melissa McMullin, B.A., Arne Popma, M.D., Niranjan S.
Karnik, M.D., Katie Araujo, Ph.D., Hans Steiner, M.D.

SCIENTIFIC AND CLINICAL REPORT SESSION 13
11:00 a.m.-12:30 p.m.
Room 104 D, Level 100, Toronto Convention Centre North

VIOLENCE, TRAUMA, AND VICTIMIZATION

Chp.: Pierre W. Gagne, M.D.
Co-Chp.: Peter B. Gruenberg, M.D.
11:00 a.m.
37 Terrorism: A Phenomenon at the Interface Between
Individual and Group Psychology
David A. Rothstein, M.D.
11:30 a.m.
38 The Role of the Psychiatrist in Hospital Emergency
Planning
Julia B. Frank, M.D.
12 noon
39 Psychopathological Effects of Work Place Harassment
Jose L. Gonzalez de Rivera, M.D., Manuel J. Rodriguez-Abuin, Ph.D.

THIS SESSION WILL BE AUDIOTAPE D.

SCIENTIFIC AND CLINICAL REPORT SESSION 14
11:00 a.m.-12:30 p.m.
Room 201 D, Level 200, Toronto Convention Centre North

EMOTIONALITY, GENDER, AND LIFE SATISFACTION IN ADOLESCENTS

Chp.: Earnest Poortinga, M.D.
Co-Chp.: Kathryn J. Ednie, M.D.

11:00 a.m.
40 The Role of Subjective Emotional Reactivity to Affective Pictures in Predicting Emotional-Behavior Disorders Over a One-Year Period in an Unselected Community Sample of Children Between the Ages of 7 to 11
Carla Sharp, Ph.D.

11:30 a.m.
41 Life Satisfaction in Young Urban Adolescents
Maribeth Pender, Ph.D.

12 noon
42 Effectiveness of Group Interventions for Parents of Gender-Variant Children
Edgardo J. Menville, M.D., Darryl B. Hill, Ph.D., Catherine Tuerk, M.A., Tyrone Hanley, B.S., Joseph Henry, M.D.

THIS SESSION WILL BE AUDIOTAPE D.

SCIENTIFIC AND CLINICAL REPORT SESSION 15
11:00 a.m.-12:30 p.m.
Room 205 A, Level 200, Toronto Convention Centre North

NEUROBIOLOGY AND PSYCHOIMMUNOLOGY

Chp.: Edward Kingstone, M.D.
Co-Chp.: Yasir Khan, M.D.

11:00 a.m.
43 Lymphocyte and Platelet Alteration of the 5HT Transporter in Patients With Psychosis
Donatella Marazziti, M.D., Mario Catena, M.D., Stefano Baroni, D.Sc., Bernardo Dell’Osso, M.Ed., Gino Giannaccini, D.Sc., Gino Giannaccini, D.Sc.

11:30 a.m.
44 Potential Role of Interleukin-6 and HPA Axis in Breast Cancer Patients With MDD
Haldun Soygur, M.D., O兹den Palaoğlu, M.D., Eyüp Akarsu, M.D., Elvan Ozalp, M.D., Eylem Cankurtaran, M.D., Levent Turhan, M.D., Ismail Haki Ayhan, M.D.

12 noon
45 NMDA Receptors and BPD: A Critical Mediator
Bernadette M. Grosjean, M.D.

THIS SESSION WILL BE AUDIOTAPE D.

SCIENTIFIC AND CLINICAL REPORT SESSION 16
11:00 a.m.-12:30 p.m.
Room 206 A/B, Level 200, Toronto Convention Centre North

MEDICATION RESPONSE IN BIPOLAR DISORDER

Chp.: Adel A. Gabriel, M.D.
Co-Chp.: Janet L. Tulk, M.D.

11:00 a.m.
46 Galantamine-CR for Cognitive Dysfunction in Bipolar Disorder: Efficacy And Biological Correlates
Dan V. Iosifescu, M.D., Constance Moore, Ph.D., Thilo Deckersbach, Ph.D., Perry F. Renshaw, M.D., Maurizio Fava, M.D., Andrew A. Nierenberg, M.D., Gary S. Sachs, M.D.

11:30 a.m.
47 Rate of Improvement With Quetiapine Across Different Symptoms and Symptom Clusters in Bipolar Disorder
Terence A. Ketter, M.D., Joseph R. Calabrese, M.D., Robert M.A. Hirschfeld, M.D.

12 noon
48 Efficacy of the Antipsychotics in Anxiety Symptoms With or Without Bipolar Disorder
Keming Gao, M.D., Joseph R. Calabrese, M.D.

THIS SESSION WILL BE AUDIOTAPE D.

SCIENTIFIC AND CLINICAL REPORT SESSION 17
11:00 a.m.-12:30 p.m.
Room 206 E/F, Level 200, Toronto Convention Centre North

PRESCRIPTION AND COMPLIANCE IN BIPOLAR DISORDER

Chp.: Joseph Berger, M.D.
Co-Chp.: Gary S. Sachs, M.D.

11:00 a.m.
49 Prescription Patterns for Latin Americans Treated for MDD in Naturalistic Clinical Practice Settings
Alan J. Brnabic, Margaret McBride, Manuel O. Sanchez, Florence Kerr-Correa, M.D., Antonio Celis-Perdomo, Hector J. Duenas

11:30 a.m.
50 Nonadherence in Bipolar Disorder: A Qualitative Study Exploring Perceptual and Practical Barriers to Taking Medication
Jane Clatworthy, Richard Bowskill, Tim Rank, Rhian Parham, Rob Horne

12 noon
51 Patient Dissatisfaction With Information Received About Medicines Prescribed for Bipolar Disorder
Richard Bowskill, Jane Clatworthy, Rhian Parham, Tim Rank, Rob Horne

THIS SESSION WILL BE AUDIOTAPE D.
SCIENTIFIC AND CLINICAL REPORT SESSION 18
11:00 a.m.-12:30 p.m.
Alberta Room, Mezzanine Floor, Royal York

SPECIAL POPULATIONS AND MOOD DISORDERS

Chp.: Norman E. Alessi, M.D.
Co-Chp.: Adrienne O. Tan, M.D.

11:00 a.m.
52 Juvenile Bipolar Disorder: Toward a Validation of the Episodic-Chronic Distinction
Gualo Perugi, M.D., Gabriele Masi, M.D., Cristina Toni, M.D., Stefania Millepiedi, M.D., Maria Mucci, M.D., Hagop S. Akiskal, M.D.

11:30 a.m.
53 Treatment of SAD With a Carbohydrate-Rich Nutrient Mixture
David Mischoulon, M.D., Judith Wurtman, Ph.D., Mark Vangel, Ph.D., Richard Wurtman, M.D.

12 noon
54 Impaired Mood and Social Functioning Among Adult Children of Parents With Depression
Ruth C. Cronkite, Ph.D., Ralph W. Swindle, Ph.D., Rebecca L. Robinson, M.S., Rudolf H. Moos, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 19
11:00 a.m.-12:30 p.m.
Confederation 3 Room, Mezzanine Floor, Royal York

BRAIN IMAGING

Chp.: Paul Fedoroff, M.D.
Co-Chp.: Sarah J. Thompson, M.D.

11:00 a.m.
55 fMRI of the Brain Reward System: Manipulation of Risk and Reward Value
Juliana Yacubian, Ph.D., Katrin Schroeder, Tobias Sommer, Jan Glaescher, Dieter F. Braus, Ph.D., Christian Buechel, Ph.D.

11:30 a.m.
56 Brain Structure and Outcome in Schizophrenia: The Northern Finland 1966 Birth Cohort
Erika Lauronen, M.D., Jouko Miettunen, Ph.D., Juha M. Veijola, M.D., Matti K. Isohanni, M.D.

12 noon
57 Progressive Glutamatergic and Gray Matter Changes in First-Episode Patients With Schizophrenia and High Field Proton MRS
Peter C. Williamson, M.D., Jean Théberge, Ph.D., Kathryn E. Williamson, B.S., Naoko Aoyama, M.S., Rahul Manchanda, M.D., Maria Densmore, B.S., Dick J. Drost, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 20
11:00 a.m.-12:30 p.m.
Confederation 5 Room, Mezzanine Floor, Royal York

MEDICAL ISSUES IN THE TREATMENT OF SCHIZOPHRENIA

Chp.: Norman C. Moore, M.D.
Co-Chp.: Michael Demas, M.D.

11:00 a.m.
58 Metabolic Syndrome in Thai Patients With Schizophrenia: Prevalence and Incidence
Manit Srisurapanont, M.D., Surinporn Likkitsathia, M.D., Vudnichai Boonyanaruthee, M.D., Chawanant Charnsilp, M.D.

11:30 a.m.
59 The Swedish Study of Metabolic Risks in Psychiatry
Urban P. Osby, M.D.

12 noon
60 Olanzapine Treatment Does Not Increase Ten-Year Cardiovascular Risk: Comparison With Haloperidol in Patients With Schizophrenia
Yoram Barak, M.D., Marina Swartz, M.D., Igor Plopsky, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 21
11:00 a.m.-12:30 p.m.
Library, Mezzanine Floor, Royal York

NEUROPSYCHIATRY

Chp.: Robert B. Shulman, M.D.
Co-Chp.: Jeffrey D. Beitel, M.D.

11:00 a.m.
61 Psychosocial Treatment of Depression in Parkinson's Disease
Amy Farabaugh, Ph.D., Aila J. McCutchen, Psy.D., Jacqueline Buchin, Ph.D., John Growdon, M.D., Lang Yap, Ph.D., Joel A. Pava, Ph.D., Maurizio Fava, M.D.

11:30 a.m.
62 Frequency of EEG Abnormalities and Results of Antiepileptic Drug Therapy in Unstable Mood Disorders
Drake Duane, M.D.

12 noon
63 How to FACE® Juvenile Epilepsy and Bipolar Disorder: Clinical Challenges
Snadar Celestin-Westreich, Ph.D., Leon-Patrice Celestin, M.D.

THIS SESSION WILL BE AUDIOTAPED.
SCIENTIFIC AND CLINICAL REPORT SESSION 22
11:00 a.m.-12:30 p.m.
Salon B, Convention Floor, Royal York

INTERNATIONAL EPIDEMIOLOGY
Chp.: Derya I. Akbıyık, M.D.
Co-Chp.: Meera Vaswani, Ph.D.

11:00 a.m.
64 Mental Health in Iranian Medical Students and Doctors
Seyed M. Assadi, M.D., Maryam Noroozian, M.D., Sayed Vahid Shariat, M.D.

11:30 a.m.
65 Three-Year, Follow-Up Study of the Psychosocial
Predictors of Delayed and Unresolved Post-Traumatic
Stress Symptoms of Geriatric Earthquake Survivors in
Yu-Chi, Taiwan
Frank H. Chou, M.D.

12 noon
66 Three-Year, Follow-Up Study of the Relationship
Between Post-Traumatic Stress Symptoms and Quality
of Life Among Geriatric Earthquake Survivors in Yu-
Chi, Taiwan
Kuan-Yi Tsai, M.D.

WORKSHOPS

COMPONENTS 29-36

COMPONENT WORKSHOP 29  11:00 a.m.-12:30 p.m.
Room 104 A, Level 100, Toronto Convention Centre North

ADVANCES IN THE TREATMENT OF INTIMATE
PARTNER VIOLENCE
APA Rhode Island Psychiatric Society's Committee on Women
Chp.: Alison M. Heru, M.D.
Participants: Patricia R. Recupero, M.D., Marilyn Price, M.D.

COMPONENT WORKSHOP 30  11:00 a.m.-12:30 p.m.
Room 205 B, Level 200, Toronto Convention Centre North

EMPLOYMENT IN THE POST-RESIDENCY YEARS:
GETTING WHAT YOU WANT
APA Committee of Residents and Fellows
Chp.: William C. Wood, M.D.
Participants: Jonathan F. Borus, M.D., Robert P. Roca, M.D.,
Tanya R. Anderson, M.D.

COMPONENT WORKSHOP 31  11:00 a.m.-12:30 p.m.
Room 205 C, Level 200, Toronto Convention Centre North

CAN WE TALK? A MODEL FOR CONSTRUCTIVE
CONVERSATION BETWEEN OPPONENTS AND
ADVOCATES OF SAME SEX RELATIONSHIPS
APA Corresponding Committee on Religion, Spirituality, and Psychiatry
Chp.: John R. Petee, M.D., Allan M. Josephson, M.D.
Participants: Paul Fechley, Chris Ambidge, Jack Drescher, M.D.

COMPONENT WORKSHOP 32  11:00 a.m.-12:30 p.m.
Room 205 D, Level 200, Toronto Convention Centre North

FROM DIAGNOSIS TO TREATMENT OF INFANTS
AND YOUNG CHILDREN
APA Corresponding Committee on Infancy and Early Childhood
Chp.: Irene Chattoor, M.D.
Participants: Joan L. Huby, M.D., Harry H. Wright III, M.D.

COMPONENT WORKSHOP 33  11:00 a.m.-12:30 p.m.
Room 206 C/D, Level 200, Toronto Convention Centre North

MOVING THE PSYCHIATRIC AGENDA IN THE
HOUSE OF MEDICINE
APA/AMA Delegation Section Council on Psychiatry
Chp.: Jack S. McIntyre, M.D.
Participants: Carolyn B. Robinowitz, M.D., Jeffrey Akana, M.D., John J. Wernert III, M.D., Karen G. Gennaro, M.D., Nakia G. Scott, M.D.

COMPONENT WORKSHOP 34  11:00 a.m.-12:30 p.m.
Room 703, Level 700, Toronto Convention Centre South

EUROPEAN PSYCHIATRY: HEALTH AND MENTAL
HEALTH POLICY AFTER THE HELSINKI SUMMIT
APA Council on Global Psychiatry and the World Psychiatric Association
Conflict Management and Conflict Resolution Section
Co-Chps.: Eliot Sorel, M.D., Rodrigo A. Munoz, M.D.
Participants: Juan J. Lopez-Ibor, Jr., M.D., Sheila Hollins, M.D.,
Sass Henning, M.D., Jiri Raboch, M.D.

COMPONENT WORKSHOP 35  11:00 a.m.-12:30 p.m.
Room 705, Level 700, Toronto Convention Centre South

FROM FANTASY TO REALITY: RECRUITMENT OF
MINORITIES IN CLINICAL RESEARCH
APA Council on Minority Mental Health and Health Disparities
Co-Chps.: Annelle B. Primm, M.D., Sanjay Dube, M.D.
Participants: Darlene Nipper, Christopher Edwards, Ph.D.,
Basil D. Halliday M.S.C., William Waggner, Ph.D.

COMPONENT WORKSHOP 36  11:00 a.m.-12:30 p.m.
Room 707, Level 700, Toronto Convention Centre South

INTEGRATING EVIDENCE-BASED PSYCHIATRY
WITH CLINICAL INTELLIGENCE
APA Lifes
Co-Chps.: Abram M. Hostetter, M.D., Sheila H. Gray, M.D.
Participants: Carl C. Bell, M.D.
TUESDAY

ISSUES 42-53

ISSUE WORKSHOP 42  11:00 a.m.-12:30 p.m.
Room 709, Level 700, Toronto Convention Centre South
TEACHING COGNITIVE BEHAVIOR THERAPY TO RESIDENTS
Co-Chps.: Judith S. Beck, Ph.D., Donna M. Sudak, M.D.
Participant: Jesse H. Wright III, M.D.

ISSUE WORKSHOP 43  11:00 a.m.-12:30 p.m.
Room 711, Level 700, Toronto Convention Centre South
TEACHING ON THE FLY: PRACTICAL TIPS FOR TEACHING MEDICAL STUDENTS ONE-TO-ONE
Co-Chps.: Andrea E. Waddell, M.D., Jodi S. Lofchy, M.D.
Participants: Lana M. Benedek, M.D., Kien T. Dang, M.D.

ISSUE WORKSHOP 44  11:00 a.m.-12:30 p.m.
Room 714 A, Level 700, Toronto Convention Centre South
INFERTILITY: FROM PATIENT CARE TO ADVOCACY AND PUBLIC POLICY
Chp.: Roxanne Dryden-Edwards, M.D.
Participant: Ellen Patterson, L.C.S.W.

ISSUE WORKSHOP 45  11:00 a.m.-12:30 p.m.
Room 717 A, Level 700, Toronto Convention Centre South
AN INTEGRATIVE APPROACH TO CULTURAL COMPETENCE TRAINING FOR RESIDENT AND STAFF PSYCHIATRISTS
Co-Chps.: Kenneth P. Fung, M.D., Ted Lo, M.D.
Participants: Lisa F. Andermann, M.D., Ari E. Zaretzky, M.D.

ISSUE WORKSHOP 46  11:00 a.m.-12:30 p.m.
Room 717 B, Level 700, Toronto Convention Centre South
CAREER ADVANCEMENT IN ACADEMIC PSYCHIATRY FOR EARLY CAREER PSYCHIATRISTS
Co-Chps.: Dimitri D. Markov, M.D., Elisabeth J.S. Kunkel, M.D.
Participants: Michelle B. Riba, M.D., David J. Lynn, M.D.,
Marina Goldman, M.D., John-Paul Gomez, M.D., Michael J. Vergare, M.D.

ISSUE WORKSHOP 47  11:00 a.m.-12:30 p.m.
Room 801 A, Level 800, Toronto Convention Centre South
HOW TO LAUNCH A SUCCESSFUL PRIVATE PRACTICE: PART 2
Chp.: William E. Callahan, Jr., M.D.
Participants: Keith W. Young, M.D., Tracy R. Gordy, M.D.,
Chester W. Schmidt, Jr., M.D.

ISSUE WORKSHOP 48  11:00 a.m.-12:30 p.m.
Room 803 A/B, Level 800, Toronto Convention Centre South
GRASSROOTS ADVOCACY FOR PATIENTS AND FOR THE PSYCHIATRIC PROFESSION: HOW MEDICAL STUDENTS, RESIDENTS, AND EARLY CAREER PSYCHIATRISTS CAN AFFECT THE LEGISLATIVE, REGULATORY, AND POLITICAL PROCESS
Co-Chps.: Jose P. Vito, M.D., Tony B. Shivers
Participants: Jason Pray, Harsh K. Trivedi, M.D.

ISSUE WORKSHOP 49  11:00 a.m.-12:30 p.m.
Room 810, Level 800, Toronto Convention Centre South
TEACHING BOUNDARIES TO PRACTICING CLINICIANS
Chp.: Werner Tschan, M.D.
Participants: Gail E. Robinson, M.D., Michael F. Myers, M.D.,
Gary R. Schoener, Psy.D., Andrea Celenza, Ph.D.

ISSUE WORKSHOP 50  11:00 a.m.-12:30 p.m.
Manitoba Room, Mezzanine Floor, Royal York
MULTIDISCIPLINARY TREATMENT OF CHRONIC PAIN
Co-Chps.: Vladimir Bokarius, M.D., Steven H. Richeiner, M.D.
Participants: Ali Nemat, M.D., Lisa Victor, Ph.D., Yogi Matharu, DPT, Mary K. Wolf, OTD

ISSUE WORKSHOP 51  11:00 a.m.-12:30 p.m.
Tudor Room, Mezzanine Floor, Royal York
ARE THERE LIMITS TO BOUNDARY LIMITS?
Chp.: Makkah T. Notman, M.D.
Participants: Carl P. Malmoquist, M.D., Linda M. Jorgenson J.D.,
Elissa P. Benedek, M.D., Lawrence B. Inderbitzin, M.D.

ISSUE WORKSHOP 52  11:00 a.m.-12:30 p.m.
Tudor 8 Room, Mezzanine Floor, Royal York
SEXUAL HISTORY: THE ART AND THE SCIENCE
Co-Chps.: Shahrad R. Amiri, M.D., Danni Z. Michaeli, M.D.
Participants: Waguhi W. Ishak, M.D., Monisha R. Vass, M.D.,
Stephanie M. Stewart, M.D., Rekha Raja, O.D.

ISSUE WORKSHOP 53  11:00 a.m.-12:30 p.m.
Salon A, Convention Floor, Royal York
THE PSYCHIATRY RESIDENT AS ADVOCATE: PRACTICAL STEPS FROM THE CLINIC TO THE CAPITOL
Co-Chps.: Joan M. Anzia, M.D., James L. Griffith, M.D.
Participants: Suena W. Huang, M.D., Jeremy A. Lazarus, M.D.,
Tiffany R. Farchione, M.D., Joel J. Silverman, M.D.
NEW RESEARCH POSTER SESSION 6
12 noon-2:00 p.m.
Exhibit Hall B, Level 300, Toronto Convention Centre North

SCHIZOPHRENIA AND COMMUNITY PSYCHIATRY

For further information on New Research submissions, please refer to the New Research Program Book included in your registration packet.

1:00 p.m. Sessions

COURSES 71-78

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 71
1:00 p.m.-5:00 p.m.
Conference Room F, Mezzanine, Sheraton Centre

HOW TO USE YOUR PALM OS PERSONAL DIGITAL ASSISTANT IN PSYCHIATRIC PRACTICE: ADVANCED COURSE

Director: John Luo, M.D.
Faculty: Richard A. Montgomery, M.D., Charles J. Rainey, M.D.,
Steven I. Altchuler, M.D., Raymond Kloss, M.D.

COURSE 72
1:00 p.m.-5:00 p.m.
Essex Room, Mezzanine, Sheraton Centre

THE WAY OF YOGA AND HERBS IN TREATMENT OF STRESS, DEPRESSION, AGGRESSION, PTSD, AND MASS TRAUMA

Co-Directors: Richard P. Brown, M.D., Patricia L. Gerbar, M.D.

COURSE 73
1:00 p.m.-5:00 p.m.
Windsor Room East, Mezzanine, Sheraton Centre

ASSESSING POSITIVE AND NEGATIVE SYMPTOMS IN PSYCHOSIS WITH THE POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS)

Co-Directors: Lewis A. Opler, M.D., Paul M. Ramirez, Ph.D.

COURSE 74
1:00 p.m.-5:00 p.m.
Windsor Room West, Mezzanine, Sheraton Centre

OVERCOMING CHALLENGES IN THE TREATMENT OF HEPATITIS C PATIENTS WITH PSYCHIATRIC ILLNESS

Co-Director: Muhamad A. Rifai, M.D., Peter Hauser, M.D.
Faculty: David Indest, Psy.D., Julie Nelligan, Ph.D.

COURSE 75
1:00 p.m.-5:00 p.m.
City Hall, Second Floor, Sheraton Centre

HOW TO GIVE A MORE EFFECTIVE LECTURE: PUNCH, PASSION, AND POLISH

Director: Phillip J. Resnick, M.D.
TUESDAY

COURSE 76 1:00 p.m.-5:00 p.m.
Dominion Ballroom North, Second Floor, Sheraton Centre
PSYCHOGENIC SYMPTOMS: A CHALLENGE FOR ALL SPECIALTIES
Director: Selim Benbadis, M.D.
Faculty: Francisco Fernandez, M.D., David J. Williamson, Ph.D.

COURSE 77 1:00 p.m.-5:00 p.m.
Huron Room, Second Floor, Sheraton Centre
NEUROCIRCUITS IN PSYCHOTHERAPY
Director: Barton J. Blinder, M.D.
Faculty: Bernard D. Berkman, M.D., George I. Viamontes, M.D., Amit Etkin, Ph.D.

COURSE 78 1:00 p.m.-5:00 p.m.
Kent Room, Second Floor, Sheraton Centre
ASSESSING THE RISK OF VIOLENCE IN FORENSIC AND SEX OFFENDER SETTINGS
Co-Directors: Bradley R. Johnson, M.D., Judith V. Becker, Ph.D.

2:00 p.m. Sessions

ADVANCES IN PSYCHODYNAMIC PSYCHOTHERAPY: THE STATE OF THE ART
2:00 p.m.-5:30 p.m.
Room 107, Level 100, Toronto Convention Centre North
Chp.: Glen O. Gallahar, M.D.

A The Psychiatric Interview: New Perspectives From Psychodynamic Psychiatry
Robert Michels, M.D.

B Transference-Focused Psychotherapy for BPD: Symptom and Structural Change
Kenneth M. Levy, M.D.

C Transference and Countertransference in Personality Disorders: Turning Clinical Observations Into Replicable Data
Drew Westen, Ph.D.

D The Mentalization-Based Treatment Approach to BPD: Emerging Outcomes From a New Psychodynamic Therapy
Peter Fonagy

LECTURES 17-19

LECTURE 17
2:00 p.m.-3:30 p.m.
Room 105, Level 100
Toronto Convention Centre North
APA'S ALEXANDRA SYMONDS AWARD LECTURE

LECTURE 18
2:00 p.m.-3:30 p.m.
Exhibit Hall A, Level 100
Toronto Convention Centre North
Henry R. Kranzler, M.D.
Pharmacogenetics of Alcohol: Are We There Yet?
Collaborative Session With the National Institute on Alcohol Abuse and Alcoholism
Chp.: Domenic Ciraulo, M.D.
Co-Chp.: Marc Galanter, M.D.

Henry R. Kranzler, M.D. is Professor of Psychiatry, Associate Scientific Director of the Alcohol Research Center, Program Director of the General Clinical Research Center, and Assistant Dean for Clinical Research at the University of Connecticut School of Medicine. After receiving his medical degree from Robert Wood Johnson Medical School, Dr. Kranzler completed a psychiatric residency and a fellowship in alcohol research at the University of Connecticut. A
A Towards a Person-Centered Comprehensive Diagnosis
Juan E. Mezzich, M.D.

B General Perspectives on National and International
Advocacy
Steven S. Sharfstein, M.D.

C Science, Faith, and Values in Healthcare Provisions: A
Medicine of the Person
John L. Cox, M.D.

D Person and Community-Centered Mental Health Care
in Developing Countries
Parameswara Deva, M.D.

E Advocacy for Women’s and Children’s Mental Health
Marta B. Rondon, M.D.

F International Advocacy for Patient’s Human Rights
Otto Steenfeldt-Foss, M.D.

Discussants: Helen Herman, M.D., K.W.M. Fulford, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIA 34-65

SYMPOSIUM 34
2:00 p.m.-5:00 p.m.
Room 104 A, Level 100, Toronto Convention Centre North

PREDICTORS OF OUTCOME AND TREATMENT
RESPONSE IN EATING DISORDERS: RESULTS FROM
NEW RESEARCH ON ANOREXIA NERVOsa,
BULIMIA NERVOsa, AND BINGE EATING
DISORDER

Chp.: Laurel Mayer, M.D.
Co-Chp.: Evelyn Attia, M.D.

A Fluoxetine Versus Placebo to Prevent Relapse in
Anorexia Nervosa
B. Timothy Walsh, M.D., Allan S. Kaplan, M.D., Evelyn
Attia, M.D., Michael J. Devlin, M.D., Kathleen M. Pike, Ph.D.,
Marion Olmsted, Ph.D., Jacqueline Carter, Ph.D., Blake
Woodside, M.D., Michael Parides, Ph.D.

B Fluoxetine Versus Placebo to Prevent Relapse in
Anorexia Nervosa: Predictors of Outcome After One
Year of Treatment
Allan S. Kaplan, M.D., B. Timothy Walsh, M.D., Evelyn
Attia, M.D., Jacqueline Carter, Ph.D., Michael Devlin, M.D.,
Marion Olmsted, Ph.D., Kathleen Pike, Ph.D., Blake
Woodside, M.D., Michael Parides, Ph.D.

C Fluoxetine Versus Placebo to Prevent Relapse in
Anorexia Nervosa: Body Composition Predicts
Outcome After One Year of Treatment
Laurel Mayer, M.D., B. Timothy Walsh, M.D., Deborah
Glasofer, M.A., Sarah Etu, B.A., Christina Roberto, B.A.,
Dymphna Gallagher, Ed.D., Jack Wang, M.S., Steven B.
Heymsfield, M.D., Richard N. Pierson, Jr., M.D.

(Continued next page)
D Early Response to Medication Among Women With Bulimia Nervosa
Robyn Sysko, M.S., B. Timothy Walsh, M.D.

E Long-Term Outcome of Psychotherapy and Medication for Binge-Eating Disorder
Michael J. Devlin, M.D., Juli A. Goldstein, Ph.D., Linxu Liu, Ph.D., Eva Petkova, Ph.D., B. Timothy Walsh, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 35 2:00 p.m.-5:00 p.m.
Room 104 C, Level 100, Toronto Convention Centre North

IMPULSIVITY IN AXIS I AND AXIS II: COMMON SUBSTRATES, DIFFERENT PRESENTATIONS?
Chp.: Carlos Blanco-Jerez, M.D.
Co-Chp.: Jon E. Grant, M.D.

A Compulsive Shopping: Epidemiology, Comorbidity, and Treatment
Donald W. Black, M.D.

B Pathological Gambling: From Neurobiology to Evidence-Based Treatment
Carlos Blanco-Jerez, M.D.

C BPD: Affective or Impulse Control Disorder?
S. Charles Schulz, M.D., A. Adityanee, M.D., Ann Romine, R.N.

D Kleptomania: Clinical Presentation, Neuroimaging, and Treatment
Jon E. Grant, M.D.

Discussant: Dan J Stein, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 36 2:00 p.m.-5:00 p.m.
Room 206 A/B, Level 200, Toronto Convention Centre North

DIAGNOSTIC CRITERIA IN ALZHEIMER'S DISEASE AND DEMENTIA: RESEARCH CHALLENGES AND IMPLICATIONS FOR DSM-5
Chp.: Trey Sunderland, M.D.

A Neuroimaging as a Surrogate Marker of Dementia
Gary W. Small, M.D.

B Neuropsychological Testing in the Diagnosis of Dementia
Mary Sano, Ph.D.

C The Search for Biomarkers as Diagnostic Aides in Alzheimer's Disease
Trey Sunderland, M.D.

D Diagnostic Criteria in Alzheimer's Disease and Dementia: Research Challenges and Implications for DSM-5
Barry Reisberg, M.D.

Discussant: Dilip V. Jeste, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 37 2:00 p.m.-5:00 p.m.
Room 206 C/D, Level 200, Toronto Convention Centre North

BULLYING IN THE WORKPLACE: PSYCHIATRIC AND PUBLIC HEALTH PERSPECTIVES
Chp.: Jorge C. Srabstein, M.D.

A Setting the Stage: Prevalence, Antecedents, and Effects of Workplace Bullying
Loraleigh Keasbly, Ph.D., Joel H. Neuman, Ph.D.

B Bullying at Work: Psychiatric Issues
Renato Gilioli, M.D., Silvia Punzi, Psy.D., Giuseppe P. Fichera, Psy.D., Paolo Campanini, Psy.D.

C Workplace Bullying, Alcohol Use and Abuse, and Service Utilization
Judith A. Richman, Ph.D.

D Workplace Bullying and Employee Benefits: Enabling the Traumatized Worker to Seek Help for Psychiatric Illness
David Yamada, J.D.

E Syndrome of Morbidity Associated With School Bullying: Implications for Adulthood
Jorge C. Srabstein, M.D.

Discussant: Jorge C. Srabstein, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 38 2:00 p.m.-5:00 p.m.
Room 206 E/F, Level 200, Toronto Convention Centre North

SCREENING, DIAGNOSIS, AND MANAGEMENT OF ALCOHOL USE DISORDERS IN PSYCHIATRIC PRACTICE
Collaborative Session With the National Institute on Alcohol Abuse and Alcoholism

Chp.: Mark L. Willenbring, M.D.

A Screening, Assessment, and Management Using the NIAAA Clinicians Guide
Mark L. Willenbring, M.D.

B Motivational Enhancement Strategies to Address Substance Use Disorders
Douglas M. Ziedonis

C Integrating Pharmacotherapy for Alcohol Dependence Into General Psychiatric Practice
Hugh Myrick, M.D.

D Meeting the Addiction Medicine Needs of Patients in a General Psychiatric Practice
Michael M. Miller, M.D.
THIS SESSION WILL BE AUDIOTAPE.
SYMPOSIUM 39  
2:00 p.m.-5:00 p.m.  
Room 701 B, Level 700, Toronto Convention Centre South  

THERAPEUTIC NEUROMODULATION: METHODS AND MECHANISMS  

Chp.: Mark Demitrack, M.D.  

A Therapeutic Neuromodulation: The Arrival of a Paradigm Shift  
Mark Demitrack, M.D.  

B Vagal Nerve Stimulation: A Review of the Evidence  
Philip G. Janicak, M.D., Jeffrey T. Rado, M.D.  

C Repetitive Transcranial Magnetic Stimulation (rTMS) at 10 Hz in the Treatment of Pharmacoresistant Major Depression: Results From a Controlled Multicenter Clinical Trial  
John P. O'Reardon, M.D.  

D Therapeutic Neuromodulation Mechanisms of Action  
Elliott Richelson, M.D.  

Discussant: Alan F. Schatzberg, M.D.  
THIS SESSION WILL BE AUDIOTAPED.  

SYMPOSIUM 40  
2:00 p.m.-5:00 p.m.  
Room 705, Level 700, Toronto Convention Centre South  

APA RESEARCH AGENDA FOR DSM-V PERSONALITY DISORDERS  

Chp.: John Livesley  
Co-Chp.: Thomas A. Widiger, Ph.D.  

A Alternative Dimensional Models: Toward an Integration  
Thomas A. Widiger, Ph.D.  

B Issues and Challenges in Developing an Etiologically-Based Dimensional Classification of Personality Disorder  
Kerry L. Jang, Ph.D.  

C Toward a Developmental View of Personality Pathology  
Rebecca L. Shiner, Ph.D.  

D The Major Dimensions of Personality: Cross-Cultural Evidence-Based on the Lexical Approach  
Kiboe L. Lee, Ph.D.  

E Clinical Application of a Dimensional Model of Personality Disorder  
John Livesley  

Discussant: Michael B. First, M.D.  
THIS SESSION WILL BE AUDIOTAPED.  

SYMPOSIUM 41  
2:00 p.m.-5:00 p.m.  
Room 707, Level 700, Toronto Convention Centre South  

SLEEP, FATIGUE, AND DEPRESSION IN MEDICALLY-ILL PATIENTS  

Chp.: Colin M. Shapiro, M.D.  
Co-Chp.: Marta Novak, MD  

A Sleep and Fatigue in Breast Cancer  
Sonia Ancoli-Israel  

B Sleep, Fatigue, Pain, and Depression in Patients With Diabetes Mellitus  
Wayne J. Katon, M.D., Michael Von Korff, Sc.D., Elizabeth H.B. Lin, M.D., Gregory E. Simon, M.D., Paul S. Giechanowski, M.D.  

C Insomnia, Depression, Quality of Life, and Survival in Patients With End-Stage Renal Disease and Following Renal Transplantation  
Marta Novak, M.D., Miklos Z. Molnar, M.D., Istvan Mucsi, M.D.  

D Sleep Disruption, Fatigue, and Depression in the Medically Ill  
Colin M. Shapiro, Ph.D.  
THIS SESSION WILL BE AUDIOTAPED.  

SYMPOSIUM 42  
2:00 p.m.-5:00 p.m.  
Room 709, Level 700, Toronto Convention Centre South  

SCALING UP AGAINST HIV/AIDS: A CULTURALLY SENSITIVE AND COMPREHENSIVE APPROACH  

Chp.: Samuel O. Okpaku, M.D.  

A Understanding the Linkages Between HIV/AIDS and Development  
Scholastica Kimaryo  

B Culture, Indigenous Knowledge and Information, and Communications Technology in the Response to the HIV/AIDS Challenge  
Joseph Okpaku, M.D.  

C Defining and Describing a Modern Epidemic: The Case of HIV/AIDS in Sub Saharan Africa  
Samuel O. Okpaku, M.D.  

D Challenges to Implement Culturally-Adapted HIV/AIDS Programs in Haiti  
Vladimir Berthaud  

Discussant: Darrel A. Regier, M.D.  
THIS SESSION WILL BE AUDIOTAPED.
SUICIDE RESEARCH IN CANADA

Chp.: Joel F. Paris, M.D.

A Neurobiological Studies of Suicide Completers
Gustavo Turecki, Ph.D.

B Prospective Community Study of Suicidality in Young Adults
Joel F. Paris, M.D.

C Affective Instability and Suicidality in BPD
Paul S. Links, M.D.

D Clinical Guidelines for Suicidality
Isaac Sainofsky, M.D.

Discussant: Alain D. Lesage, M.D.
THIS SESSION WILL BE AUDIOTAPE.

NEUROBIOLOGICAL BASIS FOR CO-OCCURRING SUBSTANCE ABUSE AND OTHER PSYCHIATRIC DISORDERS

National Institute on Drug Abuse

Chp.: Susan F. Volman, Ph.D.

A Smoking and Schizophrenia: Does Co-Morbidity of Substance Abuse and Disease Suggest Self-Medication?
Sherry Leonard, Ph.D., Sharon Menez, Ph.D., Ralph Berger, B.S.

B Insights From Animal Models of Dual Diagnosis: How Common Neurocircuit Abnormalities Underlie Both Mental Illness and Addiction Vulnerability
Robert A. Chambers, M.D.

C Nicotine-Induced Sensitization and ADHD
Jean King, Ph.D.

D Effects of Nicotine and Other Drugs of Abuse on Cognitive Dysfunction in Individuals With Schizophrenia
Tony P. George

THIS SESSION WILL BE AUDIOTAPE.

BIPOLAR DISORDER AND THE U.S. LEGAL SYSTEM

Chp.: Mark A Frye, M.D.
Co-Chp.: Cameron Quanbeck, M.D.

A Bipolar Disorder and the Legal System
Mark A. Frye, M.D.
D The OHIO CARES Initiative
   Col. Terry C. Washam, I.I.S.W.

Discussant: Michael F. Hogan, Ph.D.
THIS SESSION WILL BE AUDIOTAPE D.

SYMPOSIUM 48  2:00 p.m.-5:00 p.m.
Room 716 A, Level 700, Toronto Convention Centre South

SUBSTANCE USE DISORDERS: PLANNING A RESEARCH AGENDA FOR DSM-V
Collaborative Session With the National Institute on Alcohol Abuse and Alcoholism

Chp.: Marc A. Schuckit, M.D.
Co-Chp.: Bridget Grant, Ph.D.

A Adolescents and Substance Related Disorders: Research Agenda to Guide Decisions on DSM-V
   Thomas J. Crowley, M.D.

B Methods for DSM-V Research Work Groups to Address Key Diagnostic Issues for Substance Use Disorders
   Linda B. Cottler, Ph.D.

C Substance Use Disorder Co-Morbidity and DSM-V
   Deborah S. Hasin, Ph.D.

D What Can Human Brain Imaging Tell Us About Addiction?
   Anna R. Childress, M.D.

Discussant: Wilson M. Compton, M.D.
THIS SESSION WILL BE AUDIOTAPE D.

SYMPOSIUM 49  2:00 p.m.-5:00 p.m.
Room 716 B, Level 700, Toronto Convention Centre South

THE USE OF ATYPICAL ANTI PSYCHOTICS IN ELDERLY PATIENTS WITH DEMENTIA: WHAT NEXT?

Chp.: John M. de Figueroa, M.D.

A Use of Antipsychotics in Elderly Patients With Dementia: What's Next?
   Soo Borson, M.D.

B Pharmacological Strategies for the Management of Behavior Disorders in Dementia
   Bruce G. Pollock

C Thinking Outside the Black Box: Risk Management for Using Atypical Antipsychotic Medications With the Elderly
   Patricia R. Recupero, M.D.

THIS SESSION WILL BE AUDIOTAPE D.

SYMPOSIUM 50  2:00 p.m.-5:00 p.m.
Room 717 B, Level 700, Toronto Convention Centre South

PREVENTION OF COMMON MENTAL DISORDERS: IS IT TIME TO START?

Chp.: Robert A. Schoevers, Ph.D.

A Cost-Effectiveness of Preventing Depression in Primary Care Patients: Randomized Trial
   Filip E. Smit, M.S.C.

B Prevention of New Cases of Mental Disorders: Problems and Solutions
   Pim Cuijpers, M.D.

C Prevention of Late-Life Depression: Do We Know Where to Begin?
   Robert A. Schoevers, Ph.D., Filip Smit, M.S.C., Dorly Deeg, M.D., Pim Cuijpers, M.D., Jack Decker, M.D.,
   Willem Van Tilburg, M.D., Aartjan Beekman, M.D.

D Evidence-Based Prevention of Common Mental Disorders
   Aartjan T.F. Beekman, M.D.

SYMPOSIUM 51  2:00 p.m.-5:00 p.m.
Room 801 A, Level 800, Toronto Convention Centre South

HOW TO LAUNCH A SUCCESSFUL PRIVATE PRACTICE: PART 3

Chp.: William E. Callahan, Jr., M.D.
Co-Chp.: Keith Young, M.D.

A Personal Factors Leading to a Successful Private Practice
   William E. Callahan, Jr., M.D.

B Office Location and Design for Efficiency and Success
   Keith W. Young, M.D.

C Streamlining Overhead and Managing Your Business in Private Practice
   Keith W. Young, M.D.

D Marketing Your Unique Private Practice
   William E. Callahan, Jr., M.D.

THIS SESSION WILL BE AUDIOTAPE D.

SYMPOSIUM 52  2:00 p.m.-5:00 p.m.
Room 801 B, Level 800, Toronto Convention Centre South

CHOOSING THE RIGHT TREATMENT FOR SUBSTANCE ABUSE

Chp.: Herbert D. Kleber, M.D.
Co-Chp.: David M. McDowell, M.D.

A Choosing the Right Treatment for Cocaine Dependence
   Adam M. Bisaga, M.D.

(Continued next page)
TUESDAY

B Treatment of Comorbid Conditions
   Frances R. Levin, M.D.

C Marijuana and Club Drugs: Cutting Edge
   Developments, New and Potential Treatments
   David M. McDowell, M.D.

D Behavioral Treatments for Substance Dependence and
   Integrating Behavioral Therapy With Medication
   Edward V. Nunes, M.D.

E Choosing the Right Treatment for Opioid Dependence
   Herbert D. Kleber, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 53  2:00 p.m.-5:00 p.m.
   Room 803 A/B, Level 800, Toronto Convention Centre South

STRESS-INDUCED AND FEAR CIRCUITRY
DISORDERS: PLANNING THE RESEARCH AGENDA
FOR DSM-V

Chp.: Dennis S. Charney, M.D.

A The Role of Cognition in Stress-Induced and Fear
   Circuitry Disorders
   Edna B. Foa, Ph.D., Jonathan D. Huppert, Ph.D., Shawn
   Cahill, Ph.D.

B Overlap and Distinctiveness Among Stress-Induced and
   Fear-Circuitry Disorders
   Abby Fyer, M.D.

C Neurochemistry/Neuroendocrine Signals (and Noise)
   in Anxiety Disorders
   Rachel Yehuda, M.D.

D Serotonin, the Hippocampus, and Emotional Behavior
   Rene Hen, M.D.

E PTSD: Looking Towards DSM-V
   Elie G. Karam

Discussant: Steven E. Hyman
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 54  2:00 p.m.-5:00 p.m.
   Imperial Room, Main Floor, Royal York

THE METHAMPHETAMINE EPIDEMIC IN THE U.S.
   National Institute on Drug Abuse

Chp.: Nora D. Volkow, M.D.
Co-Chp.: Frank Vocci, Ph.D.

A Neurobiological Effects of Methamphetamine Abuse:
   Acute and Long Term
   Linda Chang, M.D., Nepspaon Saisut, Ph.D., Daniel A.
   Alicata, M.D., D. Christopher Derauf, M.D., Helenna
   Nakama, M.D., William F. Haning III, M.D., Kenneth
   Yue, Ph.D., V. Andrew Stenger, Ph.D., Thomas Ernst, Ph.D.

B Methamphetamine Use, Abuse, Dependence, and
   Treatment: Survey Findings, 2002-2004
   James D. Coliver, Ph.D.

C Methamphetamine Abuse and HIV/AIDS Comorbidity:
   Treatment Implications
   Perry N. Halkitis, Ph.D.

D Behavioral Treatment Approaches for
   Methamphetamine Dependence, Comorbid Psychiatric
   Disorders, and HIV-Related Risk Behaviors
   Richard Rawson, Ph.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 55  2:00 p.m.-5:00 p.m.
   Alberta Room, Mezzanine Floor, Royal York

PREVENTING SCHIZOPHRENIA: OPPORTUNITIES
   AND CHALLENGES

Chp.: Thomas H. McGlashan, M.D.

A Reducing the Damage of the First Psychosis Onset
   Ingrid Melle, M.D., Tor K. Larsen, M.D., Svein Fris, M.D.,
   Ulrik Haahr, M.D., Jan O. Johansen, M.D., Stein
   Opjordsmoen, M.D., Erik Simonsen, M.D., Per Vaglum, M.D.,
   Thomas H. McGlashan, M.D.

B Treatment of the Schizophrenia Prodrome: Update 2006
   Scott Woods

C Predicting Schizophrenia: Early Risk Factors
   Barbara A. Cornblatt, Ph.D.

D Psychological Interventions for Those at Ultra High
   Risk of Psychosis
   Jean Addington, Ph.D.

E Prevention Research in Psychosis: Current State
   of the Art
   Thomas H. McGlashan, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 56  2:00 p.m.-5:00 p.m.
   British Columbia Room, Mezzanine Floor, Royal York

HIV UPDATE FOR PSYCHIATRIC CARE
   APA Committee on AIDS

Chp.: Marshall Forstein, M.D.

A HIV Medical Update
   Peter Gouch, M.D.

B Hepatitis C and HIV Infection
   Antoine B. Douaihy

C Club Drugs and HIV
   Milton L. Wainberg, M.D.

D Body Image and HIV
   Marshall Forstein, M.D.
THIS SESSION WILL BE AUDIOTAPE.
SYMPOSIUM 57 2:00 p.m.-5:00 p.m.
Confederation 5 Room, Mezzanine Floor, Royal York

VOTING BY PERSONS WITH COGNITIVE IMPAIRMENT

Csp.: Paul S. Appelbaum, M.D.
Csp.: Jason Karlawish

A Voting by Persons With Cognitive Impairment: Overview of the Issues
Richard Bonnie, J.D.

B Voting by Persons With Cognitive Impairments:
The Legal Issues
Pamela Karlan

C Assessing Competence to Vote in a Cognitively Impaired Population
Paul S. Appelbaum, M.D.

D Respecting Rights and Preserving the Integrity of Elections: The Challenges of Voting in Long-Term Care Facilities
Jason Karlawish

Discussant: Alexander Keyssar, Ph.D.
THIS SESSION WILL BE AUDIOTAPEd.

SYMPOSIUM 58 2:00 p.m.-5:00 p.m.
Manitoba Room, Mezzanine Floor, Royal York

NOT YOUR PARENTS' EEG: CLINICAL APPLICATIONS OF AUDITORY AND VISUAL EVENT-RELATED POTENTIALS

Csp.: Daniel C. Javitt, M.D.

A Event-Related Potential (ERP) Abnormalities in Schizophrenia
Daniel C. Javitt, M.D.

B Probing the Cognitive, Clinical, and Functional Impairments of Schizophrenia Patients With Mismatch Negativity
Gregory A. Light, Ph.D., David L. Braff, M.D.

C ERP P300 and Mismatch Negativity Abnormalities in Patients at Ultra-High Risk for Schizophrenia
Daniel H. Mathalon, M.D., Thomas H. McGlashan, M.D., Tandy J. Miller, Ph.D., Scott W. Woods, M.D.

D Use of Auditory ERPs and Other Quantitative Measures in an Evidence-Based, Person-Centered Psychosis Treatment Program
Steven B. Schwarzkopf, M.D.
THIS SESSION WILL BE AUDIOTAPEd.

SYMPOSIUM 59 2:00 p.m.-5:00 p.m.
Quebec Room, Mezzanine Floor, Royal York

GENETIC FINDINGS RELATED TO ALCOHOL DEPENDENCE AND RELATED CONDITIONS
Collaborative Session With the National Institute on Alcohol Abuse and Alcoholism

Csp.: Victor M. Hesselbrock, Ph.D.

A Genetic Susceptibility for Alcohol Dependence: Recent Findings
Howard J. Edenberg, Ph.D.

B At Risk Families: A Multigenerational Study of Alcoholism
Laura J. Bierut, M.D., Wendy Reich, Ph.D., Marc A. Schuckit, M.D., Kathleen K. Bucholz, Ph.D.

C Further Characterization of the Risk Associated With GABA-A Receptor Genes
Danielle M. Dick, Ph.D., Laura J. Bierut, M.D., Tatiana Foroud, Ph.D., Howard Edenberg, Ph.D.

D Neurophysiological Endophenotypes and the Risk for Alcohol Dependence and Related Disorders
Bernice Porjesz, Ph.D., Henri Begleiter, Ph.D., Kevin A. Jones, Ph.D., Laura Almasy, Ph.D., Howard Edenberg, Ph.D., Laura J. Bierut, M.D., John I. Nurnberger, Jr., M.D., Danielle M. Dick, Ph.D., Victor Hesselbrock, Ph.D.

E Prediction of Alcohol Problems Using a Prospective Longitudinal Design Including Genotype
John I. Nurnberger, Jr., M.D., Ryan Wiegand M.S., Laura J. Bierut, M.D., Kathleen Bucholz, Ph.D., Tatiana Foroud, Ph.D., Howard Edenberg, Ph.D., John Kramer, Ph.D., Samuel Kupinan, M.D., Danielle M. Dick, Ph.D.
THIS SESSION WILL BE AUDIOTAPEd.

SYMPOSIUM 60 2:00 p.m.-5:00 p.m.
Territories Room, Mezzanine Floor, Royal York

THE MEANINGS OF MEDICATION: ISSUES IN PATIENTS' COMPLIANCE WITH PSYCHOTROPIC DRUGS
American Academy of Psychoanalysis and Dynamic Psychiatry

Csp.: Ann R. Turkel, M.D.

A Medication Management: A Clinical Mismomer
Leah Davidson, M.D.

B Compliance as Accord, Not Submission
Eve Leeman, MD

C Transferences to Medication and Implications for the Structure of the Ego
Eric R. Marcus, M.D.

(Continued next page)
TUESDAY

D Poison or Cure? Meanings of Medication in Schizophrenia
Paul J. Rosenfield, M.D.

E The Meanings of Medication: Issues in Patients’ Compliance With Psychotropic Drugs: Be Careful What You Wish For
Jeffrey Rubin, M.D.

Discussant: Jose L. Gonzalez de Rivera, M.D.
THIS SESSION WILL BE AUDIOTAPE D.

SYMPOSIUM 61 2:00 p.m.-5:00 p.m.
Tudor 8 Room, Mezzanine Floor, Royal York

PHARMACOGENETICS AND DRUG ABUSE RESEARCH
National Institute on Drug Abuse

Chp.: Joni L. Rutter, Ph.D.
Co-Chp.: David Shurtleff

A Allele Specific Gene Expression in Addiction Genes
Wolfgang Sadee

B Darwin’s Fingerprint: Identifying Recent Functional Genetic Variations in Neuronal Genes
Robert K. Moyzis, Ph.D.

C Pharmacogenetics and Smoking Cessation With Nicotine Replacement Therapy
Caryn Lerman, Ph.D., Neal Benowitz, M.D., Peter Shields, M.D., Timothy Rebbeck, Ph.D., Wade H. Berrettini, M.D., Rachel Tyndale, Ph.D.

D Pharmacogenetics of Smoking Cessation Using Non-Nicotine Replacement Therapies
Huijun Z. Ring, Ph.D.

E Pharmacogenetics of Alcohol Treatment
David W. Oslin, M.D.
THIS SESSION WILL BE AUDIOTAPE D.

SYMPOSIUM 62 2:00 p.m.-5:00 p.m.
Ballroom, Convention Floor, Royal York

EATING DISORDERS 2006: FROM SCIENCE TO PRACTICE

Chp.: Joel Yager, M.D.
Co-Chp.: David B. Herzog, M.D.

A Altered Dopamine and Optimal Stimulus Response in Anorexia Nervosa
Walter H. Kaye, Guido K.W. Frank, M.D., Angela Wagner, M.D., Ursula Bailer, M.D., Carolyn C. Meltzer, M.D., Julie C. Price, Ph.D., J. Christopher May, B.A., Howard J. Aizenstein, M.D.

B Gender Difference Comparisons of Eating Difference Comparisons of Eating and Other Psychiatric Disorders in Course of Illness
Katherine A. Halmi, M.D.

C Federal Advocacy for Eating Disorders
David B. Herzog, M.D., Debra L. Franko, Ph.D., Jeanine C. Cogan, Ph.D., Marc Lerro, M.A., Cynthia M. Bulik, Ph.D., Elizabeth Q. Ong, B.A., Kavita K. Thiplani, B.S.

D Night Eating Syndrome
James E. Mitchell III, M.Ed., Ross D. Crosby, Ph.D., Stephen A. Wonderlich, Ph.D., Scott Engel, Ph.D., Albert J. Stunkard, M.D., Kelly Allison, Ph.D.

E The 2006 APA Practice Guidelines for Eating Disorders
THIS SESSION WILL BE AUDIOTAPE D.

SYMPOSIUM 63 2:00 p.m.-5:00 p.m.
Ontario Room, Convention Floor, Royal York

VASCULAR DEPRESSION: MEASUREMENT AND TREATMENT ISSUES OF A PROPOSED DIAGNOSTIC ENTITY

Chp.: Joel R. Sneed, Ph.D.
Co-Chp.: Steven P. Roose, M.D.

A Vascular Risk Factors, Frontolimbic Dysfunction, and Course of Geriatric Depression
George S. Alexopoulos, M.D.

B Treatment of Vascular Depression Including New Data on rTMS
Robert G. Robinson, M.D., Ricardo E. Jorge, M.D.

C Neuroimaging of Cerebrovascular Disease
David C. Steffens, M.D.

D Vascular Depression: A Distinct Diagnostic Entity?
Joel R. Sneed, Ph.D., Steven P. Roose, M.D.

Discussant: Charles F. Reynolds III, M.D.
THIS SESSION WILL BE AUDIOTAPE D.

SYMPOSIUM 64 2:00 p.m.-5:00 p.m.
Salon A, Convention Floor, Royal York

DEEP BRAIN STIMULATION FOR TREATMENT-RESISTANT PSYCHIATRIC DISORDERS

Chp.: George E. Tesar, M.D.
Co-Chp.: Donald A. Malone, Jr. M.D.

A History and Ethics of Neurosurgery for Treatment-Refractory Psychiatric Disorders
George E. Tesar, M.D.

B Deep Brain Stimulation Surgery for Treatment of Intractable Psychiatric Disorders
Ali R. Rezaei, M.D., Donald A. Malone, Jr., M.D., Steven A. Rasmussen, M.D., Cynthia Kubu, Ph.D., Gerhard Friehs, M.D., Andre Machado, M.D., Benjamin D. Greenberg, M.D.
C DBS for OCD: Targeting and Clinical Results  
Benjamin D. Greenberg, M.D.

D Deep-Brain Stimulation in Psychiatric Disorders:  
Surgical Candidates and Preliminary Results in Major Depression  
Donald A. Malone, Jr., M.D.  
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 65 2:00 p.m.-5:00 p.m.  
Salon B, Convention Floor, Royal York

COMPLEX DEPRESSION: THE INTERFACE BETWEEN PERSONALITY DISORDERS AND MAJOR DEPRESSION
Chp.: Sidney H. Kennedy, M.D.  
Co-Chp.: Maurice Corcos, Ph.D.

A The Neurobiology of the Links Between Personality Traits and Depression  
Glenda M. MacQueen

B Patient Personality as a Differential Predictor of Treatment Outcome to Psychotherapy Versus Pharmacotherapy  
R. Michael Bagby, Ph.D., Carolina McBride, Ph.D.

C Managing Patients With Complex Depression  
Sidney H. Kennedy, M.D.

D Key Psychotherapy Issues in Complex Depression:  
Patients With Major Depression and Personality Psychopathology  
Michael B. Rosenbluth

3:00 p.m. Session

NEW RESEARCH POSTER SESSION 7  
3:00 p.m.-5:00 p.m.  
Exhibit Hall B, Level 300, Toronto Convention Centre North

PSYCHOPHARMACOLOGY AND BIOLOGICAL PSYCHIATRY

For further information on New Research submissions, please refer to the New Research Program Book included in your registration packet.

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 34-38

A MANAGEMENT OF PSYCHOSIS IN THE ELDERLY: THE SCIENCE AND THE ART  
Supported by S两人和Wyeth Pharmaceuticals
Chp.: Dilip V. Jeste, M.D.

A Evaluation of Psychosis in the Elderly  
Carl Salzman, M.D.

B Efficacy and Effectiveness of Antipsychotics in the Elderly  
Lon S. Schneider, M.D.

C Safety of Antipsychotics in Elderly Patients  
Dilip V. Jeste, M.D.

D Novel Antipsychotic Strategies: Implications for Biology and Future Treatment  
P. Murari Doraiswamy, M.D.

E Nonpharmacologic Interventions for Psychosis in the Elderly  
Warachal E. Faison, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 35  
7:00 p.m.-10:00 p.m.  
Canadian Room, Convention Floor, Royal York

MULTIPLE AND COMPLEX PRESENTATIONS OF BIPOLAR DISORDER  
Supported by Abbott Laboratories
Chp.: Charles L. Bowden, M.D.

A Presentations of Bipolar Disorder in Children and Adolescents  
Kiki D. Chang, M.D.

B The Impulsive- Aggression Symptom Domain in Personality Disorders  
Eric Hollander, M.D.

C Bipolar II Disorder and Suicidal Behaviors  
William H. Coryell, M.D.

D Predicting Maintenance Response From the Acute Episode  
Charles L. Bowden, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 36  
7:00 p.m.-10:00 p.m.  
Concert Hall, Convention Floor, Royal York

TREATING THE EARLY STAGES OF SCHIZOPHRENIA  
Supported by AstraZeneca Pharmaceuticals
Chp.: Dolores Malaspina, M.D.

A Genetic and Clinical Risk Factors for Schizophrenia: Predicting the Onset and Outcomes of the Illness and Treatment Response  
Dolores Malaspina, M.D.

(Continued next page)
TUESDAY

B Treatment of First Episode Schizophrenia: Tolerability and Adherence
   Delbert G. Robinson, M.D.

C Evaluation of Prodromal Schizophrenia
   Cheryl Corcoran, M.D.

D Pharmacologic Strategies for the Treatment of Prodromal Schizophrenia
   Daniel C. Javitt, M.D.

E Treatment of the Early Stages of Schizophrenia: The Possibility of Neuroprotection
   Jeffrey A. Lieberman, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 38
7:00 p.m.-10:00 p.m.
Metro Grand Ballroom, Second Level, Westin Harbour Castle

THE MAZE OF MOOD AND ANXIETY IN THE ELDERLY PATIENT: A CASE SERIES
Supported by GlaxoSmithKline

Chp.: Charles F. Reynolds III, M.D.

A Achieving a Better Understanding of the Neurobiology of Mood and Anxiety Disorders in the Elderly
   Prakash S. Masand, M.D.

B The Impact of Medical Comorbidity on Mood and Anxiety Disorders in the Elderly Patient
   Eric J. Lenze, M.D.

C An Evidence-Based Approach to the Acute Management of Mood and Anxiety Disorders in the Elderly Population
   Warren D. Taylor, M.D.

D Optimizing Long-Term Treatment in Old-Age Depression
   Charles F. Reynolds III, M.D.

ADVOCATING FOR CHANGE THROUGH EVIDENCE-BASED MEDICINE: A FOCUS ON ADHD
Supported by Cephalon, Inc.

Chp.: Christopher J. Kratochvil, M.D.

A Neurocircuitry of ADHD
   James J. Hudziak, M.D.

B Phenomenology and Diagnosis of ADHD
   Christopher J. Kratochvil, M.D.

C The Impact of Sleep/Wake Disturbances in ADHD
   Judith Owens, M.D.

D Evidence-Based Pharmacotherapy of ADHD
   Timothy E. Wilens, M.D.

E Role of Family and Social Support Systems in the Management of ADHD
   Scott Kollins, Pharm.D.
WEDNESDAY, MAY 24, 2006

159TH ANNUAL MEETING

7:00 a.m. Sessions

PART 1 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 39-42

INDUSTRY-SUPPORTED BREAKFAST SYMPOSUM 39, PART 1
7:00 a.m.-8:30 a.m.
Room 106, Level 100, Toronto Convention Centre North

EMERGING EVIDENCE IN THE TREATMENT OF BIPOLAR DEPRESSION
Supported by AstraZeneca Pharmaceuticals

Chp.: Joseph R. Calabrese, M.D.

A The Clinical Management of Bipolar Disorder
Frederick K. Goodwin, M.D.

B How Guidelines Influence Acute and Long-Term Treatment of Bipolar Depression
Robert M.A. Hirschfeld, M.D.

C Treatment of Alcohol and Drug Abuse in Bipolar Disorder
Kathleen T. Brady, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSUM 40, PART 1
7:00 a.m.-8:30 a.m.
Canadian Room, Convention Floor, Royal York

BIPOLAR ILLNESS: THE ROAD TO REMISSION
Supported by Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

Chp.: Prakash S. Masand, M.D.

A Is Remission Achievable in Bipolar Disorder?
John L. Beyer, M.D.

B Roadblocks to Remission in the Bipolar Patient
Prakash S. Masand, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSUM 41, PART 1
7:00 a.m.-8:30 a.m.
Grand Ballroom, Lower Concourse, Sheraton Centre

NEW FRONTIERS IN DEPRESSION: PROVIDING SOLUTIONS TO UNMET NEEDS
Supported by Solvay Pharmaceuticals and Wyeth Pharmaceuticals

Chp.: Stephen M. Stahl, M.D.

A Genetic Mechanisms of Mood and Temperament
Daniel R. Weinberger, M.D.

B Chronic Pain and Major Depression
Alan F. Schatzberg, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 42, PART 1
7:00 a.m.-8:30 a.m.
Metro Grand Ballroom, Second Level, Westin Harbour Castle

WHAT THE PSYCHIATRIST NEEDS TO KNOW ABOUT SLEEP-RELATED MOVEMENT DISORDERS
Supported by GlaxoSmithKline

Chp.: John W. Winkelmann, M.D.

A Diagnosis, Epidemiology, and Natural History of Restless Legs Syndrome and Periodic Limb Movements of Sleep
Philip M. Becker, M.D.

B Sleep, Health, and Quality of Life Consequences
R. Robert Auger, M.D.

C Diagnostic Challenges and Initial Treatment Strategies
Cynthia L. Comelia, M.D.

8:00 a.m. Sessions

COURSES 79-84

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 79
8:00 a.m.-12 noon
Conference Room D/E, Mezzanine, Sheraton Centre

COVER YOUR ASSETS: IMPROVED PATIENT CARE THROUGH MALPRACTICE PROTECTION

Director: G. Kent Mangelson, B.S.

COURSE 80
8:00 a.m.-12 noon
Conference Room F, Mezzanine, Sheraton Centre

DSM-IV-TR CULTURAL FORMULATIONS: DIAGNOSIS AND THERAPY

Director: Russell F. Lim, M.D.
Faculty: Candace M. Fleming, Ph.D., David C. Henderson, M.D., Roberto Lewis-Fernandez, M.D., Francis G. Lu, M.D., J. Charles Ndlela, M.D.
WEDNESDAY

COURSE 81 8:00 a.m.-12 noon
Windsor Room East, Mezzanine, Sheraton Centre

HOW TO USE YOUR POCKET PC PERSONAL DIGITAL ASSISTANT IN PSYCHIATRIC PRACTICE

Director: Robert J. Boland, M.D.
Faculty: Elizabeth V. Getler, M.D., Joshua L. Straus, M.D., Roger L. McRoberts III, M.D.

COURSE 82 8:00 a.m.-12 noon
Windsor Room West, Mezzanine, Sheraton Centre

CURRENT CPT CODING AND DOCUMENTATION REQUIREMENTS

Co-Directors: Chester W. Schmidt, Jr., M.D., Tracy R. Gordy, M.D.
Faculty: David K. Nace, M.D.

COURSE 83 8:00 a.m.-12 noon
City Hall, Second Floor, Sheraton Centre

INSANITY DEFENSE EVALUATIONS

Director: Phillip J. Resnick, M.D.

COURSE 84 8:00 a.m.-12 noon
Kent Room, Second Floor, Sheraton Centre

TREATING MEDICAL STUDENTS AND PHYSICIANS

Co-Directors: Michael F. Myers, M.D., Leah J. Dickstein, M.D.

9:00 a.m. Sessions

ADVANCES IN MOOD DISORDERS
9:00 a.m.-12:30 p.m.
Room 107, Level 100, Toronto Convention Centre North

Chp.: David J. Kupfer, M.D.
Co-Chair: Dan J. Stein, M.D.

A Recent Approaches to Diagnosing and Treating Bipolar Disorder
David J. Kupfer, M.D.

B New Somatic Interventions for Mood Disorders
Mark S. George, M.D.

C Advances in Mood Disorders
A. John Rush, M.D.

CLINICAL CASE CONFERENCE 4
9:00 a.m.-10:30 a.m.
Room 104 B, Level 100, Toronto Convention Centre North

CROSSING THE LINE: DETERMINING YOUR PATIENT IS TOO DANGEROUS TO DRIVE

Moderator: Carl B. Greiner, M.D.
Presenters: Steven P. Wengel, M.D., Laura W. Roberts, M.D., Nicole F. Wolfe, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

CONTINUOUS CLINICAL CASE CONFERENCE 1: PART 2
9:00 a.m.-12:30 p.m.
Room 104 C, Level 100, Toronto Convention Centre North

TWENTY THERAPIES LATER: ADDRESSING TRANSFERENCE RESISTANCE

Moderator: R. Rao Gogineni, M.D.
Presenters: Robert Michels, M.D., Richard P. Kluft, M.D., Sheila Judge, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

COURSES 85-91
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 85 9:00 a.m.-4:00 p.m.
Conference Rooms B/C, Mezzanine, Sheraton Centre

EEG NEUROFEEDBACK IN PSYCHIATRY: CLINICAL APPLICATIONS

Co-Directors: Thomas M. Brod, M.D., Michael Cohen
Faculty: Samuel E. Roura, M.D., Laurence M. Hirshberg, Ph.D.,
David A. Mitnick, M.D., Angelo S. Bolea, Ph.D., Stephen F. Buie, M.D.

COURSE 86 9:00 a.m.-4:00 p.m.
Conference Room G, Mezzanine, Sheraton Centre

AN INTRODUCTION TO COMPLICATED GRIEF TREATMENT

Director: M. Katherine Shear, M.D.
Faculty: Mario Cruz, M.D., Bonnie Gorscak, Ph.D., Allan Zuckoff, Ph.D.
COURSE 87 9:00 a.m.-4:00 p.m.  
Essex Room, Mezzanine, Sheraton Centre  

LOVE, DESIRE, INTIMACY, AND INFIDELITY: USEFUL CONCEPTS FOR THE PSYCHOTHERAPIST  

Director: Stephen B. Levine, M.D.  
Faculty: Candace B. Risen, L.C.S.W.  

COURSE 88 9:00 a.m.-4:00 p.m.  
Dominion Ballroom South, Second Floor, Sheraton Centre  

ESSENTIALS OF GERIATRIC PSYCHOPHARMACOLOGY  

Co-Directors: Helen Lavretsky, M.D., Martha Sajatovic, M.D.  
Faculty: Eric J. Lenze, M.D., Joseph A. Cheong, M.D.  

COURSE 89 9:00 a.m.-4:00 p.m.  
Hurun Room, Second Floor, Sheraton Centre  

THE ASSESSMENT AND TREATMENT OF CHILD SEXUAL ABUSERS  

Co-Directors: Gene G. Abel, M.D., John M. Bradford, M.B.  
Faculty: Tracey L. Marks, M.D.  

COURSE 90 9:00 a.m.-4:00 p.m.  
Kenora Room, Second Floor, Sheraton Centre  

NEUROANATOMY OF EMOTIONS: FROM BRAIN TO CLINICAL PRACTICE  

Director: Rosanne M. Velas, M.D.  
Faculty: Cheryl L. Grady, Ph.D.  

COURSE 91 9:00 a.m.-4:00 p.m.  
Simcoe/Dufferin Room, Second Floor, Sheraton Centre  

SEEING THE FOREST AND THE TREES: A BIOPSYCHOSOCIAL APPROACH TO THE ORAL BOARD EXAMINATION  

Director: William H. Campbell, M.D.  

DISCUSSION GROUPS 18-20  
9:00 a.m.-10:30 a.m.  

These sessions are limited to 25 participants on a first-come, first-served basis.  

18 Marc Galanter, M.D., on Substance Abuse: Network Therapy for Promoting Outpatient Compliance With Psychosocial and Pharmacological Treatment  
Grenadier Room, Main Level, Intercontinental Hotel  

19 Marcia K. Goin, M.D., on BPD: Talking With Patients About Their Illness, What Do You Say?  
Halton Room, Main Level, Intercontinental Hotel  

20 John M. Oldham, M.D., on Personality Disorders and DSM-V  
Humber Room, Main Level, Intercontinental Hotel  

LECTURES 20-22  

LECTURE 22  
9:00 a.m.-10:30 a.m.  
Room 159, Level 100  
Toronto Convention Center North  

APA'S GEORGE TARIAN AWARD LECTURE  

Dilip V. Jeste, M.D.  
Psychiatry and Aging: Contributions of the International Medical Graduates  

Chp. 1 Sajay Dube, M.D.  

Dilip V. Jeste, M.D., is the Estelle and Edgar Levi Chair in Aging, Director of the San and Rose Simith Institute for Research on Aging, and Distinguished Professor of Psychiatry and Neurosciences, University of California, San Diego (UCSD) and VA San Diego Healthcare System. He is also the Director of the Advanced Center for Intervention and Services Research at UCSD focusing on positive aging funded by the National Institute of Mental Health (NIMH), and of the John A. Hartford Center of Excellence in Geriatric Psychiatry. Dr. Jeste obtained his medical education in Poona and psychiatry training in Bombay, India. In the USA, he completed his psychiatry residency at Cornell University and neurology residency at George Washington University. He was a research fellow and later Chief of the Unit on Movement Disorders and Demence at the NIMH before moving to San Diego. He has published six books, and over 400 articles in peer-reviewed journals and books. He is in the Institute of Scientific Information list of the "world's most cited authors", comprising less than one half of one percent of all publishing researchers of the last two decades. He is the Past President of the American Association for Geriatric Psychiatry (AAGP), and the West Coast College of Biological Psychiatry (WCCBP), and the Founding President of the International College of Geriatric Psychoneuropharmacology. He is the Editor-in-Chief of the American Journal of Geriatric Psychiatry. He has been listed in "The Best Doctors in America" and has received several awards including the A.C. Bennett Neuropsychiatric Research Award from the Society of Biological Psychiatry, MEINT Award from the NIMH, the American Psychiatric Association Research Award, Geriatric Research Award from the American College of Psychiatrists, and Distinguished Investigator Award from the National Alliance for Research in Schizophrenia and Affective Disorders.  

THIS SESSION WILL BE AUDIOTAPED.
LECTURE 21

9:00 a.m. - 12:10 a.m.
Exhibit Hall A, Level 300
Toronto Convention Centre North

Karl F. Mann, M.D.

Combining Neuroimaging and Pharmacology to Better Treat Alcoholism
Collaborative Session with the National Institute of Alcohol Abuse and Alcoholism

Chp.: Richard N. Rosenthal
Co-Chp.: Doug Ziedonis, M.D.

Karl F. Mann, M.D., studied medicine in Mannheim, Germany and Vienna, Austria. He received his medical degree from the University of Mannheim in 1978 and from 1979 to 1979 he was a research fellow at the University René Descartes in Paris. From 1979 until 1985 he received his residency in psychiatry and neurology. Board certification in both domains as well as in psychotherapy was attained in 1985. From 1986 he worked first as an assistant and then as an associate professor of psychiatry at the University of Tübingen, Germany. There he concentrated on addiction research and built an interdisciplinary research group in alcohol and nicotine research. In 1999 he moved to the Central Institute of Mental Health in Mannheim, Germany which is part of the University of Heidelberg. Since then he holds the first and fully chair in addiction research in Germany. Dr. Mann is currently the speaker of the German Addiction Research Network which is funded by the federal government of Germany. He is Associate Editor (Europe) of Alcoholism: Clinical & Experimental Research. Since 2002 he is a member of the Executive Committee of the Association of European Psychiatrists where he acts as treasurer. Dr. Mann has received several research prizes. In 2004 the International Society for Biomedical Research on Alcoholism elected him as congress president for the 12th World Congress of Biomedical Alcohol Research. His main areas of research are neuroimaging and the pharmacology of alcoholism.

International Psychiatrist Lecture Series

This session will be audiotapeced.

LECTURE 22

9:00 a.m. - 10:30 a.m.
Room 216 A/B, Level 700
Toronto Convention Centre South

James P. Comer, M.D.

Psychiatry and Education: When the Twin Meet

Chp.: Mary Schwab-Storm, M.D.
Co-Chp.: Joanne M. Bleyer

James P. Comer, M.D., grew up in a low-income family in East Chicago, Indiana, but credits his parents with having no doubt about the importance of education. He obtained a B.A. degree from Indiana University. He went on to obtain a degree in medicine from Howard University College of Medicine, a Master of Public Health degree from the University of Michigan School of Public Health, and psychiatric training at the Yale University School of Medicine's Child Study Center. He currently is the Maurice Falk Professor of Child Psychiatry at the Yale University Child Study Center and an associate dean at the Yale University School of Medicine. During his years at Yale, Dr. Comer has concentrated his career on promoting a focus on child and youth development as a way of improving schools. He is best known for founding the Yale Child Study Center School Development Program in 1984, which promotes the collaboration of parents, educators, and community to improve social, emotional, and academic outcomes for children. He has written numerous articles and books, lectured widely, and has received many honors. His efforts in support of healthy development of young people are known nationally and internationally, and his latest book, published by Yale Press, September 2004, is entitled Laura No Child Behind: Preparing Today's Youth for Tomorrow's World. Distinguished Psychiatrist Lecture Series

This session will be audiotapeced.

MASTER EDUCATOR CLINICAL CONSULTATIONS 13-15

9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

13 James L. Griffith, M.D., and Christina Puchalski, M.D., on the Role of Spirituality in the Care of Patients
Room 201 A, Level 200, Toronto Convention Centre North

14 Robert P. Cabaj, M.D., on Sexual Orientation and Gender Identity in Clinical Care
Room 201 B, Level 200, Toronto Convention Centre North

15 Helga Hannesdottir, M.D., on Doing Residency Training in Psychiatry in the U.S. and Returning Home to Practice
Room 201 C, Level 200, Toronto Convention Centre North
ROUND TABLE DISCUSSION
9:00 a.m.-10:30 a.m.
Room 716 A, Level 700, Toronto Convention Centre South

CHILD AND ADOLESCENT BIPOLAR DISORDER:
OUT OF A DIAGNOSTIC QUANDARY

Moderator: Richard E. D’Alli, M.D.
Participants: Robert A. Kowatch, M.D., Barbara Geller, M.D.,
Joseph Biederman, M.D., Ellen Leibenluft, M.Ed.

WORKSHOPS

COMPONENTS 37-43

COMPONENT WORKSHOP 37 9:00 a.m.-10:30 a.m.
Room 104 A, Level 100, Toronto Convention Centre North

DATA COUPLED WITH ADVOCACY SHAPING PUBLIC POLICY
APA Illinois Psychiatric Society

Co-Chps.: Jagannathan Srinivasaraghavan, M.D., Daniel W. Hardy, M.D.
Participants: Kenneth G. Busch, M.D., Malini Patel, M.D.

COMPONENT WORKSHOP 38 9:00 a.m.-10:30 a.m.
Room 104 D, Level 100, Toronto Convention Centre North

DISASTERS, DISPARITIES, AND CULTURAL PSYCHIATRY
APA/SAMHSA Minority Fellows

Chp.: Niranjan S. Karnik, M.D.
Participants: Nakia G. Scott, M.D., Leah A. Fennell, M.D.,
Raquel Lugo, M.D., Nisba F. Husain, M.D., Cheryl Y. Salary, M.D.

COMPONENT WORKSHOP 39 9:00 a.m.-10:30 a.m.
Room 201 D, Level 200, Toronto Convention Centre North

DOING MORE WITH LESS: CHALLENGES AND REWARDS OF BECOMING A PSYCHIATRIST EXECUTIVE
APA Committee on Psychiatric Administration and Management

Chp.: Sy A. Saeed, M.D.
Participants: Brian M. Hepburn, M.D., Nalini V. Juthani, M.D.,
Arthur L. Lazarus, M.D., Shirish V. Patel, M.D., Lydia E. Weisser, D.O.

COMPONENT WORKSHOP 40 9:00 a.m.-10:30 a.m.
Room 205 A, Level 200, Toronto Convention Centre North

TEACHING THE HISTORY OF PSYCHIATRY TO STUDENTS AND RESIDENTS: A WORKSHOP DISCUSSION ON CONTENT, METHODS, AND IDEALS
APA Corresponding Committee on History and Library

Chp.: Avram H. Mack, M.D.
Participants: Laura D. Hirshbein, M.D., David J. Lynn, M.D.

COMPONENT WORKSHOP 41 9:00 a.m.-10:30 a.m.
Room 205 B, Level 200, Toronto Convention Centre North

HOW TO BE A MORE CREATIVE TEACHER:
WINNING STRATEGIES FOR RESIDENTS AND FACULTY
APA Council on Medical Education and Lifelong Learning

Co-Chps.: Joan M. Anzia, M.D., Lowell D. Tong, M.D.
Participants: Joshua T. Thornhill IV, M.D., Theodore B. Feldman, M.D.,
Margo D. Lauterbach, M.D., Suma Jacob, M.D.

COMPONENT WORKSHOP 42 9:00 a.m.-10:30 a.m.
Room 205 D, Level 200, Toronto Convention Centre North

THE NATIONAL HEALTH INFORMATION NETWORK AND PSYCHIATRY: HOW WILL THE COMING NATIONAL ELECTRONIC HEALTH RECORD IMPACT OUR PATIENTS AND OUR PRACTICE?
APA Corresponding Committee on Electronic Health Records

Chp.: John J. Boronow, M.D.
Participants: Zebulon Taintor, M.D., Robert M. Plovnick, M.D.,
Jerome Rogoff, M.D.

COMPONENT WORKSHOP 43 9:00 a.m.-10:30 a.m.
Room 206 C/D, Level 200, Toronto Convention Centre North

NOVEL CAREERS IN PSYCHIATRY: WOMEN WHO I HAVE MADE THEIR OWN WAY
APA Committee on Women

Co-Chps.: Marisa A. Giggie, M.D., Melva I. Green, M.D.
Participants: Deborah Spitz, M.D., Stephanie S. Durruthy, M.D.,
Molly J. Hall, M.D., Julianne Flynn, M.D., Esther P. Roberts, M.D.

ISSUES 54-64

ISSUE WORKSHOP 54 9:00 a.m.-10:30 a.m.
Room 205 C, Level 200, Toronto Convention Centre North

SUPERVISING THE SUPERVISORS: SEE ONE, DO ONE, TEACH ONE MODEL SHATTERED! AN INNOVATIVE GROUP TO TRAIN FACULTY TO TEACH MEDICAL STUDENTS

Co-Chps.: Joseph M. Garbely, D.O., Javed A. Joy, M.D.
Participants: Ruth M. Lamdan, M.D., Jonathan G. Shack, M.D.,
Mary Kurien, M.D.

ISSUE WORKSHOP 55 9:00 a.m.-10:30 a.m.
Room 206 A/B, Level 200, Toronto Convention Centre North

PSYCHO-KILLERS: MENTAL ILLNESS AND HOMICIDE

Chp.: Renee M. Sorrentino, M.D.
Participants: Joy E. Stankowski, M.D., Britta Ostermeyer, M.D.,
Susan J. Hatters-Friedman, M.D.
WEDNESDAY

ISSUE WORKSHOP 56
9:00 a.m.-10:30 a.m.
Room 206 E/F, Level 200, Toronto Convention Centre North

PSYCHIATRIC ASPECTS OF DEEP BRAIN STIMULATION FOR PARKINSON'S DISEASE

Chp.: Valerie Voon, M.D.
Participants: Anthony E. Lang, M.D., Andres M. Lozano, M.D., Elena Moro, M.D., Paul Krack, M.D.

ISSUE WORKSHOP 57
9:00 a.m.-10:30 a.m.
Room 701 B, Level 700, Toronto Convention Centre South

DYNAMIC THERAPY WITH SELF-DESTRUCTIVE PATIENTS WITH BPD

Co-Chps.: Eric M. Plakun, M.D., Edward R. Shapiro, M.D.

ISSUE WORKSHOP 58
9:00 a.m.-10:30 a.m.
Room 703, Level 700, Toronto Convention Centre South

TRAINING PSYCHIATRIC RESIDENTS IN THE COGNITIVE THERAPY OF SCHIZOPHRENIA

Chp.: Page Burkholder, M.D.
Participants: Douglas Turkington, M.D., Michael Garrett, M.D., Neil A. Rector, Ph.D.

ISSUE WORKSHOP 59
9:00 a.m.-10:30 a.m.
Room 705, Level 700, Toronto Convention Centre South

THE MIRROR HAS A REFLECTION: TEACHING AND MODELING CULTURAL COMPETENCY TO GENERAL PSYCHIATRY RESIDENTS

Co-Chps.: Dionne A. Hart, M.D., Renato D. Alarcon, M.D.
Participant: Annelle B. Primm, M.D.

ISSUE WORKSHOP 60
9:00 a.m.-10:30 a.m.
Room 709, Level 700, Toronto Convention Centre South

ASSISTED OUTPATIENT TREATMENT AND ITS ROLE IN THE FABRIC OF THE MENTAL HEALTH SYSTEM

Chp.: Daniel Garza, M.D.
Participants: Constantine Ioannou, M.D., Mary Zdanowicz, J.D.

ISSUE WORKSHOP 61
9:00 a.m.-10:30 a.m.
Room 711, Level 700, Toronto Convention Centre South

PSYCHIATRISTS IN THE DEAN'S OFFICE: CAREER OPPORTUNITIES AND CAREER DEVELOPMENT

Chp.: Carolyn B. Robinowitz, M.D.
Participants: Tana A. Grady-Welky, M.D., Cheryl F. McCartney, M.D., Larry R. Faulkner, M.D., Darrell G. Kirch, M.D.

ISSUE WORKSHOP 62
9:00 a.m.-10:30 a.m.
Room 714 A, Level 700, Toronto Convention Centre South

DETECTION OF MALINGERING

Chp.: Alan R. Hirsch, M.D.
Participants: David E. Hartman, Ph.D., Carl M. Wahlstrom, Jr., M.D.

ISSUE WORKSHOP 63
9:00 a.m.-10:30 a.m.
Room 714 B, Level 700, Toronto Convention Centre South

THE QUALITY INFORMATION SYSTEM: A NEW SYSTEM FOR MEASURING PROGRESS IN THE DOCTOR-PATIENT RELATIONSHIP

Chp.: Victor J.A. Buwalda, M.D.
Participants: Michelle B. Riba, M.D., Henk van den Berg, M.D., Prashant Debipersad, B.A., Richard C. Hermann, M.D.

ISSUE WORKSHOP 64
9:00 a.m.-10:30 a.m.
Room 717 A, Level 700, Toronto Convention Centre South

CONNECTION IS THE CURE: TREATING RELATIONAL DISORDERS

Co-Chps.: Glenn N. Siegel, M.D., Mary Pittman, M.S.

MEDIA 4-6

MEDIA WORKSHOP 4
9:00 a.m.-12 noon
Room 715 A/B, Level 700, Toronto Convention Centre South

I USED, I AM SORRY. CAN I COME BACK? SISTER HELEN SAYS: PISS OFF
APA Corresponding Committee on Treatment Services for Patients With Addictive Disorders

Co-Chps.: Petros Levounis, M.D., Marjorie E. Waldhauser, M.D.
Participants: Moddy H. Kiluva, M.D., Aditi M. Shrikhande, M.D., Monisha R. Vasa, M.D.

MEDIA WORKSHOP 5
9:00 a.m.-12 noon
Alberta Room, Mezzanine Floor, Royal York

THE MOVIE FUN AS A FRAME WORK FOR EXPLORING CONDUCT DISORDER IN ADOLESCENT GIRLS

Chp.: Jessica C. Morgan, M.D.
Participants: Patricia A. Daly, M.D., Erica L. O'Neal, M.D.

MEDIA WORKSHOP 6
9:00 a.m.-12 noon
Quebec Room, Mezzanine Floor, Royal York

CARTER'S ADDICTION: SUBSTANCE USE DISORDERS IN PHYSICIANS
Collaborative Session With the National Institute on Alcohol Abuse and Alcoholism

Chp.: Christopher J. Welsh, M.D.
11:00 a.m. Sessions

DISCUSSION GROUPS 21-22

11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

21 Michelle B. Riba, M.D., on the Role of the Psychiatrist in End-of-Life Care
Grenadier Room, Main Level, Intercontinental Hotel

22 Patricia Ordonica, M.D., on the Future of Psychiatry: What the Resident Should Know (Residents Only)
Niagara Room, Lower Level, Intercontinental Hotel

LECTURES 23-25

LECTURE 23
11:00 a.m.-12:30 p.m.
Room 105, Level 102
Toronto Convention Centre North

A. Leslie Morrow, Ph.D.

High on Neurosteroids: Mechanisms and Therapeutic Relevance

Chips: Christine T. Marx, M.D.
Co-Chip: Farsh Momar, M.D.

Dr. A. Leslie Morrow received a Ph.D. in Neuroscience at the University of California, San Diego in 1985 and conducted her postdoctoral training with Dr. Steven Paul at NIH in Bethesda, Maryland. She received a prestigious PRAT fellowship and National Academy of Science NRC Associate Award at NIH. Morrow joined the faculty of the University of North Carolina at Chapel Hill School of Medicine in 1990, and was promoted to professor of psychiatry and pharmacology in 2001. She served on the biomedical study section at NIAAA from 1997-2001, chairing the committee from 2001-02. Dr. Morrow has editorial responsibilities for Pharmacology and Therapeutics, Psychopharmacology, Alcoholism, and Clinical and Experimental Research. She received a Ment Award from NIAAA in 2001. She is associate director of the Bowles Center for Alcohol Studies and co-director of the NIA-funded alcohol research center grant. Countless numbers of her trainees have developed successful independent research programs.

Frontiers of Science Lecture Series
This session will be audio-taped.

LECTURE 24
12:30 p.m.-2:30 p.m.
Exhibit Hall A, Level 300
Toronto Convention Centre North

Father Edward A. Malloy, Ph.D.

A University President's Perspective on Alcohol-Related Research
Collaborative Services With the National Institute of Alcohol Abuse and Alcoholism

Chips: Deborifi Dros, M.D.

Father Edward A. Malloy, Ph.D., completed his 18th year as president of the University of Notre Dame in 2005. At the University's 16th president, Father Malloy was elected by the Board of Trustees in 1986, serving seven years as vice president and provost. Father Malloy is a full professor in the Department of Theology and has been a member of the faculty since 1974. Father Malloy has authored more than 50 articles and book chapters, is the editor or co-editor of two books, and has published six books. An ethicist by training, he is a member of the Catholic Theological Society of America and the Society of Christian Ethics. Father Malloy received his doctorate in Christian ethics from Vanderbilt University in 1975, and Vanderbilt honored him in 1999 with the establishment of a chair in Catholic studies in his name. He was ordained to the priesthood in Sacred Heart Basilica on campus in 1952. Father Malloy's service of higher education has been long-standing and presently includes membership on the boards of Vanderbilt University, the University of Portland, St. Thomas University, and Notre Dame Australia. In addition, he has played a leadership role in many of the major higher education associations including the American Council on Education (ACE), the Association of Governing Boards of Universities and Colleges (AGB), and the National Association of Independent Colleges and Universities (NAICU) and continues to serve on various committees of the NCAA. In combating substance abuse, Father Malloy has been a member of the National Advisory Council on Alcohol Abuse and Alcoholism, President Bush's Advisory Council on Drugs, the Community Anti-Drug Coalition of America, the Governor's Commission in for Drug-Free Indiana, and a member of the board of the National Center on Addiction and Substance Abuse (CASA) at Columbia University, for which he has chaired a number of commissions, particularly dealing with substance abuse among adolescents and among college and university students. He has also been co-chair of a major study on college drinking for the National Institute of Alcohol Abuse and Alcoholism.

This session will be audio-taped.
LECTURE 25
11:00 a.m.-12:30 p.m.
Room 716 A/B, Level 700
Toronto Convention Centre South

Markus Heilig, M.D.

Beyond Dopamine: Neuroadaptations, Negative Affect, and Clinically Relevant Treatment Targets in Alcoholism. Collaborative Session with the National Institute of Alcohol Abuse and Alcoholism.

Chp.: Eric Stearn, M.D.
Co-Chp.: Shadly Greenfield, M.D.

Markus Heilig, M.D., has been the Clinical Director of the National Institute on Alcohol Abuse and Alcoholism and Chief of the Laboratory of Clinical and Translational Studies at the National Institutes of Health in Bethesda, Maryland since 2004. Dr. Heilig obtained his medical degree from Lund University in Sweden in 1986 and his Ph.D. at the Department of Psychiatry and Neurochemistry at Lund University in 1989. His Ph.D. thesis described for the first time, the role of neuropeptide Y in stress and emotionality. Between 1989 and 1992, Dr. Heilig was a post-doctoral fellow with Professor George Koob at the Scripps Research Institute, La Jolla, California, where he continued to study neuropeptide systems in emotionality and stress. Following his return to Sweden, Dr. Heilig completed his clinical psychiatry training in 1995, and served in different clinical and academic leadership roles at the Karolinska Institute in Stockholm, Sweden from 1995-2004. Dr. Heilig's current research centers around development of novel pharmacological treatments for alcohol dependence, with a particular focus on target systems involved in long-term neuroadaptations following a prolonged history of dependence and recruitment of negative affect. Among key systems under study are neuropeptide systems involved in stress responses, such as neuropeptide Y, corticotropin-releasing hormone, substance P, and neocortex. The intramural developmental effort led by Dr. Heilig spans from preclinical target discovery and validation, to early human proof-of-concept trials.

MASTER EDUCATOR CLINICAL CONSULTATIONS 16-17.

11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

16 David Baron, D.O., on Performance Enhancing Drug Use in Adolescent Athletes: A Sports Psychiatry Perspective Room 201 A, Level 200, Toronto Convention Centre North

17 Ellen Haller, M.D., on Working With Lesbian, Gay, Bisexual, and Transgendered Patients: What Do You Need to Know? Room 201 B, Level 200, Toronto Convention Centre North

MEDICAL UPDATE 3
11:00 a.m.-12:30 p.m.
Room 716 A, Level 700, Toronto Convention Centre South

TESTOSTERONE REPLACEMENT THERAPY IN THE AGING MALE: IMPLICATIONS FOR PSYCHIATRY AND OTHER DISCIPLINES

Presenters: Jerald Bain, M.D.
Chp.: Dennis Kussin, M.D.
THIS SESSION WILL BE AUDIOTAPEd.

RESEARCH CONSULTATION WITH

11:00 a.m.-12:30 p.m.

This session is limited to 25 participants on a first-come, first-served basis.

3 Howard Goldman, on Mental Health Policy Research Oakville Room, Main Level, Intercontinental Hotel

SCIENTIFIC AND CLINICAL REPORT SESSIONS 23-33

SCIENTIFIC AND CLINICAL REPORT SESSION 23
11:00 a.m.-12:30 p.m.
Room 104 B, Level 100, Toronto Convention Centre North

SLEEP DISORDERS

Chp.: Karl Doghramji, M.D.
Co-Chp.: Darryl Appleton, M.D.

11:00 a.m.

67 Effect of Amodafinil on Reducing Fatigue in Patients With Narcolepsy Russell Rosenberg, Ph.D.

11:30 a.m.

68 Effect of Amodafinil on Attention in Patients With Excessive Sleepiness Associated With Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, and Shift Work Sleep Disorder Keith Wessnes, Ph.D., Gwendolyn E. Niebler, D.O., Sanjay Arora, Ph.D.

12 noon

69 Amodafinil Improves Wakefulness in Patients With Excessive Sleepiness Associated With Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, and Shift Work Sleep Disorder Milton Erman, M.D., Gary Zammit, Ph.D., Gwendolyn E. Niebler D.O., Sanjay Arora, Ph.D.

THIS SESSION WILL BE AUDIOTAPEd.
WEDNESDAY

SCIENTIFIC AND CLINICAL REPORT SESSION 24
11:00 a.m.-12:30 p.m.
Room 104 D, Level 100, Toronto Convention Centre North

ECT

Chp.: Michael A. Kling, M.D.
Co-Chp.: Eric D. Peselow, M.D.

11:00 a.m.
70 Predictors of Referral for ECT
Bonnie L. Szarek, R.N., John W. Goethe, M.D., Joanna H. Fogg-Waberski, M.D.

11:30 a.m.
71 ECT Stimulus Dose as Physiological Volume of Seizure Foci
Conrad M. Swartz, M.D.

12 noon
72 The Efficacy and Outcome of Combining ECT and Atypical Antipsychotics for Treatment-Resistant Depression
Randall T. Espinosa, M.D., Joseph Morrow, B.A., Julie King, R.N., Juanita Jackson, R.N.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 25
11:00 a.m.-12:30 p.m.
Room 201 D, Level 200, Toronto Convention Centre North

HEALTH, NUTRITION, AND WEIGHT IN SCHIZOPHRENIA

Chp.: Prakash S. Masand, M.D.
Co-Chp.: Rachel Glick, M.D.

11:00 a.m.
73 Assessing Health and Nutrition Status of Urban Psychiatric Outpatients

11:30 a.m.
74 Are Females at Special Risk for Obesity If They Become Psychotic? The Longitudinal Northern Finland 1966 Birth Cohort Study
Hannu J. Koponen, M.D., Sari Lindeman, M.D., Kaisa Saari, M.D., Helinä Hakko, Ph.D.

12 noon
75 A 12-Week Open Label Trial of Topiramate for Limiting Weight Gain During Olanzapine Treatment in Patients With Schizophrenia
Jin-Ilun Kim, Seonjin Yim, Junghyun Nam, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 26
11:00 a.m.-12:30 p.m.
Room 205 A, Level 200, Toronto Convention Centre North

DEVELOPMENTAL ISSUES IN SCHIZOPHRENIA

Chp.: Mary V. Seeman, M.D.
Co-Chp.: Don Richardson, M.D.

11:00 a.m.
76 Altered Developmental Trajectories in Schizophrenia

11:30 a.m.
77 Characteristics of the Interpersonal Distance of Patients With Schizophrenia in the Virtual Environment
Sung-Hyouk Park, M.D., Jae-Jin Kim, M.D., Hee-Georg Jang, B.A., Chan-Hyun Kim, M.D., Jeonghun Ku, Ph.D., In-Young Kim, M.D., Sun I. Kim, Ph.D.

12 noon
78 Familial Risk of Psychosis and Prodromal Features of Psychosis at the Age of 15-16 Years
Juha M. Veijola, M.D., Pirjo H. Maki, M.D., Hanna Ebeling, M.D., Irma Moilanen, M.D., Anja Taanila, Ed.D., Erika Lauronen, M.D., Jouko Miettunen, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 27
11:00 a.m.-12:30 p.m.
Room 206 A/B, Level 200, Toronto Convention Centre North

TREATMENT OF SCHIZOPHRENIA

Chp.: Michael Demas, M.D.
Co-Chp.: Meera Vaswani, Ph.D.

11:00 a.m.
79 An Effectiveness Trial of a Brief Cognitive Behavioral Intervention by Mental Health Nurses in Schizophrenia: Clinically Important Outcomes in the Medium Term
Shanaya Rathod, M.D., David G. Kingdon, M.D., Douglas Turckington, M.D.

11:30 a.m.
80 Efficacy and Tolerability of Olanzapine, Quetiapine, and Risperidone in the Treatment of First-Episode Psychosis: A Randomized, Double-Blind, 52-Week Comparison
Joseph P. McEvoy, M.D.

12 noon
81 Quetiapine for Bipolar Disorder and Schizophrenia: Appropriate Dose for Optimal Response
Arthur L. Lazarus, M.D.

THIS SESSION WILL BE AUDIOTAPED.
SCIENTIFIC AND CLINICAL REPORT SESSION 28
11:00 a.m.-12:30 p.m.
Room 206 E/F, Level 200, Toronto Convention Centre North

RECENT RESEARCH ON SSRIS

Chp.: David V. Sheehan, M.D.
Co-Chp.: Derya Irem Akbıyık, M.D.

11:00 a.m.
82 Early Symptomatic Worsening During Treatment With Fluoxetine in MDD: A Replication Study
Cristina Cusin, M.D., Roy H. Perlis, M.D., Jonathan E. Alpert, M.D., Patrick J. McGrath, M.D., Jonathan W. Stewart, M.D., Frederick M. Quitkin, M.D., Maurizio Fava, M.D.

11:30 a.m.
83 Meta-Analysis of Efficacy of Paroxetine Versus Placebo Utilizing the GlaxoSmithKline Clinical Trials Registry
Lawrence W. Adler, M.D., Lorri Cerro, Ph.D., Henri Zepp, R.N.C.

12 noon
84 Resolution of Sleepiness and Fatigue in the Treatment of MDD: A Comparison of Bupropion and SSRIs
George I. Papakostas, M.D., Rafe M. Donahue, Ph.D., Andrew A. Nierenberg, M.D., David J. Nurt, M.D., Maurizio Fava, M.D.,

THIS SESSION WILL BE AUDIOTAPEED.

SCIENTIFIC AND CLINICAL REPORT SESSION 29
11:00 a.m.-12:30 p.m.
Algonquin Room, Mezzanine Floor, Royal York

EPIDEMIOLOGICAL STUDIES OF ADVERSE EVENTS IN INSTITUTIONALIZED POPULATIONS

Chp.: Rubaba Ansari, M.D.
Co-Chp.: Daniel P. Chapman, Ph.D.

11:00 a.m.
85 Death by Unnatural Causes During Childhood and Early Adulthood in Offspring of Psychiatric Inpatients

11:30 a.m.
86 The Incidence and Prevalence of Diabetes Mellitus Among Inpatients in State-Operated Psychiatric Hospitals in New York State 1997-2004
Leslie L. Citrome, M.D., Ari B. Jaffe, M.D., Jerome M. Levine, M.D., David Martello

12 noon
87 Associations Between Psychiatric Disorder and Commitment Criteria in Acute Involuntarily Admitted Patients in the Netherlands
Cornelis Mulder, M.D.

THIS SESSION WILL BE AUDIOTAPEED.

SCIENTIFIC AND CLINICAL REPORT SESSION 30
11:00 a.m.-12:30 p.m.
Confederation 3 Room, Mezzanine Floor, Royal York

TREATMENT OF ADVERSE EVENTS

Chp.: Elissa P. Benedek, M.D.
Co-Chp.: Zubin Bhagwagar, M.D.

11:00 a.m.
88 PDE5I Sildenafil Treatment of Serotonergic Antidepressant Associated Sexual Dysfunction (SRI-AASD) in Women With MDD in Remission: An Eight-Week Randomized, Double-Blind, Placebo-Controlled Trial With Eight-Week Open-Label Continuation
H. George Nurnberg, M.D., Paula L. Hersley, M.D., Maurizio Fava, M.D., Harry A. Croft, M.D., Julia R. Heiman, Ph.D., Matthew A. Menza, M.D., Julia K. Warnock, M.D.

11:30 a.m.
89 Theoretical Implications of Improved Depression Severity by PDE5I Sildenafil Treatment of Erectile Dysfunction Associated With Treated or Untreated MDD for Endothelial Dysfunction Mediation
Richard L. Siegel, M.D., H. George Nurnberg, M.D.

12 noon
90 Efficacy of Sildenafil for the Treatment of Erectile Dysfunction in Men Taking Antidepressant Medication: Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Studies
Joseph C. Cappelleri, Ph.D., H. George Nurnberg, M.D., Li-Jung Tseng, Ph.D., Claude Tellier, B.S., Richard L. Siegel, M.D.

THIS SESSION WILL BE AUDIOTAPEED.

SCIENTIFIC AND CLINICAL REPORT SESSION 31
11:00 a.m.-12:30 p.m.
Confederation 5 Room, Mezzanine Floor, Royal York

BPD

Chp.: Bernadette Grosgean, M.D.
Co-Chp.: Kenneth Silk, M.D.

11:00 a.m.
91 Structural Brain Abnormalities in BPD
Paul H. Soloff, M.D., Jeffrey Nutech, B.S., Vaibhav Diwadkar, Ph.D.

11:30 a.m.
92 Neurobiological Correlates of Diagnosis and Underlying Traits in Patients With BPD Compared With Normal Controls
Joel F. Paris, M.D., Hallie Zweig-Frank, Ph.D., Mien-Kwong Ng, Ying Kin, Ph.D., George Schwartz, M.S., Howard Steiger, Ph.D., Vasavan N. Nair, M.D.

12 noon
93 BPD and Suicide Attempt: Are There Any Correlates Between Attempters and Non-Attempters?
Tavi Thongy, M.D., Mark Zimmerman, M.D., Joseph McGlinchey, Ph.D.
WEDNESDAY

SCIENTIFIC AND CLINICAL REPORT SESSION 32
11:00 a.m.-12:30 p.m.
Manitoba Room, Mezzanine Floor, Royal York

WOMEN'S HEALTH ISSUES

Chp.: Nafisa Y. Ghadiali, M.D.
Co-Chp.: Evangeline J. Spindler, M.D.

11:00 a.m.
94 Gender Differences in Schizophrenia and Other Psychotic Disorders: A 20-Year Follow-Up Study
Linda S. Grossman, Ph.D., Martin Harrow, Ph.D., Cherise Rosen, Ph.D., Robert Faull, B.S.

11:30 a.m.
95 Severe Personality Disorders in the Offspring of Antenatally-Depressed Mothers: A 31-Year Follow-Up of the Northern Finland 1966 Birth Cohort
Pirjo H. Maki, M.D., Juha M. Veijola, M.D., Matti Joulakama, M.D., Paula Rantakallio, M.D., Jari Jokelainen, M.S.C., Liisa Kantola, M.D., Matti K. Isohanni, M.D.

12 noon
96 Outcome of Prenatal Anxiety, Stress, and Depression
Gisèle Apter-Danon, M.D., Rozenn Graignic-Philippe, Ph.D., Emmanuel Devouche, Ph.D., Marina Gianoli-Valente, M.A., Annick Le Nestour, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 33
11:50 a.m.-12:30 p.m.
Salon B, Convention Floor, Royal York

CROSS-CULTURAL AND MINORITY ISSUES

Chp.: Leslie Horton, M.D.
Co-Chp.: Antony Fernandez, M.D.

11:50 a.m.
97 All Equal? Advocating Equity in Mental Health Services in France to Ethnic-Minority Disadvantaged Youth and Their Families Through the Evidence-Based FACE® Protocol
Leon-Patrice Celestin, M.D., Smadar Celestin-Westreich, Ph.D.

11:30 a.m.
98 Stories About Mental Health: A Cross-Cultural Relapse Prevention Study in Northern Territory Aboriginal Communities
Tricia M. Nagel, Carolyn Thompson

12 noon
99 Recognizing and Engaging Depressed Chinese Americans in Treatment in a Primary Care Setting
Albert Yeung, M.D., Jinny Yu, M.A., Freddy Fung, B.A., Sienna Vorono, B.A., Maurizio Fava, M.D.

THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS

COMPONENTS 44-49

COMPONENT WORKSHOP 44 11:00 a.m.-12:30 p.m.
Room 104 A, Level 100, Toronto Convention Centre North

GLOBAL PSYCHIATRY: ESTABLISHING FORMAL AND INFORMAL MENTAL HEALTH EXCHANGES
APA Council on Global Psychiatry

Co-Chps.: Samuel O. Okpaku, M.D., William Lawson, M.D.
Participants: Mary K. Smith, M.D., Michael A. Hollifield, M.D., Robert Kohn, M.D., Rodrigo A. Munoz, M.D.

COMPONENT WORKSHOP 45 11:00 a.m.-12:30 p.m.
Room 205 B, Level 200, Toronto Convention Centre North

SCHOOL-BASED SUICIDE PREVENTION: EVIDENCE-BASED STRATEGIES AND NEW APPROACHES
APA Corresponding Committee on Mental Health and Schools

Co-Chps.: Eugenio M. Rothe, M.D., Daniel Castellanos, M.D.
Participants: Alicia A. Munoz, LaShondra T. Washington, M.D.

COMPONENT WORKSHOP 46 11:00 a.m.-12:30 p.m.
Room 205 C, Level 200, Toronto Convention Centre North

A RESEARCH AGENDA FOR DSM-5: MENTAL HEALTH IN THE GAY, LESBIAN, AND BISEXUAL POPULATIONS
APA Committee on Gay, Lesbian, and Bisexual Issues

Co-Chps.: Benjamin H. McCommon, M.D., Jack Drescher, M.D.
Participants: Theodoros G.M. Sandfort, Ph.D., Michael B. First, M.D., Susan D. Cochran, Ph.D., Serena Y. Volpp, M.D., Robert P. Cabaj, M.D.

COMPONENT WORKSHOP 47 11:00 a.m.-12:30 p.m.
Room 205 D, Level 200, Toronto Convention Centre North

WELCOME TO THE JUNGLE: THE DYNAMICS BETWEEN RESIDENTS AND INDUSTRY
APA/GlaxoSmithKline Fellows

Co-Chps.: Lisa A. Catapano, M.D., Itai Danovitch, M.D.

COMPONENT WORKSHOP 48 11:00 a.m.-12:30 p.m.
Room 206 C/D, Level 200, Toronto Convention Centre North

TRAUMA OF HEARTS AND MINDS: RACISM AND PSYCHIATRY IN THE 21ST CENTURY
APA/SAMHSA and APA/AstraZeneca Minority Fellowships

Co-Chps.: Napoleon B. Higgins, Jr., M.D., Jean-Marie E. Alves-Bradford, M.D.
Participants: Lacertha L. Hall, M.D., Aruna S. Rao, M.D., Eric R. Williams, M.D.
WEDNESDAY

COMPONENT WORKSHOP 49  11:00 a.m.-12:30 p.m.
Room 701 B, Level 700, Toronto Convention Centre South

CURRENT ISSUES IN PSYCHIATRY AND LAW
APA Council on Psychiatry and Law

Chp.: Paul S. Appelbaum, M.D.
Participants: Howard V. Zonana, M.D., Steven K. Hoge, M.D.

ISSUES 65-75

ISSUE WORKSHOP 65  11:00 a.m.-12:30 p.m.
Room 703, Level 700, Toronto Convention Centre South

PSYCHIATRY TRAINING FOR PRIMARY CARE PHYSICIANS: AN ONGOING CHALLENGE

Chp.: Hoyle Leigh, M.D.
Participants: Don R. Lipsitt, M.D., Seth M. Powsner, M.D.
Jon M. Streltzer, M.D.

ISSUE WORKSHOP 66  11:00 a.m.-12:30 p.m.
Room 705, Level 700, Toronto Convention Centre South

WHEN THERAPEUTIC LIFESTYLE CHANGES FAIL: PHARMACOLOGIC MANAGEMENT OF METABOLIC SYNDROME IN PSYCHIATRY

Co-Chps.: Peter Manu, M.D., Raymond E. Suarez, M.D.
Participant: Christoph U. Correll, M.D.

ISSUE WORKSHOP 67  11:00 a.m.-12:30 p.m.
Room 707, Level 700, Toronto Convention Centre South

COUNTERTRANSFERENCE AND BOUNDARY ISSUES OF RESIDENTS TREATING MEDICAL STUDENTS, FELLOW RESIDENTS, AND ATTENDINGS

Chp.: Benjamin D. Lederer, M.D.
Participants: Julianne Flynn, M.D., Jeffrey M. Lammers, M.D.
David J. Walick, M.D.

ISSUE WORKSHOP 68  11:00 a.m.-12:30 p.m.
Room 709, Level 700, Toronto Convention Centre South

APPLYING FOR NATIONAL INSTITUTE OF ALCOHOL ABUSE AND ALCOHOLISM RESEARCH MONEY: SOME THINGS YOU DIDN'T LEARN IN GRADUATE SCHOOL
Collaborative Session With the National Institute on Alcohol Abuse and Alcoholism

Chp.: Robert Huebner, Ph.D.
Participant: Mark L. Willenbring, M.D.

ISSUE WORKSHOP 69  11:00 a.m.-12:30 p.m.
Room 711, Level 700, Toronto Convention Centre South

THE NATURE OF NURTURE: THE LONG-LASTING IMPACTS OF EARLY ADVERSE LIFE EVENTS

Co-Chps.: Mireya Nadal-Vicens, M.D., Stacy S. Drury, M.D.
Participants: Charles H. Zezana, Jr., M.D., Joan Kaufman, Ph.D.,
Alison Fleming, Ph.D., Michael Meaney, Ph.D.

ISSUE WORKSHOP 70  11:00 a.m.-12:30 p.m.
Room 713 A/B, Level 700, Toronto Convention Centre South

MAINTENANCE OF CERTIFICATION FOR DIPLOMATS OF THE AMERICAN BOARD OF PSYCHIATRY AND NEUROLOGY

Chp.: Stephen C. Scheiber, M.D.
Participants: Victor I. Reus, M.D., Naleen N. Andrade, M.D.,
Burton V. Reifler, M.D.

ISSUE WORKSHOP 71  11:00 a.m.-12:30 p.m.
Room 714 A, Level 700, Toronto Convention Centre South

RESPONDING TO THE IMPACT OF SUICIDE ON CLINICIANS

Chp.: Eric M. Plakun, M.D.
Participants: Edward R. Shapiro, M.D., Jane G. Tillmaa, Ph.D.

ISSUE WORKSHOP 72  11:00 a.m.-12:30 p.m.
Room 716 B, Level 700, Toronto Convention Centre South

NON-GOVERNMENTAL ORGANIZATIONS: RESPONSE TO MENTAL HEALTH CONSEQUENCES OF ASIAN TSUNAMI

Chp.: Jagannathan Srinivasasraghavan, M.D.
Participants: Syed A. Fussain, M.D., Bruce S. Singh, M.D.,
Lakshmi Vijayakumar, D.P.M.

ISSUE WORKSHOP 73  11:00 a.m.-12:30 p.m.
Room 717 A, Level 700, Toronto Convention Centre South

APPROACHES TO CHRONIC DISEASE MANAGEMENT: OPPORTUNITIES FOR PSYCHIATRY

Chp.: Nick Kates, M.B.
Participants: Michele Mach, M.S.W., Lindsey George, M.D.,
Anne Marie Crustolo, R.N.

ISSUE WORKSHOP 74  11:00 a.m.-12:30 p.m.
Room 717 B, Level 700, Toronto Convention Centre South

THE KEY TO SUCCESS, MENTORSHIP MATTERS: A PRACTICAL GUIDE FOR TRAINEES AND EDUCATORS

Chp.: Anita R. Kishore, M.D.
Participants: Harold Alan Pinus, M.D., Dorothy E.
Stubbe, M.D., Eva M. Szigethy, M.D.
ISSUE WORKSHOP 75 11:00 a.m.-12:30 p.m.
Room 803 A/B, Level 800, Toronto Convention Centre South

THE EVOLUTION OF GRANDFAMILIES: THE
PSYCHOLOGICAL, SOCIA L, AND FINANCIAL
IMPACT OF GRANDPARENTS RAISING
GRANDCHILDREN
American Academy of Child and Adolescent Psychiatry

Co-Chps.: Sandra C. Walker, M.D., James E. Lee, Jr., M.D.
Participants: O.C. White III, M.D., F.M. Baker, M.D., Esme
Fuller-Thomson, Ph.D., Harry H. Wright, M.D.

12 noon Sessions

FORUMS 12-15

FORUM 12 12 noon-1:30 p.m.
Room 701 A, Level 700, Toronto Convention Centre South

CORRECTONAL MENTAL HEALTH ISSUES: AN
INTERNATIONAL PERSPECTIVE

Chp.: Jeffrey L. Metzner, M.D.
Participant: Adrian Grounds, M.D.

FORUM 13 12 noon-1:30 p.m.
Room 714 B, Level 700, Toronto Convention Centre South

KATRINA: PSYCHIATRIC RESPONSES AND CARE
FOR INDIVIDUALS AND COMMUNITIES

Co-Chp.: Robert J. Ursano, M.D., Anthony T. Ng, M.D.
Participants: Carol S. North, M.D., Ronald Kessler, James Ray
Rundell, M.D., Howard J. Osofsky, M.D.

FORUM 14 12 noon-1:30 p.m.
Room 801 B, Level 800, Toronto Convention Centre South

ADDRESSING PSYCHIATRIC NEEDS IN ASIA
APA Council on Global Psychiatry

Chp.: Pedro Ruiz, M.D.
Participants: Russell F. D'Souza, M.D., Rodrigo Munoz, M.D.,
Aziz Javed, M.D., Bruce Singh, Ph.D., Haroon R. Chaudhry, M.D.,
Naotaka Shinuku, M.D.

FORUM 15 12 noon-1:30 p.m.
Territories Room, Mezzanine Floor, Royal York

ENVIRONMENTAL PSYCHIATRY: FROM SICK
BUILDINGS TO THE GULF WAR

Chp.: Claudia S. Miller, M.D.

NEW RESEARCH POSTER SESSION 8
12 noon-2:00 p.m.
Exhibit Hall B, Level 300, Toronto Convention Centre North

ANXIETY, ADHD, AND DISORDERS OF
CHILDHOOD

For further information on New Research submissions, please refer to the New Research Program Book included in your
registration packet.

1:00 p.m. Sessions

COURSES 92-97
Course descriptions are available in the CME
Course Brochure included in your registration
packet. Admission by ticket only.

COURSE 92 1:00 p.m.-5:00 p.m.
Conference Room D/E, Mezzanine, Sheraton Centre

TREATING COMORBID ADULT ADHD BY
COMBINING MEDICATION AND COGNITIVE
THERAPY: PRACTICAL SOLUTIONS TO COMMON
CLINICAL PROBLEMS

Co-Directors: Anthony L. Rostain, M.D., J. Russell Ransay, Ph.D.

COURSE 93 1:00 p.m.-5:00 p.m.
Windsor Room West, Mezzanine, Sheraton Centre

REEL PSYCHIATRY

Director: Luis F. Ramirez, M.D.
Faculty: David J. Robinson, M.D.

COURSE 94 1:00 p.m.-5:00 p.m.
City Hall, Second Floor, Sheraton Centre

MELATONIN AND LIGHT TREATMENT OF SAD,
SLEEP, AND OTHER BODY CLOCK DISORDERS

Director: Alfred J. Lewy, M.D.
Faculty: Robert D. Levitan, M.D.

COURSE 95 1:00 p.m.-5:00 p.m.
Dominion Ballroom North, Second Floor, Sheraton Centre

EMOTION FOCUSED THERAPY FOR COUPLES:
INTRODUCTION TO THEORY AND CLINICAL
SKILLS

Director: Wayne H. Denton, M.D.
Faculty: Susan M. Johnson, Ed.D.
WEDNESDAY

COURSE 96  1:00 p.m.-5:00 p.m.
Kent Room, Second Floor, Sheraton Centre

YOGA IN PSYCHIATRY: THEORY, CLINICAL APPLICATIONS, AND BEGINNING PRACTICE

Co-Directors: Richard P. Brown, M.D., Patricia L. Gerberg, M.D.

COURSE 97  1:00 p.m.-5:00 p.m.
Wentworth Room, Second Floor, Sheraton Centre

PSYCHIATRY AND THE INTERNET

Director: Robert S. Kennedy, M.A.
Faculty: Thomas A.M. Kramer, M.D., Carlyle H. Chan, M.D.

2:00 p.m. Sessions

ADVANCES IN SCHIZOPHRENIA
2:00 p.m.-5:30 p.m.
Room 107, Level 100, Toronto Convention Centre North

Chp.: Jeffrey A. Lieberman, M.D.

A  Pharmacotherapies for Schizophrenia
   Thomas S. Stroup, M.D.

B  Dopamine and Glutamate Interactions in the Pathology of Schizophrenia: Insights From New Imaging
   Marc Langelu, M.D.

C  A Review of the Genetics of Schizophrenia
   Patrick F. Sullivan, M.D.

D  Evaluation and Treatment of a First Psychotic Episode
   Diana O. Perkins, M.D.

E  Recent Advances in Understanding the Neurobiology of Cognitive Dysfunction in Schizophrenia
   David A. Lewis, M.D.

LECTURE 26

2:00 p.m.-3:35 p.m.
Room 103, Level 100
Toronto Convention Centre North

Bankole Johnson, M.D.

Medications That Act at Ion Channels as Treatment for Alcohol Dependence
Collaborative Session with the National Institute of Alcohol Abuse and Alcoholism

Chp.: Thomas R. Kutsen, M.D.

Bartholomew Johnson, M.D., became Professor and Chairman of the Department of Psychiatry, Medicine and Professor of Neuroscience at the University of Virginia on September 1, 2004. He graduated in Medicine from Glasgow University in 1982, trained in Psychiatry at the Royal London and Maudsley and Bethlem Royal Hospitals, trained in research at the Institute of Psychiatry (University of London), and conducted studies in psychopharmacology for his doctoral thesis (degree from Glasgow University) on the Medical Research Council Unit at Oxford University. In 2004, he earned his Doctor of Science degree in Medicine from Glasgow University. His primary area of research expertise is the psychopharmacology of addictive medications, with clinical expertise in addiction, biological, and forensic psychiatry. A licensed physician and board-certified psychiatrist in the U.S. and Europe, he is a Principal Investigator on NIH-funded research studies utilizing neuroimaging and molecular genetics techniques. Honors include service on numerous NIH Review and other committees/special panels. In 2001, he received the Dan Anderson Research Award for his distinguished contributions to the scientific knowledge of addiction recovery. He received the Distinguished Senior Scholar of Distinction Award from the National Medical Association in 2002 and was inducted into the Texas Hall of Fame in 2003. Distinguished Psychiatrist Lecture Series

PRESIDENTIAL SYMPOSIA 3-4

PRESIDENTIAL SYMPOSIUM 3
2:00 p.m.-5:00 p.m.
Room 701 A, Level 700, Toronto Convention Centre South

COLLABORATION IN CRISIS: ACADEMIC MEDICAL CENTERS' RESPONSE TO HURRICANES KATRINA AND RITA

Chp.: Joseph D. Hamilton, M.D.

A  The Acute Clinical Response
   Kimberly A. Arlinghaus, M.D.

B  Be Nice to Your Neighbors: How Tulane University Adult Psychiatry and Baylor College of Medicine Worked Together to Rescue a Residency Program and Provide Continued Psychiatry Education in the Aftermath of Hurricane Katrina
   Leslie E. Lawrence, M.D.

Discussant: Stuart C. Yudofsky, M.D.
PRESIDENTIAL SYMPOSIUM 4
2:00 p.m.-5:00 p.m.
Ballroom A, Lower Level, Intercontinental Hotel

PSYCHIATRIC PARTICIPATION IN INTERROGATION OF DETAINEES: ETHICAL CONSIDERATIONS

Chp.: Steven S. Sharfstein, M.D.
Presenters: Howard V. Zonana, M.D., Kevin C. Kiley, M.D., Alan A. Stone, M.D., Steven S. Sharfstein, M.D.

SYMPOSIA 66-99

SYMPOSIUM 66 2:00 p.m.-5:00 p.m.
Room 104 A, Level 100, Toronto Convention Centre North

RISK FACTORS, PERSONALITY VARIABLES, AND ADDICTIVE DISORDERS
Collaborative Session With the National Institute on Alcohol Abuse and Alcoholism

Chp.: Maurice Corcos, Ph.D.
Co-Chp.: Gwenolé Loas, M.D.

A Risk Factors for Addictive Disorders
Maurice Corcos, Ph.D., Martine Flament, M.D., Fernando Perez-Diaz, M.D., Olivier Halfon, M.D., François Lang, M.D., Paul Bizouard, Ph.D., Jean-Luc Venisse, M.D., Philippe Jeammet, Ph.D.

B Dependency and Suicidality in Addictive Disorders
Gwenolé Loas, M.D.

C Depressive Psychopathology in Addictive Disorders
Mario Speranza, M.D., Maurice Corcos, Ph.D., Frederic Atger, M.Eng., Gwenolé Loas, M.D., Philippe Jeammet, Ph.D.

D Sensation Seeking and Addictive Disorders
Alexandra Plam-Scottez, Fernando Perez-Diaz, M.D., Solange Carton, M.D., Julien-Daniel Guelfi, Ph.D., Philippe Jeammet, Ph.D., Maurice Corcos, Ph.D.

E Addictive Disorder: Goodman's Concept of Addiction, A Study of 692 Addictive Subjects
Ludovic A. Gicquel, Ph.D., Fernando Perez-Diaz M.Eng., Gwenolé Loas, M.D., Maurice Corcos, Ph.D., Aviel Goodman, Ph.D., Julien-Daniel Guelfi, Ph.D., Philippe Jeammet, Ph.D.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 67 2:00 p.m.-5:00 p.m.
Room 104 B, Level 100, Toronto Convention Centre North

REDUCTIONISM IN PSYCHIATRY: IMPLICATIONS AND LIMITS
Association for the Advancement of Philosophy and Psychiatry

Chp.: Christian D. Perrine, Ph.D.

A Is Modern Biological Psychiatry Reductionistic or Integrative?
G. Scott Waterman, M.D.

B Dr. Chekhov and the Multiplicity of Psychiatric Experience
Bradley E. Lewis

C Reduction in Psychiatry
Ian Gold, Ph.D.

D Reducing Reductionism: Reclaiming Psychiatry
Wesley E. Sowers, M.D.

Discussant: Peter D. Kramer
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 68 2:00 p.m.-5:00 p.m.
Room 104 C, Level 100, Toronto Convention Centre North

COMPLEX PTSD ACROSS THE LIFESPAN: IMPLICATIONS FOR DSM-V

Chp.: David B. Albert, Ph.D.

A Disorders of Extreme Stress: Results from the DSM-IV Field Trial
Bessel A. Van Der Kolk, M.D.

B Self-Regulation as a Framework for Conceptualizing and Treating Complex PTSD
Julian Ford, Ph.D.

C Early Childhood Trauma, Insecure Attachment, and Complex PTSD
Marylene Cloitre, Ph.D., Chase Stovall-McClough, Ph.D.

Discussant: Judith L. Herman, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 69 2:00 p.m.-5:00 p.m.
Room 104 D, Level 100, Toronto Convention Centre North

PHARMACEUTICAL INDUSTRY INFLUENCE IN PSYCHIATRY

Chp.: Daniel J. Carlat, M.D.

A Physicians and Industry: A Review of Commercial Influence on Medical Decision-Making
Jerome P. Kassirer, M.D.

B How to Evaluate for the Presence of Commercial Bias in CME Programs
Daniel J. Carlat, M.D.

C The ADHD/Psychostimulant Epidemic: The Role of the Pharmaceutical Industry
Lawrence H. Diller, M.D.

(Continued next page)
D Relationship Between Drug Company Funding and Outcomes of Clinical Psychiatric Research

E Psychiatric Research as Marketing: Common Distortions of Research Design in Industry-Sponsored Clinical Trials
Daniel J. Safer, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 70

2:00 p.m.-5:00 p.m.
Room 206 A/B, Level 200, Toronto Convention Centre North

NEW DIRECTIONS IN COMMUNITY PSYCHIATRY

Chp.: John S. Strauss, M.D.

A Poverty Reduction Strategies: An Important Focus for Early Intervention Programs
Terry Krupa, Ph.D.

B Aiming for the Star(s): Refining Recovery in Practice
Helen M. Glover, B.S.W.

C You Can Do It, We Can Help.
Larry Davidson, Ph.D.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 71

2:00 p.m.-5:00 p.m.
Room 206 C/D, Level 200, Toronto Convention Centre North

HOW TO PRACTICE EVIDENCE-BASED MEDICINE

Chp.: Maju Mathews

A Introduction to Evidence-Based Medicine
Kumaraswamy Budur, M.D.

B Review of Basic Statistical Concepts
Maju Mathews

C Critical Appraisal of Systematic Reviews and Meta-Analysis
Babatunde A. Adetunji

D Critical Appraisal of Randomized-Controlled Studies
Adele B. Williams

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 72

2:00 p.m.-5:00 p.m.
Room 206 E/F, Level 200, Toronto Convention Centre North

THE PROBLEM OF OUTCOMES WITH THE DIFFICULT-TO-TREAT PATIENT

Chp.: Richard L. Munich, M.D.
Co-Chp.: Throstur Bjorgvinsson, Ph.D.

A Framing the Problem of Outcome With the Difficult-to-Treat Patient
Richard L. Munich, M.D.

B Rethinking Outcomes in Mentalization-Based Treatment
Jon G. Allen, Ph.D.

E Cognitive-Behavioral Therapy for Treatment Refractory OCD and Other Anxiety Disorders: Outcome Data From a Specialized Hospital Program
Thorstor Bjorgvinsson, Ph.D., Joyce E. Davidson, M.D., Melinda Stanley, Ph.D.

D The Problem of Outcomes With the Difficult-to-Treat Patient
Norma V. Clarke, M.D.

E Future Direction of Specialized Treatment Programs: Mentalizing, Brain Imaging Studies, and Preliminary Outcomes
Efrain Bleiberg, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 73

2:00 p.m.-5:00 p.m.
Room 701 B, Level 700, Toronto Convention Centre South

THE ART AND SCIENCE OF BRIEF PSYCHOTHERAPIES

Chp.: Mantosh J. Dewan, M.D.

A Brief Cognitive Therapy
Judith S. Beck, Ph.D.

B Interpersonal Psychotherapy
Scott P. Stuart, M.D.

C Solution-Focused Brief Therapy
Brett Steenbarger

D Common Factors: Essential Ingredients for Successful Psychotherapy
Roger P. Greenberg

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 74

2:00 p.m.-5:00 p.m.
Room 705, Level 700, Toronto Convention Centre South

NEUROPSYCHIATRIC RESPONSES TO BURNS: MODELING THE DEVELOPMENTAL NEUROBIOLOGY OF TRAUMA

Chp.: Frederick J. Stoddard, Jr., M.D.

A Neurobiological Responses to Burn Trauma
John B. Levine, M.D.

B The Psychology and Physiology of Burn Stress in Very Early Childhood
Jennifer E. Drake, M.A.
C Determinants of Traumatic Stress in Older Children  
Glenn Saxe

D Pharmacological and Psychological Prevention of  
PTSD  
Rohini Luthra, Ph.D.

E Psychopharmacological Interventions for Stress in  
Children  
Frederick J. Stoddard, Jr., M.D., John B. Levine, M.D.,  
Glenn N. Saxe, M.D., Robert L. Sheridan, M.D.  
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 75  
2:00 p.m.-5:00 p.m.  
Room 707, Level 700, Toronto Convention Centre South

ACUTE BRIEF PSYCHOSES: NOSOLOGY AND BOUNDARIES

Chp.: Ezra S. Susser, M.D.  
Co-Chp.: Ramin Mojabai, M.D.

A Acute and Transient Psychotic Disorders  
Andreas Marneros, M.D.

B The Relationship Between Acute and Transient  
Psychotic Syndromes and Psychotic Symptoms in the  
General Population: Implications for Causes and  
Treatment  
Peter B. Jones, Med. Sc., Fiona McDougall, M.P.H.

C Panic Attacks With Psychotic Features: A Variant of  
Nonaffective Acute Remitting Psychoses?  
Igor I. Galynker, M.D., Liliya Malaya, Ph.D., Daniel  
Eisenberg, M.D., James Prosser, M.D., Lisa Cohen, Ph.D.

D The Place of Nonaffective Acute Remitting Psychoses in  
DSM-IV and ICD-10  
Ramin Mojabai, M.D., Ezra S. Susser, M.D., Vjjoy Varma, M.D.

Discussant: Michael B. First, M.D.  
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 76  
2:00 p.m.-5:00 p.m.  
Room 708, Level 700, Toronto Convention Centre South

ENHANCING THE WELL-BEING OF OLDER PERSONS WITH SCHIZOPHRENIA  
APA Council on Aging

Chp.: Carl I. Cohen, M.D.  
Co-Chp.: Paul Ramirez, Ph.D.

A Assessing Medical Comorbidity and Optimizing  
Medical Care in Older Patients With Schizophrenia  
Ipsit Vahia, M.D.

B Enhancing Quality of Life in Older Persons With  
Schizophrenia  
Azziza O. Bankole, M.D.

C Diminishing Depression in Older Adults With  
Schizophrenia: Targets for Intervention  
Shilpa P. Diwan, M.D.

D Adaptive Functioning in Older Persons With  
Schizophrenia  
Carl I. Cohen, M.D., Azziza O. Bankole, M.D., Shilpa P.  
Diwan, M.D., Paul M. Ramirez, Ph.D., Ipsit Vahia, M.D.

Discussant: Dilip V. Jeste, M.D.  
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 77  
2:00 p.m.-5:00 p.m.  
Room 711, Level 700, Toronto Convention Centre South

DEMORALIZATION AND PSYCHOTHERAPY: A TRIBUTE TO JEROME D. FRANK, M.D.

Chp.: John M. de Figueiredo, M.D.

A The Demoralization Hypothesis: Conceptualization,  
Epidemiology, and Clinical Relevance  
John M. de Figueiredo, M.D.

B Demoralization in the Experience of Being Ill  
David Clarke

C Brief Psychotherapy at the Bedside: Countering  
Demoralization From Medical Illness  
James L. Griffith, M.D., Lynne M. Gaby, M.D.

Discussant: Julia Frank, M.D.  
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 78  
2:00 p.m.-5:00 p.m.  
Room 713 A/B, Level 700, Toronto Convention Centre South

USE OF QUANTITATIVE INSTRUMENTS FOR  
MONITORING DEPRESSION SEVERITY: CLINICAL APPLICATIONS

Chp.: Darrel A. Regier, M.D.  
Co-Chp.: Farifteh F. Duffy, Ph.D.

A National Depression Management Leadership  
Initiative: Improving Depression Care  
Henry Chung, M.D., David J. Katzelnick, M.D., Farifteh F.  
Duffy, Ph.D., Donald S. Rae, M.S., Darrel A. Regier, M.D.

B Depression Management Experience in Private Versus  
Public Psychiatric Practices  
Rodrigo A. Munoz, M.D.

C Depression Management Experience in Primary Care  
Jack S. McIntyre, M.D.

D Depression Screening and Management in  
New York City  
Lloyd I. Sederer, M.D.

E Optimizing the Treatment of Depression: Using  
Treatment Algorithms in Conjunction With  
Standardized Instruments in Clinical Care Settings  
Madhukar H. Trivedi, M.D.  
THIS SESSION WILL BE AUDIOTAPE.
SYMPOSIUM 79 2:00 p.m.-5:00 p.m.
Room 714 A, Level 700, Toronto Convention Centre South
WOMEN'S LIFE CYCLE AND MENTAL HEALTH
Chp.: Samuel O. Okpaku, M.D.
Co-Chp.: Ponjola Coney
A The Female Life Cycle: From Childhood to Old Age
G. William Bates, M.D.
B Menopausal Management
Esther Eisenberg, M.D.
C Sociological Aspects of Family Planning
Patricia Matthews-Juarez, Ph.D.
D Psychosocial Aspects of Infertility
Samuel O. Okpaku, M.D.
Discussant: William Lawson, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 80 2:00 p.m.-5:00 p.m.
Room 714 B, Level 700, Toronto Convention Centre South
STALKING OFFENDERS AND VICTIMS
Chp.: Gail E. Robinson, M.D.
A Stalking: An Overview of the Problem
Gail E. Robinson, M.D.
B Stalking Victims: A Comprehensive Treatment Approach
Karen M. Abrams, Gail E. Robinson, M.D.
C Stalking: A Treatment Concept for Offenders
Werner Tschan, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 81 2:00 p.m.-5:00 p.m.
Room 715 A/B, Level 700, Toronto Convention Centre South
NICOTINE DEPENDENCE AND SCHIZOPHRENIA:
NEUROBEHAVIORAL PATHWAYS
National Institute on Drug Abuse
Chp.: Ivan D. Montoya, M.D.
Co-Chp.: Frank Voci, Ph.D.
A Nicotine Intake and Blood Levels in Smokers With Schizophrenia
Jill Williams
B Effects of Biological and Environmental Challenges on Smoking in Schizophrenic Versus Non-Psychiatric Heavy Smokers
Jennifer W. Tidy, Ph.D., Damaris J. Rohsenow, Ph.D.,
Gary B. Kaplan, M.D., Robert M. Swift, M.D.
C Nicotine Abuse and the Neurobiology of Schizophrenia
Robert Freedman, M.D.
D Pharmacological Treatment of Nicotine Dependence in Schizophrenia: Modulation of Outcomes by Atypical Antipsychotic Drugs, Cognitive Function, and Genetic Polymorphisms
Tony P. George
E Integrating Tobacco Dependence Treatment Into Mental Health Treatment
Douglas M. Ziedonis, M.D.
Discussant: Douglas M. Ziedonis, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 82 2:00 p.m.-5:00 p.m.
Room 716 A, Level 700, Toronto Convention Centre South
ADOLESCENT ALCOHOL USE DISORDERS AND
PSYCHIATRIC COMORBIDITY
Collaborative Session With the National Institute on Alcohol Abuse and Alcoholism
Chp.: Howard B. Moss, M.D.
A Trauma and Alcohol Use Disorders in Adolescents: Psychiatric Comorbidity and Adult Outcomes
Duncan B. Clark, M.D.
B Assessing Alcohol Problems in Adolescents With Psychiatric Comorbidity
Deborah Deas, M.D.
C Treatment of Adolescents With Alcohol Problems and Major Depression
Jack R. Cornelius, M.D.
D When ADHD and Substance Use Disorders Collide
Timothy E. Wilens, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 83 2:00 p.m.-5:00 p.m.
Room 716 B, Level 700, Toronto Convention Centre South
EDUCATING A NEW GENERATION OF PHYSICIANS IN PSYCHIATRY: FOCUS ON MEDICAL STUDENT EDUCATION
Chp.: Michelle B. Riba, M.D.
Co-Chp.: Theodore Feldman, M.D.
A Medical Student Education in Psychiatry: Where We Are and Where We Can Go
Myrl R.S. Manley
B Medical Student Education in Psychiatry: A Model That Works
Lowell D. Tong, M.D.
C Medical Student Education in Psychiatry: Impacting Career Choice and Practice
Brian A. Palmer, M.D.
D Medical Student Education in Psychiatry: What We Can Learn From Other Disciplines
Deborah Danoff, M.D.
THIS SESSION WILL BE AUDIOTAPED.
SYMPOSIUM 84  2:00 p.m.-5:00 p.m.
Room 717 A, Level 700, Toronto Convention Centre South

PATIENT SAFETY: TO ERR IS HUMAN, TO BE SAFE IS DIVINE
APA Committee on Patient Safety

Chp.: Geetha Jayaram, M.D.
Co-Chp.: Alfred Herzog, M.D.

A Length of Stay in the Psychiatric Emergency Room of an Urban Teaching Hospital
Patrick T. Triplet, M.D.

B A Primer for Prescribing: How to Prevent Medication Errors
Kathryn J. Ednie, M.D.

C Educating Faculty and Residents on Patient Safety
Carl B. Greiner, M.D.

D Suicide and Patient Safety
Geetha Jayaram, M.D.

E Your Role and All of Our Roles in Making Patient Safety a Bigger Reality
Alfred Herzog, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 85  2:00 p.m.-5:00 p.m.
Room 717 B, Level 700, Toronto Convention Centre South

RELATIONSHIPS BETWEEN AXIS I AND AXIS II
Association for Research in Personality Disorders

Chp.: James H. Reich, M.D.

A State and Trait in Personality Disorders
James H. Reich, M.D.

B Spectra of Pathology Across Axis I and Axis II Disorders
David P. Bernstein, Ph.D., David Watson, Ph.D., Lee Anna Clark, Ph.D., Arnoud Arntz, Ph.D.

C Etiological Relationships Among Dimensions of Personality Disorder and Axis I Syndromes
John Livesley, Ph.D.

D A Comparison of Mu-Opioid Receptor Activity in Depressed Subjects and in Subjects With BPD
Kenneth R Silk, M.D., Susan E. Kennedy, B.S., Sujata Guduri, M.A., Jon-Kar Zubieta, M.D.

E A Neurobiologic Perspective on the Relationship Between Axis I and Axis II Disorders
Larry J. Siever

Discussant: Donald W. Black, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 86  2:00 p.m.-5:00 p.m.
Room 801 A, Level 800, Toronto Convention Centre South

SCIENCE TO POLICY: ADVANCING WOMEN’S MENTAL HEALTH
Association of Women Psychiatrists

Chp.: Altha J. Stewart, M.D.

A Science to Policy: Psychiatric Aspects of Reproductive Health
Nada L. Stoulard, M.D.

B PTSD in Women Veterans: From Science to Policy
Marian I. Butterfield, M.D.

C Premenstrual Dysorphic Disorder: Treatment Update
Tana A. Grady-Weliky, M.D.

D Neuroactive Steroids in Men and Women: Investigations in Schizophrenia, Bipolar Disorder, and Alzheimer’s Disease
Christine E. Marx, M.D.

E Ethnic and Racial Disparities in Women’s Mental Health
Annelle B. Primm, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 87  2:00 p.m.-5:00 p.m.
Room 801 B, Level 800, Toronto Convention Centre South

ALCOHOL, DRUGS, AND PSYCHIATRIC DISORDERS IN THE U.S.
Collaborative Session With the National Institute on Alcohol Abuse and Alcoholism

Chp.: Bridget F. Grant, Ph.D.
Co-Chp.: Deborah Hasin, Ph.D.

A Comorbidity of Pain and Substance Use Disorders in the U.S.
Wilson M. Compton, M.D.

B Antisocial Personality Disorder and Lifetime Course of Alcohol Use Disorders in the U.S. General Population
Rise B. Goldstein, Ph.D., Bridget F. Grant, Ph.D., Wilson M. Compton III, M.D.

C Prevalence, Correlates, and Comorbidity of Alcohol Use Disorders in the U.S.
Frederick S. Stinson, Ph.D.

D Prevalence, Correlates, and Comorbidity of Nonmedical Sedative, Tranquilizer, Opioid, and Amphetamine Use, Abuse, and Dependence in the U.S.
Bridget F. Grant, Ph.D.

E Cannabis Withdrawal Syndrome in 2613 Lifetime Heavy Cannabis Users From a National Survey: Symptom Prevalence, Factor Structure, and Correlates
Deborah S. Hasin, Ph.D.

THIS SESSION WILL BE AUDIOTAPE.
SYMPOSIUM 88  2:00 p.m.-5:00 p.m.
Room 803 A/B, Level 800, Toronto Convention Centre South

SOBERING FACTS: ALCOHOL DEPENDENCE AND TREATMENT INTERVENTIONS
Collaborative Session With the National Institute on Alcohol Abuse and Alcoholism

Chp.: Kathleen T. Brady, M.D.

A  The Impact of Alcohol Use Disorders
   Richard J. Frances, M.D.

B  Alcohol Dependence: Difficulties in Diagnosis
   Kathleen T. Brady, M.D.

C  Integrating Pharmacotherapy and Psychosocial Support in Treating the Alcohol-Dependent Patient
   Roger D. Weiss, M.D.

D  Pharmacotherapy for the Treatment of Alcohol Dependence: Review of Outcome Data
   Robert M. Swift, M.D.

THIS SESSION WILL BE AUDIOTAPEd.

SYMPOSIUM 89  2:00 p.m.-5:00 p.m.
Imperial Room, Main Floor, Royal York

PHARMACOTHERAPY FOR SINGLE- AND DUAL-DIAGNOSED SUBSTANCE ABUSERS
American Academy of Addiction Psychiatry

Chp.: Marc Galanter, M.D.

A  Comorbidity With Opioid Dependence
   Edward V. Nunes, M.D.

B  Pharmacotherapy of Comorbid Substance Abuse and Schizophrenia
   Steven L. Batki, M.D.

C  Comorbidity of General Psychiatric Disorders and Cocaine Abuse
   Thomas R. Kosten, M.D.

D  The Comorbidity of Bipolar Spectrum Disorders and Substance Use Disorders
   Stephen Ross

Discussant: Elinore F. McCance-Katz, M.D.
THIS SESSION WILL BE AUDIOTAPEd.

SYMPOSIUM 90  2:00 p.m.-5:00 p.m.
Alberta Room, Mezzanine Floor, Royal York

SCIENCE AND REGULATION AFFECTING PRIVATE PRACTICE

Chp.: Roger Peele, M.D.
Co-Chp.: Maryam Razavi, M.D.

A  Evidence-Based Medicine in Child and Adolescent Psychiatry: What Is Your Best Guess?
   Jeffrey A. Naser, M.D.

B  Evidence-Based Medicine in Solo Private Practice: What If the Patient Doesn’t Fit?
   Ronald D. Abramson

C  Missing Resources: Comprehensive Psychiatry for People With Medical Illnesses
   John C. Urbaitis, M.D.

D  Comprehensive Psychiatry in 2006: Confidentiality and Access to Care in Private Practice and in Military Practice
   Brian Crowley

E  Affecting Care and Treatment of Children and Adults
   Harold I. Eist, M.D.

Discussant: Donna M. Norris, M.D.
THIS SESSION WILL BE AUDIOTAPEd.

SYMPOSIUM 91  2:00 p.m.-5:00 p.m.
British Columbia Room, Mezzanine Floor, Royal York

RECENT ADVANCES IN ETHNOPSYPHARMACOLOGICAL, ETHNIC, AND CULTURAL ASPECTS OF MOOD AND ANXIETY DISORDERS

Chp.: Rajesh M. Parikh, M.D.
Co-Chp.: Shamsah B. Sonawalla, M.D.

A  Ethnopsychopharmacology
   David C. Henderson, M.D.

B  Psychiatric Management of Hispanic Patients: Cross-Cultural Issues and Ethnopsychopharmacology
   David Mischoulon, M.D.

C  Impact of Cultural Beliefs on the Treatment of Depressed Chinese Americans
   Albert Yeung, M.D.

D  Challenges in the Diagnosis and Treatment of Mood and Anxiety Disorders in the Asian-Indian Population: Cross-Cultural Factors and Psychopharmacological Considerations
   Rajesh M. Parikh, M.D., Shamsah B. Sonawalla, M.D.

Discussant: Gregory L. Fricchione
THIS SESSION WILL BE AUDIOTAPEd.
SYMPHOSIUM 92  2:00 p.m.-5:00 p.m.
Confederation 5 Room, Mezzanine Floor, Royal York

ANXIETY AND EMOTIONAL DYSFUNCTION IN ENDOGENOTYPE OF SCHIZOPHRENIA

Chp.: Joseph Zohar, M.D.
Co-Chp.: Stefano Pallanti

A  Schizophrenia and OCD: The Role of Serotonergic and Dopaminergic Systems
   Joseph Zohar

B  Anxiety Comorbidities and Role of Emotion in Endophenotype of Schizophrenia
   Stefano Pallanti

C  Investigating the Cognitive and Emotional Neuropsychology of Schizophrenia Comorbid With Anxiety Disorders
   Naomi A. Fineberg, M.A., Sam R. Chamberlain, B.A.,
   Barbara Sahakian, Ph.D., Trevor W. Robbins, Ph.D.

D  Psychophysiological Investigation of Pathological Anxiety and Emotional Dysfunction in Patients With Schizophrenia
   Werner Streit, M.D., Thomas Müller, M.D., Dominik Bach, M.D.

Discussant: Lorrin M. Koran, M.D.
This session will be audiotaaped.

SYMPHOSIUM 93  2:00 p.m.-5:00 p.m.
Manitoba Room, Mezzanine Floor, Royal York

TEACHING PSYCHIATRY RESIDENTS ABOUT INFORMED CONSENT

Chp.: Bret R. Rutherford, M.D.
Co-Chp.: Paul S. Appelbaum, M.D.

A  Informed Consent in Psychiatry: An Overview
   Thomas G. Gutheil, M.D.

B  Initiation of Psychotherapeutic and Psychopharmacologic Treatment by Psychiatry Residents
   Bret R. Rutherford, M.D., Thomas G. Gutheil, M.D.

C  Informed Consent for Psychotherapy
   Thomas G. Gutheil, M.D.

D  Complications of the Informed Consent Process in Psychotherapy
   Glen O. Gabbard, M.D.

E  Informed Consent in Psychopharmacology
   Steven K. Hoge, M.D.

This session will be audiotaaped.

SYMPHOSIUM 94  2:00 p.m.-5:00 p.m.
Quebec Room, Mezzanine Floor, Royal York

SUSTAINED RECOVERY AND HEALTHY FUNCTIONING: THE LONG AND SHORT OF IT

Chp.: John C. Perry, M.D.

A  Evidence for Recovery in the Psychotherapy of Personality Disorders
   John C. Perry, M.D., Martin Drapeau, Ph.D., Trent Semeniuk, M.D.

B  Change in Psychological Risk and Recovery in Recurrent Depression
   Elisabeth Banon, John C. Perry, M.D., Trent Semeniuk, M.D.,
   Ruta Westreich, M.Psy., Philip R. Beck, M.D., Serge Lecours, Ph.D.

C  Dynamic Recovery in Patients With Treatment-Refractory Disorders
   Christopher Fowler, John C. Perry, M.D., Stefanie Speanburg, M.S.W.

D  Examining the Sequence of Recovery in Long-Term Dynamic Psychotherapy
   Michael P. Bond, John C. Perry, M.D.

E  A Review of Treatment Evidence on Sustained Recovery and Healthy Functioning
   Daniel Frank, M.D., John C. Perry, M.D., Brian M. Robertson, M.D., Paul Griss-Christoph, Ph.D.

Discussant: Brian M. Robertson, M.D.
This session will be audiotaaped.

SYMPHOSIUM 95  2:00 p.m.-5:00 p.m.
Territories Room, Mezzanine Floor, Royal York

MENTAL HEALTH DISPARITIES: CONCEPTS, ASSESSMENT, EVIDENCE-BASED PRACTICE, AND ADVOCACY

APA Council on Minority Mental Health and Health Disparities

Chp.: Francis G. Lu, M.D.
Co-Chp.: Margarita Alegria, Ph.D.

A  Estimating Mental Health Disparities for Latinos and Asians Using the National Latino and Asian American Study
   Margarita Alegria, Ph.D.

B  Strategies for Assessing Mental Health Disparities Using Health Care for Communities
   Thomas McGuire, Ph.D.

C  Addressing Mental Health Disparities in Evidence-Based Mental Health Practices
   Steve Leff

D  Reducing Mental Health Disparities for Racial and Ethnic Minorities: The APA Plan of Action
   Francis G. Lu, M.D.

This session will be audiotaaped.
SYMPOSIUM 96
2:00 p.m.-5:00 p.m.
Tudor 8 Room, Mezzanine Floor, Royal York

FEARFUL SLEEP AROUSALS
Chp.: Thomas W. Uhde, M.D.
Co-Chp.: Thomas Roth

A Does Movement Suppression Index Central Fear System Involvement in PTSD Nightmares?
Steve H. Woodward, Ph.D.

B Sleep Terrors and Sleepwalking in Children and Adults
Rosalind D. Cartwright, Ph.D.

C Nocturnal Panic Attack: An Underrecognized Fearful Arousal
Ravi K. Singareddy, M.D.

D Sleep Paralysis: Overlooked Fearful Arousal
Thomas W. Uhde, M.D., Orelia Merritt-Davis, M.D., Yury Yaroslavsky, M.D., Deborah Glitz, M.D., Ravi K.
Singareddy, M.D., Bernadette M. Cortese, M.D.

Discussant: Mark Mahowald, M.D.
THIS SESSION WILL BE AUDIOTAPE D.

SYMPOSIUM 97
2:00 p.m.-5:00 p.m.
Ballroom, Convention Floor, Royal York

TRANSLATING THE NEUROBIOLOGY OF ALCOHOLISM INTO CLINICAL TREATMENTS
Collaborative Session With the National Institute on Alcohol Abuse and Alcoholism
Chp.: Markus Heilig, M.D.
Co-Chp.: Barbara Mason, Ph.D.

A Lost in Translation: Preclinical Studies of Genetic Susceptibility and Neuroadaptations Point to a Growing List of Novel Candidate Targets for Treatment of Alcoholism
Markus Heilig, M.D.

B Medications for Treating Alcoholism: From Animal Models to Clinical Usefulness
Charles P. O'Brien, M.D.

C Animal Models for Novel Medications for Alcoholism: View From the Dark Side
George F. Koob

D Alcohol Relapse-Like Behavior in Laboratory Animals:
The Nociceptin/Orphanin Fq System: A Potential Target for the Development of New Pharmacotreatments.
Roberto Ciccolioppo, Ph.D.

E Development of a Human Laboratory Model of Risk Factors for Relapse in Alcohol Dependence:
Implications for Predicting Medication Efficacy in Clinical Trials
Barbara J. Mason, Ph.D.

THIS SESSION WILL BE AUDIOTAPE D.

SYMPOSIUM 98
2:00 p.m.-5:00 p.m.
Ontario Room, Convention Floor, Royal York

SAME SEX CIVIL MARRIAGE: HISTORICAL AND MENTAL HEALTH RESEARCH PERSPECTIVES
Chp.: Gene A. Nakajima, M.D.
Co-Chp.: Mary Read, M.D.

A Gay Marriage in History: New Manifestations of Old Traditions
Robert P. Cabaj, M.D.

B Gay Marriage in the Netherlands: The First Five Years
Nicolaas F. Flotinga, M.D.

C Leading the Way: Canadian Same Sex Marriage
Laura M. Chapman, M.D., Gene A. Nakajima, M.D.

D Six Weeks of Marriage Vows in San Francisco:
Personal Perspectives
Ellen Haller, M.D., Mary E. Read, M.D.

E Same-Sex Marriage From a Mental Health Research Perspective
Robert M. Kertzner, M.D.

Discussant: Renee L. Binder, M.D.
THIS SESSION WILL BE AUDIOTAPE D.

SYMPOSIUM 99
2:00 p.m.-5:00 p.m.
Salon B, Convention Floor, Royal York

PSYCHIATRY IN AMSTERDAM: ACUTE PSYCHIATRIC SERVICES IN A METROPOLITAN AREA
Chp.: Cecilia M.T. Gijsbers Van Wijk, Ph.D.
Co-Chp.: Robert Schoevers, Ph.D.

A The Amsterdam Model: Past, Present, and Future
Hans Sanders, M.D.

B Urbanization as a Risk Indicator for Psychiatric Disturbances
Jack J. Dekker, Ph.D., Jaap Peen, Sr., Ph.D.

C A One-Year Prospective Study of the Temporary Transitional Unit
Wijnand Mulder, M.D., Cecilia M.T. Gijsbers van Wijk, Ph.D.

D Controversies and Dilemmas Regarding the Amsterdam Model: Case Histories
Hans Nusselder, M.D.

E Community Admission Units in Amsterdam: A Benchmark Study
Cecilia M.T. Gijsbers Van Wijk, Ph.D., Wijnand Mulder, M.D.

THIS SESSION WILL BE AUDIOTAPE D.
3:00 p.m. Session

NEW RESEARCH POSTER SESSION 9
3:00 p.m.-5:00 p.m.
Exhibit Hall B, Level 300, Toronto Convention Centre North

SUBSTANCE ABUSE, SLEEP, AND OTHER TOPICS

For further information on New Research submissions, please refer to the New Research Program Book included in your registration packet.

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 43-46

INDUSTRY-SUPPORTED SYMPOSIUM 43
7:00 p.m.-10:00 p.m.
Canadian Room, Convention Floor, Royal York

WHAT IS THE ROLE OF SOMATIC AND PHYSICAL SYMPTOMS IN DEPRESSION?
Supported by Wyeth Pharmaceuticals

Chp.: Maurizio Fava, M.D.

A The Neurobiology of Somatic and Physical Symptoms in Depression
Pedro L. Delgado, M.D.

B Pain and Other Somatic Symptoms and Their Relationship to Antidepressant Treatment Outcome
George I. Papakostas, M.D.

C Diagnostic Challenges in Medically Ill Patients With Depression
Donna E. Stewart, M.D.

D Management Issues in the Treatment of Depression With Comorbid Medical Disorders
Jonathan E. Alpert, M.D.

E Are All Antidepressants Equally Effective in the Treatment of Somatic and Physical Symptoms in Depression?
Maurizio Fava, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 44
7:00 p.m.-10:00 p.m.
Concert Hall, Convention Floor, Royal York

DIAGNOSING AND TREATING ALCOHOL DEPENDENCE IN THE OFFICE
Supported by Alkermes Inc. and Cephalon Inc.

Chp.: Kathleen T. Brady, M.D.

A Alcoholism as a Chronic Disease: Implications for Office-Based Treatment
A. Thomas McLellan, Ph.D.

B Screening, Diagnosis, and Early Intervention
Kathleen T. Brady, M.D.

C Current and Emerging Treatment Options in Alcoholism
Richard N. Rosenthal, M.D.

D Office-Based Treatment of Co-Occurring Psychiatric Disorders
Shelly F. Greenfield, M.D.

E Behavioral Therapies for Alcohol Dependence
Grace Hennessy, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 45
7:00 p.m.-10:00 p.m.
Grand Ballroom, Lower Concourse, Sheraton Centre

MANAGING UNMET NEEDS IN PSYCHIATRIC ILLNESSES: A CRITICAL LOOK AT DISORDERS AND PUBLIC POLICY
Supported by Solvay Pharmaceuticals and Wyeth Pharmaceuticals

Chp.: K. Ranga R. Krishnan, M.D.

A Managing the Unmet Needs in Depression
A. John Rush, M.D.

B Managing the Unmet Needs in Bipolar Disorder
Roger S. McIntyre, M.D.

C Managing the Unmet Needs in Schizophrenia
Marvin S. Swartz, M.D.

D Managing the Unmet Needs in Dementia
K. Ranga R. Krishnan, M.D.

E Managing the Unmet Needs: A Public Health Dilemma
Junius J. Gonzales, M.D.
WEDNESDAY

INDUSTRY-SUPPORTED SYMPOSIUM 46
7:00 p.m.-10:00 p.m.
Metro Grand Ballroom, Second Level, Westin Harbour Castle

REMISSION AND RECOVERY IN SCHIZOPHRENIA:
ADVOCATING FOR OUR PATIENTS
Supported by Pfizer Inc.

Chp.: Nancy C. Andreasen, M.D.

A Defining Remission and Recovery in Schizophrenia
Nancy C. Andreasen, M.D.

B Should Functional Outcomes Be a Defining Feature of
Remission and Recovery in Schizophrenia?
Stephen R. Marder, M.D.

C An Evidence-Based Approach to Achieving Remission
and Recovery in Schizophrenia
John M. Kane, M.D.

D Barriers to Achieving Remission and Recovery in
Schizophrenia
Meera Narasimhan, M.D.
THURSDAY, MAY 25, 2006

159TH ANNUAL MEETING

7:00 a.m. Sessions

PART 2 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 39-42

INDUSTRY-SUPPORTED BREAKFAST SYMPOSION 39, PART 2
7:00 a.m.-8:30 a.m.
Room 106, Level 100, Toronto Convention Centre North

EMERGING EVIDENCE IN THE TREATMENT OF BIPOLAR DEPRESSION
Supported by Astrazeneca Pharmaceuticals

Chp.: Joseph R. Calabrese, M.D.

A Neurobiology of Bipolar Patients: What Does It Tell Us?
Sophia Frangou, M.D.

B Future Treatments: Repetitive Transcranial Magnetic Stimulation and Vagus Nerve Stimulation in Bipolar Depression
Guohua Xia, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSION 40, PART 2
7:00 a.m.-8:30 a.m.
Canadian Room, Convention Floor, Royal York

BIPOLAR ILLNESS: THE ROAD TO REMISSION
Supported by Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

Chp.: Prakash S. Masand, M.D.

A An Evidence-Based Approach to Achieving Remission in Bipolar Illness
Roger S. McIntyre, M.D.

B The Role of Nonpharmacologic Therapies in Achieving Remission
Eduard Vienia, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSION 41, PART 2
7:00 a.m.-8:30 a.m.
Grand Ballroom, Lower Concourse, Sheraton Centre

NEW FRONTIERS IN DEPRESSION: PROVIDING SOLUTIONS TO UNMET NEED
Supported by Solvay Pharmaceuticals and Wyeth Pharmaceuticals

Chp.: Stephen M. Stahl, M.D.

A Unipolar Versus Bipolar Depression: Diagnostic and Therapeutic Challenges
James M. Martinez, M.D.

B Current and Novel Treatment Options for Treatment-Resistant Depression
Lauren B. Marangell, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSION 42, PART 2
7:00 a.m.-8:30 a.m.
Metro Grand Ballroom, Second Level, Westin Harbour Castle

WHAT THE PSYCHIATRIST NEEDS TO KNOW ABOUT SLEEP-RELATED MOVEMENT DISORDERS
Supported by GlaxoSmithKline

Chp.: John W. Winkelman, M.D.

A Restless Legs Syndrome and Psychiatric Disorders: Demonstrating a Relationship
John W. Winkelman, M.D.

B Video of Patient Case: Diagnosis, QOL, and Sleep
John W. Winkelman, M.D.

C Current Therapeutic and Management Strategies in Restless Legs Syndrome
Clete A. Kushida, M.D.

8:00 a.m. Sessions

COURSES 98-101
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 98 8:00 a.m.-12 noon
Conference Room D/E, Mezzanine, Sheraton Centre

VAGUS NERVE STIMULATION

Director: Ziad H. Nahas, M.D.
Faculty: Linda L. Carpenter, M.D., Mitchel A. Kling, M.D., Robert H. Howland, M.D., Mustafa Hussain

COURSE 99 8:00 a.m.-12 noon
Conference Room F, Mezzanine, Sheraton Centre

SPIRITUALITY AND WORLDVIEW IN CLINICAL PRACTICE

Director: Allan M. Josephson, M.D.
Faculty: John R. Peteet, M.D., James L. Griffith, M.D.

COURSE 100 8:00 a.m.-12 noon
Windsor Room West, Mezzanine, Sheraton Centre

THE EVALUATION AND TREATMENT OF PHYSICIANS INVOLVED IN SEXUAL MISCONDUCT AND SEXUAL HARASSMENT

Director: Gene G. Abel, M.D.
Faculty: Tracey I. Marks, M.D., Richard B. Krueger, M.D.
THURSDAY

COURSE 101 8:00 a.m.-12 noon
Essex Room, Mezzanine, Sheraton Centre

ADVANCED ASSESSMENT AND TREATMENT OF ADD

Director: Thomas E. Brown, Ph.D
Faculty: Jefferson B. Prince, M.D.

9:00 a.m. Sessions

CLINICAL CASE CONFERENCE 5
9:00 a.m.-10:30 a.m.
Room 104 B, Level 100, Toronto Convention Centre North

CONSULT-LIAISON CASEBOOK CHALLENGE:
STRATEGIES AND LIMITATIONS IN ESTABLISHING COMPETENCY

Moderator: Dimitri D. Markov, M.D.
Presenters: Kenneth M. Certa, M.D., John Paul Gomez, M.D.,
David Lynn, M.D., Jacob Widoff, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY.
BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

WORKSHOPS

ISSUES 76-94

ISSUE WORKSHOP 76 9:00 a.m.-10:30 a.m.
Room 104 A, Level 100, Toronto Convention Centre North

DIRECT TO CONSUMER MARKETING: JUST WHO IS THE CONSUMER?

Co-Chps.: Nadeem H. Bhanji, M.D., David A. Baron, D.O.
Participants: Lawrence S. Gross, M.D., Calvin R. Sumner, M.D.,
Marcia K. Goin, M.D., Andrew E. Slaby, M.D., Bernard A.
Fischer IV, M.D.

ISSUE WORKSHOP 77 9:00 a.m.-10:30 a.m.
Room 104 D, Level 100, Toronto Convention Centre North

CAN I CHANGE? A JOURNEY THROUGH EX-GAY MINISTRIES AND BEYOND
Association of Gay and Lesbian Psychiatrists

Co-Chps.: Mary E. Barber, M.D., David L. Scasta, M.D.
Participants: Jack Drescher, M.D., Alicia J. Salzer, M.D., Anat
Salomon, Roy Harker

ISSUE WORKSHOP 78 9:00 a.m.-10:30 a.m.
Room 201 D, Level 200, Toronto Convention Centre North

A MODEL FOR IMPROVED PSYCHIATRIC SERVICES IN DEVELOPING COUNTRIES: SOUTH ASIAN FORUM
International South Asian Forum

Chp.: Jagannathan Srinivasaraghavan, M.D.
Participants: Russell F. D'Souza, M.D., Arun V. Ravindran, M.D.,
Parameshvra P. Deva, M.D., Afzal Javed, M.D.

ISSUE WORKSHOP 79 9:00 a.m.-10:30 a.m.
Room 205 A, Level 200, Toronto Convention Centre North

USE OF A STANDARDIZED COMPREHENSIVE PSYCHIATRIC ASSESSMENT TOOL TO FACILITATE EVIDENCE-BASED DECISIONS: THE INTERRAI MENTAL HEALTH

Co-Chps.: John P. Hirdes, Ph.D., Trevor F. Smith, Ph.D.
Participants: Terrie Tucker, Brent Diverty, Edgardo L.
Perez, M.D., Terry Rabinowitz, M.D.

ISSUE WORKSHOP 80 9:00 a.m.-10:30 a.m.
Room 205 B, Level 200, Toronto Convention Centre North

GOING TO THE HEART OF THE MATTER IN PATIENT INTERVIEWS

Chp.: Harold J. Burzstajn, M.D.
Participants: Thomas G. Gutheil, M.D., Max Day, M.D.,
Robindra K. Paul, M.D., Beata A. Zolovska, M.D.

ISSUE WORKSHOP 81 9:00 a.m.-10:30 a.m.
Room 205 C, Level 200, Toronto Convention Centre North

FIBROMYALGIA: CURRENT UNDERSTANDING AND FUTURE DIRECTIONS

Co-Chps.: Alan Z.A. Manevitz, M.D., James P. Halper, M.D.

ISSUE WORKSHOP 82 9:00 a.m.-10:30 a.m.
Room 205 D, Level 200, Toronto Convention Centre North

TRAUMATIZED CHILDREN IN IRAQ

Chp.: Sadiq H. Al-Samarrai, M.D.

ISSUE WORKSHOP 83 9:00 a.m.-10:30 a.m.
Room 206 A/B, Level 200, Toronto Convention Centre North

INTERNATIONAL MEDICAL GRADUATES IN TRAINING AND PRACTICE: PROFESSIONAL AND PERSONAL TRIALS

Co-Chps.: Michael F. Myers, M.D., Nyapati R. Rao, M.D.
Participants: Milton Kramer, M.D., Brunhild Kring, M.D.,
Stuart W. Twemlow, M.D., Jeffrey Goldberg, D.O.
ISSUE WORKSHOP 84 9:00 a.m.-10:30 a.m.  Room 206 C/D, Level 200, Toronto Convention Centre North
RACE AND COUNTERTRANSFERENCE IN THE CLINICAL SETTING
Co-Chps.: Sherri M. Simpson, M.D., Sandra C. Walker, M.D.  Participants: Glen O. Gabbard, M.D., Kimberlyn Leary, Ph.D.

ISSUE WORKSHOP 85 9:00 a.m.-10:30 a.m.  Room 206 E/F, Level 200, Toronto Convention Centre North
DIALECTICAL BEHAVIORAL THERAPY WITH ADOLESCENTS
Chp.: Syed S.A. Naqvi, M.D.  Participant: Viet Q. Bui, M.D.

ISSUE WORKSHOP 86 9:00 a.m.-10:30 a.m.  Room 701 A, Level 700, Toronto Convention Centre South
MENTAL HEALTH ISSUES IN THE AFTERMATH OF HURRICANE KATRINA
Co-Chps.: Philip T. Merideth, M.D., Grayson Norquist, M.D.

ISSUE WORKSHOP 87 9:00 a.m.-10:30 a.m.  Room 703, Level 700, Toronto Convention Centre South
SIZE MATTERS: TEACHING MEDICAL STUDENTS IN SMALL GROUPS
Co-Chps.: Lana M. Benedek, M.D., Bruce C. Ballon, M.D.  Participants: Kien T. Dang, M.D., Andrea E. Waddell, M.D.

ISSUE WORKSHOP 88 9:00 a.m.-10:30 a.m.  Room 705, Level 700, Toronto Convention Centre South
SO YOU WANT TO BE A CLINICAL INVESTIGATOR
Chp.: Arthur Lazarus, M.D.

ISSUE WORKSHOP 89 9:00 a.m.-10:30 a.m.  Room 707, Level 700, Toronto Convention Centre South
COLLABORATIVE MENTAL HEALTH CARE IN CANADA
Chp.: Nick Kates, M.B.  Participants: Scott Dudgeon, M.B.A., Francine L. Lemire, M.D., Phil Upshall

ISSUE WORKSHOP 90 9:00 a.m.-10:30 a.m.  Room 709, Level 700, Toronto Convention Centre South
PSYCHIATRY IN THE PRIMARY CARE SETTING: MAKING IT WORK FOR DOCTORS AND PATIENTS
Chp.: John C. Urbaitis, M.D.  Participants: Jonathan S. Davine, M.D., Shauna P. Reinblatt, M.D., Joseph M. Schwartz, M.D.

ISSUE WORKSHOP 91 9:00 a.m.-10:30 a.m.  Room 711, Level 700, Toronto Convention Centre South
COMPUTER TOOLS FOR COGNITIVE-BEHAVIOR THERAPY: INTEGRATING TECHNOLOGY INTO CLINICAL PRACTICE
Chp.: Jesse H. Wright III, M.D.  Participant: Douglas Turkington, M.D.

ISSUE WORKSHOP 92 9:00 a.m.-10:30 a.m.  Room 714 B, Level 700, Toronto Convention Centre South
CULTURAL DIVERSITY AND PSYCHIATRY: CLINICAL CARE, RESEARCH, AND EDUCATION
Chp.: Niranjan S. Karnik, M.D.  Participants: Nisha Dogra, M.D., Claire P. Rivlin, M.A., Hans Steiner, M.D.

ISSUE WORKSHOP 93 9:00 a.m.-10:30 a.m.  Room 716 A, Level 700, Toronto Convention Centre South
CARDIOVASCULAR COMPLICATIONS OF SECOND GENERATION ANTIPSYCHOTIC DRUGS
Co-Chps.: Peter Manu, M.D., Raymond E. Suarez, M.D.

ISSUE WORKSHOP 94 9:00 a.m.-10:30 a.m.  Room 716 B, Level 700, Toronto Convention Centre South
CHILDREN OF PSYCHIATRISTS
Co-Chps.: Michelle B. Riba, M.D., Leah J. Dickstein, M.D.  Participants: Judith S. Beck, Ph.D., Sami Meyerson-Bernstein, Molly R. Kaufman, Matthew Muskin, Sam Raskin, Shoshara L. Shear, M.D., Alexandra Robinson

MEDIA WORKSHOP 7 9:00 a.m.-12 noon  Quebec Room, Mezzanine Floor, Royal York
BAD EDUCATION: PORTRAYING TRANSEXUALISM, PEDOPHILIA, AND ADDICTION
Chp.: Jose P. Vito, M.D.  Participant: Richard R. Plesk, M.D.
11:00 a.m. Sessions

MEDICAL UPDATE 4
11:00 a.m.-12:30 p.m.
Room 716 A, Level 700, Toronto Convention Centre South

LIVER TRANSPLANT UPDATE: CURRENT OUTCOMES AND CHALLENGES IN 2006

Presenters: Philip Wong, M.D.
Chp.: Silvia Hafliger, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SCIENTIFIC AND CLINICAL REPORT SESSIONS 34-44

SCIENTIFIC AND CLINICAL REPORT SESSION 34
11:00 a.m.-12:30 p.m.
Room 104 B, Level 100, Toronto Convention Centre North

CURRENT RESEARCH IN DEPRESSION AND ANXIETY

Chp.: Adel A. Gabriel, M.D.
Co-Chp.: Robert B. Shulman, M.D.

11:00 a.m.
100 Desvenlafaxine: Preclinical Evidence for SERT and Norepinephrine Reuptake Inhibition, Antidepressant, and Antinociceptive Activity
Terrance H. Andrec, Ph.D., Darlene Deecher, Ph.D., Lee Dawson, Ph.D., Liza Leventhal, Ph.D., Paul Mitchell, Ph.D., Sharon Rosenzweig-Lipson, Ph.D., Chad E. Beyer, Ph.D.

11:30 a.m.
101 Efficacy and Safety of Desvenlafaxine Succinate in the Treatment of MDD
Nicholas Demartini, Ph.D., Paul Yeung, M.D., Richard Entsuah, Ph.D.

12 noon
102 Panic Disorder Associated With Severe Dizziness: Demographic and Clinical Features and Treatment With Clonazepam
Antonio E. Nardi, M.D., Marco A.U. Mezzasalma, Alexandre M. Valenca, M.D., Isabella Nascimento, M.D., Fabiana L. Lopes, M.D., Rafael C Freire, M.D., Flavia S. Franco, M.D.

11:00 a.m.
103 A 40-Year Follow-Up Study of Patients With Panic Disorder
Gabriel Rubio, M.D., Juan J. L.ópezb-Ibor, Jr., M.D.

11:30 a.m.
104 Resilience in Anxiety Disorders
Catherine Mancini, M.D., Michael Van Ameringen, M.D., Beth Patterson, B.S.N., Mark Bennett, B.A., Jonathan Oakman, Ph.D.

12 noon
105 The Naturalistic Treatment of Panic Disorder in a Real World Clinical Setting
Eric D. Peselow, M.D., Lynda O. Fazzio, M.D., Caroline B. Williams, M.D.

SCIENTIFIC AND CLINICAL REPORT SESSION 36
11:00 a.m.-12:30 p.m.
Room 201 D, Level 200, Toronto Convention Centre North

FAMILY CONTRIBUTIONS/PERSPECTIVES

Chp.: Tanya R. Anderson, M.D.
Co-Chp.: Rubaba Ansari, M.A.

11:00 a.m.
106 Family Background and Genius: Nobel Laureates in Science
Albert Rothenberg, M.D.

11:30 a.m.
107 Familial Psychiatric Disorders and Sudden Infant Death Syndrome: Is There a Significant Relationship?
Jeffrey Sverd, M.D.

12 noon
108 The Parent's Perspective on Gender Variant Children and Adolescents: Concerns, Hopes, and Joys
Darryl B. Hill, Ph.D., Edgardo J. Menvielle, M.D., Kristin Sica, Alisa Johnson

11:00 a.m.
109 Patterns of Symptom Response in the Treatment for Adolescents With Depression Study (TADS): Do Some Symptoms Respond Better to Certain Treatments?
Jessica L. Murakami M.S., Anne Simons, Ph.D., Lou Moses, Ph.D., Susan Silva, Ph.D., John S. March, M.D.

(Continued next page)
11:30 a.m.
110 Antipsychotics in the Treatment of Delirium: A Review of Prospective Trials
Dallas P. Seitz, M.D., Sudeep S. Gill, M.D., Louis T. van Zyl, M.D.

12 noon
111 Treatment Matching in the Post-Hospital Care of Patients With Depression
Gabor I. Keitner, M.D., Ivan W. Miller, Ph.D., Christine E. Ryan, Ph.D., David A. Solomon, M.D.

SCIENTIFIC AND CLINICAL REPORT SESSION 38
11:00 a.m.-12:30 p.m.
Room 206 A/B, Level 200, Toronto Convention Centre North

SUICIDE

Chp.: Paul S. Links, M.D.
Co-Chp.: Ian C. Dawe, M.D.

11:00 a.m.
112 Distinguishing Patients Who Attempt Suicide From Patients With Ideation Only
Stephen B. Woolley, M.P.H., John W. Goethe, M.D., Alexis M. May, B.A., Deborah Piez, M.S.

11:30 a.m.
113 Hopelessness and Suicidality Three Months Post-Hospital Discharge
John W. Goethe, M.D., Stephen B. Woolley, M.P.H., Deborah Piez, M.S.

12 noon
114 Parent's Socioeconomic Status, Psychiatric Disorders, and Suicidality as Risk Factors of Subsequent Suicide of Offspring: The Northern Finland 1966 Birth Cohort Study
Antti S. Alaräisänen, M.B., Jouko Miettunen, Ph.D., Pirikko Räsänen, M.D., Matti K. Isohanni, M.D., Pirjo H. Malker, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SCIENTIFIC AND CLINICAL REPORT SESSION 39
11:00 a.m.-12:30 p.m.
Room 206 E/F, Level 200, Toronto Convention Centre North

CURRENT TRENDS AND CONTROVERSIES IN PSYCHIATRY

Chp.: Laura Hirshbein, M.D.
Co-Chp.: Daniel Mayman, M.D.

11:00 a.m.
115 A Review of Chemical Castration and Its Use in the U.S. Penal System
Sara G. West, M.D.

11:30 a.m.
116 Acupuncture and Cognitive-Behavior Therapy for PTSD
Michael Hollisfield, M.D., Nityamó Lian, Teddy Warner, Ph.D., Richard Hammerschlag, Ph.D.

12 noon
117 Pseudoseizures: Interaction of Past Traumatic Stress and Current Suppression of Negative Affects
Robin Berlin, M.D., James L. Griffith, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SCIENTIFIC AND CLINICAL REPORT SESSION 40
11:30 a.m.-12:30 p.m.
Algonquin Room, Mezzanine Floor, Royal York

CULTURAL VARIATIONS IN PSYCHIATIC ILLNESS

Chp.: Nitin Gupta, M.D.
Co-Chp.: Virginia A. Wesson, M.D.

11:00 a.m.
118 BPD and Cultures
Bernadette M. Grosjean, M.D.

11:30 a.m.
118 Patterns of Antidepressant Prescribing and Suicide in Israel
Dov Aizenberg, M.D., Yoram Barak, M.D.

12 noon
120 Prevalence of PMDD Among Women in a Primary Care Outpatient Setting in the United Arab Emirates
Ossama T. Osman, M.D., Diaa Rizq, M.D., Sufyan Sabri

THIS SESSION WILL BE AUDIOTAPE.

SCIENTIFIC AND CLINICAL REPORT SESSION 41
11:00 a.m.-12:30 p.m.
Confederation 3 Room, Mezzanine Floor, Royal York

LIFESTYLE ISSUES IN MENTAL HEALTH

Chp.: Leslie A. Horton, M.D.
Co-Chp.: Matti K. Isohanni, M.D.

11:00 a.m.
121 Lifestyle Issues in Mental Health: Social Support, Diet, Fitness, and Recreation
Henry T. Chuang, M.D., Scott B. Patten, M.D.

11:30 a.m.
122 Alcoholism in Schizophrenia: Systematic Review 2000-2004
Johanna Koskinen, M.B., Jouko Miettunen, Ph.D., Erika Lauronen, M.D., Pekka Laine, M.D., Hannu J. Koponen, M.D., Matti K. Isohanni, M.D.

12 noon
123 Cigarette Smoking Among Psychiatric Outpatients: A Matched Case-Control Study in Bucaramanga, Colombia
Adalberto Campo-Arias, M.D., Luis A. Díaz-Martínez M.S., German E. Rueda-Jaimes, M.D., Mauricio Rueda-Sánchez, M.D., Daniel Farelo, M.S., Francisco J. Díaz, Ph.D., Jose de Leon, M.D.
THURSDAY

SCIENTIFIC AND CLINICAL REPORT SESSION 42
11:00 a.m.-12:30 p.m.
Confederation 5 Room, Mezzanine Floor, Royal York

STUDIES IN ADDICTION

Chp.: Pinhas N. Dannon, M.D.
Co-Chp.: Meera Vaswani, Ph.D.

11:00 a.m.
124 Substance Abuse in Bipolar Disorder
E. Sherwood Brown, M.D.

11:30 a.m.
125 Substance-Related Disorders Dual Diagnosis in a
Random Nationwide Sample of 998 Prisoners:
Prevalences and Risk Factors
Michael Lukasiewicz, M.D., Isabelle Gasquet, Ph.D., Michel
Reynaud, Bruno Falissard

12 noon
126 Stroop Performance in Pathological Gamblers
Pinhas N. Dannon, M.D.

SCIENTIFIC AND CLINICAL REPORT SESSION 43
11:00 a.m.-12:30 p.m.
Library, Mezzanine Floor, Royal York

COMPLICATION OF TREATMENTS IN
PSYCHIATRIC DISORDERS

Chp.: Geetha Jayaram, M.D.
Co-Chp.: Norman C. Moore, M.D.

11:00 a.m.
127 Armodafinil Improves Fatigue in Patients With
Excessive Sleepiness Due to Obstructive Sleep
Apnea/Hypopnea Syndrome
Steven Hall, M.D., Alan Lankford, Ph.D., Bradley D. Vince, D.O.,
Gwendolyn E. Niebler, D.O., Sanjay Arora, Ph.D.

11:30 a.m.
128 Efficacy, Tolerability, and Safety of Once-Daily
Atomoxetine Hydrochloride Versus Placebo in
Taiwanese Children and Adolescents With ADHD
Susan Shur-Fen Gau, M.D., Yu-Shu Huang, M.D., Wei-
Tsun Suong Soong, M.D., Mao-Chun Chou, M.D., Phil
Lee, M.D., Albert J. Allen

12 noon
129 Medication Nonadherence in Bipolar Disorder: The
Role of Patients Treatment Perceptions
Rob Horne, Jane Catworthby, Rhian Parham, Tim Rank,
Richard Bowskill

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 44
11:00 a.m.-12:30 p.m.
Toronto Room, Convention Floor, Royal York

THERAPEUTIC SOLUTIONS FOR CAREGIVING
FAMILIES

Chp.: Haldun Soygur, M.D.
Co-Chp.: Bulent Coskun, M.D.

11:00 a.m.
130 Spirituality and Recovery From Depression
Caroline B. Williams, M.D., Eric D. Peselow, M.D., Barbara
Ortlowski, Ph.D.

11:30 a.m.
131 Depression and Caregiver Burden in Families of
People With Schizophrenia
Lawrence Haber, Ph.D., Julie Robison, Ph.D., Kathy
Kellett, M.A., Cynthia Gruman, Ph.D.

12 noon
132 Psychodrama Groups for Psychiatric Intervention to
Family Members of Patients With Schizophrenia
Derya Iren Akbiyik, M.D., Tulin Kusgozoglu, Bahar
Gokler, M.D., Haldun Soygur, Selver Kurdoglu

THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS

ISSUES 95-109

ISSUE WORKSHOP 95 11:00 a.m.-12:30 p.m.
Room 104 A, Level 105, Toronto Convention Centre North

GROUP PSYCHOTHERAPY OF SUBSTANCE ABUSE
American Group Psychotherapy Association

Co-Chps.: David W. Brook, M.D., Henry I. Spitz, M.D.

ISSUE WORKSHOP 96 11:00 a.m.-12:30 p.m.
Room 205 B, Level 200, Toronto Convention Centre North

PROVIDING BEHAVIORAL HEALTH TREATMENT
SERVICES FOR VERY YOUNG SPECIAL NEEDS
CHILDREN AND THEIR FAMILIES

Chp.: Peter D. Ganine, M.D.
Participants: Joanne Dunnigan, M.S.W., Aura R.
Seidler, M.S.W., Vanessa Moss, L.C.S.W.
<table>
<thead>
<tr>
<th>Workshop</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISSUE WORKSHOP 97</td>
<td>11:00 a.m.-12:30 p.m.</td>
<td>Room 205 C, Level 200, Toronto Convention Centre North</td>
</tr>
<tr>
<td>THE IMPACT OF RACE AND GENDER ON THE INTERACTIONS BETWEEN FEMALE PSYCHIATRY RESIDENTS AND THEIR PATIENTS: AN INTERACTIVE GROUP WORKSHOP</td>
<td>Co-Chps.: Nancy M. Bivens, M.D., Christina V. Mangurian, M.D.</td>
<td>Participants: Stephanie LeMelle, M.D., Maria A. Oquendo, M.D., Juliana I. Ekon, M.D.</td>
</tr>
<tr>
<td>ISSUE WORKSHOP 98</td>
<td>11:00 a.m.-12:30 p.m.</td>
<td>Room 205 D, Level 200, Toronto Convention Centre North</td>
</tr>
<tr>
<td>IDENTIFYING AND MANAGING PATIENTS WITH SCHIZOPHRENIA AND A GENETIC SYNDROME</td>
<td>Chp.: Anne S. Bassett, M.D.</td>
<td>Participant: Eva W.C. Chow, M.D.</td>
</tr>
<tr>
<td>ISSUE WORKSHOP 99</td>
<td>11:00 a.m.-12:30 p.m.</td>
<td>Room 206 C/D, Level 200, Toronto Convention Centre North</td>
</tr>
<tr>
<td>DISASTERS, PUBLIC POLICY, AND ADDICTION PSYCHIATRY Collaborative Session With the National Institute on Alcohol Abuse and Alcoholism</td>
<td>Chp.: Richard J. Frances, M.D.</td>
<td>Participants: Avram H. Mack, M.D., Sheila B. Blume, M.D., Sheldon I. Miller, M.D., Frances R. Levin, M.D., Robert B. Millman, M.D., Marc Galanter, M.D.</td>
</tr>
<tr>
<td>ISSUE WORKSHOP 100</td>
<td>11:00 a.m.-12:30 p.m.</td>
<td>Room 701 B, Level 700, Toronto Convention Centre South</td>
</tr>
<tr>
<td>PERFORMANCE ENHANCEMENT PSYCHOLOGICAL TECHNIQUES IN GOLF International Society for Sport Psychiatry</td>
<td>Chp.: Syed S.A. Naqvi, M.D., Salvador R. del Rosario, Jr., M.D.</td>
<td></td>
</tr>
<tr>
<td>ISSUE WORKSHOP 101</td>
<td>11:00 a.m.-12:30 p.m.</td>
<td>Room 703, Level 700, Toronto Convention Centre South</td>
</tr>
<tr>
<td>ISSUE WORKSHOP 102</td>
<td>11:00 a.m.-12:30 p.m.</td>
<td>Room 705, Level 700, Toronto Convention Centre South</td>
</tr>
<tr>
<td>MEDICAL COMORBIDITY IN DUAL DIAGNOSIS PATIENTS Collaborative Session With the National Institute on Alcohol Abuse and Alcoholism</td>
<td>Chp.: Vasant P. Dhopesh, M.D.</td>
<td>Participant: Rosalinda Dirienzo, M.D.</td>
</tr>
<tr>
<td>ISSUE WORKSHOP 103</td>
<td>11:00 a.m.-12:30 p.m.</td>
<td>Room 707, Level 700, Toronto Convention Centre South</td>
</tr>
<tr>
<td>DETECTING BIPOLAR DISORDER</td>
<td>Co-Chps.: Gary E. Miller, M.D., Richard L. Noel, M.D.</td>
<td></td>
</tr>
<tr>
<td>ISSUE WORKSHOP 104</td>
<td>11:00 a.m.-12:30 p.m.</td>
<td>Room 709, Level 700, Toronto Convention Centre South</td>
</tr>
<tr>
<td>SIMULATIONS AND PSYCHIATRIC EDUCATION: WORKSHOP FOR STANDARDIZED PATIENT TRAINING</td>
<td>Co-Chps.: Nancy L. McNaughton, M.Ed., Kerry J. Knickle, B.A.</td>
<td>Participant: Bruce C. Ballon, M.D.</td>
</tr>
<tr>
<td>ISSUE WORKSHOP 105</td>
<td>11:00 a.m.-12:30 p.m.</td>
<td>Room 713 A/B, Level 700, Toronto Convention Centre South</td>
</tr>
<tr>
<td>MAKING IT HAPPEN: IMPLEMENTING THE APA PRACTICE GUIDELINE FOR MDD IN EVERYDAY PRACTICE</td>
<td>Chp.: Jack S. McIntyre, M.D.</td>
<td>Participants: Joel Yager, M.D., Rory P. Houghtalen, M.D.</td>
</tr>
<tr>
<td>ISSUE WORKSHOP 106</td>
<td>11:00 a.m.-12:30 p.m.</td>
<td>Room 714 A, Level 700, Toronto Convention Centre South</td>
</tr>
<tr>
<td>DESPERATE HOUSEWIVES SURVIVE THE WAR OF THE WORLDS: THERAPEUTIC PERSPECTIVES ON WOMEN'S HEALTH</td>
<td>Chp.: Richard K. Harding, M.D.</td>
<td>Participants: Nicola N. Campbell, M.D., Meera Narasimhar, M.D., Craig A. Stuck, M.D., Leslie E. Frinkes, M.D.</td>
</tr>
<tr>
<td>ISSUE WORKSHOP 107</td>
<td>11:00 a.m.-12:30 p.m.</td>
<td>Room 715 A/B, Level 700, Toronto Convention Centre South</td>
</tr>
<tr>
<td>Psychiatrists Who Have Faced Mental Illness in Themselves: There is a Silver Lining</td>
<td>Co-Chps.: Michael F. Myers, M.D., Leah J. Dickstein, M.D.</td>
<td>Participants: Melanie E. Spritz, D.O., Raymond M. Reyes, M.D., Elizabeth A. Baxter, M.D., Michael Pare, M.D., Francine Cournos, M.D.</td>
</tr>
<tr>
<td>ISSUE WORKSHOP 108</td>
<td>11:00 a.m.-12:30 p.m.</td>
<td>Room 716 B, Level 700, Toronto Convention Centre South</td>
</tr>
<tr>
<td>Teaching Human Sexuality to Health Science Students Using the Sexual Events Classification System Association for Academic Psychiatry</td>
<td>Co-Chps.: Donald C. Fidler, M.D., Gregg Dwyer, M.D.</td>
<td></td>
</tr>
</tbody>
</table>
ISSUE WORKSHOP 109  11:00 a.m.-12:30 p.m.
Room 717 A, Level 700, Toronto Convention Centre South

IMPROVING ACCESS TO HEALTHCARE FOR HOMELESS PERSONS LIVING WITH HIV/AIDS

Co-Chps.: Keith R. Stowell, M.D., Antoine B. Douaihy, M.D.
Participant: Ann L. Hackman, M.D.

12 noon Sessions

FORUM 16  12 noon-1:30 p.m.
Room 801 B, Level 800, Toronto Convention Centre South

MANY FACES OF TRAUMA: A MULTISYSTEMIC VIEW OF THE AFTERMATH OF KATRINA

Chp.: Howard J. Ososky, M.D.
Co-Chp.: Joy D. Ososky, M.D.
Participant: Patricia M. Morse, Ph.D., Robert Ursano, M.D.

NEW RESEARCH POSTER SESSION 10  12 noon-2:00 p.m.
Exhibit Hall B, Level 300, Toronto Convention Centre North

COGNITION AND OTHER TOPICS

For further information on New Research submissions, please refer to the New Research Program Book included in your registration packet.

2:00 p.m. Sessions

SYMPOSIA 100-119

SYMPOSION 100  2:00 p.m.-5:00 p.m.
Room 104 B, Level 100, Toronto Convention Centre North

IDENTIFYING SUBTYPES IN OCD

Chp.: Jane L. Eisen, M.D.
A OCD Subtypes and Drug Treatment Response
Wayne K. Goodman, M.D.
B Subtypes of OCD From a Familial Perspective
Gerald Nestadt, M.D.
C OCD Subtypes Based on Course of Illness and Clinical Features
Jane L. Eisen, M.D.
D Neurobiological Heterogeneity in OCD
Sanjaya Saxena, M.D.

Discussant: James F. Leckman
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 101  2:00 p.m.-5:00 p.m.
Room 104 D, Level 100, Toronto Convention Centre North

VIRTUAL ENVIRONMENTS AND CONVERGENT MEDIA TECHNOLOGY

Chp.: Henry J. Moller, M.D.
Co-Chp.: Pierre Boulanger, M.D.

A Virtual Reality Assets for Assessment, Therapy, and Rehabilitation
Albert A. Rizzo, Ph.D.

B Why Simulate? The Cognitive Neuroergonomics of Virtual Environments
Henry J. Moller, M.D.

C Can Virtual Reality Be Useful for the Study of Brain Functions?
Pierre Boulanger, Ph.D.

D Music Triggered Avatars: A New Way to Express Emotion in the Virtual World
Robyn Taylor, B.S.C., Pierre Boulanger, Ph.D.

E The Evolution of Clinical VR Simulation Over the Past Ten Years
Ken Graap, M.Ed.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 102  2:00 p.m.-5:00 p.m.
Room 206 A/B, Level 200, Toronto Convention Centre North

A RESEARCH AGENDA FOR DSM-IV CONCERNING RELIGIOUS AND SPIRITUAL ISSUES IN THE DIAGNOSTIC PROCESS
APA Corresponding Committee on Religion, Spirituality, and Psychiatry

Chp.: John R. Petee, M.D.
Co-Chp.: Francis Lu, M.D.

A Religious and Spiritual Aspects in the Diagnosis of Depression
Dan G. Blazer II, M.D.

B Religious and Spiritual Aspects of the Diagnosis of Anxiety Disorders and Adjustment Disorders
Samuel B. Thielman, M.D., Gerrit Glas, M.D.

C Substance, Dependence, and Spirituality
Marc Galanter, M.D.

D Religious and Spiritual Aspects of Personality Traits and Disorders
C. Robert Cloninger, M.D.

E Religious and Spiritual Aspects of Child and Adolescent Psychiatric Disorders
Mary Lynn Dett, M.D., Allan M. Josephson, M.D.

Discussant: William E. Narow, M.D.
THIS SESSION WILL BE AUDIOTAPE.
THURSDAY

SYMPOSIM 103  2:00 p.m.-5:00 p.m.
Room 206 C/D, Level 200, Toronto Convention Centre North

GLOBAL MENTAL HEALTH DISPARITIES: A CULTURAL PERSPECTIVE AND THE POTENTIAL FOR FORMAL AND INFORMAL INTERNATIONAL EXCHANGES
APA Council on Global Psychiatry

Chp.: Samuel O. Okpaku, M.D.

A The Global Treatment Gap in Mental Health Care
Robert Kohn, M.D.

B International Cooperation in Regional Psychiatric Programs
Rodrigo A. Munoz, M.D.

C Trauma Treatment at the Child Rescue Center at Bo, Sierra Leone
Michael A. Hollifield, M.D., John D. Oram, M.D.

D Socio-Economical and Environmental Realities and Cultural Factors Affecting Children's Mental Health and Treatment in Africa
Dolores Garcia-Moreno, M.D.

E An International Perspective on Disability
Samuel O. Okpaku, M.D.

Discussant: William B. Lawson, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIM 104  2:00 p.m.-5:00 p.m.
Room 206 E/F, Level 200, Toronto Convention Centre North

PSYCHIATRY ON THE SILVER SCREEN

Chp.: Rudolf A. Feijen, M.D.
Co-Chp.: Bastiaan A. Oele, M.D.

A The Movies, the Mind, and Hollywood Stereotypes
Rudolf A. Feijen, M.D.

B Teaching Psychiatry by Movie Clips: How to Overcome Stereotypes
Bastiaan L. Oele, M.D.

C Cinema in the Consulting Room: The Silver Screen as a Projection Screen
Josephine M. Gaubel, M.D.

D The Use of Film in a Psychodynamic Treatment
Willem C. Tuinebreijer, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIM 105  2:00 p.m.-5:00 p.m.
Room 701 A, Level 700, Toronto Convention Centre South

TREATMENT OF PERSONALITY DISORDERS:
PREVIEW OF TPD IV

Chp.: John G. Gunderson, M.D.

A Treatment of the Narcissistic Personality
Elsa F. Ronningstam, Ph.D., John T. Malsberger, M.D.

B Treatment of Histrionic Personality Disorder
Glen O. Gabbard, M.D.

C Psychotherapy With Cluster “A” Personality Disorders
Michael H. Stone, M.D.

D Treatment of BPD
John G. Gunderson, M.D.

E Treatment of Cluster “C” Personality Disorders and Its Empirical Support
John C. Perry, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIM 106  2:00 p.m.-5:00 p.m.
Room 701 B, Level 700, Toronto Convention Centre South

POST-DEPLOYMENT MENTAL HEALTH:
TRANSLATING RESEARCH INTO CLINICAL PRACTICE

Chp.: Gregory McCarthy

A The VA/DOD Response to OIF/OEF Mental Health Challenges
Harold S. Kudler

B Traumatic Brain Injury in OIF/OEF Veterans: Implications for Health Care
Robin A. Hurley, M.D., Katherine H. Taber, Ph.D.

C Neuroactive Steroids and Stress in Psychiatric Disorders
Christine E. Marx, M.D.

D Multi-Modal Imaging Assessment of PTSD
Rajendra A. Morey, M.D.

E The Amygdala, Stress, and Substance Abuse
Scott D. Moore

Discussant: Marian I. Butterfield, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIM 107  2:00 p.m.-5:00 p.m.
Room 705, Level 700, Toronto Convention Centre South

IMPROVING CROSS-CULTURAL COMPETENCY IN PSYCHIATRIC TRAINING

Chp.: Maria A. Velazquez, M.D.
Co-Chp.: Ruksana Iftekhar

A Preparing Psychiatrists of the Future to Treat an Increasingly Diverse Population
Annette B. Primm, M.D.

(Continued next page)
B ASIA and Psychiatry: Understanding Their Perspectives
Consuelo C. Cagande, M.D.

C Mental Disorders: Hispanics as Patients and Clinicians
Humberto Marin, M.D.

D South Asian Immigrant Physician: American Patient, Cross-Cultural Treatment
R. Rao Gogineni, M.D.
THIS SESSION WILL BE AUDIOTAPEP.

SYMPOSIUM 108 2:00 p.m.-5:00 p.m.
Room 707, Level 700, Toronto Convention Centre South

BEREAVEMENT AND THE DSM-V

Chp.: M. Katherine Shear, M.D.
Co-Chp.: Sidney Zisook, M.D.

A Should Bereavement Remain an Exclusion for Major Depression?
Sidney Zisook, M.D., Kenneth S. Kendler, M.D.

B Complicated Grief and DSM-V
Holly G. Prigerson, Ph.D.

C Complicated Grief Treatment: Implications for the DSM-V
M. Katherine Shear, M.D.

D Treatment of Bereavement Related Depression: Implications for DSM-V
Paula Hensley, M.D.

Discussant: Charles F. Reynolds III, M.D.
THIS SESSION WILL BE AUDIOTAPEP.

SYMPOSIUM 109 2:00 p.m.-5:00 p.m.
Room 709, Level 700, Toronto Convention Centre South

NAMI DOCTORS SOUND OFF
National Alliance for the Mentally Ill

Chp.: Suzanne E. Vogel-Sciubilia, M.D.

A Recovery Programs and Mental Illness
Edward F. Foulks, M.D.

B Formulary Roulette: Getting Better Odds With Access to Treatment
Kenneth Duckworth, M.D.

C Medication Adherence: Partnering With Your Patients
Stephen M. Goldfinger, M.D.

D The Changing Role of Families in Psychiatry
Anand Pandya, M.D.

E Recovering Psychiatrists
Elizabeth A. Baxter, M.D.

Discussant: Frederick J. Frese, Ph.D.
THIS SESSION WILL BE AUDIOTAPEP.

SYMPOSIUM 110 2:00 p.m.-5:00 p.m.
Room 711, Level 700, Toronto Convention Centre South

INFECTION DISEASES AND PSYCHIATRIC SYMPTOMATOLOGY

Chp.: Annette M. Matthews, M.D.
Co-Chp.: Rima Strya, M.D.

A SARS: Psychological Consequences for the Patient, the Healthcare Worker, and the General Population
Rima Strya, M.D., Wayne L. Gold, M.D., Marie Louie, M.D., Laura Hawryluck, M.D., Allison McGee, M.D., Mark Loeb, M.D.

B Psychiatric Aspects of HIV/AIDS
Stephen J. Ferrando

C Hepatitis C Disease Management Patterns in High-Risk Populations: Testing, Infection, and Treatment Rates Among Patients With Serious Mental Illness and Substance Use Disorders
Peter Hauser, M.D.

D Delusional Parasitosis: An Infectious Disease Created Within Our Own Minds and Spread as Folie-A-Deux by Primitive Biological Mechanisms
Annette M. Matthews, M.D.

Discussant: Glenn J. Treisman, M.D.
THIS SESSION WILL BE AUDIOTAPEP.

SYMPOSIUM 111 2:00 p.m.-5:00 p.m.
Room 714 B, Level 700, Toronto Convention Centre South

USING TECHNOLOGY TO IMPROVE PATIENT CARE
American Association for Technology in Psychiatry

Chp.: Carlyle H. Chan, M.D.

A Personal Digital Assistants in Psychiatric Care
John Luo, M.D.

B Quality and Cost Impact of PDA Use in Psychiatry in Florida Medicaid
Naresh A Dewan, M.D.

C Internet Resources to Assist in Clinical Decision Making
Robert S. Kennedy, M.A.
THIS SESSION WILL BE AUDIOTAPEP.
SYMPOSIUM 112  2:00 p.m.-5:00 p.m.
Room 715 A/B, Level 700, Toronto Convention Centre South

NEUROFEEDBACK ADVANCES IN ADHD: DOES THE RESEARCH VALIDATE CLINICAL USE?

Chp.: Thomas M. Brod, M.D.
Co-Chp.: Roger deBeus, Ph.D.

A  Progress in Efficacy Studies of EEG Biofeedback for ADHD
Roger J. deBeus, Ph.D.

B  The Scientific Foundation of EEG Biofeedback as an Intervention for ADHD
Laurence M. Hirshberg, Ph.D.

C  The Interaction Between Neurofeedback Training and Medication in the Treatment of ADHD: Four Case Illustrations
David A. Mitnick, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 113  2:00 p.m.-5:00 p.m.
Room 716 A, Level 700, Toronto Convention Centre South

SLEEP DEPRIVATION: THEORETICAL AND PRACTICAL IMPLICATIONS

Chp.: Thomas W. Uhde, M.D.
Co-Chp.: Andrew D. Krystal, M.D.

A  Sleep Deprivation: Overview of Implications for Mental Health Professionals
Thomas W. Uhde, M.D.

B  The Effects of Sleep Deprivation on Stress and Immune Systems
Alexandros Vgontzas, M.D.

C  Antidepressant Effects of Sleep Deprivation
Robert M. Post, M.D.

D  Sleep Deprivation and PTSD
Bernadette M. Cortese, M.D.

Discussants: Antonio Vela-Bueno, M.D., Timothy A. Roehrs
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 114  2:00 p.m.-5:00 p.m.
Room 716 B, Level 700, Toronto Convention Centre South

INTERNATIONAL PERSPECTIVE ON QUALITY IMPROVEMENT INITIATIVES
World Psychiatric Association

Chp.: Jack S. McIntyre, M.D.
Co-Chp.: Wolfgang Gaebel, M.D.

A  International Issues of Quality Assurance in Mental Health
Julio E. Arboleda-Florez, M.D.

B  Quality Management in Psychiatry: A Task for the Future
Wolfgang Gaebel, M.D.

C  Recent Advances in the Development and Implementation of Practice Guidelines
Jack S. McIntyre, M.D.

D  Malpractice Litigation and Practice Guidelines
J. Richard Ciccone, M.D.

E  Suicide Prevention in Iceland: Outcome Parameters
Hogni Oskarsson, M.D., S.P. Palsson, O. Gudmundsson, W. Nordfjord, A. Ingthorsdottir, S. Bjarnadottir, S. Gudmundsson

Discussants: Rodrigo A. Munoz, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 115  2:00 p.m.-5:00 p.m.
Room 717 A, Level 700, Toronto Convention Centre South

ARMED AND DANGEROUS: IS YOUR PATIENT SAFE TO RETURN TO WORK?
APA Corresponding Committee on Psychiatry in the Workplace

Chp.: Marie-Claude Rigaud, M.D.

A  Workplace Safety Overview
Marie-Claude Rigaud, M.D.

B  Physician Heal Yourself: The Impaired Physician
Marilyn Price, M.D.

C  The Police Problem, Problem Police
Marcia Scott, M.D.

D  Vulnerable Positions/Defining Roles
Andrea G. Stolar, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 116  2:00 p.m.-5:00 p.m.
Room 717 B, Level 700, Toronto Convention Centre South

ONE PATIENT/FOUR MINDS: INTEGRATED TREATMENT FOR MDD

Chp.: Gerard A. Leblanc, M.D.

A  Mind One: Neurobiological Perspective
Guylain Bouchard, M.D.

B  Mind Two: Interpersonal Psychotherapy for Depression
Simon Patry, M.D.
THURSDAY

C  Mind Three: Afraid to Take Medicine? Targeting the Rational Thinking
    Nicole Thibodeau, M.D.

D  Integrated Treatment for MDD
    Marie-Josee Filteau, M.D.

E  Integrated Treatment Approach for MDD
    Gerard Leblanc, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 117  2:00 p.m.-5:00 p.m.
Room 801 A, Level 800, Toronto Convention Centre South

U.S. MILITARY PSYCHIATRY AND THE OPERATION IRAQI FREEDOM: AN UPDATE

Chp.: Theodore S. Nam, M.D.

A  Mental Health Impact of Combat Operations in Iraq and Afghanistan: Update and Lessons Learned
    Charles W. Hoge, Carl A. Castro, Ph.D.

B  The Evolution of Operational Mental Health Care in the U.S. Navy and Marine Corps From WWI to Operation Iraqi Freedom
    James J. Reeves, M.D.

C  Operation Iraqi Freedom: Walter Reed Army Medical Center Inpatient Psychiatry: An Update
    Theodore S. Nam, M.D.

D  Psychiatric Intervention With Wounded Soldiers: A Consultation Liaison Approach
    Harold J. Wain, Ph.D.

E  The Challenges to Psychiatric Leadership at a Military Medical Center During Wartime
    Stephen J. Cozza, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 118  2:00 p.m.-5:00 p.m.
Room 801 B, Level 800, Toronto Convention Centre South

COMPLEMENTARY, ALTERNATIVE, AND INTEGRATIVE APPROACHES IN MENTAL HEALTH CARE

Chp.: James H. Lake, M.D.
Co-Chp.: Sudha Prathikanti, M.D.

A  Classical Homeopathy: An Overview for Psychiatrists
    Pamela A. Pappas, M.D.

B  Ayurveda: Ancient Wisdom for Modern Psychiatry
    Sudha Prathikanti, M.D.

C  No Effect of Anonymously Distant Healing on Survival Time for Patients With Glioblastoma Multiforme
    Andrew J. Freinkel, M.D., Cheryl Koopman, Ph.D.

D  Select Integrative Medicine Treatments for Depression in Women
    Priti Sinha

E  Meditation for Psychiatric Disorders: A Review of the Evidence
    Jeffrey D. Rediger, M.D.

Discussant: Andrew J. Freinkel, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 119  2:00 p.m.-5:00 p.m.
Room 803 A/B, Level 800, Toronto Convention Centre South

SUICIDE ON COLLEGE CAMPUSSES: PRACTICAL AND ETHICAL ISSUES

Chp.: Paul S. Appelbaum, M.D.
Co-Chp.: Barbara H. Stanley

A  The Epidemiology of College Student Suicide
    Morton M. Silverman, M.D.

B  Screening College Students for Suicide Risk
    Ann P. Haas, Ph.D.

C  The University Response to Suicide Prevention and Treatment
    Paul J. Barreira, M.D.

D  Ethical Dilemmas of College Student Suicide
    Paul S. Appelbaum, M.D.

E  Balancing Privacy and Protection Concerns in Suicidal College Students
    Barbara H. Stanley, Ruth Fischbach, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.
2006 ANNUAL MEETING
TOPIC AREAS FOR THE SCIENTIFIC PROGRAM

DISORDERS
1. AIDS and HIV-Related Disorders
2. Alcohol and Drug-Related Disorders
3. Anxiety Disorders
4. Attention Spectrum Disorders
5. Cognitive Disorders (Delirium, Dementia, Amnestic, etc.)
6. Dissociative Disorders
7. Eating Disorders
8. Mental Retardation (Child/Adolescent/Adult)
9. Mood Disorders
10. Personality Disorders
11. Premenstrual Dysphoric Disorder
12. Schizophrenia and Other Psychotic Disorders
13. Sexual and Gender Identity Disorders
14. Sleep Disorders
15. Somatoform Disorders

PRACTICE AREAS/SETTINGS
16. Psychiatric Administration and Services: Public, Private, and University

SUBSPECIALTY AREAS OR SPECIAL INTERESTS
17. Addiction Psychiatry
18. Biological Psychiatry and Neuroscience
19. Brain Imaging
20. Child and Adolescent Psychiatry and Disorders
21. Consultation-Liaison and Emergency Psychiatry
22. Cross-Cultural and Minority Issues
23. Diagnostic Issues
24. Emergency Psychiatry
25. Epidemiology
26. Ethics and Human Right
27. Forensic Psychiatry
28. Geriatric Psychiatry
29. Neuropsychiatry
30. Pain Management
31. Psychiatric Education
32. Psychiatric Rehabilitation
33. Psychoimmunology
34. Research Issues
35. Social and Community Psychiatry
36. Suicide
37. Violence, Trauma, and Victimization

TREATMENTS
38. Behavior and Cognitive Therapies
39. Combined Pharmacotherapy and Psychotherapy
40. Couple and Family Therapies
41. Group Therapy
42. Individual Psychotherapies
43. Other Somatic Therapies
44. Psychopharmacology
45. Treatment Techniques and Outcome Studies

OTHER ISSUES
46. Computers
47. Creativity and the Arts
48. Electronic Medical Records
49. Gender Issues
50. Health Services Research
51. Historical Questions
52. Information Technology
53. Internet
54. Lesbian/Gay/Bisexual/Transgender Issues
55. Managed Care and Health Care Funding
56. Men's Issues
57. National Institute of Alcohol Abuse and Alcoholism
58. Patient Safety
59. Personal Digital Assistants (PDAs)
60. Political Questions
61. Presidential Theme: “From Science to Public Policy: Advocacy for Patients & the Profession”
62. Professional and Personal Issues
63. Religion, Spirituality, and Psychiatry
64. Resident and Medical Student Concerns
65. Stigma/Advocacy
66. Virtual Reality
67. Women's Health Issues

GUIDE TO USING THE TOPIC INDEX
Use this index to find sessions of interest to you. There are five overall topics: Disorders, Practice Areas/Settings, Subspecialty Areas or Special Interests, Treatments, and Other Issues. Under each overall topic, you will find subtopics listed in alphabetical order with the formats (type of session) listed alphabetically underneath. Within each format, you will find the title of the individual session listed by number. The listing will also show the page number the session appears on. You should refer to the page number in this Program Book to obtain further details about the session.

103
# TOPIC INDEX

## DISORDERS

### TOPIC 1: AIDS AND HIV-RELATED DISORDERS

<table>
<thead>
<tr>
<th>LECTURE</th>
<th>Page#</th>
</tr>
</thead>
<tbody>
<tr>
<td>7 The Discourse on Human Sexuality in the Time of AIDS</td>
<td>24</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SYMPOSIA</th>
<th>Page#</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 HIV Prevention Interventions With Psychiatric Patients From Around the World: Turning Research Into Practice</td>
<td>32</td>
</tr>
<tr>
<td>56 HIV Update for Psychiatric Care</td>
<td>62</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COMPONENT WORKSHOP</th>
<th>Page#</th>
</tr>
</thead>
<tbody>
<tr>
<td>13 Sexuality and Its Impact on the HIV Pandemic</td>
<td>28</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ISSUE WORKSHOP</th>
<th>Page#</th>
</tr>
</thead>
</table>

### TOPIC 2: ALCOHOL AND DRUG-RELATED DISORDERS

<table>
<thead>
<tr>
<th>COURSES</th>
<th>Page#</th>
</tr>
</thead>
<tbody>
<tr>
<td>7 Teaching Addiction Medicine Using Films</td>
<td>1</td>
</tr>
<tr>
<td>39 Street Drugs and Mental Disorders: Overview and Treatment</td>
<td>17</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>DISCUSSION GROUPS</th>
<th>Page#</th>
</tr>
</thead>
<tbody>
<tr>
<td>8 Alcohol Dependence: What Clinicians Need to Know</td>
<td>23</td>
</tr>
<tr>
<td>18 Substance Abuse: Network Therapy for Promoting Outpatient Compliance With Psychosocial and Pharmacologic Treatment</td>
<td>69</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>INDUSTRY-SUPPORTED SYMPOSIUM</th>
<th>Page#</th>
</tr>
</thead>
<tbody>
<tr>
<td>44 Diagnosing and Treating Alcohol Dependence in the Office</td>
<td>89</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LECTURES</th>
<th>Page#</th>
</tr>
</thead>
<tbody>
<tr>
<td>19 An Evidence-Based Clinician’s Guide to the New Pharmacotherapies for Alcoholism</td>
<td>57</td>
</tr>
<tr>
<td>23 High on Neurosteroids: Mechanisms and Therapeutic Relevance</td>
<td>73</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SYMPOSIA</th>
<th>Page#</th>
</tr>
</thead>
<tbody>
<tr>
<td>16 Adolescent Brain Development: Implications for Psychiatric Treatment</td>
<td>36</td>
</tr>
<tr>
<td>54 The Methamphetamine Epidemic in the U.S.</td>
<td>62</td>
</tr>
<tr>
<td>61 Pharmacogenetics and Drug Abuse Research</td>
<td>64</td>
</tr>
<tr>
<td>89 Pharmacotherapy for Single- and Dual-Diagnosed Substance Abusers</td>
<td>86</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COMPONENT WORKSHOP</th>
<th>Page#</th>
</tr>
</thead>
<tbody>
<tr>
<td>27 Buprenorphine: Clinical Issues and Managing More Complicated Patients</td>
<td>47</td>
</tr>
</tbody>
</table>

### TOPIC 3: ANXIETY DISORDERS

<table>
<thead>
<tr>
<th>INDUSTRY-SUPPORTED SYMPOSIUM</th>
<th>Page#</th>
</tr>
</thead>
<tbody>
<tr>
<td>12 The Impact of Anxiety Disorders: A Case-Based Approach to Improving Outcomes and Removing Stigma</td>
<td>6</td>
</tr>
<tr>
<td>27 Evidence, Outcomes, and Advocacy: Shaping the Management of GAD, Part 1</td>
<td>17</td>
</tr>
<tr>
<td>27 Evidence, Outcomes, and Advocacy: Shaping the Management of GAD, Part 2</td>
<td>43</td>
</tr>
</tbody>
</table>

### TOPIC 4: ATTENTION SPECTRUM DISORDERS

<table>
<thead>
<tr>
<th>COURSES</th>
<th>Page#</th>
</tr>
</thead>
<tbody>
<tr>
<td>15 ADD in Children and Adolescents</td>
<td>5</td>
</tr>
<tr>
<td>63 ADD in Adults</td>
<td>44</td>
</tr>
<tr>
<td>101 Advanced Assessment and Treatment of ADD</td>
<td>92</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>INDUSTRY-SUPPORTED SYMPOSIUM</th>
<th>Page#</th>
</tr>
</thead>
<tbody>
<tr>
<td>11 Expanding the Neurobiological and Neuropsychological Foundation of ADHD: Impact to Clinical Practice</td>
<td>6</td>
</tr>
<tr>
<td>23 Advances in the Neurobiology and Therapeutics of ADHD</td>
<td>11</td>
</tr>
<tr>
<td>31 Understanding and Managing the Transition of ADHD From Adolescence to Young Adulthood: The Maturation of the Disorder</td>
<td>42</td>
</tr>
<tr>
<td>37 Advocating for Change Through Evidence-Based Medicine: A Focus on ADHD</td>
<td>66</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MEDICAL UPDATE</th>
<th>Page#</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 ADD Kids Get Smart Naturally</td>
<td>50</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SCIENTIFIC AND CLINICAL REPORTS</th>
<th>Page#</th>
</tr>
</thead>
<tbody>
<tr>
<td>7 Transdermal Methylphenidate Versus Placebo in Pediatric ADHD</td>
<td>26</td>
</tr>
<tr>
<td>8 Effects of Transdermal Methylphenidate in a Laboratory Classroom Study</td>
<td>26</td>
</tr>
<tr>
<td>9 Modafinil-ADHD: Long-Term Efficacy and Safety in Children and Adolescents With ADHD</td>
<td>26</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SYMPOSIUM</th>
<th>Page#</th>
</tr>
</thead>
<tbody>
<tr>
<td>35 Impulsivity in Axis I and Axis II: Common Substrates, Different Presentations?</td>
<td>58</td>
</tr>
<tr>
<td>112 Neurofeedback Advances in ADHD: Does the Research Validate Clinical Use?</td>
<td>101</td>
</tr>
</tbody>
</table>

### TOPIC 5: COGNITIVE DISORDERS (DELIRIUM, DEMENTIA, AMNESTIC, ETC.)

<table>
<thead>
<tr>
<th>COURSE</th>
<th>Page#</th>
</tr>
</thead>
<tbody>
<tr>
<td>13 The Evaluation and Identification of the Major Dementias</td>
<td>3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>INDUSTRY-SUPPORTED SYMPOSIUM</th>
<th>Page#</th>
</tr>
</thead>
<tbody>
<tr>
<td>19 Advances in the Understanding of the Dementia Spectrum</td>
<td>9</td>
</tr>
<tr>
<td>20 Alzheimer's Disease: Challenging the Practice Paradigm</td>
<td>10</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SCIENTIFIC AND CLINICAL REPORT</th>
<th>Page#</th>
</tr>
</thead>
<tbody>
<tr>
<td>110 Antipsychotics in the Treatment of Delirium: A Review of Prospective Trials</td>
<td>95</td>
</tr>
</tbody>
</table>
### Topics Index

<table>
<thead>
<tr>
<th>Topic</th>
<th>Subtopics</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Symposia</strong></td>
<td>Dementia in Patients With Down Syndrome: Risk Factors, Biomarkers, Diagnosis, and Treatment</td>
<td>39</td>
</tr>
<tr>
<td></td>
<td>The Use of Atypical Antipsychotics in Elderly Patients With Dementia: What Next?</td>
<td>61</td>
</tr>
</tbody>
</table>

**Topic 6: Dissociative Disorders**

**Advances in Session**

1. Advances in Psychopharmacology | 31 |

**Topic 7: Eating Disorders**

**Course**

8. Therapeutic Interventions in Eating Disorders: Basic Principles | 1 |

**Focus Live Session**

2. Eating Disorders and Sexual Disorders | 23 |

**Symposia**

34. Predictors of Outcome and Treatment Response in Eating Disorders: Results From New Research on Anorexia Nervosa, Bulimia Nervosa, and Binge Eating Disorder | 57 |

62. Eating Disorders 2006: From Science to Practice | 64 |

**Issue Workshops**

24. Does Beauty Equal Happiness? | 29 |

35. The Difficult-to-Treat Bulimia Nervosa | 46 |

**Media Workshop**

2. Do I Look Fat? Eating Disorder Pathology in Gay Men | 23 |

**Topic 8: Mental Retardation (Child/Adolescent/Adult)**

**Component Workshop**

25. It Takes a Village: Assessing Behavioral and Psychiatric Disorders in Mentally Retarded Individuals | 47 |

**Topic 9: Mood Disorders**

**Advances in Session**

4. Advances in Mood Disorders | 68 |

**Course**

94. Melatonin and Light: Treatment of SAD, Sleep, and Other Body Clock Disorders | 79 |

**Industry-Supported Symposia**

1. New Augmentation Strategies in Depression for Better Outcomes | 1 |

2. Strategies for Maintaining Wellness in Patients With Bipolar Disorder: Moving Beyond Efficacy to Effectiveness | 2 |

5. Mania in Special Populations | 3 |

7. Bipolar Disorder: Creating a Consensus From Science to Public Policy | 3 |

8. Treatment-Resistant Depression: New Data, New Approaches | 4 |

13. New Vistas in Treatment-Resistant Depression | 6 |

16. Interrupting the Cycle of Vascular Disease and Depression | 9 |

17. The Long-Term Clinical Course and Treatment of Recurrent Depression in 2006: New Data, and Future Directions | 9 |

18. Misdiagnosis of Bipolar II: Methods for Screening Patients at Risk for Bipolar Disorder | 9 |


28. Attaining and Sustaining Remission in Treatment of Depression With Comorbid or Residual Anxiety, Part 1 | 17 |

28. Attaining and Sustaining Remission in Treatment of Depression With Comorbid or Residual Anxiety, Part 2 | 43 |

30. Helping Depressed Patients Achieve Remission: Advocacy for Improvement | 42 |

35. Multiple and Complex Presentations of Bipolar Disorder | 65 |

39. Emerging Evidence in the Treatment of Bipolar Depression, Part 1 | 67 |

39. Emerging Evidence in the Treatment of Bipolar Depression, Part 2 | 91 |

40. Bipolar Illness: The Road to Remission, Part 1 | 67 |

40. Bipolar Illness: The Road to Remission, Part 2 | 91 |

41. New Frontiers in Depression: Providing Solutions to Unmet Needs, Part 1 | 67 |

41. New Frontiers in Depression: Providing Solutions to Unmet Needs, Part 2 | 91 |

43. What Is the Role of Somatic and Physical Symptoms in Depression? | 89 |

**Lecture**

5. Gene-Environment Interactions and Risk of Major Depression: Implications for Community-Based Prevention Strategies | 24 |

**Master Educator Clinical Consultation**

3. Refractory Depression: Diagnostic and Treatment Implications | 20 |

**Scientific and Clinical Reports**

13. Duloxetine Versus Escitalopram and Placebo in the Long-Term Treatment of Patients With MDD | 26 |

14. Conditional Probability of Response to Placebo in MDD | 26 |

15. Addition of Atomoxetine for Depression Incompletely Responsive to Sertraline: A Randomized, Double-Blind, Placebo-Controlled Study | 26 |

16. Management of Side Effects Associated With New Treatments for Bipolar Depression | 26 |

17. Treatment-Resistant Depression: Changes in Symptoms and Functioning in a Clinical Sample | 26 |

18. Specificity of Effect of Quetiapine in Bipolar Depression | 26 |

46. Galantamine-GR for Cognitive Dysfunction in Bipolar Disorder: Efficacy and Biological Correlates | 51 |

47. Rate of Improvement with Quetiapine Across Different Symptoms and Symptom Clusters in Bipolar Disorder | 51 |

48. Efficacy of the Antipsychotics in Anxiety Symptoms With or Without Bipolar Disorder | 51 |

49. Prescription Patterns for Latin Americans Treated for MDD in Naturalistic Clinical Practice Settings | 51 |

50. Nonadherence in Bipolar Disorder: A Qualitative Study Exploring Perceptual and Practical Barriers to Taking Medication | 51 |

51. Patient Dissatisfaction With Information Received About Medicines Prescribed for Bipolar Disorder | 51 |

52. Juvenile Bipolar Disorder: Toward a Validation of the Episodic-Chronic Distinction | 52 |

53. Treatment of SAD With a Carbohydrate-Rich Nutrient Mixture | 52 |

54. Impaired Mood and Social Functioning Among Adult Children of Parents With Depression | 52 |

62. Frequency of EEG Abnormalities and Results of Antiepileptic Drug Therapy in Unstable Mood Disorders | 52 |

82. Early Symptomatic Worsening During Treatment With Fluoxetine in MDD: A Replication Study | 76 |

87. PDE5 Inhibitor Treatment of Serotoninergic Antidepressant Associated Sexual Dysfunction (SRI-AASD) in Women With MDD in Remission: An Eight-Week Randomized, Double-Blind, Placebo-Controlled Trial With Eight-Week Open-Label Continuation | 76 |

124. Substance Abuse in Bipolar Disorder | 96 |

129. Medication Nonadherence in Bipolar Disorder: The Role of Patients Treatment Perceptions | 96 |
### TOPIC INDEX

#### SYMPOSIA
- **11** The Long-Term Care and Treatment of Elderly Patients With Bipolar Disorder  
  35
- **28** CANMAT Guidelines for the Management of Bipolar Disorder: An Effort Towards International Consensus  
  39
- **32** A Spanish Language Update on the Assessment and Management of Depression  
  40
- **39** Therapeutic Neuromodulation: Methods and Mechanisms  
  59
- **45** Bipolar Disorder and the U.S. Legal System  
  60
- **63** Vascular Depression: Measurement and Treatment Issues of a Proposed Diagnostic Entity  
  64
- **77** Demonization and Psychotherapy: A Tribute to Jerome D. Frank, M.D.  
  83

#### COMPONENT WORKSHOP
- **9** New Developments in APA Practice Guidelines on Bipolar Disorder, MDD, and Panic Disorder  
  21

#### ISSUE WORKSHOPS
- **11** What Is a Mood Stabilizer?  
  22
- **103** Detecting Bipolar Disorder  
  97

#### TOPIC 10: PERSONALITY DISORDERS

#### ADVANCES IN SESSION
- **2** Advances in Personality Disorders  
  44

#### COURSES
- **45** Treating the Self and Interpersonal Problems of Personality Disorder  
  18
- **53** Personality Disorders: Combining Relational Therapy and Psychopharmacology  
  31

#### DISCUSSION GROUPS
- **11** The Therapists' Experience with Borderline Patients  
  45
- **19** Borderline Personality Disorder: Talking with Patients About Their Illness, What Do You Say?  
  69
- **20** Personality Disorders and DSM-V  
  69

#### FOCUS LIVE SESSION
- **1** Personality Disorders  
  19

#### LECTURE
- **12** Personality Disorders: Psychiatry's Stepchildren Come of Age  
  45

#### MASTER EDUCATOR CLINICAL CONSULTATION
- **11** Current Issues in the Treatment of Personality Disorder  
  50

#### SCIENTIFIC AND CLINICAL REPORTS
- **45** NMDA Receptors and BPD: A Critical Mediator  
  51
- **91** Structural Brain Abnormalities in BPD  
  76
- **92** Neurobiological Correlates of Diagnosis and Underlying Traits in Patients With BPD Compared With Normal Controls  
  76
- **93** BPD and Suicide Attempt: Are There Any Correlates Between Attempters and Non-Attempters?  
  76
- **118** BPD and Culture  
  95

#### SYMPOSIA
- **18** Personality Disorders and Comorbidity: Predictive Factors and Clinical Implications  
  36
- **33** Recent Advances in Clinical Care and Clinical Research in BPD  
  40
- **40** APA Research Agenda for DSM-V Personality Disorders  
  59
- **65** Complex Depression: The Interface Between Personality Disorders and Major Depression  
  65
- **85** Relationships Between Axis I and Axis II  
  85
- **105** Treatment of Personality Disorders: Preview of TPD IV  
  99

#### ISSUE WORKSHOP
- **64** Connection Is the Cure: Treating Relational Disorders  
  72

### TOPIC 11: PREMENSTRUAL DYSPHORIC DISORDER

#### SCIENTIFIC AND CLINICAL REPORT
- **120** Prevalence of PMDD Among Women in a Primary Care Outpatient Setting in the United Arab Emirates  
  95

### TOPIC 12: SCHIZOPHRENIA AND OTHER PSYCHOTIC DISORDERS

#### ADVANCES IN SESSION
- **5** Advances in Schizophrenia  
  80

#### COURSE
- **73** Assessing Positive and Negative Symptoms in Psychosis with the Positive and Negative Syndrome Scale (PANSS)  
  55

#### DEBATE
- **1** Does CATIE Really Inform the Practice of Psychiatry?  
  19

#### FORUM
- **5** Antipsychotic Drugs Effectiveness: Results of the NIMH CATIE Trial  
  30

#### INDUSTRY-SUPPORTED SYMPOSIA
- **6** Verging on Reality: Emergent Therapeutic Approaches for Schizophrenia  
  3
- **9** Differentiating Atypical Antipsychotics in the Treatment of Schizophrenia: From Theory to Practice  
  5
- **14** New Developments in Schizophrenia: From Neurobiology to Public Health  
  8
- **21** Effectiveness of Antipsychotic Drugs in Chronic Schizophrenia: Complete Results of the CATIE Trial  
  10
- **33** Taking Control of Negative Symptoms: The Next Step for Improved Patient Outcomes in Schizophrenia  
  42
- **34** Management of Psychosis in the Elderly: The Science and the Art  
  65
- **36** Treating the Early Stages of Schizophrenia  
  65
- **46** Remission and Recovery in Schizophrenia: Advocating for Our Patients  
  90

#### LECTURE
- **6** Emotion Processing and Schizophrenia: Neuropsychiatric Perspectives  
  24

#### SCIENTIFIC AND CLINICAL REPORTS
- **10** Recurring Psychosis in Schizophrenia: A 20-Year Multi, Follow-Up Study  
  26
- **11** Identifying the Neurobiological Basis for Schizophrenia  
  26
- **12** Key Findings from the Intercontinental Schizophrenia Outpatients Health Outcomes Study (IC-SOHO): Disease Burden and Clinical Outcomes Associated With Antipsychotic Treatment for Schizophrenia  
  26
- **43** Lymphocyte and Platelet Alteration of the 5HT Transporter in Patients With Psychosis  
  51
- **57** Progressive Glutamatergic and Gray Matter Changes in First Episode Patients With Schizophrenia and High Field Proton MRS  
  52
- **58** Metabolic Syndrome in That Patients With Schizophrenia: Prevalence and Incidence  
  52
- **60** Olanzapine Treatment Does Not Increase Ten-Year Cardiovascular Risk: Comparison With Haloperidol in Patients With Schizophrenia  
  52
- **73** Assessing Health and Nutrition Status of Urban Psychiatric Outpatients  
  75
- **74** Are Females at Special Risk for Obesity If They Become Psychotic? The Longitudinal Northern Finland 1966 Birth Cohort Study  
  75
- **75** A 12-Week Open Label Trial of Topiramate for Limiting Weight Gain During Olanzapine Treatment in Patients With Schizophrenia  
  75
TOPIC INDEX

76 Altered Developmental Trajectories in Schizophrenia
77 Characteristics of the Interpersonal Distance of Patients With Schizophrenia in the Virtual Environment
78 Familial Risk of Psychosis and Prodromal Features of Psychosis at the Age of 15-16 Years
80 Efficacy and Tolerability of Olanzapine, Quetiapine, and Risperidone in the Treatment of First-Episode Psychosis: A Randomized, Double-Blind, 52-Week Comparison
122 Alcoholism in Schizophrenia: Systematic Review 2000-2004
123 Cigarette Smoking Among Psychiatric Outpatients: A Matched Case-Control Study in Bucaramanga, Colombia
131 Depression and Caregiver Burden in Families of People with Schizophrenia

SYMPOSIA
8 Treatment Issues in Schizophrenia With Comorbid Disorders
12 When Usual Treatments Fail: Augmentation Strategies for Refractory Schizophrenia
15 First-Episode Schizophrenia: How Can We Improve Treatment Outcome?
27 Not Just Dopamine Any More: Emerging Glutamatergic Therapies for Schizophrenia
55 Preparing Schizophrenia: Opportunities and Challenges
58 Not Your Parent's EEG: Clinical Applications of Auditory and Visual Event-Related Potentials
75 Acute Brief Psychoses: Nosology and Boundaries
92 Anxiety and Emotional Dysfunction in Endophenotype of Schizophrenia

ISSUE WORKSHOP
32 Metabolic Screening of Patients on Antipsychotic Medications: Development of a Quality Improvement Program in an Urban Training Clinic

TOPIC 13: SEXUAL AND GENDER IDENTITY DISORDERS

COURSE
26 The Management of the Sexual Abuse Phenomenon: A Global Perspective: A Belgian Approach

DISCUSSION GROUP
5 The Psychology of the Closet

SCIENTIFIC AND CLINICAL REPORT
42 Effectiveness of Group Interventions for Parents of Gender-Variant Children

COMPONENT WORKSHOP
31 Can We Talk? A Model for Constructive Conversation Between Opponents and Advocates of Same Sex Relationships

ISSUE WORKSHOP
52 Sexual History: The Art and the Science

TOPIC 14: SLEEP DISORDERS

INDUSTRY-SUPPORTED SYMPOSIA
4 Bridging Sleep, Science, and Public Policy
15 Vital Signs in Psychiatry: A Perspective on Sleep Across the Life Cycle
25 insomnia From the Inside Out: From Neuroscience to Clinical Experience to Public Policy
42 What the Psychiatrist Needs to Know About Sleep-Related Movement Disorders, Part 1
42 What the Psychiatrist Needs to Know About Sleep-Related Movement Disorders, Part 2

SCIENTIFIC AND CLINICAL REPORTS
67 Effect of Armodafinil on Reducing Fatigue in Patients With Narcolepsy
68 Effect of Armodafinil on Attention in Patients With Excessive Sleepiness Associated With Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, and Shift Work Sleep Disorder
69 Armodafinil Improves Wakefulness in Patients With Excessive Sleepiness Associated With Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, and Shift Work Sleep Disorder
127 Armodafinil Improves Fatigue in Patients With Excessive Sleepiness Due to Obstructive Sleep Apnea/Hypopnea Syndrome

SYMPOSIUM
96 Fearful Sleep Arousal

TOPIC 15: SOMATOFORM DISORDERS

COURSE
76 Psychogenic Symptoms: A Challenge for All Specialties

FORUM
15 Environmental Psychiatry: From Sick Buildings to the Gulf War

SCIENTIFIC AND CLINICAL REPORT
117 Pseudoencephalomesial Epilepsy: Interaction of Past Traumatic Stress and Current Suppression of Negative Affects

ISSUE WORKSHOP
81 Fibromyalgia: Current Understanding and Future Directions

PRACTICE AREAS/SETTINGS

TOPIC 16: PSYCHIATRIC ADMINISTRATION AND SERVICES: PUBLIC, PRIVATE, AND UNIVERSITY

COURSES
6 Basic Concepts in Administrative Psychiatry I: Theory, Human Resources, and Fiscal Management
17 Home Treatment for Acute Mental Disorders: An Alternative to Hospitalization
28 Basic Concepts in Administrative Psychiatry II: Care Management, Law, and Ethics
50 Managed Care Contracting for Psychiatrists
51 Contemporary Malpractice Liability 2006: A Practical Guide
69 Personnel Management for Clinician Administrators

DISCUSSION GROUP
4 Leadership Opportunities: Where and How to Look

FORUM
8 Improving the Quality of Health Care for Mental and Substance Use Conditions

INDUSTRY-SUPPORTED SYMPOSIUM

LECTURE
14 History of and Corrective Proposals for Disparities in Mental Health Care

107
## PRESIDENTIAL SYMPOSIA
1. The Public Mental Health System: Critical Issues
2. Collaboration in Crisis: Academic Medical Center's Response to Hurricanes Katrina and Rita
3. Psychiatric Participation in Interrogation of Detainees: Ethical Considerations

## SYMPOSIA
46. APA/APA: Addressing Psychiatric Patients' Needs in Latin America
47. Helping Returning Veterans: VA Community Collaborations
99. Psychiatry in Amsterdam: Acute Psychiatric Services in a Metropolitan Area
114. International Perspective on Quality Improvement Initiatives

## COMPONENT WORKSHOPS
6. Closing a Practice: What Every Psychiatrist’s Office and Their Family Should Know
20. The End of Hospitalization? Trends in Intensive Mental Health Services for Children and Adolescents
24. Doing It in Public: Opportunities in Public Sector Psychiatry
39. Doing More With Less: Challenges and Rewards of Becoming a Psychiatrist Executive

## ISSUE WORKSHOPS
46. Career Advancement in Academic Psychiatry for Early Career Psychiatrists
73. Approaches to Chronic Disease Management: Opportunities for Psychiatry
90. Psychiatry in the Primary Care Setting: Making It Work for Doctors and Patients
105. Making It Happen: Implementing the APA Practice Guideline for Major Depressive Disorder in Everyday Practice

## TOPIC 18: BIOLOGICAL PSYCHIATRY AND NEUROSCIENCE

### COURSE
90. Neuroanatomy of Emotions: From Brain to Clinical Practice

### INDUSTRY-SUPPORTED SYMPOSIUM
32. The Cognition, Neurocircuitry, and Disability Interface: Bringing Evidence to Practice

### LECTURE
2. Heart Rate Variability and Psychiatry: Beyond Heart-Mind Link

### SCIENTIFIC AND CLINICAL REPORTS
28. From Synapse to Psychotherapy: The Fascinating Evolution of Neuroscience
29. Can Neurological Soft Signs Discriminate Between Four Axis-I Diagnostic Categories in the Prison Population?
30. An Association Study of a Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Zotepine Response of Inpatients With Acute Schizophrenia

### SYMPOSIUM
44. Neurobiological Basis for Co-Occurring Substance Abuse and Other Psychiatric Disorders
64. Deep Brain Stimulation for Treatment-Resistant Psychiatric Disorders
67. Reductionism in Psychiatry: Implications and Limits
113. Sleep Deprivation: Theoretical and Practical Implications

### ISSUE WORKSHOP
56. Psychiatric Aspects of Deep Brain Stimulation for Parkinson’s Disease

## TOPIC 19: BRAIN IMAGING

### CLINICAL CASE CONFERENCE
1. Honorable Discharge: Severe Brain Injury and Psychological Symptoms in a Female Veteran

### COURSE
77. Neurocircuits in Psychotherapy

### MASTER EDUCATOR CLINICAL CONSULTATION
12. Neuropsychiatric Aspects of Traumatic Brain Injury

### SCIENTIFIC AND CLINICAL REPORTS
55. fMRI of the Brain Reward System: Manipulation of Risk and Reward Value
56. Brain Structure and Outcome in Schizophrenia: The Northern Finland 1966 Birth Cohort

## TOPIC 20: CHILD AND ADOLESCENT PSYCHIATRY AND DISORDERS

### DISCUSSION GROUP
16. Killer Adolescents: Drugs, School, and the Courts

### FORUM

### LECTURE
22. Psychiatry and Education: When the Twain Meet
<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TOPIC INDEX</strong></td>
<td></td>
</tr>
<tr>
<td><strong>ROUND TABLE DISCUSSION</strong></td>
<td></td>
</tr>
<tr>
<td>Child and Adolescent Bipolar Disorder: Out of a Diagnostic Quandry</td>
<td>71</td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORTS</strong></td>
<td></td>
</tr>
<tr>
<td>34 Prediction of Suicidality and Violence in Hospitalized Adolescents: Comparisons by Gender</td>
<td>50</td>
</tr>
<tr>
<td>35 Daily Cigarette Smoking Among Colombian High School Students: Gender Related Factors</td>
<td>50</td>
</tr>
<tr>
<td>36 Subtypes of Aggression: Incidence and Gender Differences in Adolescents</td>
<td>50</td>
</tr>
<tr>
<td>40 The Role of Subjective Emotional Reactivity to Affective Pictures in Predicting Emotional-Behavior Disorders Over a One-Year Period in an Unselected Community Sample of Children Between the Ages of 7 to 11</td>
<td>51</td>
</tr>
<tr>
<td>41 Life Satisfaction in Young Urban Adolescents</td>
<td>51</td>
</tr>
<tr>
<td>63 How to FACE Juvenile Epilepsy and Bipolar Disorder: Clinical Challenges</td>
<td>52</td>
</tr>
<tr>
<td>107 Familial Psychiatric Disorders and Sudden Infant Death Syndrome: Is There a Significant Relationship?</td>
<td>94</td>
</tr>
<tr>
<td><strong>SYMPOSIA</strong></td>
<td></td>
</tr>
<tr>
<td>19 Towards a Developmental Trauma Disorder</td>
<td>37</td>
</tr>
<tr>
<td>74 Neuropsychiatric Responses to Burns: Modeling the Developmental Neurobiology of Trauma</td>
<td>82</td>
</tr>
<tr>
<td><strong>COMPONENT WORKSHOPS</strong></td>
<td></td>
</tr>
<tr>
<td>5 Crime and Guilt Not Unusual Punishment: The Need for Juvenile Justice Mental Health Care Reform</td>
<td>21</td>
</tr>
<tr>
<td>32 From Diagnosis to Treatment of Infants and Young Children</td>
<td>53</td>
</tr>
<tr>
<td>45 School-Based Suicide Prevention: Evidence-Based Strategies and New Approaches</td>
<td>77</td>
</tr>
<tr>
<td><strong>ISSUE WORKSHOPS</strong></td>
<td></td>
</tr>
<tr>
<td>69 The Nature of Nurture: The Long-Lasting Impacts of Early Adverse Life Events</td>
<td>78</td>
</tr>
<tr>
<td>82 Traumatized Children in Iraq</td>
<td>92</td>
</tr>
<tr>
<td>96 Providing Behavioral Health Treatment Services for Very Young Special Needs Children and Their Families</td>
<td>96</td>
</tr>
<tr>
<td><strong>MEDIA WORKSHOP</strong></td>
<td></td>
</tr>
<tr>
<td>5 The Movie Fan as a Framework for Exploring Conduct Disorder in Adolescent Girls</td>
<td>72</td>
</tr>
<tr>
<td><strong>TOPIC 21: CONSULTATION-LIAISON AND EMERGENCY PSYCHIATRY</strong></td>
<td></td>
</tr>
<tr>
<td><strong>CLINICAL CASE CONFERENCE</strong></td>
<td></td>
</tr>
<tr>
<td>5 Consult-Liaison Casebook Challenge: Strategies and Limitations in Establishing Competency</td>
<td>92</td>
</tr>
<tr>
<td><strong>COURSES</strong></td>
<td></td>
</tr>
<tr>
<td>1 Dynamic Psychotherapy for Cancer Patients and Their Spouses</td>
<td>1</td>
</tr>
<tr>
<td>14 Collaboration Between Mental Health and Primary Care Providers: What Works and How to Do It</td>
<td>3</td>
</tr>
<tr>
<td>74 Overcoming Challenges in the Treatment of Hepatitis C Patients With Psychiatric Illness</td>
<td>55</td>
</tr>
<tr>
<td><strong>DISCUSSION GROUP</strong></td>
<td></td>
</tr>
<tr>
<td>21 The Role of the Psychiatrist in End of Life Care</td>
<td>73</td>
</tr>
<tr>
<td><strong>INDUSTRY-SUPPORTED SYMPOSIUM</strong></td>
<td></td>
</tr>
<tr>
<td>10 Fibromyalgia: Scientific Advances to Reduce the Burden of Illness</td>
<td>6</td>
</tr>
<tr>
<td><strong>MASTER EDUCATOR CLINICAL CONSULTATION</strong></td>
<td></td>
</tr>
<tr>
<td>16 Performance Enhancing Drug Use in Adolescent Athletes: A Sports Psychiatry Perspective</td>
<td>74</td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORTS</strong></td>
<td></td>
</tr>
<tr>
<td>22 Teaching of Psychiatry in Primary Care Residencies: Do Training Directors of Primary Care and Psychiatry See Eye to Eye?</td>
<td>27</td>
</tr>
<tr>
<td>23 Unrecognized Post-Traumatic Symptoms Triggered by Routine Hospital Care in Patients With Previous Trauma Histories</td>
<td>27</td>
</tr>
<tr>
<td>24 Is Asthma Severity Related to Current Major Depressive Episode and Generalized Anxiety Disorder: A Case-Control Study</td>
<td>27</td>
</tr>
<tr>
<td><strong>SYMPOSIA</strong></td>
<td></td>
</tr>
<tr>
<td>4 Psychosocial Intervention and Cancer Survival</td>
<td>33</td>
</tr>
<tr>
<td>41 Sleep, Fatigue, and Depression in Medically-Ill Patients</td>
<td>59</td>
</tr>
<tr>
<td><strong>COMPONENT WORKSHOP</strong></td>
<td></td>
</tr>
<tr>
<td>10 The Gift of Life: A Psychiatric Perspective on Living Hepatic Organ Donation</td>
<td>28</td>
</tr>
<tr>
<td><strong>ISSUE WORKSHOPS</strong></td>
<td></td>
</tr>
<tr>
<td>35 Legal Issues in Consultation-Liaison Psychiatry</td>
<td>48</td>
</tr>
<tr>
<td>65 Psychiatry Training for Primary Care Physicians: An Ongoing Challenge</td>
<td>78</td>
</tr>
<tr>
<td><strong>TOPIC 22: CROSS-CULTURAL AND MINORITY ISSUES</strong></td>
<td></td>
</tr>
<tr>
<td><strong>COURSE</strong></td>
<td></td>
</tr>
<tr>
<td>80 DSM-IV-TR Cultural Formulations: Diagnosis and Therapy</td>
<td>67</td>
</tr>
<tr>
<td><strong>DISCUSSION GROUP</strong></td>
<td></td>
</tr>
<tr>
<td>6 Culturally Appropriate Diagnosis and Treatment</td>
<td>23</td>
</tr>
<tr>
<td><strong>MASTER EDUCATOR CLINICAL CONSULTATION</strong></td>
<td></td>
</tr>
<tr>
<td>1 Clinical Dimensions of Cultural Psychiatry</td>
<td>20</td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORTS</strong></td>
<td></td>
</tr>
<tr>
<td>98 Stories About Mental Health: A Cross-Cultural Relapse Prevention Study in Northern Territory Aboriginal Communities</td>
<td>77</td>
</tr>
<tr>
<td>99 Recognizing and Engaging Depressed Chinese Americans in Treatment in a Primary Care Setting</td>
<td>77</td>
</tr>
<tr>
<td><strong>SYMPOSIA</strong></td>
<td></td>
</tr>
<tr>
<td>3 Migration and Mental Illness Around the World</td>
<td>33</td>
</tr>
<tr>
<td>7 The African Diaspora: Identifying and Eliminating Barriers to Mental Health</td>
<td>34</td>
</tr>
<tr>
<td>91 Recent Advances In Ethno psychopharmacological, Ethnic, and Cultural Aspects of Mood and Anxiety Disorders</td>
<td>86</td>
</tr>
<tr>
<td>95 Mental Health Disparities: Concepts, Assessment, Evidence-Based Practice, and Advocacy</td>
<td>87</td>
</tr>
<tr>
<td>107 Improving Cross-Cultural Competency in Psychiatric Training</td>
<td>99</td>
</tr>
<tr>
<td><strong>COMPONENT WORKSHOPS</strong></td>
<td></td>
</tr>
<tr>
<td>7 Conquering the Shame, Secrecy, and Stigma of Suicide in Young Asian-American Adults</td>
<td>21</td>
</tr>
<tr>
<td>11 Towards a Better Understanding of Cultural Issues in Clinical Practice: Residents Perspective of a Model Curriculum for Residency Training Programs</td>
<td>28</td>
</tr>
<tr>
<td>26 Media Outreach to Latinos: Enhancing Access and Reducing Stigma</td>
<td>47</td>
</tr>
<tr>
<td>35 From Fantasy to Reality: Recruitment of Minorities in Clinical Research</td>
<td>53</td>
</tr>
<tr>
<td>44 Global Psychiatry: Establishing Formal and Informal Mental Health Exchanges</td>
<td>77</td>
</tr>
<tr>
<td>48 Trauma of Hearts and Minds: Racism and Psychiatry in the 21st Century</td>
<td>77</td>
</tr>
</tbody>
</table>
ISSUE WORKSHOPS

45 An Integrative Approach to Cultural Competence Training for Resident and Staff Psychiatrists 54
59 The Mirror Has a Reflection: Teaching and Modeling Cultural Competency to General Psychiatry Residents 72
92 Cultural Diversity and Psychiatry: Clinical Care, Research, and Education 93

MEDIA WORKSHOP

3 Cheek: A Portrait of Multicultural America at the Flashpoint 48

TOPIC 23: DIAGNOSTIC ISSUES

SCIENTIFIC AND CLINICAL REPORTS

19 Screening for History of Physical, Emotional, and Sexual Abuse: How Do We Ask About Abuse? 27
20 Kennedy Axis V: The Next Step for Axis V? 27
21 Dimensional Approaches to DSM and the Impact on Diagnostic Instruments 27

SYMPOSIA

6 Insomnia: What Is It? 34
23 Science, Diagnoses, and the Clinician 38
102 A Research Agenda for DSM-V Concerning Religious and Spiritual Issues in the Diagnostic Process 98
108 Bereavement and the DSM-V 100

ISSUE WORKSHOP

16 Assessment of Capacity: Developments, DVDs, and Defense Organizations 29

TOPIC 24: EMERGENCY PSYCHIATRY

FORUM

14 Addressing Psychiatric Needs in Asia 79

SCIENTIFIC AND CLINICAL REPORT

87 Associations Between Psychiatric Disorder and Commitment Criteria in Acute Involuntarily Admitted Patients in the Netherlands 76

COMPONENT WORKSHOP

1 Disaster Psychiatry: Practical Skills to Help District Branches Develop Disaster Plans for Their Communities 21

TOPIC 25: EPIDEMIOLOGY

SCIENTIFIC AND CLINICAL REPORTS

64 Mental Health in Iranian Medical Students and Doctors 53
65 Three-Year, Follow-Up Study of the Psychosocial Predictors of Delayed and Unresolved Post-Traumatic Stress Symptoms of Geriatric Earthquake Survivors in Yu-Chi, Taiwan 53
66 Three-Year, Follow-Up Study of the Relationship Between Post-Traumatic Stress Symptoms and Quality of Life Among Geriatric Earthquake Survivors in Yu-Chi, Taiwan 53
85 Death by UnnaturalCause During Childhood and Early Adulthood in Offspring of Psychiatric Inpatients 76
86 The Incidence and Prevalence of Diabetes Mellitus Among Inpatients in State-Operated Psychiatric Hospitals in New York State 1997-2004 76
125 Substance-Related Disorders and Dual Diagnosis in a Random Nation-Wide Sample of 998 Prisoners: Prevalence and Risk Factors 96

SYMPOSIUM

50 Prevention of Common Mental Disorders: Is It Time to Start? 61

COMPONENT WORKSHOPS

14 Psychiatric Ethics in the United States and Throughout the World 28
28 Ten Ways to Stay Out of Trouble: Ethics and Etiquette 47

TOPIC 26: ETHICS AND HUMAN RIGHTS

COURSE

33 Bioethics Update 2006 8

SCIENTIFIC AND CLINICAL REPORTS

4 Ethics and Psychobiological Research 25
5 Terrorism and Medical Ethics: Conflicting Loyalties for American Psychiatrists 25
6 A New Mental Health Act: An Australian Experience 25

SYMPOSIA

2 Therapeutic Misconception in Clinical Research 33
57 Voting by Persons With Cognitive Impairment 63
69 Pharmaceutical Industry Influence in Psychiatry 81

ISSUE WORKSHOP

51 Are There Limits to Boundary Limits? 54

TOPIC 27: FORENSIC PSYCHIATRY

CLINICAL CASE CONFERENCE

4 Crossing the Line: Determining Your Patient is Too Dangerous to Drive 68

COURSES

42 The Psychiatrist as Expert Witness 18
62 The Detection of Malingered Mental Illness 44
83 Insanity Defense Evaluations 68

FORUM

12 Correctional Mental Health Issues: An International Perspective 55

LECTURE

1 The Challenge of Employment-Related Psychiatric Evaluations 10

SCIENTIFIC AND CLINICAL REPORT

115 A Review of Chemical Castration and Its Use in the U.S. Penal System 95

SYMPOSIA

21 Criminalization of Mental Illness: Getting In and Out In New York 37
93 Teaching Psychiatry Residents About Informed Consent 87
115 Armed and Dangerous: Is Your Patient Safe to Return to Work? 101

COMPONENT WORKSHOPS

4 Severely Mentally Ill Persons in Jails and Prisons: Who Should Stay? 21
49 Current Issues in Psychiatry and Law 78

ISSUE WORKSHOPS

55 Psycho-Killer: Mental Illness and Homicide 71
62 Detection of Malingering 72
98 Identifying and Managing Patients With Schizophrenia and a Genetic Syndrome 97
<table>
<thead>
<tr>
<th>TOPIC INDEX</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TOPIC 28: GERIATRIC PSYCHIATRY</strong></td>
</tr>
<tr>
<td>COURSES</td>
</tr>
<tr>
<td>32</td>
</tr>
<tr>
<td>41</td>
</tr>
<tr>
<td>56</td>
</tr>
<tr>
<td>60</td>
</tr>
<tr>
<td>88</td>
</tr>
<tr>
<td>INDUSTRY-SUPPORTED SYMPOSIUM</td>
</tr>
<tr>
<td>38</td>
</tr>
<tr>
<td>LECTURE</td>
</tr>
<tr>
<td>20</td>
</tr>
<tr>
<td>SCIENTIFIC AND CLINICAL REPORTS</td>
</tr>
<tr>
<td>31</td>
</tr>
<tr>
<td>32</td>
</tr>
<tr>
<td>33</td>
</tr>
<tr>
<td>SYMPOSIAS</td>
</tr>
<tr>
<td>76</td>
</tr>
<tr>
<td>COMPONENT WORKSHOPS</td>
</tr>
<tr>
<td>12</td>
</tr>
<tr>
<td>16</td>
</tr>
<tr>
<td>ISSUE WORKSHOP</td>
</tr>
<tr>
<td>101</td>
</tr>
<tr>
<td><strong>TOPIC 29: NEUROPSYCHIATRY</strong></td>
</tr>
<tr>
<td>COURSES</td>
</tr>
<tr>
<td>37</td>
</tr>
<tr>
<td>46</td>
</tr>
<tr>
<td>47</td>
</tr>
<tr>
<td>59</td>
</tr>
<tr>
<td>INDUSTRY-SUPPORTED SYMPOSIUM</td>
</tr>
<tr>
<td>22</td>
</tr>
<tr>
<td>SCIENTIFIC AND CLINICAL REPORT</td>
</tr>
<tr>
<td>61</td>
</tr>
<tr>
<td><strong>TOPIC 30: PAIN MANAGEMENT</strong></td>
</tr>
<tr>
<td>ISSUE WORKSHOP</td>
</tr>
<tr>
<td>50</td>
</tr>
<tr>
<td><strong>TOPIC 31: PSYCHIATRIC EDUCATION</strong></td>
</tr>
<tr>
<td>COURSES</td>
</tr>
<tr>
<td>5</td>
</tr>
<tr>
<td>11</td>
</tr>
<tr>
<td>40</td>
</tr>
<tr>
<td>67</td>
</tr>
<tr>
<td>70</td>
</tr>
<tr>
<td>75</td>
</tr>
<tr>
<td>91</td>
</tr>
<tr>
<td>DISCUSSION GROUP</td>
</tr>
<tr>
<td>13</td>
</tr>
<tr>
<td>MASTER EDUCATOR CLINICAL CONSULTATION</td>
</tr>
<tr>
<td>15</td>
</tr>
<tr>
<td>SCIENTIFIC AND CLINICAL REPORTS</td>
</tr>
<tr>
<td>25</td>
</tr>
<tr>
<td>26</td>
</tr>
<tr>
<td>27</td>
</tr>
<tr>
<td>SYMPOSIAS</td>
</tr>
<tr>
<td>24</td>
</tr>
<tr>
<td>71</td>
</tr>
<tr>
<td>COMPONENT WORKSHOP</td>
</tr>
<tr>
<td>41</td>
</tr>
<tr>
<td>ISSUE WORKSHOPS</td>
</tr>
<tr>
<td>1</td>
</tr>
<tr>
<td>2</td>
</tr>
<tr>
<td>20</td>
</tr>
<tr>
<td>22</td>
</tr>
<tr>
<td>29</td>
</tr>
<tr>
<td>39</td>
</tr>
<tr>
<td>42</td>
</tr>
<tr>
<td>43</td>
</tr>
<tr>
<td>54</td>
</tr>
<tr>
<td>87</td>
</tr>
<tr>
<td>104</td>
</tr>
<tr>
<td>108</td>
</tr>
<tr>
<td><strong>TOPIC 32: PSYCHIATRIC REHABILITATION</strong></td>
</tr>
<tr>
<td>COURSE</td>
</tr>
<tr>
<td>18</td>
</tr>
</tbody>
</table>
# TOPIC INDEX

## TOPIC 33: PSYCHOIMMUNOLOGY

### SCIENTIFIC AND CLINICAL REPORT
- 44 Potential Role of Interleukin-6 and HPA Axis in Breast Cancer Patients With MDD 51

## TOPIC 34: RESEARCH ISSUES

### ADVANCES IN RESEARCH
An Update for the Clinician 23

### COURSE
- 2 Research on a Shoestring Budget 1

### FORUM
- 2 Research Planning for DSM-V 30

### INDUSTRY-SUPPORTED SYMPOSIUM
- 3 Navigating the Maze: Understanding Methods, Results, and Risks in Psychiatric Research 2

### LECTURE
- 3 Rediscovering Our Place in the World 20

### MASTER EDUCATOR CLINICAL CONSULTATION
- 7 Building a Research Career in Psychiatry 46

### MEDICAL UPDATE
- 1 Congestive Heart Failure 25

### NEW RESEARCH SESSIONS
- 1 New Research Young Investigators' Poster Session 21
- 2 New Research Young Investigators' Oral/Slide Session 31
- 3 New Research Young Investigators' Oral/Slide Session 31
- 4 New Research Young Investigators' Oral/Slide Session 31
- 5 New Research Poster Session 40
- 6 New Research Poster Session 55
- 7 New Research Poster Session 65
- 8 New Research Poster Session 79
- 9 New Research Poster Session 89
- 10 New Research Poster Session 98

### RESEARCH ADVANCES IN MEDICINE
Aging, Longevity and Neurological Disorders 46

### SYMPOSIUM
- 31 Nancy C. Andreasen, M.D.: Festschrift for Her 13 Years as Journal Editor 40
- 36 Diagnostic Criteria in Alzheimer's Disease and Dementia: Research Challenges and Implications for DSM-V 58
- 53 Stress-Induced Fear in Anxiety Disorders: Planning the Research Agenda for DSM-V 62

### ISSUE WORKSHOP
- 88 So You Want to Be a Clinical Investigator 93

## TOPIC 35: SOCIAL AND COMMUNITY PSYCHIATRY

### COURSE
- 57 Overview of Correctional Psychiatry 31

## TOPIC 36: SUICIDE

### RESEARCH CONSULTATION WITH
- 2 Clinical Research Into Suicide 50

### SCIENTIFIC AND CLINICAL REPORTS
- 112 Distinguishing Patients Who Attempt Suicide From Patients With Ideation Only 95
- 113 Hopelessness and Suicidality: Three Months Post-Hospital Discharge 95
- 114 Parental Socioeconomic Status, Psychiatric Disorders, and Suicidality as Risk Factors of Subsequent Suicide of Offspring: The Northern Finland 1966 Birth Cohort Study 95
- 119 Patterns of Antidepressant Prescribing and Suicide in Israel 95

### SYMPOSIAS
- 43 Suicide Research in Canada 60
- 119 Suicide on College Campuses: Practical and Ethical Issues 102

### COMPONENT WORKSHOP
- 21 Bridge Suicide: The Prince Edward Viaduct in Toronto and the Golden Gate Bridge in San Francisco 47

### ISSUE WORKSHOP
- 71 Responding to the Impact of Suicide on Clinicians 78

## TOPIC 37: VIOLENCE, TRAUMA, AND VICTIMIZATION

### COURSES
- 21 Risk Assessment for Violence 5
- 35 Psychiatric Interventions in Disasters and Public Health Emergencies: Theory to Practice 8
- 55 Child Murder by Parents 31
- 61 Disaster Psychiatry: Terrorism, Trauma, and Things to Do 43
- 65 Personality and Political Behavior 44
- 78 Assessing the Risk of Violence in Forensic and Sex Offender Settings 56

### FORUM
- 13 Katrina: Psychiatric Responses and Care for Individuals and Communities 79
### TOPIC 38: BEHAVIOR AND COGNITIVE THERAPIES

**COURSES**

- 3 Cognitive Therapy for Schizophrenia: A New Paradigm: 1
- 8 Cognitive Therapy for Severe Mental Disorders: 8
- 6 Cognitive Therapy for the Elderly: A Practical Approach: 6
- 45 Engaging Resistant and Difficult-to-Treat Patients Into Collaborative Treatment: 45
- 48 Cognitive Therapy on the Fly: 48
- 64 Cognitive Behavioral Therapy Boot Camp for Psychiatrists: Emphasizing the Practical: 64

**DISCUSSION GROUP**

- 3 Learning From Cognitive-Behavior Therapy: What Are the Most Powerful Methods for Everyday Clinical Use?: 3

**LECTURE**

- 9 New Advances in Cognitive Therapy: 9

**ISSUE WORKSHOPS**

- 8 But Can We Do It Here? Challenges of Implementing Cognitive-Behavior Therapy for Schizophrenia Programs in the U.S.: 8
- 23 Cognitive Therapy for Psychosis: Basic Techniques for Psychiatrists: 23
- 37 Cognitive Therapy for Personality Disorders: 37
- 58 Training Psychiatric Residents in the Cognitive Therapy of Schizophrenia: 58
- 85 Dialectical Behavioral Therapy With Adolescents: 85
- 100 Performance Enhancement Psychological Techniques in Golf: 100

### TOPIC 39: COMBINED PHARMACOTHERAPY AND PSYCHOTHERAPY

**COURSES**

- 66 A Psychodynamic Approach to Treatment Refractory Mood Disorders: 66
- 92 Treating Comorbid Adult ADHD by Combining Medication and Cognitive Therapy: Practical Solutions to Common Clinical Problems: 92
# TOPIC INDEX

<table>
<thead>
<tr>
<th>COURSES</th>
<th>Page#</th>
</tr>
</thead>
<tbody>
<tr>
<td>9  A Comprehensive Review of Hypnosis Use in Clinical Psychiatry</td>
<td>1</td>
</tr>
<tr>
<td>10 Dream Translation: One Empirically-Based Approach</td>
<td>2</td>
</tr>
<tr>
<td>20 Interpersonal Psychotherapy</td>
<td>5</td>
</tr>
<tr>
<td>23 Davenko's Intensive Short-Term Dynamic Psychotherapy in Clinical Practice</td>
<td>6</td>
</tr>
<tr>
<td>27 Psychotherapy for Borderline Personality</td>
<td>7</td>
</tr>
<tr>
<td>30 Updates in Neuropsychiatry: Delirium, Traumatic Brain Injury, and Post-Stroke/Post-MI Depression</td>
<td>7</td>
</tr>
<tr>
<td>34 Short-Term Psychoanalytic Supportive Psychotherapy in the Treatment of Depression</td>
<td>8</td>
</tr>
<tr>
<td>49 Advanced Interviewing Techniques</td>
<td>18</td>
</tr>
<tr>
<td>54 The Advanced Practice of Psychotherapy</td>
<td>31</td>
</tr>
<tr>
<td>68 Achieving and Sustaining Psychotherapy Effectiveness</td>
<td>45</td>
</tr>
<tr>
<td>87 Love, Desire, Intimacy, and Infidelity: Useful Concepts for the Psychotherapist</td>
<td>69</td>
</tr>
<tr>
<td><strong>FOCUS LIVE SESSION</strong></td>
<td></td>
</tr>
<tr>
<td>3 Psychotherapy</td>
<td>31</td>
</tr>
<tr>
<td><strong>SYMPOSIUM</strong></td>
<td></td>
</tr>
<tr>
<td>73 The Art and Science of Brief Psychotherapies</td>
<td>82</td>
</tr>
<tr>
<td><strong>COMPONENT WORKSHOP</strong></td>
<td></td>
</tr>
<tr>
<td>15 Teaching the Working Alliance as a Core Process Across the Psychotherapies</td>
<td>28</td>
</tr>
<tr>
<td><strong>ISSUE WORKSHOPS</strong></td>
<td></td>
</tr>
<tr>
<td>57 Dynamic Therapy With Self-Destructive Borderlines</td>
<td>72</td>
</tr>
<tr>
<td>80 Going to the Heart of the Matter in Patient Interviews</td>
<td>92</td>
</tr>
<tr>
<td>84 Race and Countertransference in the Clinical Setting</td>
<td>93</td>
</tr>
<tr>
<td><strong>TOPIC 43: OTHER SOMATIC THERAPIES</strong></td>
<td></td>
</tr>
<tr>
<td><strong>COURSES</strong></td>
<td></td>
</tr>
<tr>
<td>12 Introduction to Transcranial Magnetic Stimulation</td>
<td>3</td>
</tr>
<tr>
<td>24 Kundalini Yoga Meditation Techniques for Mental Health</td>
<td>7</td>
</tr>
<tr>
<td>72 The Way of Yoga and Herbs in Treatment of Stress, Depression, Aggression, PTSD, and Mass Trauma</td>
<td>55</td>
</tr>
<tr>
<td>85 EEG Neurofeedback in Psychiatry: Clinical Applications</td>
<td>68</td>
</tr>
<tr>
<td>96 Yoga in Psychiatry: Theory, Clinical Applications, and Beginning Practice</td>
<td>80</td>
</tr>
<tr>
<td>98 Vagus Nerve Stimulation</td>
<td>91</td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORTS</strong></td>
<td></td>
</tr>
<tr>
<td>70 Predictors of Referral for ECT</td>
<td>75</td>
</tr>
<tr>
<td>71 ECT Stimulus Dose as Physiological Volume of Seizure Foci</td>
<td>75</td>
</tr>
<tr>
<td><strong>ISSUE WORKSHOP</strong></td>
<td></td>
</tr>
<tr>
<td>66 When Therapeutic Lifestyle Changes Fail: Pharmacologic Management of Metabolic Syndrome in Psychiatry</td>
<td>78</td>
</tr>
<tr>
<td><strong>TOPIC 44: PSYCHOPHARMACOLOGY</strong></td>
<td></td>
</tr>
<tr>
<td><strong>COURSES</strong></td>
<td></td>
</tr>
<tr>
<td>4 Interpersonal Psychotherapy</td>
<td>5</td>
</tr>
<tr>
<td>31 Drug Treatment of Schizophrenia</td>
<td>5</td>
</tr>
<tr>
<td><strong>DISCUSSION GROUP</strong></td>
<td></td>
</tr>
<tr>
<td>10 New Developments in Impulse-Control Disorders and Autism</td>
<td>45</td>
</tr>
<tr>
<td><strong>FORUM</strong></td>
<td></td>
</tr>
<tr>
<td>9 Hot Topics in Psychiatric Drug Safety</td>
<td>55</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>INDUSTRY-SUPPORTED SYMPOSIAS</th>
<th>Page#</th>
</tr>
</thead>
<tbody>
<tr>
<td>26 Clinical Implications of Choices of Atypical Antipsychotics:</td>
<td>17</td>
</tr>
<tr>
<td>Realities and Myths, Part 1</td>
<td></td>
</tr>
<tr>
<td>26 Clinical Implications of Choices of Atypical Antipsychotics:</td>
<td>43</td>
</tr>
<tr>
<td>Realities and Myths, Part 2</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MASTER EDUCATOR CLINICAL CONSULTATION</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>10 Atypical Antipsychotics: 2006 and Beyond</td>
<td>50</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SCIENTIFIC AND CLINICAL REPORTS</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>83 Meta-Analysis of Efficacy of Paroxetine Versus Placebo Utilizing the GlaxoSmithKline Clinical Trials Registry</td>
<td>76</td>
</tr>
<tr>
<td>84 Resolution of Sleepiness and Fatigue in the Treatment of MDD: A Comparison of Bupropion and SSRIs</td>
<td>76</td>
</tr>
<tr>
<td>89 Theoretical Implications of Improved Depression Severity by PDE5i Sildenafil Treatment of Erectile Dysfunction Associated With Treated or Untreated MDD for Endothelial Dysfunction Mediation</td>
<td>76</td>
</tr>
<tr>
<td>100 Desvenlafaxine: Preclinical Evidence for SHT and Norepinephrine Release Inhibition, Antidepressant, and Antisocial Activity</td>
<td>94</td>
</tr>
<tr>
<td>101 Efficacy and Safety of Desvenlafaxine Succinate in the Treatment of MDD</td>
<td>94</td>
</tr>
<tr>
<td>128 Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Taiwanese Children and Adolescents With ADHD</td>
<td>96</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SYMPOSIUM</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>60 The Meanings of Medication: Issues in Patients Compliance With Psychotropic Drugs</td>
<td>63</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ISSUE WORKSHOPS</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>4 Extrapyramidal Side Effects and Tardive Dyskinesia in the Atypical Antipsychotic Era</td>
<td>22</td>
</tr>
<tr>
<td>14 New Research Advances in Ethnopsychopharmacology</td>
<td>23</td>
</tr>
<tr>
<td>38 Evidence Supported, Risk Minimizing, and Cost-Conscious Approaches in Psychopharmacology</td>
<td>48</td>
</tr>
<tr>
<td>93 Cardiovascular Complications of Second Generation Antipsychotic Drugs</td>
<td>93</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TOPIC 45: TREATMENT TECHNIQUES AND OUTCOME STUDIES</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>COURSES</strong></td>
<td></td>
</tr>
<tr>
<td>22 Using Boundary Crossings as Creative Therapy Instead of Slippery Slopes</td>
<td>5</td>
</tr>
<tr>
<td>86 An Introduction to Complicated Grief Treatment</td>
<td>68</td>
</tr>
<tr>
<td>89 The Assessment and Treatment of Child Sexual Abusers</td>
<td>69</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MASTER EDUCATOR CLINICAL CONSULTATION</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>6 Clinical Research Across Geographic Borders: Challenges and Opportunities</td>
<td>25</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MEDICAL UPDATE</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>4 Liver Transplant Update: Current Outcomes and Challenges in 2006</td>
<td>94</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SCIENTIFIC AND CLINICAL REPORTS</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>59 The Swedish Study of Metabolic Risks in Psychiatry</td>
<td>52</td>
</tr>
<tr>
<td>72 The Efficacy and Outcome of Combining ECT and Atypical Antipsychotics for Treatment-Resistant Depression</td>
<td>75</td>
</tr>
<tr>
<td>81 Quetiapine for Bipolar Disorder and Schizophrenia: Appropriate Dose for Optimal Response</td>
<td>75</td>
</tr>
<tr>
<td>90 Efficacy of Sildenafil for the Treatment of Erectile Dysfunction in Men Taking Antidepressant Medication: Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Studies</td>
<td>76</td>
</tr>
<tr>
<td>116 Acupuncture and Cognitive-Behavior Therapy for PTSD</td>
<td>95</td>
</tr>
</tbody>
</table>
SYMPOSIA
25 Developing Strategies in Psychotherapy Research 38
72 The Problem of Outcomes With the Difficult-to-Treat Patient 82
78 Use of Quantitative Instruments for Monitoring Depression Severity: Clinical Applications 83
94 Sustained Recovery and Healthy Functioning: The Long and Short of It 87

OTHER ISSUES

TOPIC 46: COMPUTERS

ISSUE WORKSHOP
91 Computer Tools for Cognitive-Behavior Therapy: Integrating Technology into Clinical Practice 93

TOPIC 47: CREATIVITY AND THE ARTS

COURSE
93 Reel Psychiatry 79

FORUM
3 Mozart at 250: The Mind and Music of a Genius 30

SCIENTIFIC AND CLINICAL REPORT
106 Family Background and Genius: Nobel Laureates in Science 94

SYMPOSIA
14 The Mid-Life Crisis as Interpreted in Film and Television 36
104 Psychiatry on the Silver Screen 99

TOPIC 48: ELECTRONIC MEDICAL RECORDS

COMPONENT WORKSHOP
42 The National Health Information Network and Psychiatry: How Will the Coming National Electronic Health Record Impact Our Patients and Our Practice? 71

ISSUE WORKSHOP
79 Use of a Standardized Comprehensive Psychiatric Assessment Tool to Facilitate Evidence-Based Decisions: The InterRAI Mental Health 92

TOPIC 49: GENDER ISSUES

LECTURE
17 Changing the Landscape of American Psychiatry: An African-American Perspective on Expansive Personality in Women 56

MASTER EDUCATOR CLINICAL CONSULTATION
5 Late-Life Aging Processes and Mental Illness 25

SCIENTIFIC AND CLINICAL REPORT
94 Gender Differences in Schizophrenia and Other Psychotic Disorders: A 20-Year Follow-up Study 77

TOPIC 50: HEALTH SERVICES RESEARCH

LECTURE
4 The Search for Quality and Equity in Care for Psychiatric Disorders: A Story of Opportunity, Evidence, and Partners 20

RESEARCH CONSULTATION WITH
3 Mental Health Policy Research 74

SCIENTIFIC AND CLINICAL REPORTS
3 The System for Classification of Inpatient Psychiatry: A New Case-Mix Methodology for Mental Health 25
79 An Effectiveness Trial of a Brief Cognitive Behavioral Intervention by Mental Health Nurses in Schizophrenia: Clinically Important Outcomes in the Medium Term 75
97 All Equal? Advocating Equity in Mental Health Services in France to Ethnic-Minority Disadvantaged Youth and their Families through the Evidence-Based FAQ* Protocol 77
121 Lifestyle Issues in Mental Health: Social Support, Diet, Fitness, and Recreation 95

ISSUE WORKSHOPS
63 The Quality Information System: A New System for Measuring Progress in the Doctor-Patient Relationship 72
89 Collaborative Mental Health Care in Canada 93

TOPIC 51: HISTORICAL QUESTIONS

COMPONENT WORKSHOP
40 Teaching the History of Psychiatry to Students and Residents: A Workshop Discussion on Content, Methods, and Ideals 71

TOPIC 52: INFORMATION TECHNOLOGY

DISCUSSION GROUP
14 The Clinical Use of Buprenorphine 49

SYMPOSIUM
111 Using Technology to Improve Patient Care 100

TOPIC 53: INTERNET

COURSE
97 Psychiatry and the Internet 80

ISSUE WORKSHOP
15 Online Peer Support Groups and Support Group Members 23

115
## TOPIC INDEX

### TOPIC 54: LESBIAN/GAY/BISEXUAL/TRANSGENDER ISSUES

<table>
<thead>
<tr>
<th>Discussion Group</th>
<th>Page#</th>
</tr>
</thead>
<tbody>
<tr>
<td>Guy Men and Crystal Meth Abuse</td>
<td>45</td>
</tr>
<tr>
<td>Sexual Orientation and Gender Identity in Clinical Care</td>
<td>70</td>
</tr>
<tr>
<td>Working with Lesbian, Gay, Bisexual, and Transgendered Patients: What do you need to know?</td>
<td>74</td>
</tr>
</tbody>
</table>

### SCIENTIFIC AND CLINICAL REPORT

| 108 | The Parent's Perspective on Gender Variant Children and Adolescents: Concerns, Hopes, and Joys | 94 |

### SYMPOSIA

| 5 | Sexual Orientation and Sports | 33 |
| 98 | Same Sex Civil Marriage: Historical and Mental Health Research Perspectives | 88 |

### COMPONENT WORKSHOP

| 46 | A Research Agenda for DSM-V: Mental Health in the Gay, Lesbian, and Bisexual Populations | 98 |

### ISSUE WORKSHOP

| 77 | Can I Change? A Journey Through Ex-Gay Ministries and Beyond | 92 |

### MEDIA WORKSHOP

| 7 | Bad Education: Portraying Transsexualism, Pedophilia, and Addiction | 93 |

### TOPIC 55: MANAGED CARE AND HEALTH CARE FUNDING

| 82 | Current CPT Coding and Documentation Requirements | 68 |

### COURSES

| 2 | Pay for Performance: Linking Incentives to Provider Performance on Quality Measures | 21 |
| 8 | CPT Coding and Documentation Update | 21 |
| 23 | Managed Pharmacy and Pay for Performance: The New Managed Care | 47 |

### TOPIC 56: MEN'S HEALTH ISSUES

| 3 | Testosterone Replacement Therapy in the Aging Male: Implications for Psychiatry and Other Disciplines | 74 |

### TOPIC 57: NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM

| 4 | Women and Alcohol Use Disorders | 30 |
| 11 | The Future of Alcohol Research: NIAAA Resident Travel Award Winners With Discussion by a Panel of Senior Researchers | 55 |

### LECTURES

| 13 | What Have We Learned About Alcoholism From Animal Models? | 46 |
| 18 | Pharmacogenetics of Alcohol: Are We There Yet? | 56 |
| 21 | Combining Neuroimaging and Pharmacology to Better Treat Alcoholism? | 70 |
| 24 | A University President's Perspective on Alcohol Related Research | 73 |
| 25 | Beyond Dopamine: Neuroadaptations, Negative Affect, and Clinically Relevant Treatment Targets in Alcoholism | 80 |
| 26 | Medications That Act as Ion Channels as Treatment for Alcohol Dependence | 80 |

### RESEARCH CONSULTATION WITH

| 1 | Clinical Research on Alcohol Use Disorders | 25 |

### SYMPOSIA

| 13 | Substance Use Disorders in the U.S. | 35 |
| 26 | Taking Science to Policy: Efforts to Reduce Harms Related to Alcohol Misuse | 39 |
| 38 | Screening, Diagnosis, and Management of Alcohol Use Disorders in Psychiatric Practice | 58 |
| 48 | Substance Use Disorders: Planning a Research Agenda for DSM-V | 61 |
| 59 | Genetic Findings Related to Alcohol Dependence and Related Conditions | 63 |
| 66 | Risk Factors, Personality Variables, and Addictive Disorders | 81 |
| 82 | Adolescent Alcohol Use Disorders and Psychiatric Comorbidity | 84 |
| 87 | Alcohol, Drugs, and Psychiatric Disorders in the U.S. | 85 |
| 88 | Sobering Facts: Alcohol Dependence and Treatment Interventions | 86 |
| 97 | Translating the Neurobiology of Alcoholism Into Clinical Treatments | 88 |

### ISSUE WORKSHOPS

| 3 | Managing Complex Comorbid Psychiatric and Alcohol Use Disorders in Psychiatric Practice | 22 |
| 40 | Practical Pharmacotherapy for the Treatment of Alcohol Dependence | 48 |
| 68 | Applying for National Institute of Alcohol Abuse and Alcoholism Research Money: Some Things You Didn't Learn in Graduate School | 78 |
| 99 | Disasters, Public Policy, and Addiction Psychiatry | 97 |
| 102 | Medical Comorbidity in Dual Diagnosis Patients | 97 |

### MEDIA WORKSHOP

| 6 | Carter's Addiction Substance Use Disorders in Physicians | 72 |

### TOPIC 58: PATIENT SAFETY

### MASTER EDUCATOR CLINICAL CONSULTATION

| 6 | Clinical Research Across Geographic Borders: Challenges and Opportunities | 25 |

### SYMPOSIUM

| 84 | Patient Safety: To Err Is Human, To Be Safe Is Divine | 85 |

### TOPIC 59: PERSONAL DIGITAL ASSISTANTS (PDA)

### COURSES

<p>| 58 | How to Use Your Palm OS Personal Digital Assistant in Psychiatric Practice: Introductory Course | 43 |
| 71 | How to Use Your Palm OS Personal Digital Assistant in Psychiatric Practice: Advanced Course | 55 |
| 81 | How to Use Your Pocket PC Personal Digital Assistant in Psychiatric Practice | 68 |</p>
<table>
<thead>
<tr>
<th>TOPIC INDEX</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TOPIC 60: POLITICAL QUESTIONS</strong></td>
</tr>
<tr>
<td><strong>COMPONENT WORKSHOP</strong></td>
</tr>
<tr>
<td>34 European Psychiatry: Health and Mental Health Policy After the Helsinki Summit</td>
</tr>
<tr>
<td><strong>TOPIC 61: PRESIDENTIAL THEME: FROM SCIENCE TO PUBLIC POLICY: ADVOCACY FOR PATIENTS AND THE PROFESSION</strong></td>
</tr>
<tr>
<td><strong>DISCUSSION GROUP</strong></td>
</tr>
<tr>
<td>15 Getting the Psychiatric Message to the Public: You Can Do It</td>
</tr>
<tr>
<td><strong>PRESIDENTIAL SYMPOSIUM</strong></td>
</tr>
<tr>
<td>2 International Advocacy Towards a Psychiatry for the Person</td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORT</strong></td>
</tr>
<tr>
<td>2 Health Policies and the Diagnostic and Statistical Manual</td>
</tr>
<tr>
<td><strong>SYMPOSIUM</strong></td>
</tr>
<tr>
<td>90 Science and Regulation Affecting Private Practice</td>
</tr>
<tr>
<td>110 Infectious Diseases and Psychiatric Symptomatology</td>
</tr>
<tr>
<td><strong>COMPONENT WORKSHOPS</strong></td>
</tr>
<tr>
<td>17 Winning the Fight for Mental Health Benefits: Partnering With Employers</td>
</tr>
<tr>
<td>33 Moving the Psychiatric Agenda in the House of Medicine</td>
</tr>
<tr>
<td>36 Integrating Evidence-Based Psychiatry With Clinical Intelligence</td>
</tr>
<tr>
<td>37 Data Coupled With Advocacy Shaping Public Policy</td>
</tr>
<tr>
<td><strong>ISSUE WORKSHOPS</strong></td>
</tr>
<tr>
<td>31 The Creation and Function of a Mental Health Court</td>
</tr>
<tr>
<td>60 Assisted Outpatient Treatment and Its Role in the Fabric of the Mental Health System</td>
</tr>
<tr>
<td>76 Direct to Consumer Marketing: Just Who Is the Consumer?</td>
</tr>
<tr>
<td><strong>TOPIC 62: PROFESSIONAL AND PERSONAL ISSUES</strong></td>
</tr>
<tr>
<td><strong>COURSES</strong></td>
</tr>
<tr>
<td>16 Improving Your Presentation Skills: A Coaching Approach</td>
</tr>
<tr>
<td>79 Cover Your Assets: Improved Patient Care through Malpractice Protection</td>
</tr>
<tr>
<td>84 Treating Medical Students and Physicians</td>
</tr>
<tr>
<td>100 The Evaluation and Treatment of Physicians Involved in Sexual Misconduct and Sexual Harassment</td>
</tr>
<tr>
<td><strong>DISCUSSION GROUP</strong></td>
</tr>
<tr>
<td>1 The New Handbook on Professional Development for Academic Psychiatrists</td>
</tr>
<tr>
<td><strong>FORUM</strong></td>
</tr>
<tr>
<td>6 The Theory and Practice of Apology</td>
</tr>
<tr>
<td><strong>MASTER EDUCATOR CLINICAL CONSULTATION</strong></td>
</tr>
<tr>
<td>8 Treating Physicians and Their Families: Clinical Dilemmas</td>
</tr>
<tr>
<td><strong>ISSUE WORKSHOPS</strong></td>
</tr>
<tr>
<td>9 Teaching Boundaries to Practicing Clinicians</td>
</tr>
<tr>
<td><strong>SYMPOSIUM</strong></td>
</tr>
<tr>
<td>51 How to Launch a Successful Private Practice: Part 3</td>
</tr>
<tr>
<td><strong>COMPONENT WORKSHOPS</strong></td>
</tr>
<tr>
<td>19 Facilitating Minority to Excel in Academic Psychiatry</td>
</tr>
<tr>
<td>22 You Can Be Leaders Too: A Workshop for IMGs and Minorities</td>
</tr>
<tr>
<td>43 Novel Careers in Psychiatry: Women Who Have Made Their Own Way</td>
</tr>
<tr>
<td><strong>ISSUE WORKSHOPS</strong></td>
</tr>
<tr>
<td>7 Risk Management Issues in Psychiatric Practice</td>
</tr>
<tr>
<td>12 Reinventing Careers: Transitions and Later-Life Strategies for Psychiatrists</td>
</tr>
<tr>
<td>13 American Board of Psychiatry and Neurology Update: Certification and Maintenance of Certification in Psychiatry and Its Subspecialties</td>
</tr>
<tr>
<td>17 Biopsychosocial and Spiritual Aspects of Treating our Physician Colleagues</td>
</tr>
<tr>
<td>30 When Psychiatrists Get Cancer</td>
</tr>
<tr>
<td>41 How to Launch a Successful Private Practice: Part 1</td>
</tr>
<tr>
<td>47 How to Launch a Successful Private Practice: Part 2</td>
</tr>
<tr>
<td>61 Psychiatrists in the Dean’s Office: Career Opportunities and Career Development</td>
</tr>
<tr>
<td>70 Maintenance of Certification for Diplomats of the American Board of Psychiatry and Neurology</td>
</tr>
<tr>
<td>74 The Key to Success, Mentorship Matters: A Practical Guide for Trainees and Educators</td>
</tr>
<tr>
<td>83 International Medical Graduates in Training and Practice: Professional and Personal Trials</td>
</tr>
<tr>
<td>94 Children of Psychiatrists</td>
</tr>
<tr>
<td>107 Psychiatrists Who Have Faced Mental Illness in Themselves: There Is a Silver Lining</td>
</tr>
<tr>
<td><strong>TOPIC 63: RELIGION, SPIRITUALITY, AND PSYCHIATRY</strong></td>
</tr>
<tr>
<td><strong>COURSE</strong></td>
</tr>
<tr>
<td>99 Spirituality and Worldview in Clinical Practice</td>
</tr>
<tr>
<td><strong>LECTURE</strong></td>
</tr>
<tr>
<td>8 Culture, Spirituality and Psychiatry: A Psycho-Historical Study of King Saul</td>
</tr>
<tr>
<td><strong>MASTER EDUCATOR CLINICAL CONSULTATION</strong></td>
</tr>
<tr>
<td>13 The Role of Spirituality in the Care of Patients</td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORT</strong></td>
</tr>
<tr>
<td>130 Spirituality and Recovery From Depression</td>
</tr>
<tr>
<td><strong>SYMPOSIUM</strong></td>
</tr>
<tr>
<td>10 Model Curricula on Religion and Spirituality for Psychiatry Residency Training Programs</td>
</tr>
<tr>
<td>118 Complementary, Alternative, and Integrative Approaches in Mental Health Care</td>
</tr>
<tr>
<td><strong>ISSUE WORKSHOP</strong></td>
</tr>
<tr>
<td>9 Religious and Spiritual Assessment in Clinical Practice</td>
</tr>
<tr>
<td><strong>TOPIC 64: RESIDENT AND MEDICAL STUDENT CONCERNS</strong></td>
</tr>
<tr>
<td><strong>DISCUSSION GROUPS</strong></td>
</tr>
<tr>
<td>9 Your Resident Career: Getting Started, Getting Funded</td>
</tr>
<tr>
<td>17 Trauma in the Modern World: The Role of the Psychiatrist</td>
</tr>
<tr>
<td>22 The Future of Psychiatry: What the Resident Should Know.</td>
</tr>
<tr>
<td><strong>RESIDENT’S SESSION</strong></td>
</tr>
<tr>
<td>Meet the Experts: Sunny-Side Up</td>
</tr>
</tbody>
</table>
### TOPIC INDEX

**SYMPOSIUM**

<table>
<thead>
<tr>
<th>Page#</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>83</td>
<td>Educating a New Generation of Physicians in Psychiatry: Focus on Medical Student Education</td>
</tr>
</tbody>
</table>

**COMPONENT WORKSHOPS**

<table>
<thead>
<tr>
<th>Page#</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>Career Choices in Psychiatry: Exploring Fellowship Training</td>
</tr>
<tr>
<td>30</td>
<td>Employment in the Post-Residency Year: Getting What You Want</td>
</tr>
<tr>
<td>47</td>
<td>Welcome to the Jungle: The Dynamics Between Residents and Industry</td>
</tr>
</tbody>
</table>

**ISSUE WORKSHOPS**

<table>
<thead>
<tr>
<th>Page#</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>18</td>
<td>Oral Boards Boot Camp: 2006</td>
</tr>
<tr>
<td>67</td>
<td>Countertransference and Boundary Issues of Residents Treating Medical Students, Fellow Residents, and Attending</td>
</tr>
</tbody>
</table>

**TOPIC 65: STIGMA/ADVOCACY**

**LECTURE**

<table>
<thead>
<tr>
<th>Page#</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>11</td>
<td>Prevention, Early Intervention, and Elimination</td>
</tr>
</tbody>
</table>

**SCIENTIFIC AND CLINICAL REPORT**

<table>
<thead>
<tr>
<th>Page#</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>The Impact of an Integrated Community Arts Studio on Stigmatizing Beliefs and Experiences</td>
</tr>
</tbody>
</table>

**SYMPOSIUM**

<table>
<thead>
<tr>
<th>Page#</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>109</td>
<td>NAMI Doctors Sound Off</td>
</tr>
</tbody>
</table>

**ISSUE WORKSHOPS**

<table>
<thead>
<tr>
<th>Page#</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>48</td>
<td>Grassroots Advocacy for Patients and for the Psychiatric Profession: How Medical Students, Residents, and Early Career Psychiatriests Can Affect the Legislative, Regulatory, and Political Process</td>
</tr>
<tr>
<td>53</td>
<td>The Psychiatry/Resident as Advocate: Practical Steps From the Clinic to the Capitol</td>
</tr>
</tbody>
</table>

**TOPIC 66: VIRTUAL REALITY**

**SYMPOSIUM**

<table>
<thead>
<tr>
<th>Page#</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>101</td>
<td>Virtual Environments and Convergent Media Technology</td>
</tr>
</tbody>
</table>

**ISSUE WORKSHOP**

<table>
<thead>
<tr>
<th>Page#</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>27</td>
<td>Virtual Reality and Video Games in the Treatment of Mental Health Disorders and Addictions: An Evidence-Based Analysis</td>
</tr>
</tbody>
</table>

**TOPIC 67: WOMEN'S HEALTH ISSUES**

**CLINICAL CASE CONFERENCE**

<table>
<thead>
<tr>
<th>Page#</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>Rocking the Cradle: A Case of Postpartum Infanticide</td>
</tr>
</tbody>
</table>

**COURSE**

<table>
<thead>
<tr>
<th>Page#</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>19</td>
<td>Management of Psychiatric Disorders in Pregnant and Postpartum Mothers</td>
</tr>
</tbody>
</table>

**DEBATE**

<table>
<thead>
<tr>
<th>Page#</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>Medications in Pregnancy and Lactation: What Have We Learned?</td>
</tr>
</tbody>
</table>

**DISCUSSION GROUPS**

<table>
<thead>
<tr>
<th>Page#</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>Why Women's Mental Health?</td>
</tr>
<tr>
<td>7</td>
<td>Psychotherapy with Women with Breast Cancer</td>
</tr>
</tbody>
</table>

**LECTURE**

<table>
<thead>
<tr>
<th>Page#</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>15</td>
<td>Priorities, Initiatives, and Women's Health Research</td>
</tr>
</tbody>
</table>

**MASTER EDUCATOR CLINICAL CONSULTATIONS**

<table>
<thead>
<tr>
<th>Page#</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>Psychiatric Disorders Across the Female Reproductive Cycle</td>
</tr>
<tr>
<td>4</td>
<td>Perinatal Psychiatric Disorders</td>
</tr>
</tbody>
</table>

**SCIENTIFIC AND CLINICAL REPORTS**

<table>
<thead>
<tr>
<th>Page#</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>95</td>
<td>Severe Personality Disorders in the Offspring of Antenatally-Depressed Mothers: A 31-Year Follow-Up of the Northern Finland 1966 Birth Cohort</td>
</tr>
<tr>
<td>96</td>
<td>Outcome of Prenatal Anxiety, Stress, and Depression</td>
</tr>
</tbody>
</table>

**SYMPOSIA**

<table>
<thead>
<tr>
<th>Page#</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>20</td>
<td>Borderline Mothers and Infant Interactions: Chaotic Contingency</td>
</tr>
<tr>
<td>79</td>
<td>Women's Life Cycle and Mental Health</td>
</tr>
<tr>
<td>86</td>
<td>Science to Policy: Advancing Women's Mental Health</td>
</tr>
</tbody>
</table>

**ISSUE WORKSHOPS**

<table>
<thead>
<tr>
<th>Page#</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>Treatment of Pregnancy-Related Mood Disorders: From Psychiatry to Pediatrics</td>
</tr>
<tr>
<td>25</td>
<td>Establishing a Women's Mental Health Program in an Academic or Private Setting</td>
</tr>
<tr>
<td>44</td>
<td>Infertility: From Patient Care to Advocacy and Public Policy</td>
</tr>
<tr>
<td>106</td>
<td>Desperate Housewives Survive the War of the Worlds: Therapeutic Perspectives on Women's Health</td>
</tr>
</tbody>
</table>
Join APA Today and Qualify for a Rebate

How to Qualify:

You may qualify if you are a psychiatrist in the U.S. or Canada and:

1. Have paid the full-time registration fee for the Annual Meeting ($785 advance, $860 on-site) and
2. Have never been a member of APA.

1. Stop by one of the Membership booths either in the Registration area (near the Registrar) or in the APA Member Center (Exhibit Halls D & G, South Levels 800) to fill out an APA Membership Application. The application must be submitted on-site during the meeting at one of these locations.

2. Additional documentation (proof of ACGME-, AOA-, or RCPS(C)-approved psychiatry residency training and a current, valid medical license) must be received by APA no later than June 30, 2006.

1. The local psychiatric society must approve the application no later than September 30, 2006.

2. The difference in the non-member vs. member Annual Meeting registration fee ($565) will be credited towards your pro-rated 2006 national and local dues with the remaining balance of the rebate amount sent directly to you, or if you choose we can apply the remaining balance to your 2007 dues. It's up to you!

Please stop by one of the Membership booths to learn more about APA member benefits and privileges.

American Psychiatric Association
Healthy Minds. Healthy Lives.
# Participant Index

## APA 159th Annual Meeting

<table>
<thead>
<tr>
<th>A</th>
<th>pg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aaronson, Scott T.</td>
<td>26</td>
</tr>
<tr>
<td>Abbey, Susan</td>
<td>48</td>
</tr>
<tr>
<td>Abel, Kathryn M.</td>
<td>76</td>
</tr>
<tr>
<td>Abt-Durham, Ariana</td>
<td>5, 43</td>
</tr>
<tr>
<td>Abikoff, Howard</td>
<td>26</td>
</tr>
<tr>
<td>Abrams, Karen M.</td>
<td>84</td>
</tr>
<tr>
<td>Abramson, Ronald D.</td>
<td>86</td>
</tr>
<tr>
<td>Adams, Margo S.</td>
<td>21</td>
</tr>
<tr>
<td>Addington, Jean</td>
<td>62</td>
</tr>
<tr>
<td>Adenso, Babatunde A.</td>
<td>82</td>
</tr>
<tr>
<td>Adityanjee, A.</td>
<td>58</td>
</tr>
<tr>
<td>Adler, Lawrence W.</td>
<td>76</td>
</tr>
<tr>
<td>Adler, Lenard A.</td>
<td>26</td>
</tr>
<tr>
<td>Adson, David E.</td>
<td>36</td>
</tr>
<tr>
<td>Ahmed, Iqbal</td>
<td>28, 35</td>
</tr>
<tr>
<td>Asen, Paul</td>
<td>39</td>
</tr>
<tr>
<td>Aisenberg, Dov</td>
<td>95</td>
</tr>
<tr>
<td>Aizenstein, HowardJ.</td>
<td>64</td>
</tr>
<tr>
<td>Akara, Jeffrey</td>
<td>53</td>
</tr>
<tr>
<td>Akarsu, Eyup</td>
<td>51</td>
</tr>
<tr>
<td>Akaslak, Hagag S.</td>
<td>9, 52</td>
</tr>
<tr>
<td>Alarstinen, Anri S.</td>
<td>95</td>
</tr>
<tr>
<td>Alarcon, Renato D.</td>
<td>20, 72</td>
</tr>
<tr>
<td>Albert, David B.</td>
<td>81</td>
</tr>
<tr>
<td>Alejand, Asher</td>
<td>27</td>
</tr>
<tr>
<td>Alejand, Margarita</td>
<td>87</td>
</tr>
<tr>
<td>Alexopoulos, George S.</td>
<td>46</td>
</tr>
<tr>
<td>Alger, Ian E.</td>
<td>22, 48</td>
</tr>
<tr>
<td>Alcala, Daniel A.</td>
<td>62</td>
</tr>
<tr>
<td>Allen, Albert J.</td>
<td>96</td>
</tr>
<tr>
<td>Allen, Jon G.</td>
<td>82</td>
</tr>
<tr>
<td>Allison, Kelly</td>
<td>64</td>
</tr>
<tr>
<td>Almassy, Laura</td>
<td>63</td>
</tr>
<tr>
<td>Almeida, Goretta</td>
<td>75</td>
</tr>
<tr>
<td>Alpert, Jonathan E.</td>
<td>1, 2, 26, 76, 89</td>
</tr>
<tr>
<td>Al-Samarrai, Sadik H.</td>
<td>92</td>
</tr>
<tr>
<td>Alternes, Margaret</td>
<td>29</td>
</tr>
<tr>
<td>Altor, Carol L.</td>
<td>47</td>
</tr>
<tr>
<td>Alves-Bradford, Jean-Marie E.</td>
<td>77</td>
</tr>
<tr>
<td>Amaya-Naranjo, Walter</td>
<td>50</td>
</tr>
<tr>
<td>Ambidge, Cris</td>
<td>53</td>
</tr>
<tr>
<td>Amon, Shahrad M.</td>
<td>54</td>
</tr>
<tr>
<td>Amsterdam, Jay D.</td>
<td>26</td>
</tr>
<tr>
<td>Ancoli-Israel, Sonia</td>
<td>99</td>
</tr>
<tr>
<td>Andermann, Lisa F.</td>
<td>54</td>
</tr>
<tr>
<td>Anderson, Susan L.</td>
<td>37</td>
</tr>
<tr>
<td>Anderson, Allan A.</td>
<td>21, 28</td>
</tr>
<tr>
<td>Anderson, Tanya R.</td>
<td>55, 94</td>
</tr>
<tr>
<td>Andrade, Naline N.</td>
<td>23, 78</td>
</tr>
<tr>
<td>Andreasen, Nancy C.</td>
<td>40, 90</td>
</tr>
<tr>
<td>Andree, Terrance H.</td>
<td>94</td>
</tr>
<tr>
<td>Ansari, Rubaba</td>
<td>76, 94</td>
</tr>
<tr>
<td>Anta, Diana</td>
<td>48</td>
</tr>
<tr>
<td>Anna, Joan M.</td>
<td>54, 71</td>
</tr>
<tr>
<td>Asouma, Naoko</td>
<td>52</td>
</tr>
<tr>
<td>Appelbaum, Paul S.</td>
<td>33, 63, 78, 87, 102</td>
</tr>
<tr>
<td>Appleby, Louis</td>
<td>76</td>
</tr>
<tr>
<td>Appleton, Daryl</td>
<td>74</td>
</tr>
<tr>
<td>Apter-Danon, Gisele</td>
<td>37, 77</td>
</tr>
<tr>
<td>Araujo, Kate</td>
<td>50</td>
</tr>
<tr>
<td>Arboleda-Florez, Julio E.</td>
<td>28, 101</td>
</tr>
<tr>
<td>Arriazones, David B.</td>
<td>11</td>
</tr>
<tr>
<td>Arlinghaus, Kimberly A.</td>
<td>80</td>
</tr>
<tr>
<td>Arnold, Lesley M.</td>
<td>6, 26</td>
</tr>
<tr>
<td>Arnett, Amy</td>
<td>6</td>
</tr>
<tr>
<td>Arntz, Arnoud</td>
<td>85</td>
</tr>
<tr>
<td>Arora, Sanjay</td>
<td>74, 96</td>
</tr>
<tr>
<td>Arroyo, William</td>
<td>21, 32, 47</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>B</td>
<td>pg</td>
</tr>
<tr>
<td>Bach, Dominik</td>
<td>87</td>
</tr>
<tr>
<td>Bagby, R. Michael</td>
<td>37, 65</td>
</tr>
<tr>
<td>Baier, Ursula</td>
<td>64</td>
</tr>
<tr>
<td>Bain, Jerald</td>
<td>74</td>
</tr>
<tr>
<td>Baker, F. M.</td>
<td>79</td>
</tr>
<tr>
<td>Baldacchino, Claudia F.</td>
<td>2</td>
</tr>
<tr>
<td>Baldessin, Ross J.</td>
<td>97</td>
</tr>
<tr>
<td>Ballon, Bruce C.</td>
<td>22, 48, 93, 97</td>
</tr>
<tr>
<td>Banks, Azziza O.</td>
<td>83</td>
</tr>
<tr>
<td>Banon, Elisabeth</td>
<td>87</td>
</tr>
<tr>
<td>Barak, Yoram</td>
<td>28, 52, 95</td>
</tr>
<tr>
<td>Barber, Jacques</td>
<td>38</td>
</tr>
<tr>
<td>Bartz, Mary E.</td>
<td>92</td>
</tr>
<tr>
<td>Barbosa-Morin, Guillaume</td>
<td>94</td>
</tr>
<tr>
<td>Barenboim, Arkady</td>
<td>82</td>
</tr>
<tr>
<td>Bark, Nigel</td>
<td>33</td>
</tr>
<tr>
<td>Baron, David A.</td>
<td>92</td>
</tr>
<tr>
<td>Baron, Stefano</td>
<td>51</td>
</tr>
<tr>
<td>Barroso, Paul J.</td>
<td>102</td>
</tr>
<tr>
<td>Barron, Yehuda</td>
<td>28</td>
</tr>
<tr>
<td>Basset, Anne S.</td>
<td>97</td>
</tr>
<tr>
<td>Bates, Dorothy</td>
<td>30</td>
</tr>
<tr>
<td>Bates, George W.</td>
<td>84</td>
</tr>
<tr>
<td>Batch, Steven L.</td>
<td>86</td>
</tr>
<tr>
<td>Baum, Elton A.</td>
<td>33</td>
</tr>
<tr>
<td>Beamer, Elizabeth A.</td>
<td>97, 100</td>
</tr>
<tr>
<td>Beck, Aaron T.</td>
<td>32</td>
</tr>
<tr>
<td>Beck, Judith S.</td>
<td>48, 54, 82, 93</td>
</tr>
<tr>
<td>Beck, Philip R.</td>
<td>87</td>
</tr>
<tr>
<td>Becker, Daniel F.</td>
<td>50</td>
</tr>
<tr>
<td>Becker, Phillip M.</td>
<td>67</td>
</tr>
<tr>
<td>Beckman, Aartjan T.</td>
<td>29</td>
</tr>
<tr>
<td>Beezhold, Julian</td>
<td>54</td>
</tr>
<tr>
<td>Beeler, Henri</td>
<td>63</td>
</tr>
<tr>
<td>Beel, Jeffrey D.</td>
<td>52</td>
</tr>
<tr>
<td>Beilman, Bernard D.</td>
<td>28, 56</td>
</tr>
<tr>
<td>Beilman, Gregory</td>
<td>2</td>
</tr>
<tr>
<td>Belfort, Edgard</td>
<td>60</td>
</tr>
<tr>
<td>Bell, Carl C.</td>
<td>53</td>
</tr>
<tr>
<td>Bellack, Alan S.</td>
<td>34</td>
</tr>
<tr>
<td>Benedek, David</td>
<td>49</td>
</tr>
<tr>
<td>Benedek, Elisa F.</td>
<td>54, 76</td>
</tr>
<tr>
<td>Benedek, Lara M.</td>
<td>48, 54, 93</td>
</tr>
<tr>
<td>Bennett, David A.</td>
<td>9</td>
</tr>
<tr>
<td>Bennett, Mark</td>
<td>64</td>
</tr>
<tr>
<td>Benowitz, Neal</td>
<td>64</td>
</tr>
<tr>
<td>Berger, Joseph</td>
<td>51</td>
</tr>
<tr>
<td>Berger, Ralph</td>
<td>60</td>
</tr>
<tr>
<td>Berkman, Alan</td>
<td>32</td>
</tr>
<tr>
<td>Berlin, Jeff S.</td>
<td>12, 21</td>
</tr>
<tr>
<td>Berlin, Robin</td>
<td>95</td>
</tr>
<tr>
<td>Bernstein, David P.</td>
<td>27, 65</td>
</tr>
<tr>
<td>Bertelmann, Wadie C.</td>
<td>64</td>
</tr>
<tr>
<td>Berthoud, Vladimir</td>
<td>59</td>
</tr>
<tr>
<td>Beyer, Chad F.</td>
<td>94</td>
</tr>
<tr>
<td>Beyer, John L.</td>
<td>17, 67</td>
</tr>
<tr>
<td>Bhargava, Zibin</td>
<td>76, 94</td>
</tr>
<tr>
<td>Bhanu, Nadeem H.</td>
<td>92</td>
</tr>
<tr>
<td>Bialer, Philip</td>
<td>82</td>
</tr>
<tr>
<td>Biederman, Joseph</td>
<td>11, 71</td>
</tr>
<tr>
<td>Bierut, Laura J.</td>
<td>63</td>
</tr>
<tr>
<td>Bilder, Robert M.</td>
<td>29</td>
</tr>
<tr>
<td>Binder, Renee L.</td>
<td>88</td>
</tr>
<tr>
<td>Birmingham, Sarah</td>
<td>27</td>
</tr>
<tr>
<td>Binndorf, Catherine A.</td>
<td>29</td>
</tr>
<tr>
<td>Bisaga, Adam M.</td>
<td>61</td>
</tr>
<tr>
<td>Bivens, Nancy M.</td>
<td>97</td>
</tr>
<tr>
<td>Bixler, Edward</td>
<td>34</td>
</tr>
<tr>
<td>Blazier, Aurail</td>
<td>48</td>
</tr>
<tr>
<td>Bizoard, Paul</td>
<td>81</td>
</tr>
<tr>
<td>Bijnadottir, S.</td>
<td>101</td>
</tr>
<tr>
<td>Bjorgvinsson, Thorstur</td>
<td>82</td>
</tr>
<tr>
<td>Black, Donald W.</td>
<td>7, 85, 88</td>
</tr>
<tr>
<td>Blasch, Vincent J.</td>
<td>21, 45</td>
</tr>
<tr>
<td>Blanco-Jerry, Carlos</td>
<td>35, 58</td>
</tr>
<tr>
<td>Blank, Karen</td>
<td>28</td>
</tr>
<tr>
<td>Blaustein, Mel</td>
<td>47</td>
</tr>
<tr>
<td>Blazer Jr., Dan G.</td>
<td>98</td>
</tr>
<tr>
<td>Blieberg, Efrain</td>
<td>82</td>
</tr>
<tr>
<td>Bloch, Sidney</td>
<td>33</td>
</tr>
<tr>
<td>Bloom, Floyd J.</td>
<td>90</td>
</tr>
<tr>
<td>Blume, Sheila B.</td>
<td>9, 97</td>
</tr>
<tr>
<td>Bodenheimer, Alison</td>
<td>82</td>
</tr>
<tr>
<td>Boelner, Samuel W.</td>
<td>26</td>
</tr>
<tr>
<td>Bogan, Richard</td>
<td>74</td>
</tr>
<tr>
<td>Bohus, Martin</td>
<td>40, 44</td>
</tr>
<tr>
<td>Bolam, Vladimir</td>
<td>34</td>
</tr>
<tr>
<td>Boland, Robert J.</td>
<td>36, 68</td>
</tr>
<tr>
<td>Bond, Michael P.</td>
<td>87</td>
</tr>
<tr>
<td>Bonnie, Richard</td>
<td>63</td>
</tr>
<tr>
<td>Boonstraanther, Vudhichai</td>
<td>52</td>
</tr>
<tr>
<td>Boronow, John J.</td>
<td>71</td>
</tr>
<tr>
<td>Burson, S.</td>
<td>60</td>
</tr>
<tr>
<td>Borus, Jonathan F.</td>
<td>53</td>
</tr>
<tr>
<td>Boxit, Jeff Q.</td>
<td>2</td>
</tr>
<tr>
<td>Bouach, Guylain</td>
<td>101</td>
</tr>
<tr>
<td>Boulanger, Christophe</td>
<td>34</td>
</tr>
<tr>
<td>Boulanger, Pierre</td>
<td>98</td>
</tr>
<tr>
<td>Bowden, Charles L.</td>
<td>65</td>
</tr>
<tr>
<td>Bowes, Richard</td>
<td>51, 56</td>
</tr>
<tr>
<td>Bradford, Danielle</td>
<td>36</td>
</tr>
<tr>
<td>Brady, Kathleen T.</td>
<td>67, 86, 89</td>
</tr>
<tr>
<td>Brass, David I.</td>
<td>63</td>
</tr>
<tr>
<td>Brax, Dieter F.</td>
<td>52</td>
</tr>
<tr>
<td>Brister, Stephanie J.</td>
<td>46</td>
</tr>
<tr>
<td>Bruchac, Alan J.</td>
<td>51</td>
</tr>
<tr>
<td>Brown, John M.</td>
<td>68, 101</td>
</tr>
<tr>
<td>Bross, Edward S.</td>
<td>30</td>
</tr>
<tr>
<td>Brook, David W.</td>
<td>96</td>
</tr>
<tr>
<td>Brooks, Beth Ann</td>
<td>23</td>
</tr>
<tr>
<td>Brown, Sherwood</td>
<td>96</td>
</tr>
<tr>
<td>Brown, Richard P.</td>
<td>35, 50, 55, 80</td>
</tr>
<tr>
<td>Brunette, Mary F.</td>
<td>39</td>
</tr>
<tr>
<td>Buchan, Jacqueline</td>
<td>92</td>
</tr>
<tr>
<td>Bucholz, Kathleen K.</td>
<td>63</td>
</tr>
<tr>
<td>Buckley, Peter F.</td>
<td>3, 26, 35</td>
</tr>
<tr>
<td>Budur, Kumaraswamy</td>
<td>82</td>
</tr>
<tr>
<td>Buechel, Christian</td>
<td>52</td>
</tr>
<tr>
<td>Bui, Viet Q.</td>
<td>93</td>
</tr>
<tr>
<td>Buller, Philip</td>
<td>84</td>
</tr>
<tr>
<td>Bullmore, Edward</td>
<td>75</td>
</tr>
<tr>
<td>Bulmah, Eric</td>
<td>37</td>
</tr>
<tr>
<td>Buri, Ronald M.</td>
<td>21</td>
</tr>
<tr>
<td>Burkholder, Page</td>
<td>22, 72</td>
</tr>
<tr>
<td>Burns, Harold J.</td>
<td>92</td>
</tr>
<tr>
<td>Burns, Vivien K.</td>
<td>22</td>
</tr>
<tr>
<td>Burns, Gordon R.</td>
<td>2</td>
</tr>
<tr>
<td>Bush, George</td>
<td>11, 42</td>
</tr>
<tr>
<td>Butler, Lisa D.</td>
<td>33</td>
</tr>
<tr>
<td>Butterfield, Marian I.</td>
<td>10, 37, 47, 60, 85, 99</td>
</tr>
</tbody>
</table>
PARTICIPANT INDEX

Edue, Kathryn J. ........................................ 51, 85
Edwards, Christopher ................................ 53
Ehrhardt, Anke A. ..................................... 24
Eisen, Jane L. ........................................... 98
Eisenberg, Daniel ........................................ 83
Eisenberg, Esther ......................................... 84
Eisenberg, Leon ........................................... 40
Eiss, Harold I. ............................................ 86
Ekong, Juliana I. ......................................... 97
Elbaz, Zeinab S. .......................................... 26
Engel, Scott .............................................. 64
England, Mary Jane .................................... 55
Emmsah, Richard ........................................ 94
Eristoff, Larry ............................................ 40
Erman, Milton ........................................... 74
Ernst, Thomas ........................................... 62
Escober, Javier I. ........................................ 40
Espinoza, Randall T. .................................... 75
Ett, Spencer .............................................. 28, 47
Eto, Sarah .................................................. 57

F

Faison, Warachel E. ................................... 28, 65
Fallen, Bruno ............................................ 96
Fan, Alexander H. ...................................... 3
Farbarg, Amy H ......................................... 2, 52
Farooshian, Steven V .................................. 1, 112
Farchione, Tiffany R. ................................... 34
Farelo, Daniel ........................................... 95
Farvolden, Peter ......................................... 37
Faulkner, Larry R ........................................ 23, 72
Faul, Robert ............................................. 26, 77
Fava, Maurizio ........................................... 42, 52, 76, 77, 89
Fazzia, Lydia O .......................................... 94
Pareno, Paul ............................................. 33
Pedersten, Paul .......................................... 26, 52, 94
Felekly, Paul ............................................ 53
Feisen, Rudolf A .......................................... 99
Feldman, Howard ........................................ 9
Feldman, Theodore B ................................... 71
Fennell, Leah A .......................................... 71
Ferguson, Yvonne B .................................... 32
Fernandez-Antony ..................................... 77
Fernandez-Mendoza, Julio ............................. 74
Fernandez, Sherry ...................................... 55
Ficchera, Giuseppe P ................................... 58
Flidler, Donald C ....................................... 97
Filteau, Marie-Josee .................................... 102
FINDLING, Robert L .................................... 26
FINEBROG, Naomi A ................................... 87
Finkel, Sanford I ........................................ 8
First, Michael B ......................................... 18, 59, 77, 83
Fischbach, Ruth ......................................... 102
Fischbein, Ellen R ....................................... 32
FISCHBEIN, Bernard A ................................. 92
Fitz-Gerald, Mary Jo .................................. 21
Flamment, Martin ...................................... 81
Fog, Michael L ........................................... 56
Fleming, Alison ........................................ 78
Flynn, Julianne ........................................... 71, 78
Foa, Edna B ............................................. 6, 38, 62
Fobair, Pat .............................................. 33
Fochtmann, Laura J .................................... 21
Fog-Waberski, Joanna H ............................... 75
Fong, Philip ............................................. 36
Ford, Julian .............................................. 37, 81
Forde, David R .......................................... 27
Foresti, Brent P ......................................... 3, 31
FOROUAD, Tatiana ..................................... 63
Forstein, Marshall ....................................... 28, 62
Fradkin, Fred ............................................ 12, 110
Fowler, Christopher ................................... 87
Frances, Richard J ...................................... 37, 86, 97
Franco, Flavia S ........................................ 94
Frangou, Sophia ......................................... 91
Frank, Daniel .......................................... 87
Frank, Ellen ............................................. 3, 11
Frank, Guido K.W ....................................... 64
Frank, Julia ............................................. 50, 83
FRANZEN, Frances R ................................. 40
Frankle, W. Gordon .................................... 5
Franko, Debra L .......................................... 64
Freedman, Robert ....................................... 45, 84
Freeman, Marlene P ................................... 43
Freinkel, Andrew J ..................................... 102
Frey, Rafael C ........................................... 94
Fried, Judd A ............................................ 104
Fricchione, Gregory L ................................ 86
Fried, Ronni ............................................. 11
Friedman, Joseph ....................................... 35
Friedman, Richard C .................................. 18
Friebs, Gerard .......................................... 64
Fried, Bruno ............................................. 25
Fris, Sven ................................................ 64
Frisle, Leslie E ........................................... 97
Fromm, Nicole .......................................... 36
Fromson, John A ........................................ 21
Frye, Mark A ............................................ 60
Fulford, K.W ............................................ 57
Fulmer-Thompson, Esme .............................. 79
Fung, Frederick .......................................... 77
Fung, Kenneth P ........................................ 54
Fyer, Abby ............................................... 62

G

Gabbard, Glen O ....................................... 12, 19, 44, 56, 87, 93, 99
Gabriel, Adel A ......................................... 26, 51, 94
Gabri, Lynne M .......................................... 27, 83
Gadacz, Wolfgang ...................................... 36, 101
Gage, Pierre W .......................................... 50
Galambos, Harvey ...................................... 48
Galanter, Marc ......................................... 56, 69, 86, 97
Gallagher, David ........................................ 57
Galloway, Leo L .......................................... 29
Gajek, Igor I ............................................. 82, 83
Gamme, Peter D ........................................ 96
Gao, Keming ............................................ 51
Gardley, Joseph M ...................................... 71
Garcia-Macdonald, Dolores ............................ 58
Garratt, Michael ........................................ 29, 72
Garza, Daniel ............................................ 23, 72
Gasquet, Isabelle ....................................... 96
Gau, Susan Sut-Pen .................................... 96
Gaw, Albert C ........................................... 31, 47
Gebelin, Alan J ........................................... 21
Geisser, Barbara .......................................... 3, 71
Geller, Jeffrey L ......................................... 30
Gennaro, Karen G ...................................... 47, 53
Gerner, Sander G ....................................... 48
Gentiletti, Larry ......................................... 39
George, Lindsay ......................................... 3, 78
George, Mark S .......................................... 18, 66
George, Tony P .......................................... 62, 84
Gerber, Patricia L ...................................... 50, 55, 80
Gerber, Andrew J ....................................... 38
Germain, Christine ..................................... 34
Ghadiali, Nafisa Y ...................................... 77
Ghem, S. Nasser ......................................... 6, 9, 22
Gheorghi, Peter ......................................... 57
Ghosil, Harish ........................................... 33
Giacomin, Giorno ....................................... 51
Giardino-Valente, Mariano ............................ 37
Gicquel, Ludovic A .................................... 81
Giese-Davis, Janine .................................... 33
Gilberg, Morton A ...................................... 73
Gigac, Martin ............................................ 21
Gijbers, van Wijk, Cecilia ............................. 37, 88
Gillioli, Renato ......................................... 58
Gill, Sudeep S ........................................... 95
Glaeckinger, Jack ....................................... 52
Glas, Gerrit ............................................. 98
Glasofer, Deborah ...................................... 57
Gluck, Rachel ........................................... 75
Gluz, Deborah ........................................... 88
Gnanasekharan, Helen M ............................. 32
Goethe, John W ......................................... 26, 28, 75, 95
Goff, Donald C ......................................... 39
Gogini, R. Rao ........................................... 44, 68, 100
Goin, Marka C ........................................... 69, 92
Gokler, Babar ........................................... 96
Gondola, John ........................................... 70
Gold, Liza H ............................................. 7, 10
Gold, Wayne L .......................................... 100
Goldberg, Jeffrey ....................................... 92
Goldberg, Joseph F ..................................... 26
Goldstein, Julius ........................................ 58
Goldfinger, Stephen M ................................ 29, 100
Goldman, Martha ........................................ 54
Goldstein, Benjamin I ................................ 60
Goldstein, Manon Zucker .............................. 47
Goldstein, Rachel ....................................... 29
Goldstein, Risa B ........................................ 85
Gomez, John-Paul ....................................... 54
Gomberg, John .......................................... 25
Gonzalez de Rivera, Jose L ............................ 51, 64
Goodman, Aviel ......................................... 81
Goodman, Wayne K ..................................... 98
Goodwin, Frederick K ................................ 9, 22, 67
Gordon, Edward .......................................... 21
Gordon, Susan M ........................................ 70
Gordy, Tracy R .......................................... 21, 54, 68
Gottlieb, Diane B ....................................... 48
Gottlieb, Gary I .......................................... 55
Gouch, Peter ............................................ 62
Graps, Ken .............................................. 98
Graboso, Andrea D ..................................... 33
Gravish, Brenda ......................................... 33
Grady-Williams, Tana A ................................. 72, 85
Gragnic-Philipe, Rozenn ............................... 37
Grant, Bridget F .......................................... 35, 85
Grant, Jon E ............................................... 58
Grazier, Maya ........................................... 37
Graziano, Michael ...................................... 57
Gray, Sheila H ........................................... 53
Greden, John F .......................................... 12, 23, 26
Green, Melva L .......................................... 56, 71
Green, Michael .......................................... 17
Greenberg, Benjamin D ............................... 64, 65
Greenberg, Roger F ..................................... 82
Greenfield, Shelley F ................................... 82
Greenlee, Brian A ....................................... 21
Greiner, Carl B .......................................... 68, 85
Griffin, Dauda A ........................................ 28
Griffith, James L ........................................ 22, 54, 70, 83, 91, 95
Grioli, Carlos M .......................................... 50
Glynn, Linda ............................................ 12, 26
Grossman, Bernadette M ............................... 27, 51, 76, 95
Gross, Lawrence S ...................................... 92
Grossman, Linda S ...................................... 25, 26, 77
Grootendorst, John ..................................... 52
Grube, Beth A ........................................... 28
Gruen, Steven ........................................... 36
Gruen, Eilene ............................................ 50
Gruman, Cynthia ....................................... 96
Gudmundson, O .......................................... 101
Gudmundsson, S ........................................ 101
Guhuri, Sujata .......................................... 85
Guell, Juilee-Daniel .................................... 81
Guerry, John G .......................................... 46
Gupta, Neel ............................................. 95
Gur, Raquel E ............................................ 24
Gurene, Oye ............................................. 34
PAR rTICIPANT INDEX

H

Hauter, Thomas G. 22, 44, 87, 92
Hauk, Urik 62
Hass, Ann P. 102
Habei, Lawrence 96
Hackett, Ann L. 98
Hafez, Mohamad 38
Hafif, Silvia 28, 94
Haliko, Helina 75
Hales, Deborah J. 19, 23, 31
Hales, Robert E. 17, 43
Halton, Oliver 81
Halket, Perry N. 62
Hall, Heather M. 48
Hall, Lachrissa L. 77
Hall, Molly J. 71
Haller, Ellen 74, 88
Halliday, Bard D. 53
Halm, Katherine A. 64
Halper, James P. 92
Halpern, Abraham I. 47
Hamman, Stephanie 35
Hamid, Hamada 27
Hanlon, Joseph D. 80
Harmon, Tom 21
Hammerness, Paul G. 6
Hammenclagh, Richard 95
Hanin, Edward 22
Hanson, William F. 21, 62
Hanjley, Tyrone 51
Hansen, Thomas E. 22
Hartung, Kell J.R. 47
Harding, Richard K. 97
Hardy, Daniel W. 71
Harker, Roy 92
Harris, Gregory G. 72
Harrow, Martin 26, 77
Harv, Dianne A. 3
Hartman, David E. 72
Hartmann, Lawrence 47
Harvey, Philip D. 5, 14, 42
Hasin, Deborah S. 35, 61, 85
Hasan, Nael 33
Hattier-Friedman, Susan J. 71
Hauser, Peter 55, 100
Hawryluck, Laura 100
Heij, Markus 55, 74, 88
Heiman, Gary 35
Heppner, Julian A. 76
Helfand, Stacia 75
Hellerstein, David J. 75
Helzer, John E. 38
Hen, René 62
Henderson, David C. 67, 86
Henderson, Gail 33
Hendriksen, Marielle 8
Hennessy, Grace 89
Hennings, Sas 53
Henry, Joseph 51
Hensley, Paula L. 76, 100
Hepburn, Brian M. 71
Her, Herman J. 81
Hermet, Richard C. 21, 72
Herman, Helen 57
Herz, Alison M. 17, 53
Herzog, Alfred 85
Herzog, David B. 64
Hessbrock, Victor M. 63
Hettinga, Nicolas F. 88
Heymsfield, Steven B. 55
Heidlin, Frederick W. 34
Higgins, Jr., Napoleon B. 21, 77
Hill, Darryl B. 51, 94
Hilly, Donald M. 47

Hines, John K. 47
Hinson, Ralph 39
Hirdes, John P. 92
Hirsch, Alan R. 72
Hirschfeld, Robert M. A. 3, 26, 51, 67
Hirschbein, Laurence D. 71, 95
Hirschberg, Laurence M. 68, 101
Hoffman, Ellen J. 55
Hogan, Michael F. 61
Hoge, Charles W. 102
Hoge, Steven K. 78, 87
Holdenier, Fene 45, 65
Hollaner, Milton C. 49
Hollinghead, Michael a. 77, 95, 99
Hollingshead, Suzanne 29
Holliss, Sheila 15, 53
Hollen, Steven D. 38
Hoos, David 32
Horne, Rob 32
Horton, Leslie A. 77
Hostetter, Abram M. 22, 53
Houghtalen, Rorary P. 97
Howells, Valene L. 25
Huang, Robert C. 23
Huang, Suara W. 54
Huang, William 30
Huang, Yu-Shih 96
Hudziak, James J. 38, 66
Huebner, Robert 78
Hughes, Michael 29
Hull, Steven 96
Huppert, Jonathan D. 62
Huremom, Demari 29
Hurford, Matthew O. 47
Hurley, Robin A. 50, 99
Husain, Nisha F. 71
Husain, Satish A. 71
Hwang, Michael Y. 34
Hyman, Steven F. 62

I

Ictuk, Ruksana 99
Inderbitzin, Lawrence B. 34
Ingenhart, Stephen W. 71
Inghotitch, A. 101
Ioannou, Constantine 72
Ivanescu, Dan V. 48, 51
Irae, Derya 76, 96
Irebee, Joanne M. 70
Irish, Waguil W. 48, 54
Irish, Melanor 10
Isham, Matt K. 52, 75, 77, 95
Israel, Joshua A. 1

J

Jackson, Juanita 75
Jacob, Suma 71
Jacobson, Frederick 34
Jacobsen, Leslie K. 36
Jacobsen, Sandra A. 40
Jaffe, Ari B. 76
Jain, Shaily 17
Jang, Hae-Jeong 75
Jang, Henry 59
Jankovic, Philip G. 7, 59
Jaroffsky, Jeffrey 25
Jezusalski, Andrew 40
Javed, Ali 79, 92
Javist, Daniel C. 39, 63, 66
Jayaram, Geetha 19, 57, 85, 96
Jean-Marc, Philippe 81
Jette, Dilip V. 33, 58, 65, 69, 83
Jia, Aruna 21

Jhee, Stanford 40
Jiang, John G. 26
Jecho, Gregory A. 9
Jobe, Thomas H. 26
Johannesen, Jan O. 62
Johnson, Linda M. 15, 5
Josephson, Allan M. 35, 53, 91, 98
Joukamaa, Matti 77
Joy, Javed A. 71
Judge, Sheila 44, 68
Juthani, Nalini 71

K

Kahn, René 35
Kajdasz, Daniel K. 28
Kalin, Ned H. 6, 8
Kane, John M. 8, 12, 90
Kanojvalar, Lisa 77
Kantor, Edward M. 21
Kaplan, Allan S. 77
Kaplan, Gabriel 40
Kaplan, Gary B. 84
Kaplan, Kalman J. 26
Kapur, Shri 8
Karam, Elie G. 62
Karlan, Paul M. 63
Kartawish, Jason 63
Karnik, Niraj 21, 50, 71, 93
Kassier, Jerome P. 81
Kates, Nick 3, 78, 93
Katon, Wayne J. 17, 59
Katona, Cornelius 72
Katz, Ira R. 28
Katzehlrick, David J. 83
Kaufman, Joan 78
Kaufman, Molly R. 93
Kay, Jerald 29, 31
Kastor, John 63
Keeley, Joseph E. 58
Keck, Jr., Paul E. 31
Keeffe, Richard E. 10, 30
Keenan, Monique 33
Keitner, Gabor I. 95
Keller, Martin B. 9, 11
Kellett, Kathy 82
Kelley, John E. 82
Kendler, Kenneth S. 100
Kennedy, James A. 27
Kennedy, Robert S. 8, 100
Kennedy, Sidney H. 39, 65
Kennedy, Susan E. 85
Kert, Justine M. 11
Kerr-Correa, Florence 51
Kertzner, Robert M. 24, 88
Kessler, Ronald 79
Kestenbaum, Cattie J. 22
Ketter, Terence A. 9, 43, 51
Keith, Alexander 63
Khan, Afzal 55
Khan, Yasser 51
Kibour, Yashinishwar 34
Kiley, Kevin C. 81
Kilbra, Mody H. 72
Kim, Chan-Hyang 75
Kim, Hyun-Soo 75
Kim, Jee-Jin 75
Kim, Jin-Han 75
Kim, Kathy 27
PARTICIPANT INDEX

Kim, Scott Y..................47
Kim, Sun I........................56
Kim, Sun H........................58
Kim, Jennifer.......................60
Kim, Julie................................75
Kingston, Edward..................26,51
Kirch, Darrell G.....................13,72
Kirsch, Debra F.....................47
Kisely, Stephen R....................33
Kisthorpe, Anita R....................78
Kissane, David W......................33
Kleber, Herbert D....................47,61,62
Klein, Marcia.........................34
Klein, Tara................................29
Kling, Michael A.....................91
Kluft, Richard P......................48,48
Knuckle, Kerry J......................38
Knutson, James A........................26
Kocsis, James H........................98
Kogon, Richard........................30
Kohn, Robert........................77,99
Kolla, Nathan J........................40
Kollins, Scott........................66
Kolodner, George......................47
Koob, George F........................88
Koob, Simone............................8,36,37
Koopen, Cheryl........................33,102
Koponen, Hannu J......................75,95
Koran, Lorin M.M.......................87
Kornstein, Susan G.....................24
Koskeniemi, Johanna...................95
Kosten, Thomas R......................18,80,86
Kowatch, Robert A......................91
Koyanagi, Claudia Y....................21
Krak, Paul..............................72
Krakner, Helena C......................2,33
Kramer, John............................63
Kramer, Milton.........................2,92
Kramer, Peter D.........................36,81
Kranzler, Henry R.......................56
Kranzler, Ronald F........................27
Kratochvil, Christopher J...........66
Kraus, Louis J.........................21
Kring, Brunhild........................92
Krishnan, K. Ranga R..................89
Krishnan, Venkatesh.....................72
Kryger, Michel........................48
Krywulak, Andrew D....................101
Krywulak, John H........................42
Ku, Jeonghun............................75
Kubu, Cynthia...........................64
Kudler, Harold........................60,99
Kuehler, Thomas.......................33
Kunkel, Elizabeth S.J...................54
Kuo, Jack..................................30
Kupersman, Samuel.....................63
Kupfer, David J.........................2,11,23,68
Kurdugoglu, Selvet........................56
Kurten, Mary................................58
Kuuskogela, Tulin.........................96
Kushida, Oke A...........................91
Kussin, Dennis............................74
Kyomen, Helen H.........................35

Land, Yulka.............................22
Lang, Anthony E........................7
Lang, Susan ......................40,59,85
Lang, Wolfgang..........................28
Landford, Alan...........................96
Larsen, Tor K............................62
Laruelle, Marc............................80
Lau, Adam...............................82
Lauterer, Edward C......................11
Laubacher, Edward C...................11
Laubacher, Margo D.......................71
Law, David P.............................34
Lawrence, Leslie E.......................80
Lawsen, William..........................3,23,74,84,99
Lazare, Aaron..............................34
Lazarus, Arthur..........................93
Lazarus, Jeremy A..........................54
Le Neistort, Anick........................37,77
Leary, Kimberly...........................93
Leblanc, Gerard..........................101,102
Lechenan, James F........................98
Lechevalier, Serge.......................70
Lederman, Benjamin D.....................78
Lee, Jr., James E..........................79
Lee, Kim................................69
Lee, Philip W..............................96
Lee, Michael K............................62
Leeman, Eve..............................63
Lefebvre, J.P.............................55
Lehmann, Laurent S........................60
Leibensfoot, Ellen........................71
Leigh, Howard.............................27,78
Lemelle, Stephanie.......................97
Lenire, Francine L........................93
Lenzi, Eric J...............................2,66,69
Lenzinger, Mark F........................40
Leonard, Sherry...........................60
Lerman, Caryn.............................64
Lerro, Marc...............................64
Lesage, Alain D............................34,60
Leszcz, Miroslaw..........................27,33,45
Levenson, Alan L.........................22
Leventhal, Liza............................94
Lewis, Francis R...........................62,97
Levine, Jerome M........................76
Levine, John B.............................82,83
Levine, Stephen B........................23,69
Levy, Interesting.........................1,72
Levy, Kenneth M............................56
Lewis, Bradley E...........................81
Lewis, David A.............................80
Li, Eric C..................................21
Li, T-K.....................................46
Liao, Niyzyo...............................95
Liberman, Robert P.......................34
Lidz, Charles W............................33
Lieberman, Jeffrey A......................10,30,66,80
Lichtsinn, Lorne.........................121
Lichtsinn, Surspin........................52
Lin, Chien-Hui.............................27
Lin, Feng-Shia.............................81
Lin, Elizabeth H.B........................59
Lindeman, Tari.............................99
Lindemayer, Jean-Pierre..................35
Linde, Paul S...............................35
Lipton, Don R..............................78
Li, Haijun, Sarah H........................48
Liu, Liansheng.............................58
Livesley, John.............................18,50,59,85
Loo, Ted..................................104
Loas, Gwenolé.............................81
Loeb, Mark................................100
Loczy, Jody S...............................64
Lopez, Bahana..............................94
Lopez, Frank A.............................26
Lopez, Lisa M...............................72
Lopez, Maria R.............................72
Love, Anthony..............................33
Lovett, Amanda J...........................26
Loza, Nasser F.............................33
Lozano, Andres M.........................72
Lui, Francis G..............................22,28,35,48,67,87
Lubin, Joseph A.............................56
Lugo, Raquel...............................27,71
Lukaszewicz, Michael.....................96
Luna, Beatriz...............................36
Luo, John................................43,55,100
Lusskin, Shari......................2,4,7,11,22,28
Lutjens, Winter...........................30
Lyte, Constantine..........................10
Lynch, Mindy R.............................36
Lynn, David J..............................27,54,71

M

Mach, Michele.............................3,78
Machado, Andrea..........................64
Machado-Romero, Carlos A................27
Mack, Avrum H.............................28,49,71,97
MacQueen, Glenda M.......................65
Madianos, Michael G.......................33
Madras, Bertha K...........................6
Mahowald, Mark............................6
Mailau, Edward A...........................73
Malmaigt, Carl P............................54
Malone, Jr., Donald A.......................64,65
Maltsberger, John T.......................99
Manchanda, Rahul...........................52
Manchego, Claudia...........................27
Marcini, Catherine.........................94
Mariano, Alan Z.A..........................92
Mangurian, Christina V....................21,97
Markey, Myrl R.S............................84
Mann, Karl F...............................70
Manning, John.............................38
Manchek, Theodor C.........................62
Mansfield, Peter...........................78,93
Marangell, Laureen B.......................91
Marazziti, Donatella.........................51
March, John S..............................94
Marcus, Eric R..............................22,63
Marder, Stephen R.........................17,36,90
Marm, Humberto............................40,100
Marovaz, Dimitri M.........................54,92
Marneros, Vanas...........................83
Martello, David.............................76
Martin, Janet A.............................22
Martinez, Adriana M.........................77
Marzec, James M.............................93
Martinez-Mantilla, Jorge A................50
Mars, Christine E...........................50
Mason, Barbara J............................57,88
Mathalon, Daniel E........................63
Mathias, Daryl...............................64
Mathew, Sanjay.............................59
Mathews, Maju..............................82
Mathews, Travis D...........................23
Matarin, Anu A..............................29
Matthess, Annette...........................57,100
Mattos, Pedro E.............................31
Maundor, Robert............................27

L

Laine, Pekka...............................95
Lake, James H.............................102
Lamb, Richard H...........................21
Lamb, R.M.................................71
Lambers, Jeffrey M.........................78
Lancee, William............................27
Lancson, Christopher......................34
<table>
<thead>
<tr>
<th>Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mischoulon, David</td>
<td>26, 52, 86</td>
</tr>
<tr>
<td>Mitchell III, James E.</td>
<td>64</td>
</tr>
<tr>
<td>Mitchell, Paul</td>
<td>94</td>
</tr>
<tr>
<td>Mitnick, David A.</td>
<td>68, 101</td>
</tr>
<tr>
<td>Miyake, Jins</td>
<td>46</td>
</tr>
<tr>
<td>Mikiura, H.</td>
<td>11, 36, 42</td>
</tr>
<tr>
<td>Molinari, Irving</td>
<td>127</td>
</tr>
<tr>
<td>Molina, Ramin</td>
<td>83</td>
</tr>
<tr>
<td>Moller, Henry J.</td>
<td>98</td>
</tr>
<tr>
<td>Molnar, Mildos Z.</td>
<td>52</td>
</tr>
<tr>
<td>Montoya, Ivan D.</td>
<td>84</td>
</tr>
<tr>
<td>Mordenti, Gilberto</td>
<td>31</td>
</tr>
<tr>
<td>Moore, Constance</td>
<td>51</td>
</tr>
<tr>
<td>Moore, Norman C.</td>
<td>52, 96</td>
</tr>
<tr>
<td>Moore, Scott D.</td>
<td>99</td>
</tr>
<tr>
<td>Moo, Rudolph H.</td>
<td>52</td>
</tr>
<tr>
<td>Moreno, Francisco A.</td>
<td>4</td>
</tr>
<tr>
<td>Morey, Leslie C.</td>
<td>99</td>
</tr>
<tr>
<td>Morey, Raymond A.</td>
<td>99</td>
</tr>
<tr>
<td>Morgan, Jessica G.</td>
<td>72</td>
</tr>
<tr>
<td>Mro, Elena</td>
<td>72</td>
</tr>
<tr>
<td>Morrow, A. Leslie</td>
<td>73</td>
</tr>
<tr>
<td>Morrow, Joseph</td>
<td>75</td>
</tr>
<tr>
<td>Morse, Eric D.</td>
<td>39</td>
</tr>
<tr>
<td>Mortensen, E.</td>
<td>76</td>
</tr>
<tr>
<td>Moses, Lou</td>
<td>94</td>
</tr>
<tr>
<td>Mosley, Habibah E.</td>
<td>48</td>
</tr>
<tr>
<td>Moss, Howard B.</td>
<td>84</td>
</tr>
<tr>
<td>Moss, Quinton E.</td>
<td>42</td>
</tr>
<tr>
<td>Moss, Vanessa</td>
<td>96</td>
</tr>
<tr>
<td>Moyo, Robert K.</td>
<td>64</td>
</tr>
<tr>
<td>Mucci, Maria</td>
<td>52</td>
</tr>
<tr>
<td>Mucci, Istvan</td>
<td>59</td>
</tr>
<tr>
<td>Muehr, Kim T.</td>
<td>39</td>
</tr>
<tr>
<td>Mufit, Khalid A.</td>
<td>14, 33</td>
</tr>
<tr>
<td>Muhler, Cornelis</td>
<td>76</td>
</tr>
<tr>
<td>Muller, Sherman</td>
<td>60</td>
</tr>
<tr>
<td>Muller, Thomas</td>
<td>87</td>
</tr>
<tr>
<td>Munich, Richard L.</td>
<td>82</td>
</tr>
<tr>
<td>Munir, Farah</td>
<td>73</td>
</tr>
<tr>
<td>Munoz, Alicia A.</td>
<td>77</td>
</tr>
<tr>
<td>Munro, Kali</td>
<td>23</td>
</tr>
<tr>
<td>Munson, David C.</td>
<td>26</td>
</tr>
<tr>
<td>Murphy, Patricia E.</td>
<td>35</td>
</tr>
<tr>
<td>Murray, Graham</td>
<td>75</td>
</tr>
<tr>
<td>Muskin, Matthew</td>
<td>28, 93</td>
</tr>
<tr>
<td>Muskin, Philip K.</td>
<td>17, 28, 47</td>
</tr>
<tr>
<td>Muscolla, Domenique L.</td>
<td>9</td>
</tr>
<tr>
<td>Myers, Michael F.</td>
<td>21, 29, 54, 68, 92, 97</td>
</tr>
<tr>
<td>Myers, Wade C.</td>
<td>28, 47</td>
</tr>
<tr>
<td>Myrick, Hugh</td>
<td>28</td>
</tr>
<tr>
<td>Nace, David K.</td>
<td>21, 47, 68</td>
</tr>
<tr>
<td>Nadeau-Vazquez, Mireya</td>
<td>78</td>
</tr>
<tr>
<td>Nadelson, Carol C.</td>
<td>22, 37</td>
</tr>
<tr>
<td>Nagel, Tricia M.</td>
<td>77</td>
</tr>
<tr>
<td>Nair, Vasavan N.</td>
<td>76</td>
</tr>
<tr>
<td>Nakajima, Gene A.</td>
<td>88</td>
</tr>
<tr>
<td>Nakama, Helenena</td>
<td>62</td>
</tr>
<tr>
<td>Nakhaie, Mohammad Reza</td>
<td>27</td>
</tr>
<tr>
<td>Nam, Jungyun</td>
<td>96, 75</td>
</tr>
<tr>
<td>Nam, Theodore S.</td>
<td>102</td>
</tr>
<tr>
<td>Nandi, Surinder S.</td>
<td>21</td>
</tr>
<tr>
<td>Napoli, Joseph C.</td>
<td>21, 43</td>
</tr>
<tr>
<td>Naqi, Syed A.</td>
<td>22, 29, 93, 97</td>
</tr>
<tr>
<td>Narasimhan, Meera</td>
<td>3, 20, 90, 97</td>
</tr>
<tr>
<td>Nardi, Antonio E.</td>
<td>94</td>
</tr>
<tr>
<td>Narsisheh, William F.</td>
<td>98</td>
</tr>
<tr>
<td>Nascimento, Isabella</td>
<td>94</td>
</tr>
<tr>
<td>Naser, Jeffrey A.</td>
<td>40</td>
</tr>
<tr>
<td>Nasrallah, Henry A.</td>
<td>41</td>
</tr>
<tr>
<td>Nelson, J. Craig</td>
<td>9</td>
</tr>
<tr>
<td>Nemati, Ali</td>
<td>54</td>
</tr>
<tr>
<td>Nemiroff, Charles B.</td>
<td>6, 11</td>
</tr>
<tr>
<td>Nestad, Gerald</td>
<td>98</td>
</tr>
<tr>
<td>Neubauser, David N.</td>
<td>2</td>
</tr>
<tr>
<td>Neufang, Josef H.</td>
<td>97</td>
</tr>
<tr>
<td>Neustadter, Elena</td>
<td>82</td>
</tr>
<tr>
<td>Newcomer, John W.</td>
<td>5</td>
</tr>
<tr>
<td>Newkirk, Cassandra F.</td>
<td>21, 47</td>
</tr>
<tr>
<td>Newman, Alan W.</td>
<td>11</td>
</tr>
<tr>
<td>Neziroglu, Fugen</td>
<td>48</td>
</tr>
<tr>
<td>Ng, Y. K., Men K. Wong</td>
<td>8, 21, 79</td>
</tr>
<tr>
<td>Ng, Anthony T.</td>
<td>8, 21, 79</td>
</tr>
<tr>
<td>Nichols III, Alphonso</td>
<td>28</td>
</tr>
<tr>
<td>Niebler, Gwendolyn E.</td>
<td>72, 74</td>
</tr>
<tr>
<td>Nierenberg, Andrew A.</td>
<td>26, 42, 48, 51, 76</td>
</tr>
<tr>
<td>Nipper, Darlene</td>
<td>53</td>
</tr>
<tr>
<td>Njenga, Frank G.</td>
<td>33</td>
</tr>
<tr>
<td>Noel, Richard L.</td>
<td>97</td>
</tr>
<tr>
<td>Nolzinger, Eric A.</td>
<td>8</td>
</tr>
<tr>
<td>Noordy, Douglas</td>
<td>34</td>
</tr>
<tr>
<td>Nortjeff, W.</td>
<td>101</td>
</tr>
<tr>
<td>诺尔斯, Michael</td>
<td>10</td>
</tr>
<tr>
<td>Noroczi, Maryam</td>
<td>53</td>
</tr>
<tr>
<td>Noqui, Grayen B.</td>
<td>93</td>
</tr>
<tr>
<td>Norris, Donna M.</td>
<td>22, 86</td>
</tr>
<tr>
<td>North, Carol S.</td>
<td>79</td>
</tr>
<tr>
<td>Northcott, Colleen J.</td>
<td>28</td>
</tr>
<tr>
<td>Notman, Miltah T.</td>
<td>54</td>
</tr>
<tr>
<td>Notz, Ellen M.</td>
<td>97</td>
</tr>
<tr>
<td>Novak, Maria</td>
<td>97</td>
</tr>
<tr>
<td>Novak, Peter L.</td>
<td>62, 86</td>
</tr>
<tr>
<td>Nurnberg, H. George</td>
<td>76</td>
</tr>
<tr>
<td>Nurnberger, Jr., John L.</td>
<td>63</td>
</tr>
<tr>
<td>Nussler, Hans</td>
<td>76</td>
</tr>
<tr>
<td>Nutsche, Jeffrey</td>
<td>76</td>
</tr>
<tr>
<td>Nuss, David E.</td>
<td>45, 76</td>
</tr>
<tr>
<td>Oake, Jonathan</td>
<td>94</td>
</tr>
<tr>
<td>O'Brien, Charles P.</td>
<td>46, 55, 88</td>
</tr>
<tr>
<td>O'Connor, Christopher M.</td>
<td>9</td>
</tr>
<tr>
<td>O'Donovan, Caire M.</td>
<td>39</td>
</tr>
<tr>
<td>Oed, Daniel L.</td>
<td>99</td>
</tr>
<tr>
<td>Oey, John D.</td>
<td>99</td>
</tr>
<tr>
<td>Olshar, Tarek A.</td>
<td>23</td>
</tr>
<tr>
<td>O'Keefe-Wood, Linda J.</td>
<td>97</td>
</tr>
<tr>
<td>Okorocho, Gloria N.</td>
<td>55</td>
</tr>
<tr>
<td>Olpaku, Joseph</td>
<td>59</td>
</tr>
<tr>
<td>Opgada, Samuel O.</td>
<td>34, 59, 77, 84, 99</td>
</tr>
<tr>
<td>Olarte, Silvia</td>
<td>49</td>
</tr>
<tr>
<td>Oldham, John M.</td>
<td>21, 44, 69</td>
</tr>
<tr>
<td>Olmsted, Marion</td>
<td>57</td>
</tr>
<tr>
<td>Olympia, Josie L.</td>
<td>47</td>
</tr>
<tr>
<td>O'Neill, Ercin L.</td>
<td>72</td>
</tr>
<tr>
<td>O'Neill, Patrick T.</td>
<td>27</td>
</tr>
<tr>
<td>Ong, Elizabeth Q.</td>
<td>64</td>
</tr>
<tr>
<td>Oomen, Gisela</td>
<td>34</td>
</tr>
<tr>
<td>Opjerdsmoen, Stein</td>
<td>62</td>
</tr>
<tr>
<td>Opker, Lewis A.</td>
<td>23, 34, 55</td>
</tr>
<tr>
<td>Oquendo, Maria A.</td>
<td>40, 97</td>
</tr>
<tr>
<td>O'Reardon, John P.</td>
<td>3, 59</td>
</tr>
<tr>
<td>Ornatson, Edward F.</td>
<td>48</td>
</tr>
<tr>
<td>Orlowska, Barbara</td>
<td>86</td>
</tr>
<tr>
<td>Otby, Urban P.</td>
<td>52</td>
</tr>
<tr>
<td>Oxkarsson, Hogni</td>
<td>101</td>
</tr>
<tr>
<td>Olin, David W.</td>
<td>64</td>
</tr>
<tr>
<td>Orman, Osamara T.</td>
<td>95</td>
</tr>
<tr>
<td>Ooshafer, Howard J.</td>
<td>79, 98</td>
</tr>
<tr>
<td>Oser, David N.</td>
<td>94</td>
</tr>
<tr>
<td>Oster, Brent E.</td>
<td>71</td>
</tr>
<tr>
<td>Otto-Saai, Laura</td>
<td>32</td>
</tr>
<tr>
<td>Owen, Judith</td>
<td>66</td>
</tr>
<tr>
<td>Ozal, Elvan</td>
<td>51</td>
</tr>
<tr>
<td>P</td>
<td>125</td>
</tr>
</tbody>
</table>
PARTICIPANT INDEX

P

Page, Ann E. .................................. 55
Palaghi, Ordun ................................ 41
Palladini, Derek ................................. 48
Pallani, Stefano ................................. 87
Palmer, Barton W. .............................. 33
Palmer, Brian A. ................................. 84
Palsson, S.P. .................................. 101
Pandya, Anand ................................. 46, 100
Pang, Deborah .................................. 39
Papakostas, George I. .......................... 76, 89
Pappas, Pamela A. .............................. 102
Pardo, Jose V. .................................. 4
Pare, Michael .................................. 97
Parham, Kian .................................. 51, 96
Parides, Michael .................................. 57
Pare, Raghav M. ................................ 86
Parikh, Sagar V. ................................ 2, 39
Paris, Joel ........................................ 45, 60, 76
Park, Sung-Hyoun ............................... 75
Parlin, Malika .................................. 48
Patel, Bandu N. .................................. 39
Patel, Malini ..................................... 71
Patel, Shahriz V. .................................. 71
Patry, Simon ..................................... 101
Patten, Scott B. ................................. 95
Patterson, Beti .................................. 94
Patterson, Ellen ................................. 54
Paul, Robindra K. ............................... 92
Paya, Joel A. .................................... 52
Pecenak, Jan ..................................... 26
Pedersen, Cort A. ............................... 37
Peele, Roger ..................................... 25, 48, 86
Peen, Sr., Jaap ................................. 88
Pender, Jennifer D. ............................. 28
Pender, Maibeeth ............................... 91
Perez, Edgardo I. ............................... 25, 92
Perez-Diaz, Fernando .......................... 81
Perkins, Diane O. .............................. 36, 42, 80
Perlis, Roy H. .................................... 42
Perrin, Christian D. ............................. 81
Perry, John C. .................................... 87
Peruig, Giovanni ............................... 52
Pesslow, Eric D. ................................. 29, 75, 94, 96
Peters, John R. .................................. 35, 53, 91, 98
Peterlis, Allan D. ............................... 27, 45
Perjegan, Francois ............................. 34
Petrova, Eva .................................... 58
Perez-Sanchez, Esperanza ................... 58
Pil, Edmond H. .................................. 23
Pickles, Andrew R. ............................. 76
Pierre, Joseph M. ............................... 42
Pirson, Jr., Richard N. ........................ 57
Pizz, Deborah .................................... 95
Pigott, Terris A. ................................. 26
Pile, Kathleen M. ............................... 57
Pinals, Stephen .................................. 35
Pincus, Harold Alan ........................... 46, 78
Pinnin, Vivian W. ............................... 49
Pinninti, Narshma R. ........................... 23
Pitman, Mary ................................... 72
Pleane, Eric V. ................................. 28, 44, 72, 78
Plek, Richard R. ............................... 93
Plasky, Igor .................................... 52
Plough, Robert M. ............................. 71
Polcari, Ann ..................................... 37
Pollock, Bruce G. .............................. 61
Porter, Margaret.................................. 61
Popma, Arne .................................... 50
Posner, Bernice ................................. 63
Posner, Kelly ................................. 26
Post, Jerrold M. ................................. 38, 44
Post, Robert M. ................................. 101
Poth, Steven G. ................................. 42

R

Rabinowicz, Terry .............................. 92
Raboch, Jiri ..................................... 13, 53
Rado, Jeffrey T. ................................. 59
Rae, Donald S. .................................. 83
Rachel, Marcus .................................. 40
Raja, Reeta ...................................... 54
Ramez, Paul M. .................................. 55, 83
Ramos, Geraldo .................................. 47
Ramsay, J. Russell ............................. 30, 79
Randall, Carrie L. ............................. 30
Rand, Tim ...................................... 51, 96
Ransohoff, Mark A. ............................ 63
Rao, Aruna S. .................................... 77
Rao, Nypati R. ................................... 29, 92
Rappaport, Mark H. ........................... 3, 19, 23, 31, 43
Rasinen, Pirko ................................... 95
Rasgon, Natalie L. .............................. 83
Raskin, Joel ..................................... 29
Raskin, Brian M. ............................... 91
Rasmussen, Steven A. .......................... 93
Ratamene, Solomon ............................ 34
Rathod, Shalaya .................................. 29, 75
Raymond, Arun V. .............................. 92
Rava, Paula ...................................... 1, 27, 45
Reagan, Richard ............................... 70, 96
Raza, Maryam ................................... 25, 86
Read, Mary F. ................................... 88
Rebeck, Timothy ............................... 64
Rector, Neil A. ................................. 72
Reuber, Patricia R. ............................ 14, 53, 61
Redelmeier, Donald ........................... 46
Rediger, Jeffrey D. .............................. 102
Reeves, James J. ............................... 102
Regh, Nicole .................................... 29
Regner, Darrel A. .............................. 30, 38, 59, 83
Reich, D. Bradford ............................ 40
Reich, James H. .................................. 85
Reich, Wendy ..................................... 63
Reid, William H. ............................... 7, 22
Reifler, Burton V. .............................. 23, 78
Reimherr, Frederick W. ...................... 26
Reinblatt, Shaun P. ............................ 93
Reisberg, Barry ................................. 58
Reinaud, Suzooz ............................... 21
Reiner, John A. ................................. 57
Reinhaw, Perry F. ............................... 51
Resende, Cynthia I. ............................ 28
Reus, Victor I. .................................... 78
Reyes, Raymond M. ............................ 97
Rheault, Michel ................................. 96
Reynolds III, Charles F. ...................... 64, 66, 100
Rezai, Ali R. ..................................... 64
Rho, Yoon C. .................................... 28
Rhia, Michelle B. .............................. 19, 41, 47, 54, 72, 73, 84, 93
Richards, Lawrence K. ....................... 48
Richardson, Don .................................. 75
Reicheimer, Steven H. .......................... 54
Reichel, Robert ................................. 59
Richards, Judith A. ........................... 58
Ridley, Khaman ................................. 75
Rigaud, Marie-Claude ......................... 101
Riggin, Hugh Z. .................................. 64
Riune, Thomas .................................. 37
Rivo, Eva C. ..................................... 29
Rivkin, Clara P. ................................. 93
Rizzio, Dina ..................................... 95
Rizzio, Albert A. ............................... 98
Robbins, Trevor .................................. 42
Roberto, Christa .................................. 57
Roberts, Esther P. .............................. 71
Roberts, Laura W. .............................. 27, 47
Robinson, Brain M. ............................ 87
Robinson, Carolyn B. .......................... 7, 22, 53, 72
Robins, Lee N. .................................. 38
Robison, Alexandra ............................ 93
Robinson, Delbert G. ......................... 66
Robinson, Gal E. ................................. 5, 24, 54, 55, 84
Robinson, Michael J. ............................ 26
Robinson, Rebecca L. ........................... 52
Robinson, Robert G. ............................ 64
Robison, Julie .................................... 96
Roca, Robert P. ................................. 53
Rodriguez-Aubain, Manuel J. ............... 51
Rodriguez-Muñoz, Alfredo .................... 34
Rohrer, Timothy A. ............................ 101
Reiffman, Joshua ............................... 25
Rogoff, Jerome ................................. 71
Rohsenow, Damaris J. ......................... 84
Romine, Ann ..................................... 58
Rondón, Marta B. ............................... 55, 87
Roeningstam, Elsa F. ........................... 99
Roos, Steven P. ................................. 9, 38, 64
Roozegar, Moshdeh ............................ 25
Rosen, Cherise ................................. 25, 77
Rosenbaum, Jerrold F. .......................... 26
Rosenberg, Russell ............................. 74
Roth, Michael B. ............................... 65
Rosenfeld, Paul J. .............................. 64
Rosenheck, Robert A. .......................... 5, 11, 30
Rosenthal, Richard N. ......................... 72, 89
Rosenthal, Lipson, Sharon ................... 94
Rosiles, Erik J. ................................... 21
Ross, Heather .................................... 25
Ross, Stephen .................................... 36
Rosso, Isabelle M. ............................. 36
Rostain, Anthony L. ........................... 30, 79
Roth, Thomas ................................. 34, 88
Roth, Eugene M. ............................... 77
Rothenberg, Albert ............................ 94
Rothenstein, David A. ......................... 25, 38, 50
Rowland, Melissa D. .......................... 46
Roy-Byrne, Peter P. ............................ 17
Rubin, Jeffrey ................................. 64
Rubio, Gabriel ................................. 94
Rubio-Stipec, Mariza ......................... 25
Rueda-James, German E. ...................... 95
Rueda-Murillo, Lucio M. ....................... 95
Ruelaz, Aliza R. .................................. 4, 29
Ruiz, Pedro ...................................... 10, 17, 23, 29, 41, 60, 79
Bundell, James R. ............................. 79
Rush, A. John ................................. 42, 68, 89
Rutherford, Brett R. ........................... 38, 87
Rutten, Joni J. .................................... 64
Ryan, Christine E. ............................. 95
PARTICIPANT INDEX

S

Saari, Kaisa .............................................. 75
Saathoff, Gregory B. .................................. 38
Sahai, Sultai .............................................. 95
Sachs, Gary S. ........................................... 2, 51
Sadee, Wolfgang ....................................... 64
Saito, Sy A .................................................. 1, 71
Safier, Daniel J .......................................... 82
Sahakian, Barbara ...................................... 87
Sala, Luis ................................................... 16
Salama, Napanon ...................................... 16
Salinofsky, Isaac ........................................ 60
Salvy, Cheryl Y .......................................... 71
Salzmann, Anat ......................................... 92
Salzer, Alicia J .......................................... 92
Salzman, Carl ........................................... 65
Sanchez, Francis M ..................................... 47
Sanchez, Manuel O ..................................... 51
Sanders, Hans .......................................... 88
Sandfort, Theodora G.M ................................ 77
Sano, Mary ................................................. 39, 58
Satcher, David .......................................... 26
Sax, Glenn N ............................................. 83
Saxena, Sanjaya ....................................... 26
Scat, David L .............................................. 92
Schatzberg, Alan F ...................................... 9, 15, 20, 26, 31, 59, 67
Scheiber, spirit ........................................... 77
Scher, Christine D ....................................... 27
Scheffer, Randolph B .................................... 11
Schiessinger, Abigail T ................................. 47
Schmidt, Jr., Chester W .................................. 21, 54, 68
Schneider, Leon S ....................................... 65
Schmader, Richard D .................................... 68
Schoevers, Robert A .................................... 37, 61
Schoeder, Katrin ........................................ 52
Scheck, Marc A .......................................... 61, 63
Scheck, S. Charles ...................................... 36, 38
Scheck, Nicholas ........................................ 39
Schwa-Stone, Mary ..................................... 70
Schwarz, Bruce J ........................................ 21
Schwarz, George ....................................... 76
Schwarz, Joseph M ....................................... 93
Schwarzkopf, Steven B .................................. 63
Scott, Marcia ............................................. 101
Scott, Nukha G .......................................... 52, 51
Schulz, Jr. James H ................................. 7, 23, 24
Sederer, Lloyd I ........................................ 83
Seeman, Terry .......................................... 75
Seiler, Aura R ............................................. 96
Seidman, Larry J ...................................... 75
Setz, Dallas P .............................................. 95
Seligman, Roy Q ........................................ 45
Semmens, Trent ......................................... 87
Sermons-Ward, Lydia ................................... 47
Shack, Jonathan G ....................................... 71
Shaffer, David .......................................... 55
Shapiro, Colin M ........................................ 59
Shapiro, Edward B ....................................... 44, 72, 78
Shapiro, Colin M ........................................ 59
Sharfstein, Steven S ..................................... 6, 10, 17, 32, 41, 57, 81
Sharfstein, Saedy V ..................................... 53
Sharley, John ............................................. 29
Sharp, Carla .............................................. 51
Shaw, Jon A ............................................... 29
Shear, M. Katherine .................................... 38, 68, 80
Shear, Shoshana L ...................................... 93
Sheehan, David V ...................................... 43, 76
Sheridan, Robert L ...................................... 83
Sheilds, Peter .......................................... 64
Shihabuddin, Linda S .................................. 28
Shiner, Rebecca L ....................................... 59
Shirvan, Natale........................................... 29
Slivers, Tony B .......................................... 54
Shrkhande, Aditi M ..................................... 72
Shulman, Robert B ..................................... 26, 52, 94
Shurtleff, David ........................................ 64
Sica, Kristin .............................................. 94
Siegel, Glenn N ........................................ 72
Siegel, Richard L ........................................ 76
Siew, Larry R ............................................. 85
Sile, Kenneth ........................................... 40, 76, 84
Silver, Susan ............................................ 94
Silver, Ivan .............................................. 22
Silver, Marietta M ....................................... 36
Silverman, Joel J ........................................ 54
Silverman, Morton M ................................... 102
Silverman, Wayne R .................................... 39, 88
Simon, Gregory E ....................................... 59
Simon, Anne ............................................ 94
Simonsen, Erik ......................................... 62
Simpson, Sheryll M ..................................... 20, 93
Singh, Andrew .......................................... 86
Singh, Bruce ............................................ 78, 79
Singh, Priit ............................................... 102
Skolod II, Andrew E .................................... 44
Slaby, Andrew E ........................................ 92
Small, Gary W .......................................... 58
Smiit, Filip .............................................. 61
Smith, Graeme C ........................................ 37
Smith, Mary K .......................................... 27
Smith, Trevor R .......................................... 92
Sneed, Joel R ............................................. 92
Sneuvruhov, Roman .................................... 19
Soloff, Paul H ........................................... 76
Sokol, David ............................................ 65
Sommer, Tobias ........................................ 102
Sonawala, Shamsul B .................................. 86
Soord, Arsalan M ........................................ 29
Soort, Weizman ........................................ 96
Soyeur, Hakiv ........................................... 51
Speckh, Sperg ........................................... 86
Spence, Thomas ........................................ 46
Spezis, Mario ........................................... 81
Spiegel, David .......................................... 51
Spen, Alain J ............................................ 75
Stamler, Evangeline J ................................... 77
Sptz, Deborah .......................................... 73
Sptz, Henry L ........................................... 96
Sptz, Melanie E .......................................... 50
Srbane, Rose C .......................................... 78
Srivastava, Krishnamachari ............................. 19
Srivastava, Rajvi, Jansh fulfiller .................... 92
Srivastava, Manish M ................................... 12
Srivastava, Laurence R .................................. 36
Stanford, Sharon B ..................................... 6
Stankowski, Joy E ...................................... 29, 71
Stanley, Barbara H ...................................... 102
Stanley, Melinda ........................................ 82
Steiner, Bruce .......................................... 72
Steensland, Foss, Oxt ................................... 47
Steensland, Foss, Oxt ................................... 57
Steineck, Michael ...................................... 33
Steffens, David C ........................................ 9, 64
Steiger, Howard ......................................... 33
Stein, Bradley D .......................................... 46
Stein, Dan J ................................................ 58
Stein, Donald M .......................................... 37
Steiner, Hans ............................................ 50, 93
Steiger, V. Andrew ...................................... 62
Stem, Harriet C .......................................... 47
Stewart, Alka J .......................................... 33, 56, 85
Stewart, Deborah C ..................................... 27
Stewart, Donna E ........................................ 19, 25, 41, 49
Stewart, Jonathan T ..................................... 97
Stewart, Jonathan W .................................... 76
Stewart, Stephanie M .................................... 22, 29, 54
Stirton, Frederick S .................................... 35, 85
Stoddard, J., Frederick J ............................... 82, 83
Stolar, Andrea G ........................................ 101
Stone, Alan A ............................................ 81
Stone, Michael II ........................................ 99
Stotland, Ned .......................................... 49, 85
Stovall-McClough, Chase ............................. 85
Stowell, Keith R ......................................... 98
Strain, Eric C ............................................ 18, 47, 55
Straus, Joshua .......................................... 68
Stauss, Jennifer L ....................................... 37, 60
Stauss, John S ............................................ 82
Streicher, Jon M ......................................... 78
Stuz, Werner ............................................. 107
Stroup, Thomas S ....................................... 10, 80
Stuart, Scott P .......................................... 1, 38, 82
Stubbe, Dorothy E ...................................... 78
Stuck, Craig A .......................................... 35, 97
Sturman, Albert J ....................................... 64
Suyra, Ruma ............................................. 100
Suarez, Raymond E .................................... 78, 93
Suchinsky, Richard T ................................... 46
Sudak, Donna M ........................................ 54
Sugden, Steve .......................................... 47
Sullivan, Patrick P ....................................... 80
Summers, Alan L ........................................ 80
Summers, Calvin R ...................................... 92
Sunderland, Trey ....................................... 30, 40, 58
Surma, Craig H .......................................... 42
Susser, Ezra S ............................................ 33, 83
Suzuki, David T .......................................... 20
Swift, Jeffrey ............................................. 94
Swartz, Conrad M ....................................... 75
Swartz, Holly A ......................................... 26
Swartz, Marilyn .......................................... 52
Swartz, Marvin S ......................................... 89
Swift, Robert M .......................................... 41, 84, 86
Swindle, Ralph W ....................................... 52
Swanson, Robert D ...................................... 81
Szarek, Bobby L .......................................... 28, 75
Szarfman, Anna ......................................... 55
Szeghy, Eva M .......................................... 30, 78
Szuck, Agata ............................................ 26
T

Taanila, Anja ............................................ 75
Tabor, Katherine H ..................................... 99
Tahalani, Kavita K ..................................... 64
Taintor, Zebulon C ..................................... 12, 22, 37, 46, 71
Talbott, John A .......................................... 34
Tammings, Carol A ..................................... 33
Tanner, Stephen ........................................ 10
Tandon, Rajiv ............................................ 7, 26
Tar et, Pierre N .......................................... 10
Taylor, Robyn .......................................... 98
Taylor, Warren E ........................................ 66
Teich, Martin H .......................................... 37
Teckel, Janet L .......................................... 51
Teller, Claire .............................................. 76
Temple, Scott ............................................ 22
Tesar, George E ......................................... 64
Thase, Michael E ........................................ 8, 11, 38, 42
Théliberg, Jean .......................................... 52
Thibou, Nicole .......................................... 102
Thielman, Sam B ........................................ 71
Thomson, Brent D ....................................... 27
Thompson Fullilove, Mandy ........................... 49
Thompson, Ann .......................................... 34
Thompson, Carolyn .................................... 77
Thompson, Sarah J ..................................... 52
Thongly, Tavi ............................................ 76
ThomlR, Joshua .......................... 25, 41, 49, 85
Thode, Jennifer W ...................................... 84
Tillman, Jane G .......................................... 78
Titus-Valdeouin, Mary .................................. 34
Tomoda, Akemi .......................................... 37
Start Spreading The News...
October 5-8, 2006 • New York, NY
TRAUMA AND VIOLENCE IN OUR COMMUNITIES

Save the date now to attend the American Psychiatric Association’s 58th Institute on Psychiatric Services, APA’s leading educational conference on clinical issues and community mental health to meet the service needs of people with severe mental illness.

This four-day event will feature more than 100 exhibits that complement the educational program, popular networking events, and over 200 expertly-led educational sessions on topics including:

- Violence, Trauma, and Victimization; Social and Community Psychiatry
- Psychopharmacology; Resident and Medical Student Concerns
- Substance Abuse/Child and Adolescent Issues; AIDS and HIV-related Disorders; Cross-Cultural and Minority Issues; Psychiatric Administration and Services; Treatment Techniques and Outcome Studies; Cognitive Disorders; Health Service Research; Mood Disorders; Schizophrenia and Other Psychotic Disorders; and much more.

Who Should Attend?
- All APA Members
- Psychiatrists and mental health professionals in community practice or the public sector including state and Veterans Affairs hospitals, community clinics, and jails and prisons
- Psychiatric Administrators
- Mental health professionals interested in social issues that have an impact on patients and their families
- Minority psychiatrists and International Medical Graduates
- Psychiatric Residents (only $60 for advance registration)
- Nonmember Residents and Advocacy Group Members (only $85 for advance registration)
- Medical Students (free registration); and
- Consumers interested in recovery issues

Why Should You Attend?
- Earn up to 40 hours of category 1 CME credit
- Receive a 40% discount on APA member registration fees
- Network with colleagues at receptions and other events
- Industry-supported lunch and dinner symposia
- Valuable exhibit hall prizes drawn each day
- Visit New York City’s fabulous restaurants, theaters, museums, and shopping!

How Will You Benefit?
- Learn about the latest updates and acquire new skills in clinical psychiatry, that can be utilized to improve patient care;
- Acquire a deeper understanding of how the current health care system affects patient care;
- Demonstrate and apply new skills useful in clinical and public psychiatry settings;
- Recognize and improve mental health disparities in the community;
- Understand all aspects of recovery and how this affects families and the community; and
- Learn to diagnose and treat victims of trauma and violence in the community.

The Preliminary Program, which includes registration, housing, and travel information will be available in May at www.psych.org/2006IPS or call 1-888-35-PSYCH and request a copy.

Online registration will begin on June 1.

For more information, please contact:
American Psychiatric Association
1000 Wilson Blvd., Suite 1825
Arlington, VA 22209-3901
Phone: 1-888-35-PSYCH or (703) 907-7300
Fax: (703) 907-1090
E-mail: apa@psych.org
Web: www.psych.org/2006IPS
THE FIRST AND LAST

APPI BOOKSTORE AT THE 2006 APA ANNUAL MEETING IN TORONTO!

Psychiatry’s premiere publisher brings the cutting-edge titles you’ve been waiting for directly to you! Check out APPI’s latest groundbreaking selection, from the newest textbooks, review series, and journals, to electronic products for your handheld or online—including PsychiatryOnline.com.

The APPI Bookstore is the one place you can go to gather all the resources you’ll need in the next year. Update subscriptions, complete your series collections, browse through hard to find titles, and even develop your course adoptions—all in one stop. Don’t miss Author Book Signings or discounts for APA Members—see you there!

THE AMERICANPSYCHIATRIC PUBLISHING

The American Psychiatric Publishing

Textbook of Schizophrenia
Edited by Jeffrey A. Lieberman, M.D., T. Scott Stroup, M.D., M.P.H., and Diana O. Perkins, M.D., M.P.H.

2004 • 444 pages • ISBN 1-58562-191-4 • Hardcover
$95.00 • Item #62213

Essentials of Child and Adolescent Psychiatry
Edited by Mina K. Dulcan, M.D., and Jerry M. Wiener, M.D.

2006 • 772 pages • ISBN 1-58562-217-6 • Paperback
$55.50 • Item #62217

The American Psychiatric Publishing

Textbook of Suicide Assessment and Management
Edited by Robert I. Simon, M.D., and Robert E. Hales, M.D., M.B.A.

2004 • 688 pages • ISBN 1-58562-213-6 • Hardcover
$85.00 • Item #62213

American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders
Compendium 2006
American Psychiatric Association

2006 • 1,700 pages • ISBN 0-89042-383-0 • Hardcover + $99.00 • Item #2383
2006 • 1,700 pages • ISBN 0-89042-383-1 • Paperback + $72.00 • Item #2383

Quick Reference to the American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders
Compendium 2006
American Psychiatric Association

2006 • 275 pages • ISBN 0-89042-382-3 • Paperback
$36.95 • Item #2382

THE AMERICANPSYCHIATRIC PUBLISHING

Learning Cognitive-Behavior Therapy: An Illustrated Guide
Core Competencies in Psychotherapy
Jesse H. Wright, M.D., Ph.D., Monica R. Basco, Ph.D., and Michael E. Thase, M.D.
Glen A. Gabbard, M.D., Series Editor

2006 • 316 pages • ISBN 1-58562-183-5 • Paperback
$49.00 • Item #62153

Infant and Early Childhood Mental Health: A Comprehensive Developmental Approach to Assessment and Intervention
Stanley I. Greenspan, M.D., and Serena Wieder, Ph.D.

2006 • 599 pages • ISBN 1-58562-166-1 • Paperback
$49.00 • Item #62164

Essentials of Clinical Psychopharmacology, Second Edition
Edited by Alan F. Schatzberg, M.D., and Charles T. Nemeroof, M.D.

2006 • 848 pages • ISBN 1-58562-243-3 • Paperback
$99.00 • Item #62243

The First and Last Word in Psychiatry

1000 Wilson Boulevard, Suite 1825
Arlington, VA 22209-3901

Phone: 703-907-7322 or 1-800-368-5777 • Mon.-Fri., 9 am to 5:30 pm, ET
Fax: 703-907-1091 Email: appi@psych.org Web: www.appi.org

Please reference priority code AP631 when ordering
January

Coping With Depression
From Catch-22 to Hope
Jon G. Allen, Ph.D.
2006 * 341 pages * ISBN 1-58562-211-7 * Paperback
$29.95 * Item #62211

Psychotherapy for Borderline Personality
Focusing on Object Relations
John F. Clarkin, Ph.D., Frank E. Yeomans, M.D., Ph.D., and Otto F. Kernberg, M.D.
$55.00 * Item #62210

April

Study Guide to Geriatric Psychiatry
Lloyd Benjamin, M.D., James A. Bourgeois, O.D., M.D., Narriman C. Shahrokhi, and Dan G. Blazer, M.D., Ph.D.
$29.95 * Item #62263

Study Guide to Neuropsychiatry and Clinical Neurosciences
James A. Bourgeois, O.D., M.D., Narriman C. Shahrokhi, Robert E. Hales, M.D., M.B.A., and Stuart C. Yudofsky, M.D.
$29.95 * Item #62259

May

Pocket Guideline for the Assessment and Treatment of Major Depressive Disorder
American Psychiatric Association
$14.95 * Item #52834
Set of 5: $49.95 * Item #5095

Handbook of Medicine in Psychiatry
Edited by Peter Manu, M.D., Raymond E. Saiter, M.D., and Barbara J. Barnett, M.D.
$69.00 * Item #62182

Homicide
A Psychiatric Perspective, Second Edition
Carl P. Malminquist, M.D., M.S.
2006 * 432 pages * ISBN 1-58562-204-4 * Paperback
$49.00 * Item #62204

Concise Guide to Psychopharmacology, Second Edition
Lauren B. Marangell, M.D., and James M. Martinez, M.D.
$27.95 * Item #62255

Clinical Manual of Cultural Psychiatry
Edited by Russell F. Lin, M.D.
2006 * 368 pages * ISBN 1-58562-256-7 * Paperback
$46.00 * Item #62256

Clinical Manual of Substance Abuse Treatment
A Companion to The American Psychiatric Publishing Textbook of Substance Abuse Treatment, Third Edition
Stephen Ross, M.D., and Francis Hayden, M.D.
$29.95 * Item #62252

Clinical Manual of Forensic Psychiatry
A Companion to The American Psychiatric Publishing Textbook of Forensic Psychiatry
Robert L. Simon, M.D., and Liza H. Gold, M.D.
2006 * 304 pages * ISBN 1-58562-256-4 * Paperback
$29.95 * Item #62234

Understanding and Treating Adults With Attention Deficit Hyperactivity Disorder
Brian B. Doyle, M.D.
2006 * 400 pages * ISBN 1-58562-221-4 * Paperback
$47.00 * Item #62221

Bipolar Depression
A Comprehensive Guide
Edited by Rif S. El-Mallakh, M.D., and S. Nassir Ghaemi, M.D.
$46.00 * Item #62171

Clinical Manual of Geriatric Psychiatry
James E. Spar, M.D., and Asenath La Rue, Ph.D.
$58.00 * Item #62195

PsychiatryOnline.com—a state-of-the-art website offering access to the most trusted and reliable psychiatric references for patient diagnosis, treatment, research, and professional development and lifelong learning, including DSM-IV-TR® and American Journal of Psychiatry. Featuring search, navigation, and cross-referencing tools, custom-designed for psychiatrists. Subscribe now at www.psychiatryonline.com. See demo at APPI Bookstore.
American Psychiatric Foundation
Advancing public understanding of mental illnesses

EDUCATION. ENTERTAINMENT. PHILANTHROPY.

Join the American Psychiatric Foundation for four special events at the 2006 APA Annual Meeting.

2006 Annual Benefit "Toronto Tapestry"

Saturday, May 20, 2006
7:00 – 10:00 p.m.
The Royal Ontario Museum
100 Queen’s Park
Toronto, Ontario

You are invited to an exciting special evening featuring the Royal Ontario Museum’s historic art collections, a menu of eclectic and delicious international cuisine, live music and the presentation of the Awards for Advancing Minority Mental Health. Event proceeds support the foundation’s programs that advance public understanding that mental illnesses are real and treatable.

Tickets:
$100 USD per person if purchased by April 1 or $125 USD per person thereafter. To order tickets, please call (703) 907-8512 or visit www.psychfoundation.org.

Supported By:

AstraZeneca
Abbott Laboratories
Cyberonics, Inc.
Forest Laboratories, Inc.
Otsuka America Pharmaceutical, Inc.
Professional Risk Management Services, Inc.
Takeda Pharmaceuticals North America, Inc.

"Conversations" featuring Mariel Hemingway

Tuesday, May 23, 2006 - 5:30 – 6:30 p.m.
Hall A of the Toronto Convention Center
Open to all annual meeting attendees

Don’t miss our 5th annual "Conversations" event, an interactive series that offers psychiatrists an opportunity to hear unique perspectives on mental illness. Mariel Hemingway, a successful model, actress, author and mother, will be our guest. Hemingway will discuss her family connection with mental illness and its impact on future generations.

Supported by an unrestricted educational grant from: AstraZeneca

Take Me Out to the Ball Game

Tuesday, May 23, 2006 – 7:00 p.m. $22 CAD per ticket ($7 to the foundation) – Ticket value of $29
Wednesday May 24, 2006 – 7:00 p.m. $30 CAD per ticket ($10 to the foundation) – Ticket value of $39

Enjoy a spring evening at the ball park (directly across from the convention center) while supporting the philanthropic work of the foundation. First-rate, field-level baseline tickets are available for two Toronto Blue Jays vs. the Tampa Bay Devil Rays games through a special discount offer. A portion of each ticket sold is contributed to the foundation. To order tickets, call Harry Einbinder at (888) 654-6529 ext.1666 or harry.einbinder@bluejays.com. For a seating chart and order form, visit www.psychfoundation.org.

Golfers of the APA 2006 Annual Golf Tournament

Monday, May 22, 2006
7:30 a.m. with a shotgun start
Angus Glen Golf Club

Enjoy friendly competition and 18 holes of golf at the north course of Angus Glen, site of the 2007 Canadian Open. $250 USD includes transportation, greens fees, carts and prizes. All event proceeds will benefit the foundation. For more information on the course, visit www.angusglen.com. To enter the tournament, contact Stan Jennings at mbears@comcast.net or (804) 320-7881.
American Psychiatric Association – 160th Annual Meeting
May 19-24, 2007
San Diego, CA

CALL FOR PAPERS

PRESIDENT'S THEME:
Addressing Patient Needs: Access, Parity, and Humane Care

Pedro Ruiz, M.D.
President

Marian I. Butterfield, M.D., Chairperson
Scientific Program Committee

THE SUBMISSION SCHEDULE

<table>
<thead>
<tr>
<th>Format</th>
<th>Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Industry-Supported Symposia</td>
<td>June 2, 2006</td>
</tr>
<tr>
<td>Courses</td>
<td>September 10, 2006</td>
</tr>
<tr>
<td>Reports</td>
<td>September 10, 2006</td>
</tr>
<tr>
<td>Symposia</td>
<td></td>
</tr>
<tr>
<td>Chair deadline:</td>
<td>September 6, 2006 (no new submissions accepted after this date)</td>
</tr>
<tr>
<td>Author deadline:</td>
<td>September 10, 2006 (deadline to complete all information)</td>
</tr>
<tr>
<td>Workshops</td>
<td></td>
</tr>
<tr>
<td>Issue &amp; Media:</td>
<td>September 10, 2006</td>
</tr>
<tr>
<td>Component:</td>
<td>September 24, 2006</td>
</tr>
<tr>
<td>New Research</td>
<td>December 11, 2006</td>
</tr>
</tbody>
</table>

Submissions can only be made and accepted online by visiting www.psych.org. Click on the Annual Meeting logo, then click on the submission box. Feel free to contact the APA toll free at 1-888-357-7924 to speak directly with an Answer Center Coordinator.

Paper submissions, as well as incomplete submissions, will not be accepted or considered.

If you would like to volunteer to chair a session, please send a letter to the attention of Dr. Butterfield at the American Psychiatric Association. Please indicate your name, address, area of expertise, and the type of session you would like to chair. Please be aware that we receive more requests than available slots. If you are selected as a chairperson, you will be notified by the end of November.
NEW AUGMENTATION STRATEGIES IN DEPRESSION FOR BETTER OUTCOMES

SATURDAY, MAY 20
12-12:30 PM LUNCH • 12:30-3:30 PM CLINICAL PROGRAM
TORONTO CONVENTION CENTRE • JOHN BASSETT THEATRE, NORTH BUILDING, LEVEL 100

A five-minute Q&A is included at the end of each presentation.

Introduction
Jonathan E. Alpert, MD, PhD
Symposium Chair & Speaker

Pharmacological Antidotes for Antidepressant-Induced Side Effects
Anita H. Clayton, MD
University of Virginia Health System

Polypharmacy for Depression: How Often Is It Used and Why?
Joshua A. Israel, MD
University of California San Francisco

“How To” Augmentation Strategies in Resistant Depression
Charles DeBattista, DMH, MD
Stanford University School of Medicine

When Does Polypharmacy Lead to Higher Remission Rates?
Jonathan E. Alpert, MD, PhD
Harvard Medical School

Adding Psychotherapy: Pearls for Improved Outcomes
Amy H. Farabough, PhD
Massachusetts General Hospital

Program Concludes

EDUCATIONAL OBJECTIVES

At the conclusion of this symposium, the participant should be able to discuss polypharmacy in the treatment of depression, review antipsychotic approaches to manage common side-effect side effects, address medical syndromes, construct a treatment plan for resistant depression, and incorporate working knowledge of psychotherapy to optimize treatment outcome.

MAINTAINING WELLNESS

2006 APA ANNUAL MEETING
IN PATIENTS WITH BIPOLAR DISORDER MOVING BEYOND EFICACY TO EFFECTIVENESS
DATE SATURDAY, MAY 20th TIME 12:30 PM - 3:30 PM ACTIVITY CHAIRPERSON GARY SACHS, MD
THE FAIRMONT ROYAL YORK • CANADIAN ROOM • TORONTO, CANADA

PROGRAM OVERVIEW

Bipolar disorder is commonly misdiagnosed as unipolar depression because patients more often present with depressive rather than manic symptoms. Furthermore, comorbidities such as anxiety and substance abuse are frequently present in this patient population and further contribute to misdiagnosis. Proper diagnosis is the first, but possibly not the only, avenue to achieving positive outcomes in patients with bipolar disorder. The roles of blood testing, mood stabilizers, mood stabilizer therapy, patient satisfaction with pharmacologic and nonpharmacologic treatments, and the maintenance of wellness and the management of bipolar disorder are reviewed in this symposium. The treatment and management of bipolar disorder will review the most recent clinical trials evaluating various treatment interventions, the potential implications of genetics, and brain imaging studies on the future management of bipolar disorder will also be presented.

LEARNING OBJECTIVES

After attending this symposium, participants should be able to:

- Discuss basic epidemiology and pathophysiologic factors underlying the presentation of bipolar disorder
- Discuss the clinical manifestations of bipolar disorder and their treatment by examining clinical presentation
- Evaluate the treatment of bipolar disorder
- Evaluate the most recent clinical trial data that assess the efficacy of behavioral and pharmacologic interventions for bipolar disorder

ACCREDITATION STATEMENT

The American Psychiatric Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Psychiatric Association designates this educational activity for a maximum of 3 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Sponsored by an educational grant from

INDUSTRY-SUPPORTED SYMPOSIUM 2
Saturday, May 20, 2006, 12:30 p.m. - 3:30 p.m.
Royal York, Convention Floor, Canadian Room
INDUSTRY-SUPPORTED SYMPOSIUM 3
Saturday, May 20, 2006, 12:30 p.m. - 3:30 p.m.
Royal York, Convention Floor, Concert Hall

Navigating the Maze: Understanding Methods, Results and Risk in Psychiatric Research

APA 2006 SYMPOSIUM AGENDA
12:30 - 12:45 PM
Welcome and Introduction
DAVID J. KUFAK, MD. SYMPOSIUM CHAIRMAN
UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE WESTERN PSYCHIATRIC INSTITUTE AND CLINIC
12:45 - 1:00 PM
Assessing Statistical and Clinical Significance in Medical Research
DAVID J. KUFAK, MD
UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE WESTERN PSYCHIATRIC INSTITUTE AND CLINIC
1:05 - 1:10 PM Questions
1:10 - 1:35 PM
All Risk Factors Are Not Created Equal: The Importance of Defining and Interpreting Risk on Medical Decision Making and Patient Care
HELENA CHIYURO KRAEHNER, PHD
STANFORD UNIVERSITY
1:35 - 1:40 PM Questions
1:40 - 2:05 PM
Determining Efficacy: Sound Clinical Trial Design and Interpretation
CONRADUS KATONA, MD, FCP
KENT INSTITUTE OF MEDICINE AND HEALTH SCIENCES UNIVERSITY OF KENT
2:05 - 2:10 PM Questions
2:10 - 2:35 PM
Treating Depression in Children and Adolescents: What's a Clinician to Do?
JEFF Q. BOSTIC, MD, EDO
MASSACHUSETTS GENERAL HOSPITAL
2:35 - 2:40 PM Questions
2:40 - 2:55 PM
How to Treat in the Absence of Scientific Evidence: A Focus on Anxiety Disorders in the Elderly
ERIC J. LEMIEUX, MD
UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE WESTERN PSYCHIATRIC INSTITUTE AND CLINIC
2:55 - 3:00 PM Questions

INDUSTRY-SUPPORTED SYMPOSIUM 4
Saturday, May 20, 2006, 12:30 p.m. - 3:30 p.m
Sheraton Centre, Lower Concourse, Grand Ballroom

APA 2006 ANNUAL MEETING Sponsored by the American Psychiatric Association
BRIDGING
Sleep Science & Public Policy

SATURDAY, MAY 20, 2006
Lunch: 12:00 noon – 12:30 pm
Symposium: 12:30 pm – 3:30 pm

Learning Objectives:
At the conclusion of this symposium, the participants should be able to:
• Recognize the manifestations of sleep deprivation and chronic insomnia
• Understand the risks associated with increasing populations
• Appreciate the role of public policy and regulatory guidelines in addressing these clinical problems

Program Chair:
David W. Neubauer, MD
Associate Professor of Psychiatry
Johns Hopkins University School of Medicine
Director, Sleep Disorders Center
Johns Hopkins Sleep Disorders Center
Psychiatry and Behavioral Medicine
Baltimore, MD

3.0 CME Credits
are designated for participation in this Educational Symposium.

Agenda:
12:00 noon – 12:30 pm
Complimentary Lunch
12:30 pm – 12:55 pm
Welcome and Introduction
David R. Neubauer, MD
Johns Hopkins University School of Medicine
12:35 pm – 1:00 pm
The Science of Sleep
David R. Neubauer, MD
1:00 pm – 1:35 pm
Adolescents and School Start Times:
The Intersection of Research and Public Policy
Robert Auger, MD
Mayo Clinic College of Medicine
1:35 pm – 1:50 pm
Shiftwork, Sleep, and Performance
Gregory Belknap, MD
Washington State University - Spokane
1:50 pm – 2:15 pm
Medical Education and Resident Duty Hours
Phyllis C. Zuck, MD, PhD
Northeastern University
2:15 pm – 2:40 pm
Insomnia and Public Policy
David J. Buysse, MD
University of Pittsburgh School of Medicine
2:40 pm – 3:00 pm
Summary and Conclusions
David W. Neubauer, MD

Accreditation:
Attendants must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come,
first-serve basis. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA at 331-670-3122.
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Supported by an educational grant from Takeda Pharmaceuticals North America, Inc.
VERGING ON REALITY 2006 APA ANNUAL MEETING
EMERGENT THERAPEUTIC APPROACHES FOR SCHIZOPHRENIA
DATE SATURDAY, MAY 27TH, 2006 TIME 6:00 PM – 9:00 PM
ACTIVITY CHAIRPERSON: PETER E. BUCKLEY, M.D.
THE FAIRMOUNToyal PALACE • CANADIAN ROOM • EXETER, CANADA

AGENDA
SATURDAY MAY 20, 2006
5:30 pm – 6:00 pm
DINNER
6:00 pm – 6:05 pm
WELCOME AND INTRODUCTION
PETER E. BUCKLEY, M.D.
6:05 pm – 6:30 pm
FUNCTIONAL GENOMICS AND THERAPEUTIC EFFECTS OF ANTI-PSYCHOTICS
AL RUBIO, M.D.
6:35 pm – 7:05 pm
INSIGHTS FROM NEUROMARKETING TO GUIDE DRUG CHOICE AND DEVELOPMENT
CARL A. DOMINGUE, M.D.
THE SCIENCE OF SUBJECTIVE TOLERABILITY: "WELLNESS" AS A TREATMENT OUTCOME
MASSIMO, M.D.

Leaning Objectives
After attending this symposium, participants should be better able to:
1. Describe the role of genetic effects on clinical pharmacology and treatment response in schizophrenia.
2. Recognize insights from neurofeedback on the physiology of psychopharmacology and the implications for drug development.
3. Discuss the differential dose-effect relationships and use novel therapeutic agents with regard to patients with comorbid conditions.
4. Understand the implications for treating co-morbid conditions in schizophrenia.

Accreditation Statement
This symposium is accredited by the American Academy of Psychiatry and Neurology by the Accreditation Council for Continuing Medical Education to provide 3.0 CME credit.

Registration Statement
This program includes 3.0 hours of structured education as defined by the American Academy of Psychiatry and Neurology in accordance with AAMC Policy 402.1.
INDUSTRY-SUPPORTED SYMPOSIUM 7
Saturday, May 20, 2006, 6:00 p.m. - 9:00 p.m.
Royal York, Convention Floor, Concert Hall

Sponsored by the American Psychiatric Association
Take Advantage of this Invaluable Educational Opportunity at APA 2006!

Bipolar Disorder: Creating a Consensus from Science to Public Policy

3.0 CME Credits are designated for participation in this Educational Symposium.

SATURDAY, MAY 20, 2006
5:30 – 6:00 p.m. DINNER
6:00 – 9:00 p.m. PROGRAM
Royal York Convention Center
Concert Hall Room
Fairmont Royal York Hotel
Toronto, Canada

LEARNING OBJECTIVES:
At the end of this symposium the participants should be able to:

• Discuss the onset and course of Bipolar disorder in children and adolescents
• Outline the severity of dysfunction associated with bipolar disorder and its individual and societal impact on the legal system
• Evaluate the relative benefits and limitations of current treatment for mood disorders
• Identify risk factors for bipolar disorder
• Evaluate the strengths and limitations of existing data about alternative traditional and nonpharmacological therapies for bipolar disorder

AGENDA
5:30 – 6:00 p.m. Complimentary Dinner
6:00 – 6:10 p.m. Introduction and Welcome
6:10 – 6:55 p.m. The Impact of Psychosocial Treatment on the Course and Prognosis of Bipolar Disorder
6:55 – 7:00 p.m. A Rational Approach to the Longitudinal Pharmacologic Management of Patients with Bipolar Disorder: An Argument
7:05 – 7:25 p.m. Alternative Pharmacologic Approaches to the Care of Bipolar Patients
7:25 – 7:50 p.m. Treatment Considerations for Mania in Young Children
7:50 – 8:15 p.m. Treatment of Bipolar Disorder in U.S. jails and Prisons
8:15 – 9:00 p.m. Questions-and-Answer Session

PROGRAM CHAIR:
Mark H. Rapport, MD
Assistant Professor of Psychiatry
University of Pittsburgh School of Medicine

INDUSTRY-SUPPORTED SYMPOSIUM 8
Saturday, May 20, 2006, 6:00 p.m. - 9:00 p.m.
Sheraton Centre, Lower Concourse, Grand Ballroom

Treatment-Resistant Depression: New Data, New Approaches

Saturday, May 20, 2006 | Dinner: 5:30-6:00 PM | Scientific Program: 6:00-9:00 PM
Sheraton Centre | Toronto Hotel | Lower Concourse Grand Ballroom | Toronto, Ontario, Canada

Agenda
1:00 - 1:55PM
Introduction
David L. Dunner, MD - Chairman • University of Washington School of Medicine
2:00 - 2:55PM
Depression and the Clinical Characterization of Treatment-Resistant Depression
Robert L. Charney, MD • Columbia University College of Physicians & Surgeons
3:00 - 3:55PM
Treatment Resistant mood: The Biology vs. Pharmacology Enigma
Kenneth A. McElroy, MD • University of Rochester College of Medicine
4:00 - 4:55PM
Frontal Neuroimaging in Chronic Unipolar Depression: Stimulus for Stimulating New Approaches to Treatment
Joy F. Parkin, MD • University of British Columbia Medical School
5:00 - 5:55PM
Augmentation Strategies for Patients With Difficult-to-Treat Major Depression
Abbe Harkavy, MD • Cedars-Sinai Health System
6:00 - 6:55PM
Brain Imaging Therapies for Treatment-Resistant Depression
Linda L. Carson, MD • Oregon Health Science University
7:00 - 7:55PM
Conclusion
The American Psychiatric Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This symposium will provide 4.0 hours of Category 1 CME credits as defined by the ACP. The symposium will also provide 3.0 hours of Category 2 CME credits as defined by the APA. Participants may claim a maximum of 5.0 hours of Category 1 CME credits for attendance at both this symposium and The American Psychiatric Association's Annual Meeting 2006.

Statement of Need
This symposium will present new findings regarding treatment-resistant depression (TRD). About half of all patients who are treated for depression either do not respond to therapy or do not achieve a full remission of symptoms. Persistence of depression in these patients results in continued impairment in psychosocial function and increases the likelihood of medical morbidity and suicide mortality. In this symposium, there will be a discussion of the definition of TRD, the clinical, neuroimaging, and familial characteristics, and psychopharmacologic treatment strategies, and the use of physical therapies to enhance responses. New treatments underlying research in this population will be presented. Patients with TRD pose considerable problems for clinicians involved in their care. Prescriptions from this symposium will be aimed at providing rational and systematic approaches for clinicians to improve outcomes in patients with TRD.

Educational Objectives
The conclusion of this program, the participants should be able to:

• Identify the complexities of a diagnosis of TRD
• Recognize the "multidimensional" treatment outcome of TRD
• Identify brain metabolic correlates of TRD and describe the effects of chronic venlafaxine treatment (MMS) on brain metabolism in TRD
• Define the role of genetics in depressive disorders
• Describe genetic and environmental influences in the biology of depression and treatment resistance
• Evaluate the strengths and weaknesses of the existing acute treatment data investigating the efficacy of augmentation treatment for difficult-to-treat major depressive disorder
• Utilize efficacy data for established and investigational novel neurobiological treatments for TRD, including electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS), magnetic seizure therapy (MST), and vagus nerve stimulation (VNS) Therapy

Supported by an educational grant from:

Cyberonics

137
INDUSTRY-SUPPORTED SYMPOSIUM 9
Sunday, May 21, 2006, 8:00 a.m. - 11:00 a.m.
Toronto Convention Centre, North Level 100, Room 102

APA 2006 Annual Meeting

Differentiating Atypical Antipsychotics in the Treatment of Schizophrenia:
From Theory to Practice

Sunday, May 21, 2006 • 7:30 AM – 8:00 AM Breakfast • 8:00 AM – 11:00 AM Symposium
Toronto Convention Centre, North Building, Level 100, John Bassett Thorson/Room 102, Toronto

OBJECTIVES
At the conclusion of this program, participants should be able to:
• Differentiate among atypical antipsychotic agents based on the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study findings.
• Apply the findings of CATIE to choices among atypical antipsychotic medications.

Attendees must be registered for the American Psychiatric Association Annual Meeting to attend this symposium. Seating is limited to first-come, first-served basis. For more information about the CATIE study, please visit the APA website at www.psychiatryonline.org or call 1-866-121-2612 (within the United States) or 703-907-2600.

The APA is accredited by theAccreditation Council for Continuing Medical Education to provide continued medical education. The APA designates this educational activity for a maximum of 3.5 Credits. Physicians should only claim credit commensurate with the extent of their participation in the activity.

INDUSTRY-SUPPORTED SYMPOSIUM 10
Sunday, May 21, 2006, 8:00 a.m. - 11:00 a.m.
Royal York, Convention Floor, Canadian Room

Don't Miss This important Educational Activity!

Fibromyalgia: Scientific Advances to Reduce the Burden of Illness

Sunday, May 21, 2006
7:30AM-8:00AM Breakfast
8:00AM-11:00AM Educational Activity

The Fairmont Royal York
Convention Floor, Canadian Room
Toronto, Ontario, Canada

Learning Objectives
Upon completion of the activity, participants should be able to:
1. Recognize the significant morbidity associated with fibromyalgia.
2. Recognize the impact of social functioning and work-related disability in those suffering from fibromyalgia.
3. Recognize the pathophysiologic potential role in the systemic burden of fibromyalgia.
4. Recognize that a small number of diseases are associated with fibromyalgia.
5. Explain the rationale for the use of therapeutic agents in the treatment of fibromyalgia.
6. Discuss the clinical data of drug use in the treatment of fibromyalgia.
7. Develop an algorithm for the treatment of patients with fibromyalgia.
8. Discuss the role of physical activity, exercise, and therapy on the health of the fibromyalgia patient.

Accreditation Statement
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
**INDUSTRY-SUPPORTED SYMPOSIUM 11**
Sunday, May 21, 2006, 8:00 a.m. - 11:00 a.m.
Royal York, Convention Floor, Concert Hall

**APA 2006 ANNUAL MEETING: ISS-11**
Expanding the Neurobiological and Neuropsychological Foundation of ADHD: Impact to Clinical Practice

**Breakfast**
7:30 am - 8:00 am

**Program**
8:00 am • Welcome/Introduction
Thomas J. Spencer, MD, Chair
Massachusetts General Hospital

8:05 am • ADHD Neuropsychology and Executive Function Deficits
Larry J. Schram, PhD
Harvard Medical School

8:50 am • Stimulants: Therapeutic and Reinforcing Effects
Nora D. Volkow, MD
National Institute on Drug Abuse

9:55 am • The Relevance of the Trace Amine Phenylethylamine (PEA) to ADHD
Bertha K. Madras, PhD
Harvard Medical School

**Learning Objectives:**
At the conclusion of this symposium, the participant should be able to:
1. Describe neuropsychological dysfunctions in ADHD
2. Explain the mechanism of action of various psychostimulants used for ADHD
3. Describe the involvement of the dopaminergic and serotonergic systems in the pathophysiology of ADHD
4. Evaluate available psychopharmacological options for ADHD

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 Category I credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

**Shire**

---

**Sponsored by the American Psychiatric Association**

---

**INDUSTRY-SUPPORTED SYMPOSIUM 12**
Sunday, May 21, 2006, 8:00 a.m. - 11:00 a.m.
Sheraton Centre, Lower Concourse, Grand Ballroom

**THE IMPACT OF ANXIETY DISORDERS: A CASE-BASED APPROACH TO IMPROVING OUTCOMES AND REMOVING STIGMA**

**LEARNING OBJECTIVES**
At the conclusion of this symposium the participant should be able to:
- Assess the public and individual health consequences of anxiety disorders.
- Discuss the neurobiological underpinnings of anxiety disorders.
- Implement a treatment plan that incorporates non-pharmacologic and pharmacologic strategies to enhance patient outcomes.

**ACREDITATION STATEMENT**
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**CREDIT DESIGNATION**
The APA designates this educational activity for a maximum of 3 AMA PRA Category I Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

**REGISTRATION**
Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA website at www.psych.org.

---

**Symposium to be held at the APA 2006 Annual Meeting**

**SCIENTIFIC PROGRAM AGENDA**
8:00 AM – 8:10 AM
Welcome and Introduction
Ned E. Kline, MD (Symposium Chair)

8:10 AM – 8:35 AM
Public Health Consequences of Anxiety
A Surgeon General's Perspective
David Satcher, MD, PhD
Uniformed Services University of Medicine

8:35 AM – 9:00 AM
Individual Consequences of Anxiety
Paul E. Wender, PhD
Brigham University

9:00 AM – 9:25 AM
Anxiety Disorders: A Glimpse Inside the Brain
Paul E. Kline, MD
University of Wisconsin

9:25 AM – 9:50 AM
Linking Symptoms to Treatment Selection in Anxiety Disorders
Murray B. Stein, MD, FRCP, MPH
University of California, San Diego

9:50 AM – 10:15 AM
Non-Pharmacologic Approach to the Treatment of Anxiety Disorders
Edna E. Foa, PhD
University of Pennsylvania

10:15 AM – 11:00 AM
Panel Discussion/Question-and-Answer Session

---

139
NEW VISTAS IN TREATMENT-RESISTANT DEPRESSION

SUNDAY, MAY 21, 2006 • 9:15 AM – 9:45 AM

Welcome and Introduction
Charles B. Nemeroff, MD, PhD
Reuette W. Harris Professor and Chairman
Department of Psychiatry and Behavioral Sciences
Emory University School of Medicine
Atlanta, GA

OBJECTIVES
At the conclusion of this program, participants will be able to:
• Understand the evolving definition of treatment resistance.
• Understand the evolving concepts and clinical approaches to
  treatment-resistant depression.
• Discuss the impact of mood disorders on public health and
  public policy.
• Discuss the predictors of antidepressant response.

New Strategies for Treatment-Resistant Depression
Linda L. Carpenter, MD
Associate Professor
Department of Psychiatry and Human Behavior
Brown Medical School
Providence, RI

Re-evaluating Concepts of Depression: Bipolar Spectrum
S. N. Assaf Chamsi, MD, MPH
Associate Professor of Psychiatry and Public Health
Emory University School of Medicine
Atlanta, GA

9:15 AM – 10:15 AM

Question and Answer Session
Faculty Panel

SUNDAY, MAY 21, 2006 • 1:00 PM – 1:30 PM

LUNCH

SUNDAY, MAY 21, 2006 • 1:30 PM – 4:30 PM

PROGRAM

AGENDA
1:30 – 1:40 PM
Introduction and Welcome
John M. Kane, MD
Albert Einstein College of Medicine
Bronx, NY

1:40 – 2:10 PM
Pharmacologic Treatment of Schizophrenia: The State of the Art
From Dopamine to Dystonia: Understanding Psychosis from the
Bench to the Bedside
John M. Kane, MD
Sina A. Kavanagh, MD
University of Toronto

2:10 – 2:40 PM
Cognitive Functioning in Schizophrenia: Cognitive Impairments as
Gates for Treatment Development
Robert M. Biddle, PhD
David Geffen School of Medicine at UCLA

2:40 – 3:10 PM
Metabolic Risks of Second-Generation Antipsychotics
Chadwick L. Goodwin, MD
Albert Einstein College of Medicine

3:10 – 3:40 PM
Question and Answer Session
Entire Panel

Akers, New York

LEARNING OBJECTIVES:
At the end of this symposium the participants should be able to:
• Discuss recent developments in the pharmacologic treatment of
  schizophrenia.
• Describe the current thinking as to the assessment and management of
  cognitive dysfunction in schizophrenia.
• Describe the current understanding of the neurobiology of psychosis.
• List the metabolic adverse effects of antipsychotic medication and how to
  mitigate them.
• Discuss the public health implications of treatment decisions and disease
  management in schizophrenia.

SUNDAY, MAY 21, 2006
1:00 PM – 1:30 PM LUNCH
1:30 PM – 4:30 PM PROGRAM

CONTRIBUTORS
John M. Kane, MD
Professor of Psychiatry, Neurology and Neuroscience
The Albert Einstein College of Medicine
Bronx, New York

Chadwick L. Goodwin, MD
Albert Einstein College of Medicine

Shin A. Kavanagh, MD
University of Toronto

Robert M. Biddle, PhD
David Geffen School of Medicine at UCLA

ACCREDITATION
The American Psychiatric Association (APA) is accredited by the Accreditation Council
for Continuing Medical Education to provide continuing medical education for
physicians. This activity has been planned and implemented in accordance with the
Accreditation Council for Continuing Medical Education’s Essentials
and Policies, in collaboration with the Harvard Medical School. This activity
has been approved for a maximum of 3.0 CME credits toward the AMA
Presbyterian Physician’s Recognition Award.

Sponsored by the American Psychiatric Association
Take Advantage of this Invaluable Educational Opportunity at APA 2006!
VITAL SIGNS IN PSYCHIATRY:
A PERSPECTIVE ON SLEEP ACROSS THE LIFE CYCLE

A CME symposium to be held during the 2006 American Psychiatric Association (APA) Annual Meeting

TARGET AUDIENCE
This activity has been designed to meet the educational needs of practitioners involved in the management of sleep dysfunction and insomnia.

LEARNING OBJECTIVES
At the conclusion of the symposium, the participant should be able to:
- Understand normal sleep patterns, sleep architecture, and sleep behaviors as they develop and change from infancy through old age.
- Discuss the epidemiology, impact, evaluation, and general approach to the treatment of insomnia in the adult population.
- Review medical and psychiatric comorbidities associated with insomnia and discuss the importance of addressing underlying conditions when managing sleep dysfunction.
- Discuss gender-related differences in sleep architecture and the development of sleep-related disorders.
- Identify changes in the pattern of normal sleep that occur with advancing age.

REGISTRATION
Attendees must be registered for the APA Annual Meeting to attend the symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.apa.org or contact the APA office at 800-374-7924 (within the US or Canada) or 703-907-7300.

ACCREDITATION STATEMENT
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Supported by an educational grant from Sepracor Inc., sponsored by the American Psychiatric Association

INTERRUPTING THE CYCLE OF VASCULAR DISEASE AND DEPRESSION

Held at the APA 2006 Annual Meeting

Sunday, May 21, 2006 • Lunch: 1:00–1:30 pm • Scientific Program: 1:30–4:30 pm
Fairmont Royal York Hotel • Convention Floor Concert Hall • Toronto, Canada

1:00 PM Lunch
1:30 Welcome and Introduction
Steven P. Roose, MD—Chairman
Columbia University and the New York State Psychiatric Institute
1:40 Vascular Disease: Mechanisms Underlying the Relationship
Dominique Massuilet, MD—Emory University School of Medicine
2:10 The Bidirectional Relationship Between Diabetes and Depression
Gregory J. Mathews, MD—Mount Sinai School of Medicine
2:40 Post-Stroke Depression and the Vascular Depression Hypothesis
David C. Steffens, MD—Duke University Medical Center
3:10 Vascular Disease and Depression Challenges in Management and Treatment
Christopher M. O'Connor, MD—Harvard Medical School
3:40 Clinical Treatment Perspectives: A Focus on Diagnosis and Safety
J. Craig Nelson, MD
University of California, San Francisco School of Medicine
4:10 Panel Discussion and Q & A Session
4:30 Conclusion

*Each presentation will include 5 minutes for audience questions

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for up to 3 hours in category 1 credit toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should only claim credit commensurate with the extent of his or her participation in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.apa.org or contact the APA at 1-888-357-7924 (within the US or Canada) or 703-907-7300.

EDUCATIONAL OBJECTIVES
At the conclusion of this program, participants should be able to:
- Identify the mechanisms that underlie the relationship between vascular disease and depression
- Define the relationship between depression and metabolism as it relates to diabetes
- Recognize the impact of stress on the development of depression
- Manage and treat patients with comorbid depression and vascular disease
- Appraise safe and effective treatments for patients with vascular disease and depression

Supported by an educational grant from Forest Pharmaceuticals, Inc.
INDUSTRY-SUPPORTED SYMPOSIUM 17
Sunday, May 21, 2006, 1:30 p.m. - 4:30 p.m.
Sheraton Centre, Lower Concourse, Grand Ballroom

Update on Insights From and Future Course of the Collaborative Depression Study
Sunday, May 21, 2006
1:00–1:30 PM Lunch
1:30–4:30 PM

Learning Objectives
At the conclusion of this symposium, the participant should be able to...
1. Summarize current insights into the naturalistic course of depression, as informed by several long-term naturalistic observational studies
2. Integrate insights from research in neurobiology, neuroimaging, and genomics with new epidemiologic perspectives on the pathophysiology of depression
3. Discuss current treatment strategies and candidates for future treatments as informed by these epidemiologic and other research findings

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 category 1 credits toward the APA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity. Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-557-7924 (within the US or Canada) or 1-703-997-7300.

Agenda
1:00–1:30 PM
Lunch

1:30–1:40 PM
Welcome and Overview
Martin Keller, MD
Brown University

1:40–2:05 PM
The Pernicious Course of Depression and the Impact of New Insights From Imaging, Genomics, Neurobiology, and Learning
Martin Keller, MD
Brown University

2:05–2:30 PM
Update on the Clinical Course of Major Depression
Andrew Tyska, MD
Brown University

2:30–2:55 PM
Using Pharmacogenetics in Practice
Alan Schatzberg, MD
Stanford University

2:55–3:20 PM
Biological and Imaging Changes in Depression
K. Ramya R. Krishnan, MD
Duke University Medical Center

3:20–3:45 PM
Review of the Current State of Efficacy-based Treatment of Depression
Madhukar Trivedi, MD
University of Texas Southwestern

3:45–4:30 PM
Panel Discussion and Q & A
Martin Keller, MD
Brown University

Sponsored by the American Psychiatric Association and supported by an educational grant from Wyeth

INDUSTRY-SUPPORTED SYMPOSIUM 18
Sunday, May 21, 2006, 1:30 p.m. - 4:30 p.m.
Westin Harbour Castle, Street Level, Frontenac Room

MISDIAGNOSIS OF BIPOLAR
Methods for Screening Patients at Risk for Bipolar Disorder

Scientific Agenda and Distinguished Faculty
SUNDAY, MAY 21
1:00PM: Lunch
1:30PM: Introduction
1:40PM: Diagnosing Bipolar Disorder and the Role of Screening Instruments
Teresita Ketter, MD
Professor of Psychiatry and Behavioral Sciences
Quatar University School of Medicine

2:00PM: Major Depression: Clues to Baseline Change in Bipolar and Depression
Hans J. Moskowitz
Professor of Psychiatry and Director of the Mood Disorders
University of California at San Diego

3:30PM: Bipolar Depression: Implications for Mortality, Morbidity, and Therapeutics
Texas J. Bledsoe, MD
Professor of Psychiatry (Neuroscience)
Harvard Medical School

4:30PM: Antidepressants and the Bipolar Spectrum
Giuseppe Deligianni, MD, MPH
Associate Professor of Psychiatry and Public Health
Emory University

5:30PM: Depression and the Affective Spectrum: The Role of Mood Disorders
Frederick K. Goodwin, MD
Professor of Psychiatry
Director, Center for Neuropsychiatric, Medical Progress and Society
George Washington University Medical Center

4:35PM: Q&A Session
4:30PM: Adjourn

Registration Statement: Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-557-7924 (within the US or Canada) or 1-703-997-7300.

Accreditation Statement: The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Statement of Need: The beginning of this session will suggest that the classical Koszegiakos classification of the essential activity of the more recurrent forms of affective illness, both bipolar and unipolar, promises a more sound basis for diagnosis and treatment than contemporary diagnostic systems that focus on polarity, other than recurrence or cyclicity, as their primary organizing principle. Also, evidence will be reviewed that indicates a bipolar history is frequently missed when patients present with depression; practical approaches to minimize the common diagnostic error will be presented, including screening questionnaires. Features of unipolar depression associated with a family history of bipolar disorder will be outlined, and will describe depressive features of bipolar II patients that differentiate them from unipolar patients, focusing on "depressive mixed states." The implications of bipolar depression for mortality and morbidity will then be discussed, noting that across the affective spectrum much of the mortality associated with these disorders is inpatient. Finally, the implications of the affective spectrum concept for treatment will be outlined, focusing on a modification of the triad-treatment role of antidepressants and an expanded role for mood stabilizers across this spectrum.

Intended Audience: Psychiatrists
Educational Objectives: At the conclusion of this session, participants should be able to recognize and describe:

- Depressive features in unipolar patients suggestive of a bipolar illness
- Highly recurrent unipolar depression
- Depressive mixed states
- The affective spectrum and how it differs from the bipolar spectrum
- Treatment strategies for depression in the bipolar spectrum

Program Administration and Americans with Disabilities Act: Event staff will be glad to assist you with any special needs (e.g., physical, dietary). Please contact Carrie Medina prior to the event at 750-116-6000 or e-mail at carrie.medina@Wyeth.com.

Sponsored by the American Psychiatric Association and supported by an educational grant from Wyeth
INDUSTRY-SUPPORTED SYMPOSIUM 19
Sunday, May 21, 2006, 1:30 p.m. - 4:30 p.m.
Westin Harbour Castle, Second Level, Metro Grand Ballroom

APA 2006 Annual Meeting

Advances in the Understanding of the Dementia Spectrum

Sunday, May 21, 2006 • 1:00 PM – 1:30 PM Lunch • 1:30 PM – 4:30 PM Symposium
Metropolitan Grand Ballroom, Second Level, Westin Harbour Castle • Toronto, Ontario, Canada

1:30 PM – 1:35 PM
Welcome and Introduction
Jeffrey L. Cummings, MD, Program Chairperson
UCLA Alzheimer's Disease Center
Los Angeles, California

1:35 PM – 2:00 PM
The Neurology of Alzheimer's Disease
David A. Bennett, MD
Rush Alzheimer's Disease Center
Chicago, Illinois

2:00 PM – 2:25 PM
Therapeutic Options in the Management of Vascular Dementia
David Williamson, MB, ChB, MRCP, FRCPsych
Memory Assessment and Research Centre
Queen's Hospital
Southampton, United Kingdom

2:25 PM – 2:50 PM
Evolution of the Understanding and Treatment of Mild Cognitive Impairment
Gregory A. Jicha, MD, PhD
Alzheimer's Disease Center
Sandia-Brown Center on Aging
University of Kentucky Medical Center
Lexington, Kentucky

2:50 PM – 3:35 PM
Improving Outcomes for Patients with Advanced Dementia
Howard Feldman, MD, CM, FRCP(C)
University of British Columbia (UBC) and Vancouver Hospital
UBC Clinic for Alzheimer's Disease and Related Disorders
Vancouver, British Columbia, Canada

3:15 PM – 3:45 PM
Optimizing Behavioral Outcomes Across the Dementing Spectrum
Jeffrey L. Cummings, MD

3:40 PM – 3:45 PM
Concluding Remarks

3:45 PM – 4:30 PM
Question and Answer Session
Faculty Panel

OBJECTIVES
At the conclusion of this program participants should be able to:

1. Describe the epidemiological foundation of dementia.

2. Discuss strategies for identifying and educating caregivers.

3. Explain the differences between presenile and late-onset dementia.

4. Discuss the role of mild cognitive impairment (MCI) and advanced cognitive impairment in disease progression.

5. Review the treatment strategies for patients with advanced dementia.

6. Identify strategies for optimizing behavioral outcomes with dementia.

Attendees must be registered for the American Psychiatric Association (APA) Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll-free at 1-800-366-7394 (within the U.S. or Canada) or 703-907-7300.

The APA reserves the right to modify the agenda and content of the meeting to provide the best education to participants.

The APA designates this educational activity for a maximum of 5 AMA PRA Category 1 Credits™. Physicians should claim credit commensurate with the extent of their participation in the activity.

Sponsored by: 

Supporting the Research on Alzheimer’s Disease

INDUSTRY-SUPPORTED SYMPOSIUM 20
Sunday, May 21, 2006, 7:00 p.m. - 10:00 p.m.
Toronto Convention Centre, North Level 100, Room 102

Alzheimer's Disease: Challenging the Practice Paradigm

Agenda and Faculty

6:30 PM – 7:00 PM
Dinner

7:00 PM – 7:10 PM
Introduction
Pierre N. Tarot, MD (Chairperson)
University of Medicine and Science

7:10 PM – 7:40 PM
Variability in the Clinical Presentation of Alzheimer's Disease
M. Salerno Tarot, MD
University of Rochester Medical Center

7:40 PM – 8:10 PM
Treatment Initiation in Alzheimer's Disease
Pierre N. Tarot, MD

8:10 PM – 8:40 PM
Individualizing Alzheimer's Disease Therapy
Over the Disease Course
Constantine Lyketsos, MD, MHS
The John Hopkins University School of Medicine

8:40 PM – 9:10 PM
Neuropsychiatric Symptoms in Alzheimer's Disease: Preventing Emergence and Decreasing Severity
Jeffrey L. Cummings, MD
UCLA Department of Neurology

9:10 PM – 9:45 PM
Discussion/Q&A

9:45 PM – 10:00 PM
Concluding Remarks & Close
Pierre N. Tarot, MD

Educational Objectives

At the conclusion of the symposium, activity participants should be able to:

1. Understand variability in the patient population that presents with Alzheimer's disease and formulate appropriate management plans based on individual patient needs and/or medical concerns.

2. Implement the rational and critically evaluate clinical safety and efficacy of current therapeutic approaches in treatment-naive and treatment-experienced patients.

3. Discuss the impact of neuropsychiatric symptoms in Alzheimer's disease, outline safety issues associated with the use of psychotropics in the elderly, and delineate efficacy of current Alzheimer's disease therapies in reducing the severity of behavioral symptoms.

The American Psychiatric Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 5 AMA PRA Category 1 Credits™. Physicians should claim credit commensurate with the extent of their participation in the activity.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll-free at 1-800-366-7394 (within the U.S. or Canada) or 703-907-7300.

The symposium is sponsored by the American Psychiatric Association.

Supported by an educational grant from Forest Pharmaceuticals, Inc.
INDUSTRY-SUPPORTED SYMPOSIUM 21
Sunday, May 21, 2006, 7:00 p.m. - 10:00 p.m.
Royal York, Convention Floor, Canadian Room

A Dinner Symposium Held During the APA 2006 Annual Meeting

Effectiveness of Antipsychotic Drugs in Chronic Schizophrenia: Complete Results of the CATIE Trial

6:30pm-7:00pm Dinner
7:00pm Welcome and Introduction
Jeffrey A. Lieberman, MD
Program Chairperson
Columbia University Medical Center
7:10pm Comparison of Primary Outcome Measures of Efficacy and Safety
Jeffrey A. Lieberman, MD
Program Chairperson
7:30pm Comparison of Clozapine vs Other Antipsychotics in Prospectively Defined Unresponsive Patients
Joseph T. McGinty, MD
Duke University School of Medicine
8:00pm Comparison of Ziprasidone vs Other Atypical Drugs in Prospectively Defined Unresponsive Patients
T. Scott Strong, MD, MPh
University of North Carolina at Chapel Hill
8:25pm Comparison of Treatment Effects on Cognition
Richard S. Keefe, MD
Dana University Medical Center
8:50pm Comparison of Treatments on Health Service Utilization and Cost-Effectiveness Measures
Robert A. Rosenthal, MD
Yale University School of Medicine
9:15pm Question and Answer Session
10:00pm Program Adjournment

Learning Objectives:
Upon completion of this activity, participants should be able to:
1. Identify the primary outcome measures used to measure efficacy in the CATIE Trial.
2. Discuss the impact of antipsychotics on cognitive function in schizophrenia.
3. Compare differences in the efficacy of antipsychotics in defined-antipsychotic patients.

Accreditation Statement:
The American Psychiatric Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
The APA designates this educational activity for a maximum of 1 category 1 credit toward the AMA Physician's Recognition Award. Physicians should claim only those credits that actually spent in the activity.

Faculty Disclosure Statement:
All faculty are required to disclose to the audience any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the educational activity. The faculty disclosure statements will be listed in the course syllabus and at the beginning of each topic presentation.

Supported by Shire.

Don't Miss This Important Educational Activity!

INDUSTRY-SUPPORTED SYMPOSIUM 22
Sunday, May 21, 2006, 7:00 p.m. - 10:00 p.m.
Royal York, Convention Floor, Concert Hall

Mania in Special Populations
Agenda and Faculty
Welcome and Introduction
Robert A. Rosenthal, MD
The University of South Florida
Recent Developments in the Treatment of Mania
Robert A. Rosenthal, MD
The University of South Florida
Adolescent Bipolar Disorder
Karen E. Wagner, MD, PhD
The University of Texas Health Science Center
Bipolar Disorders in Women
Clinical and Neuroendocrine Correlates
Natalie L. Rimanowicz, MD, PhD
Stanford University School of Medicine
Bipolar Disorder in the Older Patient
Brent W. Hales, MD
Memorial Hospital
Bipolar Disorder in African Americans
William H. Legrand, MD, PhD, DNB
Howard University College of Medicine
D.A. Discussion
All Faculty
Concluding Remarks
Robert A. Rosenthal, MD

Educational Objectives:
1. To describe how new evidence on the biology of mania can inform treatment strategies.
2. To describe the clinical presentation of bipolar disorder in children and adolescents, as well as the current state of treatment options in this population.
3. To describe current issues regarding manic in children, with focus on the natural history of mania and bipolar disorder, and the management of various clinical syndromes of mania, including rapid cycling.
4. To describe current understandings of bipolar disorder in women, including the relationship between bipolar disorder and endocrine disturbances, and the treatment of bipolar disorder in the context of other medical conditions.
5. To provide knowledge about how drug development in African Americans is impacted by specific considerations and how these findings may translate to other racial/ethnic groups.

The American Psychiatric Association (APA), accredited by the Accreditation Council for Continuing Medical Education (ACE), is committed to ensuring that all continuing medical education (CME) activities remain free from any bias resulting from commercial support. To meet this commitment, all individuals in a position to control the content of this activity have provided disclosures of relevant financial relationships with commercial interests. All relevant financial relationships are in compliance with the ACCME's Criteria for Commercial Support and the policies of the APA. All relevant disclosures have been reviewed and approved by the appropriate person in the CME office. The APA takes measures to ensure that the educational content is independent of commercial interests. Attendees should be aware that this CME activity may offer commercial support to the APA and may result in financial benefits to the APA. Additional information about commercial support is provided in the program.

This course is supported by Shire Australia.
PRESENTING  IN  THE

NEUROBIOLOGY AND
THERAPEUTICS OF ADHD

LEARNING OBJECTIVES
At the conclusion of this symposium the participant should be able to:

- describe new horizons in the neurobiology and psychopharmacology of ADHD
- associate new findings between ADHD and sleep disorders
- review new findings pertaining to neurobiological impairments in ADHD and their functional consequences.
- discover new developments in the psychopharmacology of ADHD.

ACCREDITATION STATEMENT
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION
The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

REGISTRATION
Attendees must register for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA website at www.psych.org.

INDUSTRY-SUPPORTED SYMPOSIUM 24
Sunday, May 21, 2006 - 7:00 p.m. - 10:00 p.m.
Westin Harbour Castle, Street Level, Frontenac Room

Presented at the APA 2006 Annual Meeting
Atypical Depression: Merging Evidence and Public Policy
Sunday, May 21, 2006 - 7:00 p.m. - 10:00 p.m. (Dinner 6:30 p.m. - 7:00 p.m.)
Westin Harbour Castle, Street Level, Frontenac Room, Toronto, Canada

Program Agenda
6:30 p.m. - 7:00 p.m.: Dinner
7:00 p.m. - 7:10 p.m.: Welcome and Introduction
7:10 p.m. - 7:35 p.m.: The Neurobiology of Depression: Bringing the Latest in Science to Clinicians
7:35 p.m. - 8:00 p.m.: Pharmacology of Atypical Depression
8:00 p.m. - 8:25 p.m.: An Evidence-Based Approach to Managing the Disabilities of Atypical Depression
8:25 p.m. - 8:50 p.m.: Future Directions in the Treatment of Atypical Depression
8:50 p.m. - 9:15 p.m.: Interactive Patient Cases
9:15 p.m. - 10:00 p.m.: Panel Discussion/Q&A

Learning Objectives
- Identify the clinical features of atypical depression.
- Examine the neurobiological underpinnings of atypical depression.
- Implement a treatment plan that incorporates non-pharmacologic and pharmacologic strategies to enhance patient outcomes.

Statement of Need
Atypical depression is a common subtype of depression that affects 25 to 42 percent of depressed patients. Patients with atypical depression have unique differences in symptomatology, risk factors, and response to drug treatment. A diagnosis of atypical depression must include mood reactivity and at least two of the following symptoms: hyperphagia, hyperemophilia, lassitude, psychomotor retardation, and blunted affect. The National Comorbidity Survey found that among patients diagnosed with atypical depression, a higher percentage are women and those with higher scores on the Beck Depression Inventory tend to have a higher prevalence of suicidality and disability. Patients with atypical depression are at increased risk for suicidal ideation and suicide attempts. Atypical depression is a common comorbidity that may result in increased burden on the healthcare system and hospital emergency rooms. Patients with atypical depression have significantly more comorbidity and disability due to mental health than patients with typical depression. A correct diagnosis of atypical depression is critical to appropriate treatment selection and patient outcomes. Utilizing a case-based, interactive presentation, the experts will explore the unique presentations of atypical depression to enhance the audience's understanding of atypical depression and improve patient outcomes.

References:
INDUSTRY-SUPPORTED SYMPOSIUM 25
Sunday, May 21, 2006, 7:00 p.m. - 10:00 p.m.
Westin Harbour Castle, Second Level, Metro Grand Ballroom

APA 2006 Annual Meeting

Insomnia From the Inside-Out
(From Neuroscience to Clinical Experience to Public Policy)

Sunday, May 21, 2006 • 6:30 PM - 7:00 PM Dinner • 7:00 PM - 10:00 PM Symposium
Metropolitan Ballroom, Convention Level, Westin Harbour Castle • Toronto, Ontario, Canada

7:00 PM - 7:15 PM
Welcome and Introduction
Ellen Frank, PhD, Chair
University of Pittsburgh School of Medicine
Western Psychiatric Institute and Clinic
David Kopker, MD, Co-Chair
University of Pittsburgh School of Medicine
Western Psychiatric Institute and Clinic
Pittsburgh, PA

8:15 PM - 8:45 PM
Putting the Science to Work
Daniel Boyer, MD
University of Pittsburgh School of Medicine
Pittsburgh, PA

8:45 PM - 9:15 PM
Insomnia: Cost of Illness, Public Policy, and Medical-Legal Issues
Alan Newman, MD
Georgetown University Hospital
Washington, DC

9:15 PM - 10:00 PM
Question-and-Answer Session
Faculty Panel

OBJECTIVES
At the conclusion of this program, participants will:
• Review the science of insomnia from the neuroscience to clinical experiences to public policy
• Assess the ways practitioners can be informed by the science of insomnia
• Demonstrate an understanding of the impact of insomnia on individual, healthcare, and public policy.

Attendees must be registered for the APA Annual Meeting to attend the symposium. Seating is limited and will be based on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org or contact APA at 800-374-2649 (within the US or Canada) or 703-370-7700.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for up to 1.5 continuing education credits toward the APA Physician Recognition Award. The APA Physician Recognition Award is granted to physicians who participate in the activity. APA, AR, ME.

Supported by an educational grant from

INDUSTRY-SUPPORTED SYMPOSIUM 26
Monday, May 22, 2006, 7:00 a.m. - 8:30 a.m.
Tuesday, May 23, 2006, 7:00 a.m. - 8:30 a.m.
Royal York, Convention Floor, Canadian Room

CLINICAL IMPLICATIONS OF CHOICE OF ATYPICAL ANTIPSYCHOTIC REALITIES AND MYTHS
2006 APA ANNUAL MEETING

AGENDA
MONDAY, MAY 22, 2006

<table>
<thead>
<tr>
<th>TIME</th>
<th>ACTIVITY/SESSION</th>
<th>LOCATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM - 7:20 AM</td>
<td>WELCOME AND INTRODUCTION</td>
<td>Royal York, Canadian Room</td>
</tr>
<tr>
<td>7:20 AM - 7:55 AM</td>
<td>BREAKFAST</td>
<td>Royal York, Canadian Room</td>
</tr>
<tr>
<td>7:55 AM - 8:25 AM</td>
<td>PANEL DISCUSSION</td>
<td>Royal York, Canadian Room</td>
</tr>
<tr>
<td>8:25 AM - 8:30 AM</td>
<td>CLOSING REMARKS</td>
<td>Royal York, Canadian Room</td>
</tr>
</tbody>
</table>

TUESDAY, MAY 23, 2006

<table>
<thead>
<tr>
<th>TIME</th>
<th>ACTIVITY/SESSION</th>
<th>LOCATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM - 7:20 AM</td>
<td>WELCOME AND INTRODUCTION</td>
<td>Royal York, Canadian Room</td>
</tr>
<tr>
<td>7:20 AM - 7:55 AM</td>
<td>BREAKFAST</td>
<td>Royal York, Canadian Room</td>
</tr>
<tr>
<td>7:55 AM - 8:25 AM</td>
<td>PANEL DISCUSSION</td>
<td>Royal York, Canadian Room</td>
</tr>
<tr>
<td>8:25 AM - 8:30 AM</td>
<td>CLOSING REMARKS</td>
<td>Royal York, Canadian Room</td>
</tr>
</tbody>
</table>

Participants must be registered for the 2006 APA Annual Meeting to attend this symposium. Seating is limited and will be based on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org or contact APA at 800-374-2649 (within the US or Canada) or 703-370-7700.
INDUSTRY-SUPPORTED SYMPOSIUM 27
Monday, May 22, 2006, 7:00 a.m. - 8:30 a.m.
Tuesday, May 23, 2006, 7:00 a.m. - 8:30 a.m.
Sheraton Centre, Lower Concourse, Grand Ballroom

EVIDENCE, OUTCOMES, AND ADVOCACY: SHAPING THE MANAGEMENT OF GAD

LEARNING OBJECTIVES
At the conclusion of this symposium the participant should be able to:

- Identify and recognize the myriad presentations of anxiety disorders.
- Recognize the somatic comorbidities of anxiety disorders.
- Evaluate targeted non-pharmacologic and pharmacologic strategies for the optimal treatment of generalized anxiety disorder.

ACCREDITATION STATEMENT
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credit(s)™. Physicians should claim credit commensurate with the extent of their participation in the activity.

REGISTRATION
Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org.

Sponsored by the American Psychiatric Association
Supported by Cephalon, Inc.

INDUSTRY-SUPPORTED SYMPOSIUM 28
Monday, May 22, 2006, 7:00 a.m. - 8:30 a.m.
Tuesday, May 23, 2006, 7:00 a.m. - 8:30 a.m.
Westin Harbour Castle, Second Level, Metro Grand Ballroom

Learning Objectives
At the conclusion of this symposium, the participant should be able to:

- Identify and manage coexistent or residual anxiety in patients with depression; address the needs of different patient populations with depression and anxiety with respect to presentation, response to therapy, comorbidity, and psychosocial needs.
- Describe the therapeutic challenges of treating patients with anxiety and depression and the relative efficacy of therapeutic options; describe the prevalence and impact of anxiety in patients with depression; and summarize evidence from randomized controlled trials describing the safety and efficacy of different antidepressant agents used in the management of depression and anxiety.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 category 1 credits toward the APA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity. Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-800-999-7700 (within the U.S. or Canada) or +1-703-907-7300.

Sponsored by the American Psychiatric Association and supported by an educational grant from Wyeth

Part 1

Part 2

Part 3

APA 198th Annual Meeting
Please join us for a two-part CME breakfast symposium on...
AGENDA:

8:00-8:35 AM  Pharmacotherapy of Psychotic and Mood Disorders in the Context of Treandablock Disease
QUINTON E. BOSS, MD
University of Cincinnati

8:35-9:05 AM  When Mental Illness Is Complicated by Respiratory Symptoms: Management Implications
PETER J. WEIDEN, MD
SINT Center for Medical Education

7:35-8:00 AM  Patients With Mental Illness and Cancer
DIANA O. PERKINS, MD, MPH
University of North Carolina School of Medicine

LEARNING OBJECTIVES:
- Identify the method for achieving the optimal pharmacotherapy in patients who have psychotic and mood disorders complicating medical disorders.
- Discuss the management of mental illness in a patient who also has a diagnosis of cancer.
- Review the appropriate pharmacotherapy of psychiatric and mood disorders in the presence of Treandablock disease.
- Analyze the management implications when treating a person with mental illness complicated by the presence of respiratory symptoms.
- Discuss the pharmacotherapy of psychiatric problems in the patient with AIDS.

CME STATEMENT
The symposium will be conducted on May 22, 2006, during the APA 2006 Annual Meeting. The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This symposium is eligible for a maximum of 1 category 1 credit toward the APA Psychiatry Recognition Award and for the CME requirement of the APA. Each physician should only claim those credits that he/she actually spent in the activity.

INDUSTRY-SUPPORTED SYMPOSIUM 30
Monday, May 22, 2006, 7:00 p.m. - 10:00 p.m.
Royal York, Convention Floor, Canadian Room

Presented at the APA 2006 Annual Meeting

Helping Depressed Patients Achieve Remission: Advocacy for Improvement

Learning Objectives:
- Recognizing factors contributing to heterogeneity in response and remission and their implications for treatment outcomes.
- Evaluate strategies for partial or non-responders that include switching, augmentation, and combination treatments.
- Examine the role of pharmacogenomics in treatment selection.
- Design a treatment plan that utilizes non-pharmacologic and pharmacologic strategies to achieve remission.

Statement of Need
Symptom remission is the goal of treating depression. However, many patients are "treatment resistant" and don’t achieve remission with any one treatment, likely reflecting the heterogeneously pathobiology underlying depression. Current practice recommends a range of "trial and error" sequential treatment steps, including switching, augmentation, and combination treatments. Unfortunately, few prospective randomized controlled trials have compared multiple augmentation or switch treatments. This symposium will present findings from controlled treatment trials—including the Sequenced Treatment Alternatives to Relieve Depression (START-D) trial—that have investigated augmentation/combination treatments at the second and third treatment steps and switch treatments at the second, third, and fourth treatment steps.

References:

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first come, first served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-888-357-7924 (within the U.S. or Canada) or 703-967-7920.

Supported by an educational grant from Bristol-Myers Squibb Company.

148
APRA ANNUAL MEETING: ISS-31
Understanding and Managing the Transition of ADHD From Adolescence to Young Adulthood: The Maturation of the Disorder

Dinner
6:30 PM - 7:00 PM

Program
7:00 PM • Welcome/Introduction
Timothy E. Wilens, MD, Chair
Massachusetts General Hospital
7:10 PM • Imaging the Brains of ADHD Adults: New Findings
George Bush, MD
Massachusetts General Hospital
7:35 PM • ADHD 'Not Otherwise Specified': Conceptual Issues
Stephen V. Faraone, PhD
SUNY Upstate Medical University
8:00 PM • ADHD Behind the Wheel: Driving With ADHD
Craig B. Surman, MD
Massachusetts General Hospital

Learning Objectives:
At the conclusion of this symposium, the participant should be able to:
1. Understand the clinical presentation of ADHD through young adulthood
2. Appreciate the special considerations in the diagnosis and treatment of young adults with ADHD
3. Discuss new and emerging pharmacological treatments for adolescents and adults with ADHD

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

Supported by the American Psychiatric Association.
INDUSTRY-SUPPORTED SYMPOSIUM 33
Monday, May 22, 2006, 7:00 p.m. - 10:00 p.m.
Westin Harbour Castle, Second Level, Metro Grand Ballroom

APA 2006 Annual Meeting • Monday, May 22, 2006

Taking Control of Negative Symptoms:
The Next Step for Improved Patient Outcomes in Schizophrenia

Dinner • 6:30PM – 7:00PM • Symposium • 7:00 PM – 10:00 PM
Metro Grand Ballroom, Second Level, Westin Harbour Castle • Toronto, Canada

6:30 PM - 7:00 PM Dinner

7:00 PM - 7:15 PM Welcoming and Introduction
Stevens G. Pollock, M.D., Chairman
Department of Psychiatry and Human Behavior,
University of California, Irvine

7:15 PM - 7:45 PM Recognizing Negative Symptoms and Their Importance
Joseph M. Pine, M.D.
Department of Psychiatry and Behavioral Sciences
University of California, Los Angeles

7:45 PM - 8:15 PM Psychosis Circuits, Negative Symptoms, and Brain Imaging
Steven G. Pollock, M.D.

8:15 PM - 8:45 PM Treatment of Negative Symptoms
Hans-Jurgen Muller, M.D.
Department of Psychiatry,
Ludwig Maxiimilians-University

8:45 PM - 9:15 PM Positive Outcomes with Negative Symptoms: Measuring and Monitoring Your Patients
Dawn E. Wittman, Ph.D.
Department of Psychiatry,
University of Texas H.S.C.

9:15 PM - 10:00 PM Question-and-Answer Session
Facility Panel

OBJECTIVES
After attending this symposium, the participant will be able to:
• Recognize that patients with schizophrenia continue to experience negative
  symptoms, which severely limit their function
• Distinguish negative symptoms from cognitively impaired symptoms in
  independent symptom domains in schizophrenia
• Demonstrate understanding of the neuropathology and potential negative
  symptoms
• Understand treatment strategies to reduce negative symptoms in patients with
  schizophrenia
• Utilize an informed approach to improve treatment for these difficult patients
• Measure and monitor negative symptoms in patients

Attendees must be registered for the APA Annual Meeting 2006 to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA web site at www.psych.org or contact the APA at 1-888-357-7624 (with the U.S. or Canada) or (703) 907-7300.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 1.5 CME credits. Physicians should only claim credit corresponding to the extent of their participation in the activity.

This symposium is supported by an educational grant from GlaxoSmithKline.

INDUSTRY-SUPPORTED SYMPOSIUM 34
Tuesday, May 23, 2006, 7:00 p.m. - 10:00 p.m.
Toronto Convention Centre, North Level 100, Room 102

Sponsored by the American Psychiatric Association
Take Advantage of this Invaluable Educational Opportunity at APA 2006!

Management of Psychosis in the Elderly:
The Science and the Art

3.0 CME Credits are designated for participation in this Educational Symposium.

TUESDAY, MAY 23, 2006
6:30 - 7:00 PM DINNER
7:00 - 10:00 PM PROGRAM
Toronto Convention Centre
North Level 100, Room 106

LEARNING OBJECTIVES:
At the end of this symposium, the participants should be able to:
• Develop different diagnoses and differential diagnosis of psychotic disorders in elderly
• Treat psychotic disorders in elderly with appropriate pharmacotherapy
• Recognize adverse effects of medications in older patients
• Choose appropriate psychosocial interventions in older psychotic patients

AGENDA:
6:30 PM - 7:00 PM Complimentary Dinner
7:00 PM - 7:20 PM Welcome and Introduction
Robert F. Jones, M.D.
University of California, San Diego

7:25 PM - 7:35 PM Evaluation of Psychosis in the Elderly
Carl S. Grant, M.D.
Harvard Medical School

7:35 PM - 7:50 PM Discussion from the Floor
Lynn S. Hidema, M.D.
University of Southern California

7:50 PM - 8:00 PM Safety of Antipsychotics in the Elderly
Mark P. Lendeckel, M.D.
Florida State University

8:00 PM - 8:20 PM Safety of Antipsychotics
Cheryl E. Mihalik, M.D.
Florida State University

8:20 PM - 8:30 PM Safety of Antipsychotics
Mark P. Lendeckel, M.D.
Florida State University

8:30 PM - 8:40 PM Safety of Antipsychotics
Cheryl E. Mihalik, M.D.
Florida State University

8:40 PM - 8:50 PM Safety of Antipsychotics
Mark P. Lendeckel, M.D.
Florida State University

8:50 PM - 9:00 PM Safety of Antipsychotics
Cheryl E. Mihalik, M.D.
Florida State University

9:00 PM - 9:15 PM Discussion from the Floor
9:15 PM - 9:30 PM Novel Antipsychotic Strategies
9:30 PM - 9:45 PM Implications for Biology and Future Treatment
9:45 PM - 10:00 PM Discussion from the Floor
10:00 PM - 10:15 PM Question-and-Answer Session

PROGRAM CHAIR:
Robert F. Jones, M.D.
Professor of Psychiatry and Neurosciences
Director, Geriatric Neuropsychiatry Program
University of California, San Diego

150
MULTIPLE AND COMPLEX PRESENTATIONS OF BIPOLAR DISORDER
Charles L. Bowden, MD - Program Chairman
Tuesday, May 23, 2006

The Fairmont Royal York - Convention Floor, Canadian Room

6:30–7:00 pm  Dinner
7:00–7:10 pm  Welcome and Introduction
Charles L. Bowden, MD - Program Chairman
University of Texas Health Science Center at San Antonio

7:10–7:40 pm  Presentations of Bipolar Disorder in Children and Adolescents
Kiki D. Chang, MD
Stanford University School of Medicine

7:40–8:10 pm  The Impulsive-Aggression Symptom Domain in Personality Disorders
Eric Hauri, MD
Mount Sinai School of Medicine

8:10–8:40 pm  Bipolar Ill Disorder and Suicidal Behaviors
William H. Coryell, MD
University of Iowa Carver College of Medicine

8:40–9:10 pm  Predicting Maintenance Response from the Acute Episode
Charles L. Bowden, MD

9:10–10:00 pm  Q&A Panel Discussion
All Faculty

10:00 pm  Adjourn

INDUSTRY-SUPPORTED SYMPOSIUM 36
Tuesday, May 23, 2006, 7:00 p.m. - 10:00 p.m.
Royal York, Convention Floor, Concert Hall

TREATING the EARLY STAGES OF SCHIZOPHRENIA
Tuesday, May 23, 2006 • Dinner: 6:30–7:00 pm • Symposium: 7:00–10:00 pm
The Fairmont Royal York - Convention Floor, Concert Hall • Toronto, Ontario, Canada

AGENDA:
6:30–7:00 pm  Dinner
7:00–7:10 pm  Welcome and Introduction
DOLORES MALLASPINHA, MD, MSPH
CHAIRPERSON
Columbia University Medical Center
New York State Psychiatric Institute

7:10–7:25 pm  Genetic and Clinical Risk Factors for Schizophrenia: Predicting the Onset and Outcomes of the Illness and Treatment Response
DOLORES MALLASPINHA, MD, MSPH
Columbia University Medical Center
New York State Psychiatric Institute

7:25–8:00 pm  Treatment of the Early Stages of Schizophrenia: The Possibility of Neuroprotection
JEFFREY A. LIEBERMAN, MD
Columbia University Medical Center

8:00–8:25 pm  Evaluation of Procedural Schizophrenia
CHERYL CORKCORAN, MD
Columbia University Medical Center
New York State Psychiatric Institute

8:25–8:50 pm  Pharmacologic Strategies for the Treatment of Procedural Schizophrenia
DANIEL C. JAVITT, MD, PhD
New York University School of Medicine

8:50–9:15 pm  Treatment of the Early Stages of Schizophrenia: The Possibility of Neuroprotection
JEFFREY A. LIEBERMAN, MD
Columbia University Medical Center

9:15–10:00 pm  Question and Answer Session
ALL FACULTY

INDUSTRY-SUPPORTED SYMPOSIUM 35
Tuesday, May 23, 2006, 7:00 p.m. - 10:00 p.m.
Royal York, Convention Floor, Canadian Room

LEARNING OBJECTIVES:
- Discuss and differentiate between presentations of bipolar disorder.
- Understand the subgroups in the bipolar spectrum, with emphasis on early diagnosis and individualized pharmacotherapy.

ACCREDITATION:
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The APA designates this educational activity for a maximum of 3 category 1 credits toward the APA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

TREATING the EARLY STAGES of SCHIZOPHRENIA
Tuesday, May 23, 2006 • Dinner: 6:30–7:00 pm • Symposium: 7:00–10:00 pm
The Fairmont Royal York - Convention Floor, Concert Hall • Toronto, Ontario, Canada

LEARNING OBJECTIVES:
After attending this symposium, participants will be able to:
- Discuss how genetic and clinical risk factors influence the onset, treatment response, and outcomes for patients with schizophrenia
- Recognize the impact of tolerability and adherence in treating first-episode schizophrenia
- Discuss the pharmacological approaches to the treatment of prodromal schizophrenia
- Interpret the evidence of neuroprotection associated with the treatment of early stages of schizophrenia

CASE STATEMENT:
This symposium will be conducted on May 23, 2006, during the APA 2006 Annual Meeting. The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 category I credits toward the APA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity. If you are interested in a registration for this symposium, please visit the APA web site at www.psych.org or contact the APA toll-free at (800) 557-7274 (within the U.S. or Canada) or (703) 771-7300.
INDUSTRY-SUPPORTED SYMPOSIUM 37
Tuesday, May 23, 2006, 7:00 p.m. - 10:00 p.m.
Sheraton Centre, Lower Concours, Grand Ballroom

ADVOCATING FOR CHANGE THROUGH EVIDENCE-BASED MEDICINE: A FOCUS ON ADHD

Tuesday, May 23, 2006
6:30 PM - 7:00 PM Dinner
7:00 PM - 9:30 PM Scientific Session
Sheraton Centre - Lower Concours, Grand Ballroom
123 Queens St. West, Toronto, Ontario, Canada M5H 2MG

LEARNING OBJECTIVES
At the conclusion of this symposium the participant should be able to:

- Link attentional deficits, impulsivity, and hyperactivity to neurocircuity.
- Recognize the impact of sleep/wake disturbances on patients with ADHD.
- Design a treatment plan that utilizes non-pharmacologic and pharmacologic strategies to improve patient outcomes.

ACCREDITATION STATEMENT
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (CME) to provide continuing medical education for physicians.

CREDIT DESIGNATION
The APA designates this educational activity for a maximum of 3 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ATTENDANCE
To be eligible for CME credit, participants must attend the symposium in its entirety.

REGISTRATION
Attendees must register for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis.

Industrially-Supported Symposium 38
Tuesday, May 23, 2006, 7:00 p.m. - 10:00 p.m.
Westin Harbour Castle, Second Level, Metro Grand Ballroom

The Maze of Mood and Anxiety in the Elderly Patient: A Case Series

Presented at the APA 2006 Annual Meeting
Tuesday, May 23, 2006
7:00 p.m. – 10:00 p.m. (Dinner 6:30 p.m. – 7:00 p.m.)
Westin Harbour Castle, Second Level Metro, Grand Ballroom, Toronto, Canada

Learning Objectives
- Identify comorbidities that may mimic mood and anxiety disorders.
- Recognize the complex relationship between depression and anxiety disorders in the elderly.
- Evaluate targeted non-pharmacologic, psychotherapeutic, and pharmacologic options for the optimal treatment of anxiety and mood disorders in the elderly.

Many studies report that mood and anxiety disorders are less frequent among the elderly than in younger people. However, other data suggest that these disorders are actually undiagnosed and undertreated in the elderly because the physiologic symptoms of mood and anxiety disorders overlap with other medical problems associated with aging. Multiple physical and psychological conditions can mimic, exacerbate, or accompany symptoms of anxiety and mood disorders, including cardiovascular disease, cerebrovascular accidents, hypothyroidism, lithium impairments, and dementia.

Attentional depression may be the most common clinical presentation of anxiety in older patients, with an estimated 30% of patients with CDA also fulfilling criteria for depression. CDA may arise secondarily to a depression, and recovery is closely associated with recovery from depression. Available data suggest that certain psychosocial interventions may be effective for anxiety disorders in older adults, and that clinicians should consider the effects of aging on safety and tolerability to various medications when choosing a medication regimen. This interactive, case-based symposium will provide practical diagnostic tools and review current evidence supporting age-appropriate psychotherapeutic and pharmacologic treatment to best accommodate this challenging population.

References:

Index Terms: Depression, Anxiety, Elders, Pharmacotherapy.
EMERGING EVIDENCE in the TREATMENT of BIPOLAR DEPRESSION

Wednesday, May 24 & Thursday, May 25, 2006 • Breakfast: 6:30–7:00 AM • Symposium: 7:00–8:30 AM
Toronto Convention Centre, North Level 100, Room 102

AGENDA:

WEDNESDAY, MAY 24

6:30–7:00 AM Breakfast
7:00–7:05 AM Welcome and Introduction
JOSEPH H. CALABRESI, MD (Chairperson)
Case Western Reserve University School of Medicine
7:05–7:25 AM The Clinical Management of Bipolar Disorder
FREDERICK R. GOODWIN, MD
George Washington University
7:25–7:45 AM How Goldfish Influence Acute and Long-term Treatment of Bipolar Depression
ROBERT M. WINTERNITZ, MD
University of Texas Southwestern Medical Center at Dallas
7:45–8:05 AM Treatment of Mood and Drug Abuse in Bipolar Disorder
KATHLEEN E. MADJ, MD, PhD
Medical University of South Carolina
8:05–8:30 AM Questions and Answers Session
ALL FACULTY
8:30 AM Adjourn

THURSDAY, MAY 25

6:30–7:00 AM Breakfast
7:00–7:05 AM Welcome and Introduction
JOSEPH H. CALABRESI, MD (Chairperson)
Case Western Reserve University School of Medicine
7:05–7:25 AM Neurobiology of Bipolar Psychotic Episode
SOPHIA FRANGOU, MD, PhD
Institute of Psychiatry
7:25–7:45 AM Future Treatment: Risperidone Interventions for Symptoms and Negative Symptoms in Bipolar Depression
GUCIOHA XU, MD, PhD
Case Western Reserve University School of Medicine
7:45–8:05 AM Questions and Answers Session
ALL FACULTY
8:05 AM Adjourn

LEARNING OBJECTIVES:

After attending this symposium, participants will be able to:
• Review the management of patients with bipolar depression and how emerging evidence may impact current practice;
• Assess current guidelines for the treatment of bipolar depression and how to use these guidelines to achieve therapeutic success;
• Explore strategies for the management of comorbid alcohol and drug abuse in patients with bipolar disorder;
• Examine the etiology of bipolar disorder and how it relates to the management of patients with bipolar disorder;
• Define progress related to EEG and MRI in the research field of emerging interventional psychiatry for treatment of bipolar depression

CASE STATEMENT

The patient will not be reevaluated on the 30th of June, 2006. For the APA 2006 Annual Meeting, the American Psychiatric Association has developed a new case study format to assist physicians in understanding and discussing current medical advances. APA is committed to providing current medical information to its members. The three case studies presented will be used to demonstrate the benefit of new treatments for the management of this condition. Treatment will be recommended to the patient. The patient will be evaluated at the next visit, the 20th of July, 2006. At that time, the patient’s condition will be monitored, and the use of a new antidepressant will be considered.

Industry-Supported Symposium 39

INDUSTRY-SUPPORTED SYMPOSIUM 39
Wednesday, May 24, 2006, 7:00 a.m. – 8:30 a.m.
Thursday, May 25, 2006, 7:00 a.m. – 8:30 a.m.
Toronto Convention Centre, North Level 100, Room 102

Industry-Supported Symposium 40

INDUSTRY-SUPPORTED SYMPOSIUM 40
Wednesday, May 24, 2006, 7:00 a.m. – 8:30 a.m.
Thursday, May 25, 2006, 7:00 a.m. – 8:30 a.m.
Royal York, Convention Floor, Canadian Room

BIPOLAR ILLNESS

2006 APA ANNUAL MEETING
THE ROAD TO REMISSION

DATE: WEDNESDAY, MAY 24TH FROM 7:00 AM – 8:30 AM
ACTIVITY: CHAIRPERSON: PRASHANT S. MASAARD, MD
THURSDAY, MAY 25TH FROM 7:00 AM – 8:30 AM
THE FRANKIN BEYER, CANADIAN ROOM – TORONTO, ONTARIO

AGENDA:

WEDNESDAY, MAY 24, 2006

7:00–7:30 AM BREAKFAST
7:30–7:55 AM WELCOME AND INTRODUCTION
Prakash S. Masaad, MD
8:05–8:25 AM PANEL DISCUSSION
Moderate: Prakash S. Masaad, MD
8:25–8:30 AM CLOSING REMARKS
Prakash S. Masaad, MD

THURSDAY, MAY 25, 2006

7:00–7:30 AM BREAKFAST
7:30–7:55 AM WHERE DO WE LEAVE OFF THE ROAD TO REMISSION?
Prakash S. Masaad, MD
8:05–8:25 AM PANEL DISCUSSION
Moderate: Prakash S. Masaad, MD
8:25–8:30 AM CLOSING REMARKS
Prakash S. Masaad, MD

PROGRAM OVERVIEW

Remission of symptoms in patients with bipolar disorder is a complex concept to define and a difficult goal to achieve. The American Psychiatric Association guidelines define remission as a virtual lack of symptoms and a complete return to baseline level of functioning. The latter part of this definition may be more useful for a clinical psychologist, because the psychiatrist alone may not accurately reflect a patient's functional status. The goal of this symposium is to provide the psychiatric community with the best evidence to date about the management of patients with bipolar disorder. The aim of this symposium is to discuss the criteria for remission and how they are applied in clinical practice. The symposium will examine the evidence for the use of current medications for the treatment of bipolar disorder and the use of new medications for the treatment of bipolar disorder. The symposium will also discuss the use of newer medications for the treatment of bipolar disorder and the use of new medications for the treatment of bipolar disorder. The symposium will also discuss the use of newer medications for the treatment of bipolar disorder and the use of new medications for the treatment of bipolar disorder. The symposium will also discuss the use of newer medications for the treatment of bipolar disorder and the use of new medications for the treatment of bipolar disorder.

LEARNING OBJECTIVES:

After attending this symposium, participants should be able to:
• Outline a treatment plan strategy to enhance symptom control and control adverse events;
• Discuss the role of psychosocial interventions in maintaining remission in patients with bipolar disorder;
• Discuss the role of pharmacotherapeutics in maintaining remission in patients with bipolar disorder;
• Define progress related to EEG and MRI in the research field of emerging interventional psychiatry for treatment of bipolar depression.

DESIGNATION STATEMENT

The American Psychological Association is accredited by the Canadian Council for Continuing Medical Education to provide continuing medical education for physicians.

DESIGNATION STATEMENT

The APA designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s)™. Physicians should only claim credits commensurate with the extent of their participation in the activity.

153
INDUSTRY-SUPPORTED SYMPOSIUM 41
Wednesday, May 24, 2006, 7:00 a.m. - 8:30 a.m.
Thursday, May 25, 2006, 7:00 a.m. - 8:30 a.m.
Sheraton Centre, Lower Concourse, Grand Ballroom

Sponsored by the American Psychiatric Association
Take Advantage of this Invaluable Educational Opportunity at APA 2006!

New Frontiers in Depression: Solving with Antidepressants to Unmet Needs, Parts 1 & 2

LEARNING OBJECTIVES:
- Identify the current knowledge of the diagnosis and treatment of major depressive disorder, the importance of early recognition and treatment, and the necessity of distinguishing major depressive disorder from other conditions that can mimic major depressive disorder.
- Describe the latest treatment options for depression, including the impact of the use of antidepressants in the treatment of depression.
- Review the current approach to treating resistant depression, and the role of new treatments for depression on the horizon.

AGENDA (WEDNESDAY, MAY 24):
6:30 - 7:00 am Complimentary Breakfast
7:00 - 7:10 am Introduction and Welcome
7:10 - 7:40 am Genetic Mechanisms of Mood and Temperature
7:40 - 8:10 am Chronic Pain and Major Depression
8:10 - 8:30 am Question-and-Answer Session

AGENDA (THURSDAY, MAY 25):
6:30 - 7:00 am Complimentary Breakfast
7:00 - 7:10 am Welcome and Part 1: Neuronal Activity
7:10 - 7:30 am Uptake and Inhibition of Dopamine: A Pharmacologic Approach
7:30 - 7:50 am Diabetic and Therapeutic Challenges
7:50 - 8:10 am Current and Novel Treatment Options for Treatment-Resistant Depression
8:10 - 8:30 am Question-and-Answer Session from Day 2

INDUSTRY-SUPPORTED SYMPOSIUM 42
Wednesday, May 24, 2006, 7:00 a.m. - 8:30 a.m.
Thursday, May 25, 2006, 7:00 a.m. - 8:30 a.m.
Westin Harbour Castle, Second Level, Metro Grand Ballroom

What the Psychiatrist Needs to Know About Sleep-Related Movement Disorders

Wednesday, May 24, 2006 and Thursday, May 25, 2006 • Breakfast: 6:30 AM – 7:00 AM • Symposium: 7:00 AM – 8:30 AM
Location: Westin Harbour Castle • Second Level, Metro Grand Ballroom • Toronto, Ontario, Canada

HELD DURING THE APA’S 159TH ANNUAL MEETING

Learning Objectives:
- Identify factors that contribute to the development and course of sleep-related movement disorders.
- Discuss the diagnosis and management of restless legs syndrome (RLS) and periodic limb movement disorder (PLMD).
- Describe the relationship between Parkinson's disease and RLS.
- Understand the role of genetics in the development of sleep-related movement disorders.
- Evaluate the effectiveness of pharmacological and non-pharmacological treatments for sleep-related movement disorders.

Supported by an educational grant from Wyeth Pharmaceuticals and Iytoy Pharmaceuticals.
Industri-supported Symposium 43
Wednesday, May 24, 2006, 7:00 p.m. - 10:00 p.m.
Royal York, Convention Floor, Canadian Room

What Is the Role of Somatic and Physical Symptoms in Depression?
Wednesday, May 24, 2006
6:30-7:00 p.m. Dinner
7:00-10:00 p.m.

Learning Objectives
At the conclusion of this symposium, the participant should be able to:
- Describe the somatic and physical symptom presentations of depression and interpret their prognostic value
- Understand the role played by the neurotransmitter systems in the pathophysiology of these symptoms
- Describe the diagnostic and management approaches to depressed patients with physical and somatic symptoms, particularly among depressed patients with comorbid medical illnesses
- Upon completion of this medical education activity, participants should have improved overall knowledge, skills, and attitudes concerning the diagnosis and treatment of depression and comorbid medical conditions

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 5 category 1 credits toward the APA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity. Attendance must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll-free at 1-800-355-7954 (within the U.S. or Canada) or +1-705-907-7300.

INDUSTRY-SUPPORTED SYMPOSIUM 44
Wednesday, May 24, 2006, 7:00 p.m. - 10:00 p.m.
Royal York, Convention Floor, Concert Hall

Diagnosing and Treating Alcohol Dependence in the Office
Wednesday, May 24, 2006
6:30 p.m. - 7:00 p.m. Dinner
7:00 p.m. - 10:00 p.m. Scientific Session
The Fortmorn Royal York - Convention Floor, Concert Hall
100 Front Street W, Toronto, Ontario, Canada M5J 1E3

Learning Objectives
At the conclusion of this symposium, the participant should be able to:
- Describe the chronic nature of alcoholism and how it affects treatment in the office setting
- Discuss screening, diagnosis, and early intervention for alcohol dependence
- Review the rationale, mechanism, and relevant data of current and emerging treatments for alcohol dependence
- Identify the most common co-occurring psychiatric disorders seen with alcohol dependence and discuss treatment options
- Discuss the various types of behavioral therapies used in office-based practice for the treatment of alcohol-dependent patients.

Accreditation Statement
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 5 AMA PRA Category 1 Credits®. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit Designation
The APA designates this educational activity for a maximum of 5 AMA PRA Category 1 Credits®. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Registration
Attendance must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website at www.psych.org.

Scientific Program Agenda
7:00 p.m. - 7:10 p.m.
Program Introduction
Kathleen Brady, MD, PhD (Symposium Chair)

7:10 p.m. - 7:40 p.m.
Alcoholism as a Chronic Disease:
Implication for Office-based Treatment
Thomas McKellar, MD
Innsmouth Research Institute

7:40 p.m. - 8:10 p.m.
Screening, Diagnosis, and Early Intervention
Kathleen Brady, MD, PhD
Medical University of South Carolina

8:10 p.m. - 8:40 p.m.
Current and Emerging Treatment
Options in Alcoholism
Richard N. Rosenthal, MD
Columbia University College of Physicians & Surgeons

8:40 p.m. - 9:10 p.m.
Office-based Treatment of Co-occurring Psychiatric Disorders
Shelly Grenzeb, MD, MPH
Harvard Medical School

9:10 p.m. - 9:40 p.m.
Behavioral Therapies for Alcohol Dependence
Grace Hennessy, MD
New York Veterans Administration Hospital

9:40 p.m. - 10:00 p.m.
Panel Discussion/Question-and-Answer Session

INDUSTRY-SUPPORTED SYMPOSIUM 45
Wednesday, May 24, 2006, 7:00 p.m. - 10:00 p.m.
Royal York, Convention Floor, Canadian Room

Agenda
6:30-7:00 p.m.
Dinner
7:00-7:10 p.m.
Introduction and Overview
Maurizio Fara, MD
Massachusetts General Hospital

7:10-7:35 p.m.
The Neurobiology of Somatic and Physical Symptoms in Depression
Pedro Delgado, MD

University of Texas Health Science Center

7:35-8:00 p.m.
Pain and Other Somatic Symptoms and Their Relationship to Antidepressant Treatment Outcome
George Papadostat, MD
Massachusetts General Hospital

8:00-8:25 p.m.
Diagnostic Challenges in Medically Ill Patients With Depression
Donna E. Stelwag, MD
University Health Network, Canada

8:25-8:50 p.m.
Management Issues in the Treatment of Depression with Comorbid Medical Disorders
Jonathan E. Alpert, MD
Massachusetts General Hospital

8:50-9:15 p.m.
Are All Antidepressants Equally Effective in the Treatment of Somatic and Physical Symptoms in Depression?
Maurizio Fara, MD
Massachusetts General Hospital

9:15-10:00 p.m.
Panel Discussion and Q & A
Maurizio Fara, MD
Massachusetts General Hospital

Sponsored by the American Psychiatric Association and supported by an educational grant from Wyeth
MANAGING UNMET NEEDS IN PSYCHIATRIC ILLNESS: A CRITICAL LOOK AT DISORDERS AND PUBLIC POLICY

Program Agenda
6:30 p.m.-7:00 p.m. Dinner
7:00 p.m.-7:10 p.m. Welcome and Introduction
K. Ranga Krishnan, MD (Chair)
Duke University Medical Center

7:10 p.m.-7:35 p.m.
Managing the Unmet Needs in Depression
A. John Rush, MD
UT Southwestern Medical Center

7:35 p.m.-8:00 p.m.
Managing the Unmet Needs in Bipolar Disorder
Roger S. McIntyre, MD, FRCP
University of Toronto

8:00 p.m.-8:25 p.m.
Managing the Unmet Needs in Schizophrenia
Marvin S. Swartz, MD
Duke University Medical Center

8:25 p.m.-8:50 p.m.
Managing the Unmet Needs in Dementia
K. Ranga Krishnan, MD
Duke University Medical Center

8:50 p.m.-9:15 p.m.
Managing the Unmet Needs: A Public Health Dilemma
James J. Gonzalez, MD, MHA
The George Washington University

9:15 p.m.-10:00 p.m. Panel Discussion/Q&A

LEARNING OBJECTIVES
- Describe underserved patient populations in depression, bipolar disorder, schizophrenia, and dementia.
- Enumerate public policy positions to address unmet needs in psychiatric disorders.
- Evaluate management strategies to improve access to care, reduce stigma, and improve outcomes.

Statement of Need
In psychiatry, underserved patient populations exist across multiple disorders and for myriad reasons. A common thread that may explain these unmet needs is not a paucity of treatment modalities, but rather inconsistent or ineffective use of them. Can public policy be crafted and calculated in the clinical community so as to achieve better access to services, combat social stigma, and enhance adherence to treatment regiments? How do key psychiatric disorders differ and resemble one another in their likelihood to benefit from this approach? Stakeholders at every level of the care continuum must find ways to embrace and refine this new paradigm and lend their efforts to reduce the number of underserved patients. In this evidence-based and forward-looking symposium, the experts will explore the unmet needs in depression, bipolar disorder, schizophrenia, and dementia, addressing treatment strategies and current/potential public policy positions affecting these illnesses.

References:
2. Wang PS, et al. Many individuals with mental disorders may be untreated or poorly treated. Arch Gen Psychiatry. 2003;60:639-646.

Wyeth Supported by an educational grant from Wyeth Pharmaceuticals and Solvay Pharmaceuticals, Inc.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 5 category 1 credits toward the AMA Physician's Recognition Award. For the CME requirements of the APA, each physician should claim only those credits that he/she actually spent in the activity.

INDUSTRY-SUPPORTED SYMPOSIUM 46
Wednesday, May 24, 2006 - 7:00 p.m. - 10:00 p.m.
Westin Harbour Castle, Second Level, Metro Grand Ballroom
Visit the APA Member Center
Find out how APA helps you in your profession

Whether you are a psychiatrist in patient care, administration, research, teaching, or a resident/medical student, the APA Member Center has relevant information for you.

New this year! Get your questions answered by experts. The APA Member Center provides you the opportunity to discuss clinical, administrative, research or academic questions with experts in the field. Check The Daily Bulletin, APA's annual meeting newspaper, for topics, dates and times.

At the APA Member Center you can:
- Apply for APA membership on-site and find out how you may be eligible for a rebate
- Pick up the APA Resource Handbook and benefit information
- Find out how to navigate Medicare Part D
- Get help with payment issues
- Participate in APA advocacy efforts
- Search the Job Bank for the latest employment opportunities
- Activate your online subscriptions to APA journals
- Learn how "OMNA On Tour" can help your community eliminate mental health disparities
- Explore APA Fellowship opportunities for residents and medical students
- Find out how APA’s CME Journal FOCUS can help you prepare for recertification
- Learn how to use the Annual Meeting Online Library for CME credit
- Pick up information about updates on the APA Practice Guidelines
- Obtain valuable resources on HIV psychiatry and learn how to schedule onsite training
- Find out about SSRI updates (ParentsMedGuide.org)
- Keep up to date on the DSM-V Prelude Project: Research and Outreach
- Find out about APA’s revised “Let’s Talk Facts” patient information brochures
- Learn how the Foundation’s public education programs promote awareness of mental illness
- And more!

While at the exhibit, learn about the key roles of these APA subsidiaries:

AMERICAN PSYCHIATRIC INSTITUTE
APIRE
for RESEARCH and EDUCATION
Contributing to psychiatry’s science base and improving psychiatric care through research, education, health policy analysis and dissemination.

American Psychiatric Foundation
Advancing public understanding of mental illnesses
A charitable and educational subsidiary whose mission is to advance public understanding that mental illnesses are real and can be effectively treated.

The APA Member Center (booth #644) is in the exhibit hall next to the APPI Bookstore

Hours:
Saturday, May 20 10:00-5:00
Sunday, May 21 10:00-4:30
Monday, May 22 10:00-5:30
Tuesday, May 23 10:00-6:00
Wednesday, May 24 10:00-3:00